Evaluation of the Home Health Value-Based Purchasing (HHVBP) Model

Sixth Annual Report
Technical Appendices

May 2023

Arbor Research Collaborative for Health and L&M Policy Research

Prepared by:

Alyssa Pozniak, Marc Turenne, Eric Lammers, Purna Mukhopadhyay, Lisa Green, Vladislav Slanchev, Claudia Schur, Judy Ng, Julia Doherty, Mike Arbit, Chad Cogan, Zhechen Ding, Rashmi Goyat, Katherine Hanslits, Nan Ji, Rebecca Mandell, Kaden Milkovich, Jeffrey Pearson, Kaitlyn Repeck, Samira Rochotte, Jillian Schrager, Jiawei Xing, Eric Young, Lisa Tomai, Mei-Chia Fong, Isabella Smith, Rose Nagele, Angel Rollo, and Nikhita Allam

Prepared for:

Centers for Medicare & Medicaid Services (CMS)

Center for Medicare & Medicaid Innovation
7500 Security Boulevard
Baltimore, MD 21244

Federal Project Officer
Susan Mathew

Prepared by:

Prime Contractor:

Arbor Research Collaborative for Health
3989 Research Park Dr
Ann Arbor, MI 48108

Project Director
Alyssa Pozniak, PhD

Principal Investigator
Marc Turenne, PhD

Subcontractor:

L&M Policy Research
1743 Connecticut Ave NW
Suite 200
Washington, DC 20009

Deputy Project Director
Lisa Green, PhD

Table of Contents

Exhibits

Acronym List

Acronym	Term
AAPI	Asian American/Pacific Islander
ACH	Acute Care Hospitalization
ACS	American Community Survey
ACO	Accountable Care Organization
ADL	Activities of Daily Living
AHRQ	Agency for Healthcare Research and Quality
AHRF	Area Health Resource File
AI/AN	American Indian/Alaska Native
AKI	Acute Kidney Injury
APM	Alternative Payment Model
AT	Achievement Threshold
BETOS	Berenson-Eggers Type of Service
BM	Benchmark
BPCI	Bundled Payment for Care Improvement
CBSA	Core-Based Statistical Area
CCN	CMS Certification Number
CCS	Clinical Classifications Software
CCW	Chronic Conditions Data Warehouse
CI	Confidence Interval
CJR	Comprehensive Care for Joint Replacement
CME	Common Medicare Environment
CMMI	Center for Medicare & Medicaid Innovation
CMS	Centers for Medicare and Medicaid Services
COP	Conditions of Participation
CPT	Current Procedural Terminology
CY	Calendar Year
D-in-D	Difference-in-Differences
D-in-D-in-D	Difference-in-Difference-in-Differences
DME	Durable Medical Equipment
ED	Emergency Department
EOC	End of Care
ESRD	End-Stage Renal Disease
FFS	Fee-for-Service
FY	Fiscal Year
GEM	General Equivalence Mapping
GME	Graduate Medical Education
HCC	Hierarchical Condition Category
HCPCS	Healthcare Common Procedure Coding System
HH	Home Health
HHA	Home Health Agency
HHC	Home Health Compare
HHCAHPS	Home Health Consumer Assessment of Healthcare Providers and Systems
HHS	US Department of Health and Human Services

Acronym	Term
HHVBP	Home Health Value-Based Purchasing
HICN	Health Insurance Claim Number
HMO	Health Maintenance Organization
HUD	US Department of Housing and Urban Development
ICD	International Classification of Diseases
IDR	Integrated Data Repository
IME	Indirect Medical Education
IP	Inpatient
IPF	Inpatient Psychiatric Facility
iQIES	internet Quality Improvement and Evaluation System
IRF	Inpatient Rehabilitation Facility
LTCH	Long-Term Care Hospital
LUPA	Low Utilization Payment Adjustment
MA	Medicare Advantage
MBSF	Master Beneficiary Summary File
MDC	Major Diagnostic Category
MDD	Master Data Demonstration
MDM	Master Data Management
MDS	Minimum Data Set
MedPAC	Medicare Payment Advisory Commission
MedPAR	Medicare Provider Analysis and Review
MMTA	Medication Management, Teaching, and Assessment
MS-DRG	Medicare Severity Diagnosis Related Group
MSA	Metropolitan Statistical Area
MSSP	Medicare Shared Savings Program
NCH	National Claims History
NPI	National Provider Identifier
NPPES	National Plan and Provider Enumeration System
OASIS	Outcome and Assessment Information Set
OCM	Oncology Care Model
PAC	Post-Acute Care
PDGM	Patient-Driven Groupings Model
PECOS	Provider Enrollment, Chain, and Ownership System
PEP	Partial Episode Payment
PHE	Public Health Emergency
POS	Provider of Services
Q	Quarter
QAPI	Quality Assessment and Performance Improvement
QI	Quality Improvement
QIES	Quality Improvement and Evaluation System
RCD	Review Choice Demonstration
RIF	Research Identifiable File
ROC	Resumption of Care
SNF	Skilled Nursing Facility
SOC	Start of Care

Acronym	Term
TA	Technical Assistance
TNC	Total Normalized Composite
TPS	Total Performance Score
UAF	Unified Analytic File
VRDC	Virtual Research Data Center

Appendix A:
Technical Appendix

This Technical Appendix provides details about the data sources and methods used to conduct the quantitative analyses for this Annual Report. Each of the following topics is covered below:

1. Detailed discussion of our quantitative analytic approach, including a discussion of the rationale and methods for defining the comparison group, our difference-in-differences (D-in-D) framework, and results of parallel trend tests that informed the selection of our analytic approach
(see **Section A.1, "Analytic Approach"**)
2. Detailed explanations of the descriptive variables and impact measures that are presented in the Annual Report, covering Quarter (Q)1, 2013 through Q4, 2020
(see **Section A.2, "Variable and Impact Measure Definitions"**)
3. Information about data acquisition and processing to create the analytic files that are necessary to define the impact measures of interest and conduct the analyses for this Annual Report (see **Section A.3, "Data Sources"**)
4. Step-by-step discussion of how we created the analytic file that we used to generate the results presented in this Annual Report (see **Section A.5, "Analytic File Creation"**)
5. Presentation of a Glossary (see **Section A.6, "Glossary"**)

A.1 Analytic Approach

We designed our quantitative analysis to address the question: What was the effect of the original Home Health Value-Based Purchasing (HHVBP) Model on impact measures of interest, such as health care utilization, quality of health care, health outcomes, and health care costs. All Medicare-certified home health agencies (HHAs) in Arizona, Florida, Iowa, Massachusetts, Maryland, Nebraska, North Carolina, Tennessee, and Washington were required to participate in the original HHVBP Model. These states were selected at random from nine state regional groups defined based on geographic location, utilization, demographics, and clinical characteristics, with each regional grouping containing five or six states.[1] To evaluate the impact of HHVBP by comparing the experience of beneficiaries and HHAs in HHVBP and non-HHVBP states, our empirical model had to address differing characteristics of beneficiaries and HHAs between HHVBP and non-HHVBP groups. Our analyses used data from multiple sources (described in Section A.3) to estimate impacts of HHVBP on the cumulative impact of HHVBP across the nine HHVBP states. Per direction from the Centers for Medicare and Medicaid Services (CMS), we focused on national-level findings in this report. Most of the relevant data elements for this evaluation were available for both HHVBP and non-HHVBP groups before and after the start of the HHVBP Model (i.e., during the evaluation baseline period from 2013-2015 and the post-implementation period starting in 2016). This allowed for comparing outcomes between HHVBP and non-HHVBP beneficiary populations and assessing whether the relative outcomes for these two groups changed from before to after the start of the original HHVBP Model.

Below, we describe the descriptive variables and impact measures used in this report. We then describe our overall analytic approach to construct a comparison group for the impact measures.

A.1.1 Descriptive Variables

An important step for this evaluation was to assess patterns and trends among HHVBP states in the characteristics of home health patients and HHAs and in the utilization of home health services. We compared descriptive measures in HHVBP and non-HHVBP states for individual years before and after implementation of the HHVBP Model. In multiple ways, these analyses informed the design of our analytic approach for evaluating effects of HHVBP. First, we used these analyses to assess the degree of balance between HHVBP states and all non-HHVBP states as a comparison prior to implementation of the HHVBP Model. In addition, we used these analyses to identify any relevant trends that preceded implementation of HHVBP and any trends that coincided with the post-implementation period. The descriptive variables used for these analyses are defined below in Section A.2.1.

A.1.2 Impact Measures

We note two general reasons why outcomes may differ across HHVBP and non-HHVBP states: 1) differing observed characteristics of beneficiaries and HHAs studied; and 2) differing *un*observed characteristics of beneficiaries and HHAs. Our empirical strategies used information on observed characteristics to address differences between the treated populations (i.e., HHVBP states) and the comparison population (i.e., non-HHVBP states). Specifically, these strategies established a comparison group to address observed differences and the use of a difference-in-differences (D-in-D) framework to address unobserved differences.

---

[1] See 2015 Final Rule here.

A.1.3 Conceptual Framework

The effectiveness of the HHVBP Model in achieving improved quality for beneficiaries served by HHAs depends on the extent to which it incentivizes HHAs to modify their operations and care delivery in ways that improve the quality of home health care and patient outcomes while controlling or reducing costs to Medicare. Our evaluation emphasizes the collection, analysis, and synthesis of information that is most relevant to how HHAs in the nine model states respond to the HHVBP Model, in comparison to equivalent non-model HHAs throughout the same time period. By using observations of HHAs and the beneficiaries for whom they provide care in non-model states, we attempted to answer the question: What would have occurred in these agencies and for their beneficiaries if the HHVBP Model had not been implemented? Our analyses examined whether the HHVBP Model is achieving its overarching goal—to improve the quality of home health services and efficiency of care—and identify any potential unintended consequences.

The conceptual framework in Exhibit A-1 highlights key pathways for change under the HHVBP Model which informed our approach to addressing the evaluation research questions presented in Section 1 of the main Annual Report. The HHVBP Model's financial incentives aim to incentivize agencies to take steps to improve their performance or otherwise maintain high levels of performance on the measures that determine their total performance scores (TPS). The TPS results for each HHA and their corresponding (and growing) changes in Medicare payments may in turn influence their future behavior. The design of the model encourages agencies to review their performance and make adjustments in response to them. This may include subsequent changes in agency operations designed to raise or bolster performance in certain areas. Additionally, HHVBP payment adjustments may influence agency decisions regarding market entry/exit or perhaps consolidation. Changes in the overall availability of agencies could have implications for the utilization of home health services and beneficiary access to care.

The response of agencies to HHVBP may have implications for the manner in which they arrange for and deliver home health services, which may in turn result in detectable changes in claims and Outcome and Assessment Information Set (OASIS) data for the use of home health services and corresponding Medicare expenditures. Examples of HHA responses to HHVBP may include changes to the frequency, timing, types of visits, or processes of care during home health episodes, or the extent to which agencies seek recertification for an additional episode to meet patient needs. HHAs may target changes in services to patients in specific diagnosis categories if they perceive greater potential gains through doing so. In addition to potentially reflecting changes in practice patterns, changes in the delivery of home health services could have implications for other forms of utilization. For instance, if the quality of care provided by agencies improves, this may reduce the need for utilization of certain resource-intensive services, such as avoidable hospitalizations, emergency department (ED) visits, or transfer to a skilled nursing facility (SNF).

Importantly, we expected to observe variation between agencies and between geographic areas in the impact of the model. HHAs will respond differently to the HHVBP Model depending on their individual circumstances. For example, agencies may differ in their perceptions of the financial risks and opportunities related to HHVBP and their readiness to adopt new processes that are designed to improve performance. Some types of agencies may have more limited experience and/or resources to successfully undertake quality improvement initiatives. Depending on factors such as the organizational

characteristics of these agencies, their characteristics of geographic location and markets, and the types of populations they serve, the HHVBP Model may have a differential impact on certain beneficiary subgroups who tend to receive services from these agencies. This evaluation sheds light on what circumstances are associated with this variation and if there are any areas of concern.

As reflected in Exhibit A-1, the incentives introduced under the HHVBP Model could potentially lead HHAs to make changes in their admission patterns and how they treat particular types of patients. For example, HHAs might avoid initiating episodes for beneficiaries for whom higher quality outcomes in the home health setting may be difficult to achieve. This different profile of patient needs may result in changes in the volume or mix of services used by beneficiaries, which, in turn, may result in changes in overall Medicare expenditures. Thus, it is important to disentangle to what extent changes in observed practice patterns are associated with treating patients differently, such as changing the types of services provided to a particular patient, versus treating different patients (for example by admitting patients with a more favorable case mix).

Our focus in this Report is to examine the impact of the HHVBP Model on cost, quality, and utilization after the first six years of implementation (2016-2021). This includes data and supporting analyses for 2021, the fourth year that HHAs in the HHVBP states are subject to positive and negative payment adjustments up to 7 percent. We use data available from 2013-2021 to evaluate the effects of the model on agency performance observed through measures that comprise the TPS as well as examine the impact of larger weights applied to the Acute Care Hospitalization (ACH) measure in 2019, 2020 and 2021.[2] There were two exogenous events in 2020 that had implications for our evaluation of the HHVBP Model, including the introduction of the Patient-Driven Groupings Model (PDGM) and the onset of COVID-19 Public Health Emergency (PHE). These two events continued in 2021. If either of these changes affected our outcomes of interest in the nine HHVBP states differently than those in the 41 comparison states, our estimates of the impact of HHVBP during 2020-2021 may be biased. We examined the impact of both the events and discuss how we mitigated this concern for each event.

Additionally, we explored whether entry/exit of agencies have implications for beneficiary access to care and examined home health utilization, utilization and availability of higher quality HHAs and potential substitutes to home health services (e.g., SNF visits) among post-acute Medicare Fee-for-Service (FFS) beneficiaries. We updated Alternative Payment Model (APM) data for the current reporting year and explored how implementation of the Review Choice Demonstration (RCD) could affect agency behavior. We examined the model's impact on the case-mix of home health patients, and on underserved populations (e.g., dually eligible patients, Black, and Hispanic beneficiaries) and other subgroups of interest (e.g., aligned with Accountable Care Organization [ACO] vs. not) to explore potential unintended consequences and potential heterogeneity in effects of the model. Furthermore, we tested for potential heterogeneous impacts of HHVBP on the use of frontloading—that is, distributing a greater share of home health visits earlier in home health episodes—by skilled nurses and therapists across subgroups determined by presence or absence of conditions that put patients at risk of limited improvement in functional status while receiving home health care, as identified through diagnoses in claims from the year preceding the start of home health care. New this year we also explored if the original HHVBP Model has any spillover effects on non-Medicare FFS beneficiaries. Particularly, we examined if there was any impact of the model on one of the key measures of health care utilization (unplanned ACHs)

---

[2] See 2018 Final Rule here.

during or shortly after home health episodes, among Medicare Advantage (MA) beneficiaries. As the HHVBP Model progresses, we will further explore pathways for change under the model depicted in Exhibit A-1.

Exhibit A-1. HHVBP Evaluation Conceptual Framework

A.1.3.1   D-in-D Approach for Impact Measures

We used a D-in-D framework to compare changes in impact measures observed over time in the HHVBP states relative to those in non-HHVBP states as the basis for evaluating the effects of HHVBP. The D-in-D framework offers a quasi-experimental design that can address many threats to validity, and rests on the critical assumption that, in the absence of the HHVBP Model, the impact measures in the two groups would have changed in a parallel manner over time. Our D-in-D analysis compared changes in impact measures observed over time in the combined HHVBP states to corresponding changes in the comparison group. The basic D-in-D estimate was defined as the difference in an outcome of interest over time in the model states, after subtracting the difference, over time, in the comparison group:

$$D\text{-}in\text{-}D = [Y_{INT,POST} - Y_{INT,PRE}] - [Y_{COMP,POST} - Y_{COMP,PRE}]$$

where $Y_{INT,POST}$ and $Y_{INT,PRE}$ are the post- and pre-intervention outcome levels, respectively, for the HHVBP group, and $Y_{COMP,POST}$ and $Y_{COMP,PRE}$ are the post- and pre-intervention outcome levels, respectively, for the comparison group.

With this model specification, the impact estimate is the differential change in an outcome for the HHVBP states between the baseline and follow-up period(s), relative to that same change for the comparison group. That is, the differential change in the outcome over time for the HHVBP states relative to non-HHVBP states represents the estimated effect of HHVBP. The D-in-D design controls for unobserved, time-varying changes that are common to all beneficiaries (i.e., cyclical or seasonal trends or broader changes in the health system), as well as time-invariant, unmeasured differences between HHVBP and comparison states' markets and beneficiary populations. Moreover, through the use of a multivariate regression, we were able to adjust for observed characteristics of beneficiaries influencing the outcome. We also included state fixed effects to account for time-invariant, unobserved differences across states that may correlate with outcomes and with HHVBP participation.

For most of the impact measures of interest for this Annual Report, we used a D-in-D approach to estimate effects of the model for all HHVBP states combined.[3] We implemented this approach in a consistent multivariate linear regression framework for a broad range of impact measures of interest for this evaluation. We provide details regarding the specification of D-in-D models below in Section A.1.5.

A.1.4 Construction of the Comparison Group

A.1.4.1   Background

We continued to use the unified comparison group methodology that we employed in our Second Annual Report. Balancing the HHVBP and comparison groups on factors that impact our outcomes of interest is important to reduce observed differences in the two populations that could lead us to incorrectly infer an effect of HHVBP that is actually a result of differences in the underlying populations. However, there are numerous and diverse impact measures of interest for this evaluation that correspond to different populations (e.g., Medicare FFS beneficiaries who receive home health care, all home health patients with Medicare or Medicaid coverage, HHAs) with different underlying factors that affect the outcome. In addition, broader changes are occurring in the home health landscape that could

---

[3] We were unable to use a D-in-D approach for the three measures that are self-reported by HHAs via the Secure Web Portal since these data are only available for HHAs in the HHVBP states. As such, we instead focused on reporting rates among HHAs in the nine HHVBP states.

have varying implications for each of the impact measures. Together, these factors posed considerable challenges in developing a unified comparison group approach that would achieve balance for *all* impact measures of interest. Therefore, we used a unified comparison group approach that focused balancing efforts on a <u>subset of impact measures</u> of cost, quality, and utilization that apply across a diverse group of home health populations relevant to the HHVBP measure set. Prioritizing some impact measures as core to the evaluation allowed us to efficiently determine the best comparison group and covariate adjustment strategy.

We focused on the four HHVBP measures that comprised the TPS. The two claims-based HHVBP measures—Unplanned ACH/First FFS Home Health (HH) Episodes and ED Use (No Hospitalization) among First HH Episodes—correspond to measures of quality that were both directly incentivized by the model and could be indicators of the quality of home health care. The two OASIS-based HHVBP measures—namely, the Improvement in Ambulation-Locomotion and Discharged to Community— covered a broader population than the claims-based HHVBP measures and represented different aspects of quality that are incentivized under HHVBP. The use of the National Quality Forum-endorsed Improvement in Ambulation-Locomotion measure—an indicator of Activities of Daily Living (ADL)— ensured that the comparison group design accounted for functional outcome improvement. The other OASIS measure—Discharged to Community—identified successful discharges to remain at home without formal assistive services. The OASIS items used to define this measure are related to the type of assessment and are less likely to be manipulated than other OASIS-based measures.[4]

Among the measures of Medicare spending, we prioritized Average Medicare Spending per Day <u>during and following</u> FFS HH Episodes of Care, Average Medicare Spending per Day <u>during</u> FFS HH Episodes of Care, Average Medicare Spending per Day <u>following</u> FFS HH Episodes of Care, and Average Medicare Spending per Day for Unplanned ACHs among FFS HH Beneficiaries. The three measures of average daily Medicare spending were important, as they could inform conclusions about the impact of HHVBP on Medicare spending for beneficiaries across a wide range of services during and following episodes of home health care. We had also included an aspect of spending that related more directly to incentives under the model—spending for unplanned ACHs—which could reflect any overall changes in spending that resulted from the HHVBP Model.

Together, these few impact measures served as our basis for developing a simplified, more unified comparison group approach for this evaluation. As discussed below, the methodology we employed to establish a valid comparison group for these measures was then applied to other outcomes of interest, while also allowing for a degree of flexibility where supported by a theory and empirical evidence.

A.1.4.2 Comparison Group

We designed the quantitative analyses for this report to evaluate the effect of the HHVBP Model on a range of impact measures that included Medicare spending, utilization of services, quality of care, and patient experience. As discussed above, we prioritized a subset of impact measures as we developed

---

[4] For example, the two OASIS items used in constructing the measure are not as subjective as other OASIS-based measures. First, Reason for Assessment (M0100) must indicate that the assessment is a discharge assessment and not a transfer to an inpatient facility, or death at home, and differing items are to be collected. Second, Discharge Disposition (M2420) is used and indicates that the individual remained in the community after discharge, either with or without formal assistance.

and tested the design of our overall approach, which we then extended to other impact measures of interest. To facilitate the interpretation of findings across measures, we established a common comparison group approach for our analyses. These analyses involved comparisons for beneficiaries and agencies between HHVBP and non-HHVBP states.

As important aspects of the design of the HHVBP Model, the randomized selection of nine HHVBP states and mandatory participation of all HHAs in these selected states helped to guard against selection bias. As reflected in the results of our descriptive analyses (see Section B.1 below), we found that the model design achieved reasonably close balance between HHVBP states and the remaining states in many beneficiary and agency characteristics and aspects of home health care. Given the extent of diversity in beneficiary and agency characteristics and treatment patterns across states, not all factors were balanced between the two groups through randomization alone, with a degree of imbalance observed for certain factors.

Given the design attributes of randomization and mandatory participation and the degree of balance observed for a range of factors, we defined a single comparison population consisting of beneficiaries and agencies in the 41 states not selected for participation in the HHVBP Model.[5] We used a multivariate linear regression approach to compare observations in the nine HHVBP states with those in the 41 comparison states while adjusting for a common set of covariates across measures to the extent possible. In the context of a parametric regression framework, we controlled for observed differences between the HHVBP and comparison groups, generated a D-in-D estimator, and examined adjusted baseline differences for consideration of the estimator's key parallel trend assumption.

To address the various research questions of interest for this evaluation, given the goals of the HHVBP Model and the incentives reflected in the HHVBP performance measures, we used this analytic approach and single comparison group to examine a range of impact measures for this report. These impact measures are enumerated below in Exhibit A-2.

---

[5] The evaluation restricts comparisons to the 41 non-HHVBP states and excludes the District of Columbia and United States (US) territories, as they were not eligible for selection into the HHVBP Model.

Exhibit A-2. Impact Measures Used to Evaluate the HHVBP Model

Measure	Unit of Analysis
HHA TPS[a] (Section 5)	HHA-Level
Home Health Utilization Measures (Section 3)	
Percent of FFS Beneficiaries with at Least One HH Episode	County-Year
Number of HH Days of Care per FFS Beneficiary	County-Year
FFS Claims-Based and OASIS-Based Case-Mix Measures (Section 3)	
Hierarchical Condition Category (HCC) Score at the Start of Care (SOC)	FFS Episode-Level
Count of HCCs Present at SOC	OASIS Episode-Level
Total Normalized Composite (TNC) Mobility at SOC	OASIS Episode-Level
TNC Self-Care at SOC	OASIS Episode-Level
FFS Beneficiaries with at Least One HH Episode [b]	Beneficiary-Year
FFS Claims-Based Measures Examining Post-Acute Care (PAC) [c](Section 3)	
Home Health Care	FFS Hospital Discharge-Level
Any Institutional PAC (i.e., SNF, Inpatient Rehabilitation, or Long-Term Care Hospitalization)	FFS Hospital Discharge-Level
Hospital Outpatient Therapy	FFS Hospital Discharge-Level
Self-Care (i.e., No Formal PAC)	FFS Hospital Discharge-Level
FFS Claims-Based HHA Operations Measures (Section 4)	
Frontloading Skilled Nurse Visits	FFS Episode-Level
Frontloading Therapy Visits	FFS Episode-Level
Utilization Measures (Section 6)	
FFS Claims-Based Utilization Measures	
Unplanned ACH/First FFS HH Episodes	FFS Episode-Level
Outpatient ED Use (No Hospitalization)/First FFS HH Episodes [d]	FFS Episode-Level
ED Use followed by Inpatient Admission/First FFS HH Episodes [d]	FFS Episode-Level
Total ED Use (Outpatient or Inpatient Claims)/First FFS HH Episodes	FFS Episode-Level
Unplanned ACH/All FFS HH Episodes	FFS Episode-Level
SNF Use/All FFS HH Episodes	FFS Episode-Level
MA Utilization Measures	
Unplanned ACH/All MA OASIS HH Episodes [e]	MA OASIS Episode-Level
Percent of MA Beneficiaries with at Least One OASIS HH Episode*	MA Beneficiary-Year
Unplanned ACH/All FFS OASIS HH Episodes*	FFS OASIS Episode-Level
Percent of FFS Beneficiaries with at Least One OASIS HH Episode*	FFS Beneficiary-Year
FFS Claims-Based Spending Measures [f] (Section 7)	
Average Medicare Spending per Day <u>during and following</u> FFS HH Episodes of Care	FFS Episode-Level
Average Medicare Spending per Day <u>during</u> FFS HH Episodes of Care	FFS Episode-Level
Average Medicare Spending per Day <u>following</u> FFS HH Episodes of Care	FFS Episode-Level
OASIS-Based Outcome Quality Measures (Section 8)	
Discharged to Community	OASIS Episode-Level
TNC Change in Self-Care	OASIS Episode-Level
TNC Change in Mobility	OASIS Episode-Level
Improvement in Dyspnea	OASIS Episode-Level

Measure	Unit of Analysis
Improvement in Management of Oral Medications	OASIS Episode-Level
FFS Claims-Based Quality Measure (Section 8)	
Mortality Rate/All FFS Home Health Episodes	FFS Episode-Level
HHCAHPS-Based Patient Experience Measures (Section 9)	
How often the home health team gave care in a professional way (Professional Care)	HHA-Level
How well did the home health team communicate with patients (Communication)	HHA-Level
Did the home health team discuss medicines, pain, and home safety with patients (Discussion of Care)	HHA-Level
How do patients rate the overall care from the home health agency (Overall Care)	HHA-Level
Would patients recommend the home health agency to friends and family (Likely to Recommend)	HHA-Level

*Section numbers refer to corresponding sections in the main summary report. HHVBP Measures indicated by italic text.| All measures have a baseline period of 2013-2015 except for HHA TPS which has a baseline period of 2015 | [a] As discussed in Section A.1.7, a D-in-D approach is not used for analysis of agency TPS. | [b] We analyzed stratified by presence of conditions at risk of limited functional improvement during HH care (see Exhibit A-44 in the Technical Appendix for a list of HCCs identified as at-risk). | [c] We analyzed stratified by presence of conditions at risk of limited functional improvement during HH care and alignment with ACO. | [d] For outpatient ED use and ED use followed by inpatient admission, we analyzed common condition specific categories as defined by Part C (Chapter-Specific Coding Guidelines) of the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Official Guidelines for Coding and Reporting Fiscal Year (FY) 2021. For details, please refer to Technical Appendix Exhibit A-50, Exhibit A-51. | [e] There are two versions of this measure with numerator calculated two ways - using shadow claims and MA inpatient encounters. For details, please refer to Technical Appendix Exhibit A-59. *We did not do D-in-D analysis on these measures, they were used for descriptive analyses | [f] For each of the three spending measures, we also analyze their components: Medicare Part B carrier and durable medical equipment (DME) combined, HH, Hospice, Inpatient, Outpatient ED and Observation Stays, other Outpatient/Outpatient types combined, and SNF.*

A key step in designing our regression-based comparison group approach was to select factors for covariate adjustment. We considered a combination of several criteria in selecting factors for inclusion in the regression analyses. While not every factor that was chosen was equally preferred based on each criterion, each factor that was chosen was seen as having advantages for inclusion when balancing among these various criteria and in achieving unbiased estimates of the effects of HHVBP. Below, we describe the criteria used in selecting potential factors for covariate adjustment:

- **Adoption of a uniform analytic approach.** To the extent possible, we sought to adjust for similar factors in examining the range of impact measures that are of interest for this evaluation. We used this strategy to facilitate interpretation of the estimated effects of HHVBP across numerous impact measures.

- **Availability of data across multiple populations of interest.** In particular, while data reported in OASIS were reported for all home health patients with Medicare or Medicaid coverage, there was other information that could be obtained only from Medicare claims or other CMS data sources for Medicare FFS beneficiaries and were therefore not available for analysis of OASIS-based impact measures. In seeking a relatively uniform analytic approach, we therefore sought to limit the selection of factors available for Medicare FFS beneficiaries only unless there was a compelling rationale based on other criteria.

- **Degree of imbalance between HHVBP and non-HHVBP states.** As a result of the randomized selection of states for participation in the HHVBP Model, there were many similarities between

HHVBP and non-HHVBP states during the baseline period. However, there were larger differences between the two groups in certain beneficiary and agency characteristics. We described baseline differences in such factors in the report (e.g., patient race/ethnicity and rural location) and included them as covariates to achieve balance.

- **Relationship with impact measures of interest for this evaluation.** Factors found to have a relatively strong relationship with certain impact measures and/or to have a relationship with multiple impact measures of interest were given greater emphasis, provided they also satisfied other criteria.

- **Differential trends in HHVBP and non-HHVBP states prior to implementation of the HHVBP Model.** Factors exhibiting such trends may be both exogenous to the HHVBP Model and pose a greater risk of introducing bias should their baseline trends extend into the post-HHVBP period. The extent of this risk also depended on other criteria, such as the strength of their relationship with the impact measures. Adjustment for such factors may help to satisfy the parallel trends assumption of our D-in-D approach.

- **Potential endogeneity.** We sought to avoid selection of factors that were endogenous to the HHVBP Model. For example, adjustment for clinical characteristics of patients influenced by the quality of prior home health care may lead to biased estimates of the effects of HHVBP. To minimize this risk, we used caution in selecting factors that changed differentially for HHVBP and non-HHVBP states between the pre-implementation and post-implementation periods, unless such differential trends were evident during the pre-implementation period and it was supported by other criteria.

- **Degree of subjectivity in measurement.** We also sought to avoid factors reported by agencies perceived as being subjective measures of patient status and are therefore more susceptible to changes over time in reporting. We note that, in certain instances, other considerations, such as the strength of the relationship with patient outcomes, were given precedence. This was relevant when considering the initial status corresponding to each of the OASIS outcome improvement measures (e.g., improvement in ambulation), where there is often a degree of subjectivity in determining the patient's initial status.

- **Correlation with other factors being considered for covariate adjustment.** We did not select factors strongly correlated with other factors that were preferred as covariates based on other criteria.

Beginning in January 2019, the OASIS assessment form was updated from version C2 to D, which included the removal of four questions (without replacement) that the HHVBP Evaluation used as covariates in our D-in-D analyses in the Third Annual Report. As explained in the Fourth Annual Report, omitting these four OASIS-based covariates from the D-in-D model caused some claims-based measures to fail the falsification test, which indicated lack of parallel trends in the baseline period (2013-2015) between the HHVBP and non-HHVBP states. The parallel trends assumption is critical to support valid inferences about the impact of HHVBP for the D-in-D models. In contrast, we found that the omission of these four OASIS-based covariates did not materially affect our findings for the OASIS-based outcome measures. Hence, it became necessary for us to revise and update the covariate list used in the D-in-D model specification specifically for the claims-based measures. The process of selecting covariates based on these criteria resulted in: (a) a core set of covariates that were used for analyses of a broad range of impact measures; and (b) the inclusion of a relatively small number of additional covariates for the analysis of either a particular impact measure or of a related group of impact measures. In the following

sections, we describe the core set of factors that were used for covariate adjustment as part of our standard model specification (listed in Exhibit A-3) and the additional covariates or other refinements that apply to a subset of impact measures.

Exhibit A-3. Core Set of Factors for Covariate Adjustment for FFS Claims and OASIS Outcome Measures

Beneficiary Characteristics	Core Clinical Indicators Used for Episode-Level Impact Measures*
Age	**Ambulation and Locomotion**
<65 years	Able to independently walk with the use of a one-handed device
65-84 years	Requires two-handed device for level ground or human assistance for stairs and uneven ground
85 years and older	Walks only with supervision or assistance from another at all times
% Female	Chairfast to bedfast
Race/Ethnicity (Mutually Exclusive)	**Interaction of HHVBP (treatment) Indicator with each of the Four Levels of Ambulation and Locomotion**
Hispanic (regardless of Black/White/Other Race)	**Risk for Hospitalization**
Non-Hispanic Black	Multiple hospitalizations in past 6 months
Non-Hispanic White	History of falls
Non-Hispanic Other	Currently taking 5 or more medications
Non-Hispanic Multiracial	**Surgical Wound**
% Dually Eligible	**Requires Urinary Catheter**
% Rural	**Discharged from Inpatient Facility in Last 14 Days**
% of Persons in the Patient's County of Residence who are Ages 25 years and Older with Less than a High School Diploma	**Pressure Ulcer**
Agency Characteristics	Pressure ulcer stage 2
Ownership	Pressure ulcer stage 3
For-profit	Pressure ulcer stage 4
Non-profit	Pressure ulcer not stageable
Government-owned	**Neoplasm Diagnosis**
Setting	
Hospital-based	
Freestanding	
Chain Affiliation	
Yes	
No	
Missing	
Undetermined	
HHA Age	
<4 years	
4-10 years	
>10 years	
Agency Size: Number of OASIS episodes	
1-59	
60-249	
250-499	
500-999	
1000+	

Derived from OASIS assessment at start of home health care.

As noted above, this core list of model covariates was, in certain instances, augmented or otherwise refined for analyses of specific impact measures. In each case, the criteria described above were used in determining whether there was a rationale for inclusion or exclusion of specific covariates. However, these additional covariates were not included among the core list of covariates, either because they were obtained from a data source that was not available for the entire population of interest, the rationale for inclusion only applied to a subset of impact measures, or for other reasons given below.

A new development during 2020 that was exogenous to the HHVBP Model, the COVID-19 PHE continued in 2021. It posed risks to our evaluation of 2020-2021 data. If the COVID-19 PHE affected our outcomes of interest in the nine HHVBP states differently than those in the 41 comparison states, our estimates of the impact of HHVBP during 2020-2021 may be biased. We did not find COVID-19 to have a markedly different impact on home health beneficiaries in HHVBP states and non-HHVBP states; overall, we observed relatively similar trends in the percentage of HH episodes with an initial COVID-19 diagnosis in the two groups of states throughout 2020-2021 (See Exhibit 4 in the main report). Nevertheless, to account for potential confounding due to the COVID-19 PHE on home health utilization and HHVBP Model, we defined two county-level and five episode-level risk-adjustment variables (Exhibit A-4 and Exhibit A-5). They are: (1) county-month-level rates of Medicare FFS inpatient stays associated with COVID-19 diagnoses; (2) county-month-level rates of incidence of COVID-19 diagnoses from USAFacts.org; (3) episode-level variables that indicate a COVID-19 diagnosis found in claims data during the episode, following the episode through 30 days or within 90 days prior to the episode start. These variables are defined in Section A.2.1.2.

Exhibit A-4. County-Level Covariates Related to COVID-19 PHE

County-Level Covariate
Regional rates of Medicare FFS inpatient stays associated with COVID-19 diagnoses
Regional rates of incidence of COVID-19 diagnoses from USAFacts.org

Exhibit A-5. Episode-Level Covariates Related to COVID-19 PHE

Episode-Level Covariate
Initial COVID-19 diagnosis 61-90 days before HH episode start date
Initial COVID-19 diagnosis 31-60 days before HH episode start date
Initial COVID-19 diagnosis 1-30 days before HH episode start date
Initial COVID-19 diagnosis during HH episode
Initial COVID-19 diagnosis 1-30 days following HH episode end date

We also conducted a sensitivity analysis and evaluated the impact of HHVBP from a model that did not adjust for these five COVID covariates. Details in Section A.2.10.

Covariate Refinements

FFS Claims-Based Utilization, Spending Measures, HHA Operations measures

Due to the changes in OASIS data collection, as explained above, from the Fourth Annual Report onwards, we included the three clinical factors (Exhibit A-6) as additional covariates: oxygen indicator, PDGM home health admission source, and PDGM-defined clinical grouping (see Section A.2.1.2 for variable definition) that helped to achieve balance in the baseline period between the HHVBP and non-HHVBP states and, importantly, satisfied the parallel trends assumption for the measures.

Exhibit A-6. Claims-Based Covariates

Covariate Label	Reasoning
Oxygen indicator	Substitutes for the four OASIS questions unavailable as of 2019
PDGM home health admission source	
PDGM-defined clinical grouping	
% Original End-Stage Renal Disease (ESRD)	Reason for Medicare Entitlement available only FFS episodes
% Original disabled	
% Current ESRD	
% Current disabled	

Additionally, we adjusted for end-stage renal disease (ESRD) or disability as the reason for Medicare entitlement, for which comparable information was not available for non-Medicare patients. For more details, please refer to Section A.2.1.2. We also adjusted for all the indicators listed out in Exhibit A-4 and Exhibit A-5 to account for potential confounding due to COVID-19 in 2020-2021.

For the two HHA operations (frontloading) measures, we additionally adjusted for number of ED visits occurring within that two-week time-frame. This was done in order to control for potential confounding between ED use that may prohibit some early home health visits while also indicating greater likelihood to use the ED after the initial two weeks of care. We also adjusted for episode-level HCC score (defined in Section A.2.1.2).

OASIS-Based Outcome Quality Measures

For OASIS episode-level impact measures, we added an adjustment for Medicaid coverage among patients who were not reported as being dually eligible for Medicare and Medicaid. This covariate was not applicable for analysis of claims-based impact measures, which are limited to Medicare FFS beneficiaries.

For each of the three OASIS-based outcome improvement measures, which were used to assess improvement over time in patient functioning or other clinical characteristics, we adjusted for outcome-specific SOC indicators of patient status. More specifically, we adjusted for the indicator of a patient's status from the initial OASIS assessment corresponding to the OASIS outcome of interest being examined. In selecting these relevant initial status indicators as covariates, we considered multiple factors. First, in our analyses of each of these measures, we found a relatively strong positive relationship of greater initial impairment or severity with greater improvement over time in patient status (i.e., such that there was greater opportunity for improvement). In addition, for many of these measures, there was a notable trend toward higher levels of impairment being reported at initial assessment that began during the pre-implementation period. These pre-implementation trends may have reflected agency efforts to increase accuracy in coding in response to public reporting initiatives. Given these considerations, we determined that inclusion of these outcome-specific covariates would allow us to avoid omitted variable bias related to the patient's initial status reported in OASIS.

Additionally, we included an interaction term between the outcome-specific SOC variables and the HHVBP (i.e., treatment) indicator to account for any differences in coding of patient status at the SOC between HHVBP and non-HHVBP states. For example, when modeling improvement in dyspnea, we adjusted for the initial level of dyspnea status and also interacted indicators of the level of dyspnea status with the HHVBP indicator. We used a similar approach in analyzing each of the other OASIS-based improvement measures.

For the two new TNC change in Self-Care and Change in Mobility measures, we followed the exact same rules. Since these are composite measures, the SOC values ranged from 0-23 for the TNC Change in Self-Care measure and 0-15 for the TNC Change in Mobility measure. The ranges of values for each composite measure were then grouped into four categories and included as covariates in the model. Consistent with other OASIS outcome measures, we included interaction terms between the TNC measure-specific SOC categories and the HHVBP (i.e., treatment) indicator for these two measures to account for any differential coding in patient status between the two groups. See Section A.2.1 for details.

For all five OASIS measures, we included the two regional rates calculated at the county-month level (Exhibit A-4) as risk-adjusters in the D-in-D model for 2020 data.

Home Health Utilization Measures
The denominator for these two home health utilization measures is total number of Medicare-eligible FFS beneficiaries per county in a particular year. The following covariates from the Master Beneficiary Summary File (MBSF), available for the national Medicare FFS population, were used for adjustment representing the percentage of FFS Medicare beneficiaries with each characteristic at the county level: age at the end of the year, sex, race and ethnicity, dual eligibility, original Medicare entitlement reason, current Medicare entitlement reason, and ESRD. In addition, county-level rural status and two county-level COVID-19 PHE indicators listed in Exhibit A-4 were used.

FFS Claims-Based and OASIS-Based Case-Mix Measures
We adjusted for agency characteristics as listed in Exhibit A-3 for these five impact measures. We also controlled for rural status and education (% of Persons in the Patient's County of Residence who are Ages 25 years and Older with Less than a High School Diploma), county-level covariates related to the COVID-19 PHE (Exhibit A-4). We also included interaction terms between the HHVBP [i.e., treatment] indicator and each of the agency characteristics, as well as interactions between the HHVBP [i.e., treatment] indicator and rural and education. We did not control for beneficiary characteristics or clinical characteristics, as the focus was to evaluate changes in case-mix of home health beneficiaries and controlling for these factors that reflect patient clinical severity could potentially bias estimated effects.

FFS Claims-Based Measures Examining PAC
These four measures were adjusted for only a subset of factors listed in Exhibit A-3, namely age, rural status, education (% of Persons in the Patient's County of Residence who are Ages 25 years and Older with Less than a High School Diploma), ACO Shared Savings Program (SSP), and ACO Pioneer APM flags. Additionally, we adjusted for a measure of poverty (percent of persons in deep poverty), which is a county-level variable extracted from the 2018-19 AHRF, and based on 2013-17 estimates from the Census American Community Survey (ACS). For 2020-2021, we adjusted for two county-level covariates related to the COVID-19 PHE (Exhibit A-4). The unit of analyses for these measures are hospital discharges.

HHA-Level Impact Measures
We examined two distinct sets of HHA-level impact measures: agency TPS and Home Health Consumer Assessment of Healthcare Providers and Systems (HHCAHPS)-derived measures. For analyses of these measures, we included all of the core beneficiary characteristics (aggregated to the agency level), agency characteristics, and the two county-level covariates related to COVID-19 PHE listed in Exhibit A-4

as covariates, with a few exceptions. For HHCAHPS measures, we excluded patient age and area education variables since comparable factors were already accounted for in the risk adjusted HHCAHPS measure values. Additionally, we did not specify OASIS episode characteristics (aggregated to the agency level) as covariates for analyses of the HHA-level impact measures, given that each of these measure values already reflected risk adjustment based on any clinical factors that were deemed relevant to measuring agency performance under HHVBP.

Further details regarding how individual covariates were defined for inclusion in regression analyses are provided in Section A.2.1.

Adjustment for APMs

Other CMS initiatives and APMs have potential to impact HHA operations and beneficiaries' use of home health services. Like the past three years, we had access to secondary data sources for a number of APMs that enabled us to investigate their potential impact and how best to account for such external factors in our analyses. The relevant APMs that were active during 2013-2021, and for which we had data available were: the Bundled Payment for Care Improvement (BPCI) Initiative, the Comprehensive Care for Joint Replacement Model (CJR), the Oncology Care Model (OCM), and ACO-centered models, including the MSSP, the Pioneer ACO Model, and the Next Generation ACO Model.

Home health beneficiaries participating in APMs may have a different course of care than home health beneficiaries not aligned with APMs. For example, under the voluntary BPCI and its later iteration BPCI Advanced, participating acute care hospitals and PAC providers receive bundled payments for services rendered during a defined episode of care, such that these providers are incentivized to contain costs and improve the quality of care. Like BPCI, the CJR Model requires coordination between participating hospitals and physicians and PAC providers, as beneficiary alignment to the model (and the hospital's financial responsibility for patient outcomes) begins with lower extremity joint replacement (LEJR) and continues through a 90-day post-acute period. This model was mandatory for hospitals within 67 selected Metropolitan Statistical Areas (MSAs) for the first two years and voluntary thereafter. Similarly, since the enactment of the Affordable Care Act, CMS has established a number of ACO-based APMs tasked with improving coordination and quality of patient care, often under a dual-sided financial risk- and reward-based agreement with CMS. Through participation in the OCM, practitioners assume financial risk on a voluntary basis over the course of a beneficiary's chemotherapy care, with the goal of improving care coordination and ultimately patient outcomes.

As shown in Exhibit A-7, there was an increasing trend in the share of home health episodes linked to an APM through 2018 in HHVBP and non-HHVBP states, with home health episodes in HHVBP states showing consistently higher APM penetration than non-HHVBP episodes. In 2013, 17.2 percent of home health episodes were aligned with one or more APM in HHVBP states, compared to 11.9 percent in non-HHVBP states. By the first performance year (2016) of the HHVBP Model, APM penetration had increased to 35.0 percent in HHVBP states and 30.5 percent in non-HHVBP states. In recent years, home health beneficiary alignment to APMs has decreased somewhat. In 2021, 44.4 percent of home health episodes in HHVBP states were aligned to one or more APMs compared to 37.9 percent of non-HHVBP episodes. The increase in APM penetration over earlier years of the reporting period was partially attributable to growth in the number of active APMs, which peaked in 2016 when the MSSP, the Pioneer ACO Model, the Next Generation ACO, BPCI Models 2 and 3, CJR, and OCM were all active. In regard to recent APM activity, the Next Generation ACO model concluded on December 31, 2021. Additionally,

the CJR model, which was originally scheduled to end in September 2021, received an extension through 2024.

Therefore, to account for these initiatives, which may affect HHA performance under HHVBP, we adjusted for beneficiary alignment to APMs at any time during their home health episode in our D-in-D regression model. Information on APM alignment was only available for FFS claims-based episodes; for claims-based utilization, Medicare spending, and HHA operations measures, we adjusted for APM indicators (Exhibit A-7 below) in addition to the core list (Exhibit A-3) and covariate refinements discussed above. Additional information on the APMs used in our covariate list are outlined in Sections A.2.6 and A.3.11 below.

Exhibit A-7. APM Penetration among Home Health Episodes for FFS Beneficiaries in HHVBP and Non-HHVBP States, 2013-2021

RCD

In 2020, CMS commenced development and implementation of the RCD in five demonstration states (Illinois, Ohio, Texas, North Carolina, and Florida). Demonstration for Illinois had started early in June 2019. Home health claims in these states with billing periods beginning on or after August 31, 2020 are subject to review under requirements of the choice selected. However, the demonstration was still in early stages in all five states during the period of our analysis, and its full impact is undetermined at this time. Due to the COVID-19 PHE, CMS phased-in participation in the RCD for some HHAs in participating states to help ease transition during the PHE. CMS discontinued exercising the phased-in participation for home health RCD providers in North Carolina and Florida and full implementation began effective September 1, 2021. However, it is likely to have impacts on how HHAs provide care, and potentially on the case-mix of patients admitted to home health care in those five states. Because the demonstration has only been implemented during the 5th year of the HHVBP Model, and it takes place in HHVBP (Florida and North Carolina) and non-HHVBP comparison states (Ohio, Texas, and Illinois), we included covariate adjustments in our claims-based analyses to mitigate any potential confounding threat this may pose for estimation of HHVBP impacts. The risk-adjustment covariates are episode-level variables that indicate one of three situations: (1) the agency participated in the RCD during the episode; (2) the

agency had previously participated but was not actively participating in the RCD during the episode; or (3) the agency was not a participant in the RCD during the episode.

Therefore, to account for these initiatives that may affect HHA performance under HHVBP, we adjusted for these factors (APM and RCD indicators, Exhibit A-8) in our D-in-D regression model. Similar to APM indicators, since information on RCD alignment was only available for FFS claims-based episodes, for claims-based utilization, Medicare spending and HHA operations measures were adjusted for these indicators in addition to the core list (Exhibit A-3) and covariate refinements discussed above. Additional information on RCD is outlined in Section A.3.12 below.

Exhibit A-8. Claims-Based Covariates Related to Other CMS Initiatives

Alignment with Select APMs
BPCI-Model 2
BPCI-Model 3
BPCI Advanced
CJR
MSSP
Next Generation ACO
OCM
Pioneer ACO
Alignment with RCD
RCD Participant – Active
RCD Participant – Inactive
RCD Non-Participant

State Fixed Effects

In general, given the random selection of the states into the HHVBP model, the D-in-D approach (as described above) helps to control for unobserved time-invariant heterogeneity in the treatment model. However, to control for residual time-invariant confounding and to limit selection bias in the estimation of causal effects, we adjusted for a full set of state fixed effects in the D-in-D model specification. By exploiting within-group variation over time, fixed effects regression is a powerful tool for mitigating the risk that omitted variables drive any associations between dependent and independent variables.

As was done in prior Annual Reports, we also analyzed impact measures at the state level. Section A.1.6 below describes the comparison group for each of the nine HHVBP states.

Introduction of PDGM

In 2020, the PDGM, a revised case-mix adjustment methodology, was implemented, which resulted in a change in the unit of payment from 60-day to 30-day episodes of care. This change from 60-day to 30-day episodes did not affect the two HHVBP measures (Unplanned Hospitalizations and ED Use [No Hospitalization] among First Home Health Episodes) as well as the ED Use Followed by Inpatient Admission and Total ED Use (Outpatient or Inpatient Claims) among First FFS Home Health Episodes measures. The denominator for all these measures is restricted to the first home health episode in the sequence only, and the measure lookout period is 60 days from the start of the episode, regardless of the length of the episode. However, this change in episode length affected other measures, i.e., all home health episodes in a sequence. This included all the measures of Medicare Spending and the other

two claims-based utilization measures (e.g., Unplanned Hospitalizations among All Home Health Episodes, SNF Use/All FFS HH Episodes).

We explored the possible implications of PDGM on Medicare spending measures. We noted that, during 2013-2019, there was a steady rise in average spending per HH episode, with somewhat faster growth among non-HHVBP states that gradually narrowed the gap between the two groups of states (left panel of Exhibit A-9). There was then a similarly large decline in average spending per HH episode for the two groups during 2020 when PDGM was introduced. That is, there was no apparent acceleration in the convergence in average spending per episode for HHVBP and non-HHVBP states between 2019 and 2020. For the most recent year (2021), we observed an increase in average spending per home health episode for both groups at a similar rate.

In contrast, there is a discernible convergence in the average number of days during HH episodes of care for HHVBP and non-HHVBP states between 2019 and 2020 (right panel of Exhibit A-9). Prior to 2020, there was a difference of approximately two to three average days per HH episode of care between HHVBP and non-HHVBP states, with the gap becoming slightly smaller over time. However, the average number of days per HH episode then fell sharply to 28 days in HHVBP and non-HHVBP states in 2020, and then remained stable in 2021. This reflects a sharp convergence in the denominator for our measure of average spending per day during HH episodes of care in 2020-2021.

Exhibit A-9. Total Medicare Part A and B Spending during HH Episodes of Care: Average Spending per HH Episode (left panel) and Average Number of Eligible Days per HH Episode (right panel), 2013-2021

The trends show that a disproportionately larger decline in the measure *denominator* in non-HHVBP states compared to HHVBP states during 2019-2021 (average number of days per episode in the right panel of Exhibit A-9) is accompanied by a similar decline in the measure *numerator* for the two groups during 2019-2021 (average spending per episode in the left panel of Exhibit A-9). Together, these trends translate to an increase in average spending per day in non-HHVBP states relative to HHVBP states during 2019-2021, resulting in an acceleration in the convergence in average spending per day between the two groups during 2019-2021 compared to what we had observed during the 2013-2019 period.

Based on this, we concluded that PDGM is likely to be the driver of a differential shift in eligible days for our measure of spending during HH episodes of care and consequently in average spending per day between HHVBP and non-HHVBP states in 2020-2021. The concern for our evaluation is that, based on our D-in-D analyses, we might falsely attribute a decrease in average spending in HHVBP states relative to non-HHVBP states in 2020-2021 to the HHVBP Model instead of attributing it to PDGM. To avoid this, we explored alternative approaches to the measure definitions in the following section.

To mitigate this potential source of bias due to PDGM, we opted for alternative and standardized approach to defining Medicare spending measures starting from 2020. Rather than determine the end of the follow-up period during HH episodes of care based on the timing of the last HH visit during the episode, we established: 1) a standard 60-day window following the start of HH care prior to 2020; and 2) a standard 30-day window following the start of HH care during 2020 and afterwards. As we have done with our spending analyses for previous Annual Reports, we ended follow-up earlier in the event of a loss of Part A eligibility or death.

This standardized approach used to estimate impacts in 2020-2021 thereby avoids a PDGM-induced differential change between HHVBP and non-HHVBP states in the follow-up period for spending per day measures. In consultation with CMS, we continued using the same approach that was followed in the previous Annual Reports (pre-PDGM method) for years prior to 2020 and opted for the alternative approach only for post-PDGM years (i.e., 2020-2021 for this report). Please refer to Section A.2.2 for details. Thus, for spending measures, we estimated impacts for 2016 through 2019 from one regression model and impacts for 2020-2021 from a separate regression model using the alternative approach. The cumulative estimate is a weighted average of 2016-2019 HHVBP impacts (estimated from one regression model) and 2020-2021 impact (estimated from another regression model that incorporates the post-PDGM approach); weighted by the number of eligible days in that year. The baseline means were also calculated using two methods. For years 2016-2019, D-in-D yearly impact estimates corresponded to a baseline mean calculated using the pre-PDGM approach. On the other hand, for post-PDGM years 2020-2021, the yearly estimate corresponded to a baseline mean that incorporated the post-PDGM standardized approach. Similarly, we calculated a weighted average baseline for HHVBP states during 2016-2021 by weighting the pre-PDGM baseline average and post-PDGM baseline average by the number of eligible home health days in HHVBP states in 2016-2019 and 2020-2021, respectively. The cumulative estimate corresponded to this weighted average baseline value when calculating relative change (Refer to Section A.2.8 for details on relative change).

On the contrary, the introduction of PDGM did not affect four out of six claims-based utilization measures (Unplanned Hospitalizations and ED Use [No Hospitalization] among First Home Health Episodes, ED Use Followed by Inpatient Admission and Total ED Use (Outpatient or Inpatient Claims) among First FFS Home Health Episodes measures). The denominator for all these measures is restricted to the first home health episode in the sequence only, and the measure lookout period is 60 days from the start of the episode, regardless of the length of the episode. However, the 60-day to 30-day change in episode length affected the other two measures that include *all* home health episodes in a sequence (Unplanned Hospitalizations among All Home Health Episodes, SNF Use/All FFS HH Episodes). Even for these two measures, the decline in the follow-up days with the introduction of PDGM was fairly similar in HHVBP and non-HHVBP states. Though it does not suggest that PDGM represents an important source of confounding, we conducted a sensitivity analysis to examine the impact of HHVBP model on all-episode utilization measures where we standardized the follow-up period of the episodes in 2020-2021 to be 60 days. We adjusted the timing of the subsequent episodes so that the follow-up period of all episodes in 2020 -2021 was equivalent to that in pre-PDGM years. This is discussed further in Section A.2.10.

A.1.5 Difference-in-Differences Model

With a baseline period for analysis of 2013-2015, we included data for all years in a single regression model per impact measure and used a D-in-D model to estimate yearly average treatment effects separately for the six post-implementation years: 2016, 2017, 2018, 2019, 2020 and 2021. We also estimated a cumulative average effect over all six years (2016-2021).

A.1.5.1 Yearly D-in-D Estimator

We included data for all years (2013-2021) to obtain the individual yearly HHVBP estimates in the post-implementation period, i.e., D-in-D estimates for 2016, 2017, 2018, 2019, 2020 and 2021; and also to calculate the cumulative average effect over 2016-2021 (Exhibit A-10).

For measuring expenditure per day, we estimate impacts for 2016-2019 from one regression model, and impacts for 2020-2021 from a separate regression model using a modified approach, as explained above.

Defining each episode i in time t, identifying the treatment episodes with an indicator variable $Treat_i$, identifying the post-implementation year variables t with an indicator variable $I(t = t_k)$, and identifying a vector of covariates as $\mathbf{P}_{Cov}$ (defined in Section A.1.4), the D-in-D estimator for outcome Y is implemented as:

$$Y_{i,t} = \alpha_0 + \alpha_1 Treat_i + \sum_{k=1}^{k=6} \beta_k I(t = t_k) + \sum_{k=1}^{k=6} \delta_k Treat_i * I(t = t_k) + \sum_{j=1}^{j=3} \rho_j I(q = j) + \omega \mathbf{P}_{Cov}$$
$$+ \sum_{s=3}^{s=50} \theta_s I(S = s) + \epsilon_{i,t}$$

Where k indexes the HHVBP Model years 1 to 5 (2016-2021).

- $Treat_i$: 1, 0 indicator (1= HHVBP states, 0= Non-HHVBP states)
- $I(t = t_1)$: 1 , 0 indicator (1 when year = 2016, 0 otherwise)
- $I(t = t_2)$: 1 , 0 indicator (1 when year = 2017, 0 otherwise)
- $I(t = t_3)$: 1 , 0 indicator (1 when year = 2018, 0 otherwise)
- $I(t = t_4)$: 1 , 0 indicator (1 when year = 2019, 0 otherwise)
- $I(t = t_5)$: 1 , 0 indicator (1 when year = 2020, 0 otherwise)
- $I(t = t_6)$: 1 , 0 indicator (1 when year = 2021, 0 otherwise)
- α_0 is an intercept
- α_1 is the average difference between the HHVBP and comparison populations over the pre-implementation period
- β_k is the average change from pre- to post-implementation for the HHVBP population, where k = 1 for year 2016, k = 2 for year 2017, k = 3 for year 2018, k = 4 for year 2019, k = 5 for year 2020, k = 6 for year 2021
- δ_k is the yearly D-in-D effect, for k = 1, 2, 3, 4, 5, 6; the difference in the change from pre-implementation to post-implementation for the HHVBP population relative to the comparison population (i.e., to estimate the treatment effect of HHVBP)
- ρ_j coefficients capture seasonal effects associated with the four quarters of the year, where j = 1, 2, 3 (one quarter omitted as reference)

- ω is a vector of coefficients associated with vector of covariates $\mathbf{P}_{Cov}$
- $I(S = s)$: 1, 0 indicator (1 when from state s, 0 otherwise); two states omitted as reference since "treat" is also included in the model
- θ_s coefficients are fixed effects for each state s
- $\epsilon_{i,t}$ episode-specific error term.

In the regression equation, we included three estimates (ρ_1, ρ_2, ρ_3) capturing quarterly effects since we included a constant in the equation. Each episode was given an equal weight except for the three average Medicare spending per day measures, which were appropriately weighted by the number of days included in the denominator (see Section A.2.2).

In order to obtain the average annual (cumulative) impact estimate over the HHVBP Model years (i.e., 2016, 2017, …, 2021), we calculate a linear combination of the five-year-specific impact estimates to ensure that the cumulative estimate is consistent with the yearly D-in-D estimates. The linear combination incorporates weights for the impact estimate of each year in each of the measure domains as follows:
- For the claims-based utilization measures – the proportion of claims episodes from each year
- For the claims-based Medicare spending measures – the proportion of eligible days from each year. To reiterate, the cumulative estimate for spending measures would be the weighted average of the yearly impact estimates, with 2016-2019 estimates calculated by one regression model (approach used in previous Annual Reports), and 2020-2021 calculated using the modified regression model as noted above; weighted by the number of eligible days in each year.
- For OASIS-based outcome measures – the proportion of OASIS episodes from each year
- For HHCAHPS-based measures – the proportion of all agency-year observations from each year

Given the phase-in structure of the payment adjustments of the HHVBP Model, we compared the average estimated HHVBP impacts on the measures in 2018-2021, when HHAs received performance-based payment adjustments, to the average impact during HHVBP Model years 2016-2017, prior to payment adjustments. We estimated and tested the equivalence of the following linear combinations of the earlier and later post-implementation years:

$$w_1 \delta_1 + w_2 \delta_2 = w_3 \delta_3 + w_4 \delta_4 + w_5 \delta_5 + w_6 \delta_6.$$

where weights are constructed based on the number of episodes (or days for the spending measures or agency for HHCAHPS) in that year and normalized such that $w_1 + w_2 = 1$ and $w_3 + w_4 + w_5 + w_6 = 1$.

Standard errors were clustered at the agency-level because implementation of HHVBP directly impacts HHAs. Since home health episodes within the same agency are correlated, accounting for agency clusters protects against the potential underestimation of standard errors, thereby minimizing the risk that we make false positive inferences about the effect of HHVBP. We also stratified at the state level in the model to account for greater homogeneity within states than across states, i.e., the variance of the outcome variable potentially being smaller within the state than in the population as a whole. Given that the HHVBP effect is analyzed at the national level, and all HHA clusters are nested within states, stratification is a method of breaking up the population into different groups and accurately estimating the standard error of the estimates. Stratification exploits this homogeneity within states to produce

smaller standard errors for a given overall sample size, thus minimizing the risk of false negative inferences (Type 2 errors) from hypothesis tests.

The derivation of the mean outcome in the HHVBP and comparison group by pre- and post-implementation period is presented below. The D-in-D estimators for 2016, 2017, 2018, 2019, 2020 and 2021 are given by the coefficients $\delta_1, \delta_2, \delta_3, \delta_4, \delta_5$, and δ_6 respectively. Between-group differences changed from α_1 in the pre-implementation period to $\alpha_1 + \delta_k, k = 1,2,3,4,5,6$ in the post-implementation period. The D-in-D coefficient, δ_k, indicates whether between-group differences increased ($\delta_k > 0, k = 1,2,3,4,5,6$) or decreased ($\delta_k < 0, k = 1,2,3,4,5,6$) after implementation of HHVBP.

Exhibit A-10. D-in-D Estimators for Individual Post-Implementation Years

Group	Pre-Implementation	Post-Implementation	Pre-Post Difference
2016 D-in-D Estimator			
HHVBP	$\alpha_0 + \alpha_1$	$\alpha_0 + \alpha_1 + \beta_1 + \delta_1$	$\beta_1 + \delta_1$
Non-HHVBP	α_0	$\alpha_0 + \beta_1$	β_1
Between group	α_1	$\alpha_1 + \delta_1$	δ_1
2017 D-in-D Estimator			
HHVBP	$\alpha_0 + \alpha_1$	$\alpha_0 + \alpha_1 + \beta_2 + \delta_2$	$\beta_2 + \delta_2$
Non-HHVBP	α_0	$\alpha_0 + \beta_2$	β_2
Between group	α_1	$\alpha_1 + \delta_2$	δ_2
2018 D-in-D Estimator			
HHVBP	$\alpha_0 + \alpha_1$	$\alpha_0 + \alpha_1 + \beta_3 + \delta_3$	$\beta_3 + \delta_3$
Non-HHVBP	α_0	$\alpha_0 + \beta_3$	β_3
Between group	α_1	$\alpha_1 + \delta_3$	δ_3
2019 D-in-D Estimator			
HHVBP	$\alpha_0 + \alpha_1$	$\alpha_0 + \alpha_1 + \beta_4 + \delta_4$	$\beta_4 + \delta_4$
Non-HHVBP	α_0	$\alpha_0 + \beta_4$	β_4
Between group	α_1	$\alpha_1 + \delta_4$	δ_4
2020 D-in-D Estimator			
HHVBP	$\alpha_0 + \alpha_1$	$\alpha_0 + \alpha_1 + \beta_5 + \delta_5$	$\beta_5 + \delta_5$
Non-HHVBP	α_0	$\alpha_0 + \beta_5$	β_5
Between group	α_1	$\alpha_1 + \delta_5$	δ_5
2021 D-in-D Estimator			
HHVBP	$\alpha_0 + \alpha_1$	$\alpha_0 + \alpha_1 + \beta_6 + \delta_6$	$\beta_6 + \delta_6$
Non-HHVBP	α_0	$\alpha_0 + \beta_6$	β_6
Between group	α_1	$\alpha_1 + \delta_6$	δ_6

A.1.5.2   Parallel Trends Testing

As discussed above, our primary analytic approach involved the use of a D-in-D estimator to measure the effects of HHVBP on a range of measures. With this estimator, we measured treatment effects based on changes occurring between the pre- and post-implementations periods in the nine HHVBP states relative to those occurring in the 41 comparison group states. We used a multivariate linear regression framework to adjust for key factors (i.e., Exhibit A-3) that remain imperfectly balanced between the two groups in a context of randomized selection and mandatory participation.

A key assumption with the D-in-D estimator is that the change in outcomes experienced in the comparison population is an accurate portrayal of the change that would have occurred in HHVBP states in the absence of HHVBP, also known as the parallel trends assumption. While the counterfactual of what would have occurred in the absence of HHVBP cannot be observed, we examined whether the

measures of interest moved similarly over the baseline period (2013-2015) in the nine HHVBP states and the 41 comparison states. That is, we compared relative trends in these measures for the HHVBP and comparison groups during the three years prior to the implementation of HHVBP.

We conducted these analyses with two goals in mind. First, we used the results of these analyses to help inform our analytic approach, and specifically decisions about model covariate selection. As discussed above, one of the criteria we considered as the basis for selecting covariates for adjustment was the presence of differential trends between the HHVBP and comparison groups during the baseline period. We used analyses of baseline trends in impact measures to ascertain how well a particular model specification satisfied the parallel trends assumption. With the results of these analyses, we were able to consider whether certain types of covariates helped to strengthen the validity of this assumption. We considered such benefits in conjunction with any tradeoffs where the inclusion of additional covariates increased complexity and a lack of uniformity in our approach across impact measures. Secondly, beyond informing the design of our analytic approach, the results of these analyses also helped us to determine our level of confidence in using the resulting D-in-D estimator to make inferences about the effects of HHVBP as well as potentially motivating the exploration of alternative model specifications.

To accomplish these goals, we performed two types of analyses of parallel trends that adjust for our core set of covariates (i.e., Exhibit A-3) along with covariate refinements as explained above and state fixed effects. Each type of analysis is discussed in turn below.

Comparison of Annual Trends between HHVBP and Non-HHVBP States
To assess parallel trends, we compared annual trends in impact measures between HHVBP and non-HHVBP states. We calculated the difference in means of the adjusted measure values for HHVBP and non-HHVBP states across the individual years of the baseline period (2013-2015) as well as for the implementation period (2016-2021). Similarly, we also calculated the difference in means of the unadjusted measure values for the two groups across the individual years. We assessed parallel trends for two FFS claims-based quality measures, three OASIS-based quality measures, and three measures of FFS claims-based Medicare spending.

For each of these eight impact measures, we plotted the differences in both unadjusted and covariate-adjusted (with state fixed effects) measure values between HHVBP and non-HHVBP states in each year (with the difference calculated as the estimated HHVBP measure value minus the estimated non-HHVBP measure value). We examined the slopes of the plotted lines for each measure during 2013-2015, and compared results based on an unadjusted regression model (i.e., having no beneficiary or agency characteristics as covariates), with results based on the adjusted model using the core set of covariates listed in Exhibit A-3, and covariate refinement as explained above along with state fixed effects. Slopes of the plotted lines that were close to zero during 2013-2015 would indicate that impact measures for the two groups moved in a parallel manner over the baseline period.

We display results using plots of the difference in yearly means for each of eight impact measures (Exhibit A-11), grouped as FFS claims-based quality measures, OASIS-based quality measures, and FFS claims-based Medicare spending measures. To facilitate interpretation of results across impact measures, the y-axis scales for the eight plots in Exhibit A-11 are standardized such that the difference between the minimum and maximum values shown on each y-axis corresponds to a difference of approximately 20 percent of the mean measure value for HHVBP and non-HHVBP states combined during 2013-2015. For example, the difference between the minimum and maximum values on the y-

axis for the unplanned ACH measure plot (1.5 percent – (-1.5 percent) = 3.0 percent) corresponds to approximately 20 percent of the national average hospitalization rate of 16 percent.

Upward or downward sloping lines during 2013-2015 indicate a lack of parallel trends, as differences between the HHVBP and comparison groups become larger or smaller during the baseline period. For some of the measures—such as unplanned ACH—the unadjusted line (corresponding to the model without any covariate adjustment) shows evidence of a time trend. In comparison, with covariate adjustment, the plotted lines for these measures (including unplanned ACH) show greater indication of parallel trends in the adjusted measure values, with trend lines having slopes closer to zero. Together, these plots for the eight key impact measures reinforced two facts:

1. As clearly shown by the contrast between the unadjusted and adjusted plots, covariate adjustment tended to result in improvements in both the degree of balance and parallel trends between HHVBP and non-HHVBP groups during the baseline period.

2. Overall, the plotted lines showing trends in the difference in measure values between HHVBP and non-HHVBP populations from the adjusted model (that included state fixed effects) have slopes that tend to be close to zero for some impact measures (e.g., unplanned acute hospitalizations, ED utilization) but not all measures.

Measures, such as the three Medicare spending per day measures and the three OASIS measures, tended to have downward slopes during the baseline period. This suggests that adjusting for state fixed effects alone is not adequate to account for non-parallel trends in the baseline period for all measures. It also reinforced the need to control for pre-HHVBP differences in trends between HHVBP and comparison states, thereby warranting a model that included both state fixed effects and state-specific linear trends along with other covariates for some impact measures, which are discussed in turn below.

Exhibit A-11. Assessing Parallel Trends for Key Impact Measures based on Unadjusted vs. Adjusted Models[6]

---

[6] The trend lines from the adjusted model (which includes an interaction term of the treatment indicator with each of the three levels of Ambulation and Locomotion along with other covariates and state fixed effects) are plotted on the assumption that the net effect of HHVBP on different levels of ambulation at the SOC is zero.

Falsification Test

We tested for differential changes in impact measures between the HHVBP and comparison groups between the first two years of the baseline period (i.e., 2013-2014) and the last year of the baseline period (i.e., 2015) as a "placebo test." That is, we applied the exact same D-in-D specification (as described above) while assigning 2013-2014 as the baseline period and falsely assigning 2015 as the post-intervention time period, and computed a D-in-D estimate for 2015. Such estimated effects for HHVBP for 2015 should be null since the initial HHVBP performance period did not begin until 2016. Where D-in-D estimates are not statistically different from zero, we would fail to reject the parallel trends assumption (i.e., suggesting that the impact measures moved in a parallel manner for the two groups over the baseline period).

Results of these falsification tests are summarized in Exhibit A-12 through Exhibit A-21. We report the 2013 mean value for each impact measure in the HHVBP states to facilitate interpretation of the magnitude of the estimated 2015 HHVBP effect. We also use the mean value to calculate the relative change corresponding to the D-in-D falsification estimate for each measure, by expressing the estimated effect as a percentage of the 2013 mean value. The results of these calculations are shown in the last column of each table.

We found a null effect during 2015 for the two home health utilization measures: 1) percent of FFS beneficiaries with at least one home health episode per year; and 2) number of home health days of care per FFS beneficiary per year (Exhibit A-12). For three of the four health status levels at the SOC measures, the falsification tests showed evidence of non-parallel trends. HCC score at the SOC and the two TNC SOC measures had statistically significant estimated effects at the $p<0.05$ level and estimates ranging from 1.2% to 1.5% of the 2013 HHVBP mean value (Exhibit A-13). We found a null effect during 2015 for the measure of home health utilization among all Medicare FFS beneficiaries at risk of limited functional improvement (Exhibit A-14).

The results of the falsification testing on the PAC alternatives within 14 days following hospital discharges generally did not show evidence of non-parallel trends during the pre-intervention period, except for institutional care (Exhibit A-15). The 2015 impact estimate of -0.18%, which was statistically significant (at $p<0.1$ level), corresponded to a 0.6 percent decline in the proportion of institution admissions relative to the 2013 rate of 29.2% in HHVBP states.

Falsification tests for claims-based HHA operations measures of frontloading indicated the absence of parallel trends for both outcome measures of interest (Exhibit A-16). Impact estimates for 2015 were statistically significant (at $p<0.05$ level) for the skilled nursing and therapy binary frontloading outcomes among post-institutional episodes, which indicates a larger number of skilled nursing or therapy visits within the first week of home health care compared to the second week. For this reason, a state linear trend term was added to D-in-D models for these measures.

Results of falsification tests for the claims-based quality measures indicated null effects during 2015 for six measures (Exhibit A-17), with the exception of SNF Use/All FFS HH Episodes where the statistically significant D-in-D falsification estimate (at $p <0.10$ level) corresponded to -1.3 percent of the baseline average value.

The result of the falsification test for unplanned ACHs among all MA OASIS episodes (based on Medicare shadow claims) was not statistically significant (Exhibit A-18). Thus, the D-in-D model for this measure did not require further adjustment.

As explained earlier, we obtain estimates for 2016-2019 from one regression model and that of 2020-2021 from another regression model that implemented the modified approach. Consequently, we performed two falsification tests: one that would assess the validity of inferences for 2016-2019, and another for 2020-2021. As noted, the standardized approach used to estimate impacts in 2020 and 2021 reflects use of a standard 60-day follow-up period for years 2013-2019 and a standard 30-day follow-up period during 2020-2021. Using this approach, we obtained an HHVBP impact for 2015 (falsification test) that helped us assess whether the spending measures, using the standardized approach as noted above, moved in a parallel manner in the baseline period. Using the spending measure definition implemented pre-PDGM, we found a null effect for two out of the three claims-based spending measures. However, the average Medicare spending per day during FFS HH Episodes of Care showed evidence of non-parallel trends in the baseline period, with the statistically significant D-in-D falsification estimate (-$0.83, p value < 0.05) corresponding to -0.6% of mean value for these measures in 2013. In comparison, the alternate spending measure falsification test showed a null effect for all three spending measures and no evidence of non-parallel trends (Exhibit A-19).

Overall, there was a tendency for the falsification tests to indicate non-parallel trends for the OASIS outcome measures (Exhibit A-20). In particular, there were statistically significant estimated effects (at p<0.10 level) for two of the five OASIS outcome quality measures, with estimates at or exceeding 1.0% of the 2013 mean value for two measures (Discharge to Community and in Management of Oral Medications; Exhibit A-20). Results of falsification tests for the HHCAHPS-based impact measures indicated null effects during 2015 for each of these five measures (Exhibit A-21).

Exhibit A-12. Results of Falsification Tests for Assessing the Impact of the HHVBP Model on Home Health Utilization Measures

Measure	Model Estimates			D-in-D Falsification[b]	Average Value in HHVBP States, 2013	Estimated Effect of Falsification Findings as % of 2013 Mean
	D-in-D	Lower 90% CI	Upper 90% CI			
Percent of FFS Beneficiaries with at Least One HH Episode[a]						
2016	-0.24	-0.53	0.04			
2017	-0.26	-0.64	0.11			
2018	-0.15	-0.53	0.22			
2019	-0.09	-0.45	0.26	-0.12	9.93%	-1.2%
2020	-0.16	-0.55	0.22			
2021	-0.21	-0.61	0.18			
Cumulative	-0.19	-0.55	0.17			
Number of HH Days of Care per FFS Beneficiary						
2016	-0.08	-0.38	0.21			
2017	0.12	-0.26	0.50			
2018	0.37	-0.01	0.76	0.05	7.56	0.6%
2019	0.59**	0.20	0.98			
2020	0.67**	0.25	1.09			

Measure	Model Estimates			D-in-D Falsification[b]	Average Value in HHVBP States, 2013	Estimated Effect of Falsification Findings as % of 2013 Mean
	D-in-D	Lower 90% CI	Upper 90% CI			
2021	0.64**	0.18	1.10			
Cumulative	0.38*	0.004	0.76			

[a] Values represent percentage point changes. [b] Represents the estimated effect of HHVBP in 2015. *p<0.10, **p<0.05. CI= Confidence Interval.

Exhibit A-13. Results of Falsification Tests for Assessing the Impact of the HHVBP Model on FFS Claims-Based and OASIS-Based Case-Mix Measures

Measure	Model Estimates			D-in-D Falsification[a]	Average Value in HHVBP States, 2013	Estimated Effect of Falsification Findings as % of 2013 Mean
	D-in-D	Lower 90% CI	Upper 90% CI			
HCC Score at the SOC						
2016	0.03**	0.02	0.04			
2017	0.03**	0.01	0.04			
2018	0.02**	0.01	0.04			
2019	0.02*	0.002	0.03	0.03**	2.6	1.2%
2020	0.03**	0.01	0.04			
2021	0.04**	0.02	0.06			
Cumulative	0.03**	0.02	0.04			
TNC Mobility at SOC						
2016	0.14**	0.10	0.18			
2017	0.18**	0.13	0.24			
2018	0.17**	0.10	0.23			
2019	0.13**	0.07	0.20	0.07**	4.7	1.5%
2020	0.10**	0.02	0.18			
2021	0.12**	0.04	0.21			
Cumulative	0.14**	0.09	0.20			
TNC Self-Care at SOC						
2016	0.23**	0.15	0.31			
2017	0.28**	0.19	0.37			
2018	0.26**	0.15	0.37			
2019	0.20**	0.08	0.32	0.11**	9.3	1.2%
2020	0.11	-0.03	0.25			
2021	0.11	-0.03	0.26			
Cumulative	0.20**	0.10	0.30			
Count of HCC Conditions Present at SOC						
2016	0.01	-0.004	0.03			
2017	0.03**	0.01	0.05			
2018	0.03**	0.01	0.05			
2019	0.03**	0.01	0.05	0.01	1.6	0.6%
2020	0.02	-0.01	0.04			
2021	0.01	-0.02	0.04			
Cumulative	0.02*	0.002	0.04			

[a] *Represents the estimated effect of HHVBP in 2015. *p<0.10, **p<0.05. CI= Confidence Interval.*

Exhibit A-14. Results of Falsification Tests for Assessing the Impact of the HHVBP Model on FFS Claims-Based Measure of Home Health Utilization among all Medicare FFS Beneficiaries at Risk and Not at Risk of Limited Improvement

	At-Risk HCCs			Other			Difference Between Impacts in At-Risk and Other Beneficiaries		
	D-in-D	D-in-D Falsifica-tion [a]	% Relative Change [b]	D-in-D	D-in-D Falsifica-tion [a]	% Relative Change [c]	D-in-D-in-D	D-in-D Falsifica tion [a]	% Relative Change [b]
Home Health Utilization	-0.27	-0.27	-1.0%	-0.17	-0.16	-2.4%	-0.09	-0.11	-0.3%

[a] *Represents the estimated effect of HHVBP in 2015.* [b]*Calculated by dividing the model estimate by the 2013 mean for patients at-risk based on HCCs in HHVBP states.* [c] *Calculated by dividing the model estimate by the 2013 mean for other patients in HHVBP states. *p<0.10, **p<0.05. CI=Confidence Interval.*

Exhibit A-15. Results of Falsification Tests for Assessing the Impact of the HHVBP Model on FFS Claims-Based Measures Examining PAC

Measure	Model Estimates			D-in-D Falsification[a, b]	Average Value in HHVBP States, 2013	Estimated Effect of Falsification Findings as % of 2013 Mean
	D-in-D[a]	Lower 90% CI[a]	Upper 90% CI[a]			
Home Health Care						
2016	0.03	-0.17	0.23	-0.03	22.9%	-0.1%
2017	0.06	-0.21	0.32			
2018	0.40**	0.09	0.71			
2019	0.46**	0.11	0.80			
2020	0.89**	0.49	1.28			
2021	0.64**	0.23	1.06			
Cumulative	0.38**	0.10	0.66			
Any Institutional PAC (i.e., SNF, Inpatient Rehabilitation, or Long-Term Care Hospitalization)						
2016	-0.21*	-0.40	-0.02	-0.18*	29.2%	-0.6%
2017	-0.05	-0.27	0.18			
2018	-0.14	-0.40	0.11			
2019	-0.14	-0.42	0.14			
2020	-0.43**	-0.77	-0.09			
2021	-0.26	-0.60	0.08			
Cumulative	-0.19	-0.43	0.04			
Self-Care						
2016	0.16	-0.06	0.38	0.17	39.5%	0.4%
2017	0.10	-0.16	0.37			
2018	-0.11	-0.41	0.20			
2019	-0.07	-0.39	0.25			
2020	-0.34	-0.69	0.01			
2021	-0.27	-0.65	0.11			
Cumulative	-0.07	-0.33	0.20			
Hospital Outpatient Therapy						
2016	0.03	-0.03	0.09	0.03	2.2%	1.4%
2017	-0.004	-0.07	0.06			
2018	-0.01	-0.09	0.06			
2019	-0.08	-0.16	<0.001			
2020	-0.01	-0.09	0.06			
2021	0.01	-0.07	0.08			
Cumulative	-0.01	-0.07	0.04			

[a] Values represent percentage point changes. [b] Represents the estimated effect of HHVBP in 2015. *p<0.10, **p<0.05. CI= Confidence Interval. | Regression adjustment for these D-in-D models use a standard set of covariates across all forms of PAC to control for observed and unobserved imbalances at baseline, quarter-year fixed effects, age, rural status, and participation in an ACO Advanced APM.

Exhibit A-16. Results of Falsification Tests for Assessing the Impact of the HHVBP Model on FFS Claims-Based HHA Operations Measures

Measure	Model Estimates			D-in-D Falsification[b]	Average Value in HHVBP States, 2013	Estimated Effect of Falsification Findings as % of 2013 Mean
	D-in-D	Lower 90% CI	Upper 90% CI			
Frontloading Skilled Nurse Visits – Post-Institutional Episodes[a]						
2016	-0.68**	-1.13	-0.23	-0.73**	59.67%	-1.2%
2017	-0.49	-1.08	0.10			
2018	-0.60	-1.24	0.04			
2019	-0.40**	-1.11	0.32			
2020	-0.59	-1.35	0.17			
2021	-1.33*	-2.14	-0.51			
Cumulative	-0.67**	-1.22	-0.11			
Frontloading Therapy Visits – Post-Institutional Episodes[a]						
2016	0.08	-0.33	0.49	-0.72**	30.51%	-2.3%
2017	-0.01	-0.50	0.48			
2018	0.33	-0.21	0.88			
2019	0.50	-0.13	1.13			
2020	1.3027**	0.59	2.02			
2021	1.48**	0.71	2.24			
Cumulative	0.59**	0.12	1.06			

[a]Values represent percentage point changes. [b] Represents the estimated effect of HHVBP in 2015. *p<0.10, **p<0.05. CI=Confidence Interval.

Exhibit A-17. Results of Falsification Tests for Assessing the Impact of the HHVBP Model on FFS Claims-Based Utilization Outcome Measures

Measure	Model Estimates			D-in-D Falsification[a,b]	Average Value in HHVBP States, 2013	Estimated Effect of Falsification Findings as % of 2013 Mean
	D-in-D[a]	Lower 90% CI[a]	Upper 90% CI[a]			
Unplanned ACH/First FFS HH Episodes						
2016	-0.23**	-0.36	-0.09			
2017	-0.03	-0.17	0.12			
2018	-0.13	-0.28	0.02			
2019	-0.25**	-0.41	-0.09	0.06	15.3%	0.4%
2020	-0.10	-0.27	0.08			
2021	-0.45**	-0.64	-0.27			
Cumulative	-0.19**	-0.32	-0.07			
ED Use (No Hospitalization)/First FFS HH Episodes						
2016	0.25**	0.14	0.37			
2017	0.22**	0.10	0.35			
2018	0.37**	0.24	0.49			
2019	0.35**	0.21	0.50	0.06	11.3%	0.5%
2020	0.20**	0.05	0.35			
2021	0.01	-0.15	0.17			
Cumulative	0.24**	0.13	0.35			
ED Use followed by Inpatient Admission/First FFS HH Episodes						
2016	-0.19**	-0.32	-0.06			
2017	-0.04	-0.17	0.10			
2018	-0.11	-0.26	0.04			
2019	-0.26**	-0.42	-0.10	0.09	13.8%	0.7%
2020	-0.20*	-0.37	-0.02			
2021	-0.49**	-0.68	-0.30			
Cumulative	-0.21**	-0.33	-0.09			
Total ED Use (Outpatient or Inpatient Claims)/First FFS HH Episodes						
2016	0.03	-0.13	0.19			
2017	0.17	-0.02	0.36			
2018	0.25**	0.06	0.44			
2019	0.13	-0.07	0.33	0.11	25.8%	0.4%
2020	0.03	-0.19	0.26			
2021	-0.48**	-0.71	-0.26			
Cumulative	0.03	-0.12	0.19			
Unplanned ACH/All FFS HH Episodes						
2016	-0.16**	-0.27	-0.04			
2017	-0.10	-0.23	0.03			
2018	-0.21**	-0.35	-0.08			
2019	-0.29**	-0.44	-0.14	0.10	16.8%	0.6%
2020	-0.50**	-0.66	-0.34			
2021	-0.77**	-0.94	-0.61			
Cumulative	-0.38**	-0.50	-0.26			
SNF Use/All FFS HH Episodes						
2016	-0.19**	-0.24	-0.14			
2017	-0.20**	-0.26	-0.13	-0.06*	4.7%	-1.3%
2018	-0.27**	-0.33	-0.20			

Measure	Model Estimates			D-in-D Falsification[a,b]	Average Value in HHVBP States, 2013	Estimated Effect of Falsification Findings as % of 2013 Mean
	D-in-D[a]	Lower 90% CI[a]	Upper 90% CI[a]			
2019	-0.29**	-0.36	-0.22			
2020	-0.59**	-0.67	-0.51			
2021	-0.67**	-0.74	-0.60			
Cumulative	-0.40**	-0.46	-0.35			
Mortality Rate/All FFS Home Health Episodes						
2016	-0.12**	-0.16	-0.08			
2017	-0.09**	-0.14	-0.05			
2018	-0.09**	-0.13	-0.04			
2019	-0.11**	-0.17	-0.06	-0.04	3.4%	-1.2%
2020	-0.20**	-0.26	-0.15			
2021	-0.24**	-0.30	-0.18			
Cumulative	-0.15**	-0.19	-0.11			

[a] Values represent percentage point changes. [b] Represents the estimated effect of HHVBP in 2015. *p<0.10, **p<0.05. CI= Confidence Interval. | HHVBP performance measures in italics.

Exhibit A-18. Results of Falsification Tests for Assessing the Impact of the HHVBP Model on MA Shadow Claims-Based Utilization Outcome Measures

Measure /All MA OASIS HH	Model Estimates			D-in-D Falsification[b]	Average Value in HHVBP States, 2013	Estimated Effect of Falsification Findings as % of 2013 Mean
	D-in-D	Lower 90% CI	Upper 90% CI			
Unplanned ACHs/All MA OASIS Episodes (Shadow Claims)						
2016	-0.23	-0.52	0.05			
2017	-0.33	-0.68	0.02			
2018	-0.37	-0.76	0.01	0.07	18.4%	0.4%
2019	-0.53**	-0.95	-0.11			
2020	-0.23	-0.71	0.25			
Cumulative	-0.35*	-0.69	-0.01			

[a] Values represent percentage point changes. [b] Represents the estimated effect of HHVBP in 2015. *p<0.10, **p<0.05. CI= Confidence Interval. | HHVBP performance measures in italics.

Exhibit A-19. Results of Falsification Tests for Assessing the Impact of the HHVBP Model on FFS Claims-Based Spending Measures

Measure	Model Estimates			D-in-D Falsification[a]	Average Value in HHVBP States, 2013	Estimated Effect of Falsification Findings as % of 2013 Mean
	D-in-D	Lower 90% CI	Upper 90% CI			
Average Medicare Spending per Day <u>during and following</u> FFS HH Episodes of Care						
2016	-$1.84**	-$2.42	-$1.26	-$0.54	$135.41	-0.4%
2017	-$3.07**	-$3.77	-$2.37			
2018	-$3.37**	-$4.14	-$2.61			
2019	-$4.30**	-$5.15	-$3.45			
2020	-$5.33**	-$6.46	-$4.20	-$0.43	$127.78	-0.3%
2021	-$7.10**	-$8.29	-$5.90			
Average Medicare Spending per Day <u>during</u> FFS HH Episodes of Care						
2016	-$2.06**	-$2.80	-$1.32	-$0.83**	$148.31	-0.6%
2017	-$3.47**	-$4.32	-$2.62			
2018	-$4.00**	-$4.96	-$3.04			
2019	-$4.68**	-$5.78	-$3.58			
2020	-$6.43**	-$7.86	-$5.00	-$0.50	$141.24	-0.4%
2021	-$8.08**	-$9.59	-$6.57			
Average Medicare Spending per Day <u>following</u> FFS HH Episodes of Care						
2016	-$1.28**	-$2.12	-$0.43	-$0.63	$102.03	-0.6%
2017	-$1.71**	-$2.66	-$0.75			
2018	-$1.13*	-$2.15	-$0.12			
2019	-$2.18**	-$3.24	-$1.12			
2020	-$1.76**	-$2.83	-$0.69	-$0.36	$79.25	-0.5%
2021	-$3.39**	-$4.51	-$2.27			

[a] *Represents the estimated effect of HHVBP in 2015. Two falsification tests were conducted: one for assessing the validity of inferences for 2016-2019; and one for the first two years of PDGM (2020-2021), using the alternative post-PDGM definition (See Section A.1.4.2). *p<0.10, **p<0.05. CI=Confidence Interval.*

Exhibit A-20. Results of Falsification Tests for Assessing the Impact of the HHVBP Model on OASIS-Based Outcome Quality Measures

Measure	Model Estimates			D-in-D Falsification[b]	Average Value in HHVBP States, 2013	Estimated Effect of Falsification Findings as % of 2013 Mean
	D-in-D	Lower 90% CI	Upper 90% CI			
Discharged to Community[a]						
2016	-0.63**	-0.90	-0.36	-0.83**	73.0%	-1.1%
2017	-1.02**	-1.35	-0.70			
2018	-1.12**	-1.50	-0.74			
2019	-1.41**	-1.81	-1.01			
2020	-1.73**	-2.20	-1.26			
2021	-1.67**	-2.16	-1.19			
Cumulative	-1.27**	-1.61	-0.92			
TNC Change in Self-Care						
2016	0.01	-0.01	0.02	-0.01	1.29	-0.8%
2017	0.01	-0.01	0.03			
2018	0.02	-0.003	0.03			
2019	0.01	-0.01	0.03			
2020	-0.002	-0.03	0.02			
2021	-0.01	-0.05	0.02			
Cumulative	0.01	-0.01	0.02			
TNC Change in Mobility						
2016	0.01**	0.001	0.01	0.0003	0.39	0.1%
2017	0.01**	0.001	0.01			
2018	0.01**	0.003	0.02			
2019	0.01	-0.0005	0.02			
2020	0.004	-0.006	0.01			
2021	0.004	-0.009	0.02			
Cumulative	0.01	-0.0002	0.01			
Improvement in Dyspnea[a]						
2016	1.33**	0.73	1.94	0.51	64.5%	0.8%
2017	1.50**	0.78	2.23			
2018	1.05**	0.36	1.73			
2019	0.81*	0.11	1.51			
2020	-0.01	-0.81	0.79			
2021	0.22	-0.56	1.01			
Cumulative	0.79**	0.18	1.41			
Improvement in Management of Oral Medications[a]						
2016	2.45**	1.68	3.22	0.66*	48.8%	1.4%
2017	3.82**	2.89	4.75			
2018	4.22**	3.28	5.16			
2019	3.96**	2.89	5.03			
2020	3.30**	2.08	4.52			
2021	3.41**	2.03	4.80			
Cumulative	3.56**	2.64	4.47			

[a] Values represent percentage point changes. [b] Represents the estimated effect of HHVBP in 2015. *p<0.10, **p<0.05. CI= Confidence Interval. | HHVBP performance measures in italics.

Exhibit A-21. Results of Falsification Tests for Assessing the Impact of the HHVBP Model on HHCAHPS-Based Patient Experience Measures

Measure	Model Estimates			D-in-D Falsification[a,b]	Average Value in HHVBP States, 2013	Estimated Effect of Falsification Findings as % of 2013 Mean
	D-in-D[a]	Lower 90% CI[a]	Upper 90% CI[a]			
How often the home health team gave care in a professional way (Professional Care)						
2016	-0.11	-0.34	0.12	-0.06	89.0%	-0.1%
2017	0.02	-0.24	0.28			
2018	-0.08	-0.33	0.18			
2019	-0.40**	-0.68	-0.13			
2020	-0.47**	-0.77	-0.16			
2021	-0.62**	-0.95	-0.29			
Cumulative	-0.27**	-0.46	-0.09			
How well did the home health team communicate with patients (Communication)						
2016	-0.23	-0.49	0.04	-0.23	86.2%	-0.3%
2017	-0.05	-0.34	0.24			
2018	-0.30	-0.59	0.002			
2019	-0.40**	-0.72	-0.09			
2020	-0.18	-0.52	0.16			
2021	-0.70**	-1.06	-0.34			
Cumulative	-0.31**	-0.52	-0.10			
Did the home health team discuss medicines, pain, and home safety with patients (Discussion of Care)						
2016	-0.35*	-0.66	-0.04	0.23	82.9%	0.3%
2017	0.22	-0.10	0.54			
2018	-0.22	-0.57	0.12			
2019	-0.60**	-0.97	-0.23			
2020	-0.57**	-0.97	-0.17			
2021	-0.95**	-1.38	-0.52			
Cumulative	-0.41**	-0.65	-0.17			
How do patients rate the overall care from the home health agency (Overall Care)						
2016	-0.10	-0.48	0.29	-0.15	84.6%	-0.2%
2017	0.04	-0.36	0.43			
2018	0.26	-0.15	0.66			
2019	-0.17	-0.60	0.26			
2020	-0.15	-0.61	0.32			
2021	-0.45	-0.97	0.07			
Cumulative	-0.09	-0.38	0.19			
Would patients recommend the home health agency to friends and family (Likely to Recommend)						
2016	0.01	-0.44	0.46	-0.29	79.8%	-0.4%
2017	0.30	-0.17	0.76			
2018	0.40	-0.09	0.90			
2019	-0.02	-0.52	0.49			
2020	-0.64*	-1.21	-0.08			
2021	-0.49	-1.09	0.11			
Cumulative	-0.07	-0.42	0.27			

[a] Values represent percentage point changes. [b] Represents the estimated effect of HHVBP in 2015. * p<0.10, **p<0.05. CI=Confidence Interval. | HHVBP performance measures in italics.

The validity of inferences that are based on the D-in-D estimator will depend on whether the assumption of parallel trends between the treatment and comparison groups during the baseline period is satisfied. If baseline trends for the two groups were not found to be parallel, the comparison group would not provide a strong counterfactual for what would have been observed in the post-implementation period in the absence of HHVBP. Instead, the D-in-D estimator would, in part, capture the effects of any pre-existing differential trends between the two groups, where those trends would have otherwise continued in the post-implementation period. This would lead D-in-D estimates to either overestimate or underestimate the true effects of the treatment. Since our falsification tests rejected the null hypothesis of no difference in baseline trends between HHVBP and non-HHVBP states for certain impact measures of interest (i.e., FFS claims-based and OASIS-based case-mix measures, FFS claims-based HHA operations measures, FFS claims-based spending measures, and the OASIS-based outcome quality measures), we explored alternative model specifications for estimating the effects of HHVBP on these impact measures. As described below, for the impact measures that failed to pass the falsification test with a model specification that adjusted for a set of covariates and state fixed effects, we also adjusted for state-specific linear trends to account for any non-parallel linear trends in the baseline period between the states.

A.1.5.3   Predicted Plots

As deemed appropriate, we have plotted trends in risk-adjusted values of the measures using the parameter estimates of the multivariable D-in-D model and average value of all the covariates (calculated using all episodes or episodes belonging to a particular subgroup depending on the analyses). Using the model indicators for year and treatment, the risk-adjusted values were obtained for each year of the intervention period for HHVBP and non-HHVBP states, separately, in reference to the pooled 2013-2015 baseline period. Having a pooled 2013-2015 baseline period is similar to what is done when calculating the impact estimates in the D-in-D model as opposed to having different risk adjusted values across the baseline years (in prior annual reports, the reference value was based using the 2015 model indicator implying that the risk-adjusted values varied across 2013-2015). For example, we examined the risk-adjusted trend lines of the Mortality Rate/All FFS Home Health Episodes measure based on the multivariable D-in-D model between HHVBP and non-HHVBP states over 2013-2020 (see Exhibit B-68). This method was further extended to D-in-D-in-D models to obtain risk adjusted values for measures within specified subgroups as shown in chapter 11. In the panels below, we show risk adjusted trend lines for HHVBP and non-HHVBP states over 2013-2021 for the six utilization measures (Exhibit A-22), three spending measures (Exhibit A-23), five OASIS-based outcome measures (Exhibit A-24) and five HHCAHPS measures (Exhibit A-25).

Exhibit A-22. Panel Showing Adjusted Trends for Claims-Based Utilization Measures for HHVBP And Non-HHVBP States, 2013-2021

Exhibit A-23. Panel Showing Adjusted Trends for Claims-Based Spending Measures for HHVBP And Non-HHVBP States, 2013-2021

Exhibit A-24. Panel Showing Adjusted Trends for OASIS-Based Outcome Quality Measures for HHVBP And Non-HHVBP States, 2013-2021

Exhibit A-25. Panel Showing Adjusted Trends for HHCAHPS-Based Measures for HHVBP And Non-HHVBP States, 2013-2021

A.1.5.4 Incorporating State-Specific Linear Time Trends to Account for Non-Parallel Trends during the Baseline Period

Given our findings of non-parallel trends in certain impact measures during the baseline period, we conducted regression analyses using an alternative D-in-D model that incorporated state-specific linear time trends. We added linear time trends interacting with each state indicator along with state fixed effects to the covariate list discussed above in Section A.1.4.2, which can be used to account for different linear trends during the baseline period between the states. We included data for all years (2013-2021) to obtain individual yearly HHVBP estimates in the post-implementation period, i.e., D-in-D estimates for 2016, 2017, 2018, 2019, 2020 and 2021.

Defining each episode i in time t, identifying the treatment episodes with an indicator variable $Treat_i$, identifying the post-implementation year variables t with an indicator variable $I(t = t_k)$, and identifying a vector of covariates as $\mathbf{P}_{Cov}$ (defined in Section A.1.4), the D-in-D estimator for outcome Y that included state-specific linear time trends was implemented as:

$$Y_{i,t} = \alpha_0 + \alpha_1 Treat_i + \sum_{k=1}^{k=6} \beta_k I(t = t_k) + \sum_{k=1}^{k=6} \delta_k Treat_i * I(t = t_k) + \sum_{j=1}^{j=3} \rho_j I(q = j) + \sum_{s=3}^{s=50} \theta_s I(S = s)$$

$$+ \sum_{s=1}^{s=50} \gamma_s time * I(S = s) + \omega \mathbf{P}_{Cov} + \epsilon_{i,t}$$

Where k goes from 1 to 6 for years 2016 -2021.

- $Treat_i$:   1, 0 indicator (1= HHVBP states, 0= Non-HHVBP states)
- $I(t = t_1)$: 1 , 0 indicator (1 when year = 2016, 0 otherwise)
- $I(t = t_2)$: 1 , 0 indicator (1 when year = 2017, 0 otherwise)
- $I(t = t_3)$: 1 , 0 indicator (1 when year = 2018, 0 otherwise)
- $I(t = t_4)$: 1 , 0 indicator (1 when year = 2019, 0 otherwise)
- $I(t = t_5)$: 1 , 0 indicator (1 when year = 2020, 0 otherwise)
- $I(t = t_6)$: 1 , 0 indicator (1 when year = 2021, 0 otherwise)
- α_0 is an intercept
- α_1 is the average difference between the HHVBP and comparison populations over the pre-implementation period
- α_0 is an intercept
- α_1 is the average difference between the HHVBP and comparison populations over the pre-implementation period
- β_k is the average change from pre- to post-implementation for the HHVBP population, where k = 1 for 2016, k = 2 for 2017, k = 3 for 2018, k = 4 for 2019, k = 5 for 2020, k = 6 for 2021
- δ_k is the yearly D-in-D effect, for k = 1, 2, 3, 4, 5, 6; the difference in the change from pre-implementation to post-implementation for the HHVBP population relative to the comparison population (i.e., to estimate the treatment effect of HHVBP) from a model that adjusts for state fixed effects and state-specific linear trends
- ρ_j coefficients capture seasonal effects associated with the four quarters of the year, where j = 1, 2, 3 (one quarter omitted as reference)

- $I(S = s)$: 1, 0 indicator (1 when from state s, 0 otherwise); two states omitted as reference since "treat" is also included in the model
- θ_s coefficients are fixed effects for each state s
- $time$: linear term ranging from 2013-2021
- γ_s: coefficients associated with state-specific linear trends, time trends for each state interacted with fixed effects indicator for each state s
- ω is a vector of coefficients associated with the vector of covariates $\mathbf{P}_{Cov}$
- $\epsilon_{i,t}$ episode-specific error term.

With this model, the D-in-D estimator measures the difference in deviations from the average of state trend lines between HHVBP and comparison groups in the post-HHVBP period, while accounting for any non-parallel linear trends in the baseline period between the states.

In the regression equation, we included three estimates (ρ_1, ρ_2, ρ_3) capturing quarterly effects since we included a constant in the equation. Standard errors are calculated the same way as described above in Section A.1.5.1. Also, as described in Section A.1.5.1, we calculate the cumulative estimate as the weighted average of the yearly estimates to ensure the cumulative estimate is consistent with the yearly D-in-D estimates. We also estimated a linear combination of the post-implementation years to obtain an average annual D-in-D impact estimate for models that included state-specific linear trends.

Exhibit A-26 shows a side-by-side comparison of the cumulative D-in-D estimates obtained from two alternative D-in-D models for the measure sets where there was a pattern of non-parallel trends for some of the individual measures. The first column reports estimates based on the D-in-D model specified in Section A.1.5.1, whereas the last column shows estimates from the D-in-D model that additionally adjusts for state-specific linear trends. We observe that the inclusion of state-specific linear time trends results in a smaller but still statistically significant estimate (e.g., total Medicare spending during and following home health care, improvement in management of oral medications) after accounting for the relative trends already occurring in the HHVBP states in the pre-HHVBP period. The D-in-D estimates for SNF Use/All FFS HH Episodes were statistically significant for both the models and very similar in magnitude (-0.40 vs. -0.36 percentage points).

Exhibit A-26. Comparison of Cumulative D-in-D Estimates between Models with and without State-Specific Linear Time Trends

Measures	D-in-D Estimate[a]	D-in-D Estimate with State- Specific Linear Time Trend[a]
SNF Use/All FFS HH Episodes[b]	-0.40**	-0.36**
Average Medicare Spending per Day among FFS HH beneficiaries during and following HH Episodes of Care	-$4.09**	-$2.63**
Average Medicare Spending per Day among FFS HH beneficiaries during HH Episodes of Care	-$4.70**	-$2.63**
Average Medicare Spending per Day among FFS HH beneficiaries following HH Episodes of Care	-$1.88**	-$0.25
Discharged to Community[b]	-1.27**	1.08**
TNC Change in Mobility	0.01	0.01**
TNC Change in Self-Care	0.01	0.04**

Measures	D-in-D Estimate[a]	D-in-D Estimate with State- Specific Linear Time Trend[a]
Improvement in Dyspnea[b]	0.79**	-0.38
Improvement in Management of Oral Medications[b]	3.56**	2.26**

[a] *Cumulative estimates for 2016-2021 combined.* | [b] *Represents percentage point changes. * p<0.10, **p<0.05. | HHVBP performance measures in italics.*

Although incorporating state-specific linear time trends in our D-in-D model allows us to account for non-parallel trends in the baseline period between the HHVBP and comparison groups for certain impact measures, it assumes that the average difference in slopes between HHVBP state trends and the comparison state trends observed in the baseline period would have continued to change at the same rate in the absence of HHVBP; keeping in mind that that this is an increasingly strong assumption to make throughout the course of this six-year evaluation. Addition of state linear trends, however, leads to a reduction in the level of precision of the annual D-in-D estimates as we incorporate additional years of data into the analyses.[7] Consequently, it may affect the statistical significance of the cumulative estimate, which is a weighted average of the yearly D-in-D estimates. Nevertheless, this adjustment of state linear trends is a well-motivated method for establishing a valid comparison group and making inferences about the impact of HHVBP. This underscores the importance of checking the practical significance of impact estimates in addition to their statistical significance.[8] It is important to carefully weigh the strength of the evidence in terms of the magnitude of point estimates and consistency of impact findings over multiple years along with other criteria (Section 2.2.3) to facilitate interpretation of results. It is also possible for there to be residual non-linear, non-parallel trends based on a model that adjusts for state fixed effects and state-specific linear trends. We continue to analyze the influence of such potential deviations from model assumptions on impact estimates throughout the course of this evaluation.

Consistent with our approach that was implemented in our Third and Fourth Annual Reports, we therefore incorporated state-specific linear time trends for the following measure sets that failed the falsification test: FFS claims-based and OASIS-based **case-mix measures** (Exhibit A-13), FFS claims-based **HHA operations measures** (Exhibit A-16), FFS claims-based **spending measures** (Exhibit A-19), and the **OASIS-based outcome** quality measures (Exhibit A-20). Though not all measures in each of the measure sets rejected the null hypothesis of parallel trends in the baseline period (for example, two out of five OASIS outcome measures,) we used state-specific linear time trends for all measures within these measure sets. In contrast, only one of six utilization (SNF Use/ All FFS HH episodes) failed falsification with state fixed effects at 0.1 level of significance (Exhibit A-17). However, as noted in Exhibit A-26, the D-in-D estimates of SNF Use measure were very similar between a model that adjusted for state linear trends versus not (-0.40 vs.-0.36); hence, we used state fixed effects for all FFS claims-based utilization measures. Again, for the Home Health Utilization measures, we adjusted for both state fixed effects and state linear trends as it was failing falsification tests for state -specific models (HHVBP states vs. regional comparison groups; results not sown) and we aimed for consistency between national and state level results. All these efforts were done to facilitate interpretation of results among strongly related impact

---

[7] Angrist JD, Pischke JS. (2015). *Mastering metrics: The path from cause to effect*.
[8] Wasserstein R, Schirm A, Lazar N. (2019) Moving to a World Beyond "p < 0.05". The American Statistician 73(Suppl1): 1-19.

measures and to maintain a uniform analytic approach where possible. Similarly, for HHCAHPS-based quality measures, we employed the simpler D-in-D model specification discussed in Section A.1.5.1, given the findings for the falsification test for these measures (Exhibit A-21). Exhibit A-27 provides an at-a-glance summary of the risk factors that are adjusted for in the multivariable regression model. For details, please refer to Section A.1.3.1.

Exhibit A-27. Summarizing Model Specifications for All the Impact Measures Used to Evaluate the HHVBP Model

Measure	List of Covariates included in Multivariable D-in-D Model	Additional Adjusters
HHA TPS[a] (Section 5)		
Home Health Utilization Measures (Section 3)		
Percent of FFS Beneficiaries with at Least One HH Episode	Beneficiary Age, Sex, Current and Original Reason for Medicare Entitlement, ESRD, Race/ethnicity, Dual Eligibility, Rural, and Exhibit A-4	State Fixed Effects + State Linear Trends
Number of HH Days of Care per FFS Beneficiary		
FFS Claims-Based and OASIS-Based Case-Mix Measures (Section 3)		
HCC Score at the SOC	Select Beneficiary Characteristic and Agency Characteristics Listed in Exhibit A-3, Exhibit A-4, Exhibit A-5	State Fixed Effects + State Linear Trends
Count of HCCs Present at SOC		
TNC Mobility at SOC		
TNC Self-Care at SOC		
FFS Beneficiaries with at Least One HH Episode [b]		State Fixed Effects
FFS Claims-Based Measures Examining PAC [c] (Section 3)		
Home Health Care	Beneficiary Age, Rural, Poverty and Education Indicators Aggregated to the County Level, Select APM Indicators Listed in Exhibit A-8, Exhibit A-4	None
SNF		
Any Institutional PAC (i.e., SNF, Inpatient Rehabilitation, or Long-Term Care Hospitalization)		
Hospital Outpatient Therapy		
Self-Care (i.e., No Formal PAC)		
FFS Claims-Based HHA Operations Measures (Section 4)		
Frontloading Skilled Nurse Visits	Exhibit A-3, Exhibit A-4, Exhibit A-5, Exhibit A-6, Exhibit A-8, Count of ED Visits + HCC Score	State Fixed Effects + State Linear Trends
Frontloading Therapy Visits		
FFS Claims-Based Utilization Measures (Section 6)		
FFS Claims-Based Utilization Measures		

Measure	List of Covariates included in Multivariable D-in-D Model	Additional Adjusters
Unplanned ACH/First FFS HH Episodes	Exhibit A-3, Exhibit A-4, Exhibit A-5, Exhibit A-6, Exhibit A-8	State Fixed Effects
Outpatient ED Use (No Hospitalization)/First FFS HH Episodes [d]		
ED Use followed by Inpatient Admission/First FFS HH Episodes [d]		
Total ED Use (Outpatient or Inpatient Claims)/First FFS HH Episodes		
Unplanned ACH/All FFS HH Episodes		
SNF Use/All FFS HH Episodes		
MA Utilization Measures		
Unplanned ACH/All MA OASIS HH Episodes [e]	Exhibit A.3, Exhibit A-4, Medicaid Indicator	State Fixed Effects
Unplanned ACH/All FFS OASIS HH Episodes		State Fixed Effects + State Linear Trends
Percent of MA Beneficiaries with at Least One OASIS HH Episode*		
Percent of FFS Beneficiaries with at Least One OASIS HH Episode*		
FFS Claims-Based Spending Measures [f] (Section 7)		
Average Medicare Spending per Day during and following FFS HH Episodes of Care	Exhibit A-3, Exhibit A-4, Exhibit A-5, Exhibit A-6, Exhibit A-8	State Fixed Effects + State Linear Trends
Average Medicare Spending per Day during FFS HH Episodes of Care		
Average Medicare Spending per Day following FFS HH Episodes of Care		
OASIS-Based Outcome Quality Measures (Section 8)		
Discharged to Community	Exhibit A.3, Exhibit A-4, Medicaid Indicator + SOC Values for the Respective Measures (as Applicable)	State Fixed Effects + State Linear Trends
TNC Change in Self-Care		
TNC Change in Mobility		
Improvement in Dyspnea		
Improvement in Management of Oral Medications		
FFS Claims-Based Quality Measure (Section 8)		
Mortality Rate/All FFS Home Health Episodes	Exhibit A-3, Exhibit A-4, Exhibit A-5, Exhibit A-6, Exhibit A-8	State Fixed Effects
HHCAHPS-Based Patient Experience Measures (Section 9)		
How often the home health team gave care in a professional way (Professional Care) *How well did the home health team communicate with patients (Communication)*	Subset of Factors Listed in Exhibit A-3 Aggregated to the Agency Level, Exhibit A-4	State Fixed Effects

Measure	List of Covariates included in Multivariable D-in-D Model	Additional Adjusters
Did the home health team discuss medicines, pain, and home safety with patients (Discussion of Care)		
How do patients rate the overall care from the home health agency (Overall Care)		
Would patients recommend the home health agency to friends and family (Likely to Recommend)		

Section numbers refer to corresponding sections in the main summary report. HHVBP Measures indicated by italic text.). | All measures have a baseline period of 2013-2015 except for HHA TPS which has a baseline period of 2015 | [a] As discussed in Section A.1.7, a D-in-D approach is not used for analysis of agency TPS. | [b] We analyzed stratified by presence of conditions at risk of limited functional improvement during HH care (see Exhibit A-44 in the Technical Appendix for a list of HCCs identified as at-risk). | [c] We analyzed stratified by presence of conditions at risk of limited functional improvement during HH care and alignment with ACO. | [d] For outpatient ED use and ED use followed by inpatient admission, we analyzed common condition specific categories as defined by Part C (Chapter-Specific Coding Guidelines) of the ICD-10-CM Official Guidelines for Coding and Reporting FY 2021. For details, please refer to Exhibit A-50, Exhibit A-51. | [e] There are two versions of this measure with numerator calculated two ways - using shadow claims and MA inpatient encounters. For details, please refer to Technical Appendix Exhibit A-59. |*We did not do D-in-D analysis on these measures, they were used for descriptive analyses |[f] For each of the three spending measures, we also analyze their components: Medicare Part B carrier and DME combined, HH, Hospice, Inpatient, Outpatient ED and Observation Stays, other Outpatient/Outpatient types combined, and SNF.

A.1.6 Comparison Group for State-Level Analyses

For the state-specific analyses presented in this report, the choice of an appropriate comparison group for each HHVBP state was largely driven by the extent of balance that exists between the treatment and comparison groups on factors that can potentially impact outcomes of interest. Achieving this balance and reducing observed differences in the two populations was important, as it would otherwise lead us to erroneously infer an effect of HHVBP that was actually a result of differences in the underlying populations. Leveraging the design of the model, the regional groups from which CMS randomly selected the HHVBP states, were used as comparison groups for each state, as listed below (Exhibit A-28). As specified in the CY 2016 Final Rule,[9] each regional grouping included states that were similar in utilization, demographics, and clinical characteristics while being geographically located in close proximity to one another. Another motivation for choosing the regional groups as comparison groups was that, collectively, they constituted all the 41 non-HHVBP states, which would help us to reconcile the national-level results with the state-specific results.

Exhibit A-28. HHVBP States and their Corresponding Regional Group

HHVBP State	Non-HHVBP States in Regional Group
Arizona (AZ)	New Mexico, California, Nevada, Utah, Colorado
Florida (FL)	Texas, Oklahoma, Louisiana, Mississippi
Iowa (IA)	North Dakota, South Dakota, Montana, Wisconsin, Minnesota
Massachusetts (MA)	Vermont, Maine, Connecticut, Rhode Island, New Hampshire
Maryland (MD)	Delaware, New Jersey, Pennsylvania, New York
North Carolina (NC)	Alabama, Georgia, South Carolina, Virginia
Nebraska (NE)	Ohio, West Virginia, Indiana, Missouri, Kansas

---

[9] See 2015 Final Rule here.

HHVBP State	Non-HHVBP States in Regional Group
Tennessee (TN)	Illinois, Kentucky, Arkansas, Michigan
Washington (WA)	Oregon, Alaska, Hawaii, Wyoming, Idaho

Based on our assessment of the degree of balance among a wide range of the characteristics of each HHVBP state and the regional grouping from which it was selected, and a goal of maintaining uniformity with the approach we use for our national-level analyses, we adopted a similar comparison group approach for individual states.

As explained in the Third Annual Report, most of the covariates and the priority measures exhibited a reasonably strong degree of balance between each HHVBP state and its corresponding regional grouping. Factors that demonstrated less balance at the state level also tended to show less balance at the national level (e.g., beneficiary race/ ethnicity, agency for-profit, non-profit, or government ownership, hospital or freestanding setting, chain status, and agency size). As we did for our analyses of the impact of HHVBP at the national level, we used multivariate regression to achieve balance on those factors that remained imperfectly balanced between each HHVBP state and its respective comparison group.

As noted in the Third Annual Report, we assessed the validity of the comparison group by testing the assumption of parallel baseline trends in impact measures between the HHVBP states and their respective regional comparison groups. The tests concluded that using a regional group as the comparison group for each of the nine HHVBP states helped to achieve an overall pattern of reasonably similar baseline trends for many of the impact measures of interest for this evaluation. At the national level, for impact measures that exhibited a lack of parallel trends during the baseline period, we incorporated state-specific linear time trends (Section A.1.5.4 and Exhibit A-27). Similarly, at the state level, for impact measures exhibiting a lack of parallel trends during the baseline period, we incorporated state-specific linear time trends for their respective measure sets. At the state level, these measure sets were FFS claims-based and OASIS-based case-mix measures, FFS claims-based utilization measures, FFS claims-based Medicare spending measures, and OASIS-based outcome measures.

A.1.7 Analytic Approach for Agency Total Performance Scores

As a metric that combines agency performance on the range of quality measures included in HHVBP and used to determine Medicare payment adjustments for HHAs in the HHVBP states, the TPS represents a broad measure of agency performance that is incentivized under HHVBP. As such, the TPS is of interest as an overall performance indicator for comparison between agencies in model states with those in non-model states where this metric does not affect Medicare payments to HHAs.

Given the considerations discussed in this section, we examined the impact of the HHVBP Model on overall agency performance by comparing TPS values in model states with those in non-model states. We used multivariate linear regression to examine agency TPS in each year from 2016-2021 while accounting for differences in certain characteristics of HHAs between HHVBP and non-HHVBP states. These factors included agency size, chain status, ownership type, age, and freestanding versus hospital-based, as well as indicators of patient demographic characteristics and insurance. We also included the regional COVID-19 adjustors, which were included in the D-in-D analyses of claims-based measures in this report.

As discussed above, our primary analytic approach for this evaluation involves a D-in-D methodology, where we test for differential changes from the baseline period to the post-HHVBP period in the model group relative to the comparison group. A D-in-D approach to examining TPS values, however, is not optimal over the duration of this evaluation and was not used. A key consideration is that the methodology for computing TPS is expected to change over time. For example, one of the initial performance measures, the Drug Education on All Medications Provided to Patient/Caregiver during All Episodes of Care, was removed from the HHVBP measure set starting in the third performance year of the model (2018) since many HHAs were found to be achieving full performance on this measure.[10] Further changes to both the HHVBP measure set and to the measure weights took effect in 2019, the fourth performance year of the model.[11] One effect of such changes in methodology is that TPS values from different payment years are less comparable, as changes in TPS across payment years may in part reflect changes in the components of the TPS rather than necessarily changes in agency performance.

In addition, the TPS already captures changes over time in performance. For each HHA, the TPS is calculated by summing the applicable measure scores. For each measure, the performance of individual HHAs is measured based on a combination of: (a) their levels of achievement on the measure relative to their state cohort's performance during the baseline period; and (b) their improvement over time relative to their own previous performance levels. For each measure, agencies receive the higher of their achievement score or their improvement score. However, regardless of which score is higher for a specific measure, the average score that results among HHAs in a state represents a measure of improvement in performance relative to that observed in a prior period—whether to that of the overall state cohort or of those particular HHAs. As a result, the TPS calculation inherently captures changes over time in performance, which are reflected in the results of a cross-sectional regression analysis.

As a test of whether the HHA measure scores (which comprise the TPS) reflect improvement relative to an HHA's own baseline as well as its state cohort's baseline, we examined correlations between average measure scores among HHAs in each state and each of the following:

- The average difference between the measure rate for each HHA during the performance period and its state-level achievement threshold (AT).[12]
- The average difference between the measure rate for each HHA during the performance period and its own baseline performance measure rate.

Among the individual performance measures, we generally found correlations of between 0.6 and 0.9 for both types of correlations above.[13] These results indicate that average HHA measure scores in a state have a moderately strong correlation with *both*: (a) the amount by which average HHA performance levels in a given performance year exceed their state cohort's baseline performance; and (b) the extent of improvement in average HHA performance over baseline performance. That is, in the aggregate, higher measure scores tended to indicate greater improvement in HHA performance relative to both the state cohort's baseline performance and to an HHA's own baseline performance.

---

[10] See 2017 Final Rule here.
[11] See 2018 Final Rule here.
[12] See 2015 Final Rule here.
[13] See Section C.3 in our Third Annual Report Technical Appendix here.

A limitation of comparing TPS across states is that each agency's achievement on a measure is determined relative to the baseline performance for that agency's specific state cohort. The ATs and benchmarks (BMs) that were used to determine agency achievement scores were calculated separately for each state. HHA achievement scores are therefore calculated relative to baseline performance levels that can vary across states. Large differences across states in baseline performance levels used to calculate measure scores could theoretically have implications for comparisons of measure scores and, in turn, TPS across states or groups of states. Therefore, we examined relative performance in HHVBP and non-HHVBP states to rule out the possibility of higher average achievement scores among agencies in HHVBP states being due to a lower baseline level of performance among agencies in those states. This scenario would indicate greater room for improvement at the time the HHVBP Model was implemented. Below, we examined (and rejected) the possibility that differences in baseline performance levels between agencies in HHVBP and non-HHVBP states might have implications for comparisons of TPS between these groups.

For each HHVBP measure, we examined ATs and BMs among agencies in HHVBP states relative to non-HHVBP states in 2021 (Exhibit A-29).[14] For HHVBP measures that reflect indicators of utilization based on Medicare claims (i.e., ACH and ED visits), indicators of care processes based on OASIS data, and indicators of patient satisfaction based on HHCAHPS data, average ATs and average BMs were within one-half of one percentage point. For example, during 2021, the average AT for the unplanned ACH measure was 15.8 percent among agencies in HHVBP states and 15.5 percent among those in non-model states.

Exhibit A-29. Average Measure ATs and BMs, HHVBP Performance Year 2021

HHVBP Performance Measure	Average AT		Average BM	
	HHVBP	Non-HHVBP	HHVBP	Non-HHVBP
ED Use (No Hospitalization)/First FFS Home Health Episodes	11.8%	12.2%	6.1%	5.9%
Unplanned ACH/First FFS Home Health Episodes	15.8%	15.5%	8.9%	8.7%
Discharged to Community	71.1%	69.4%	83.8%	85.3%
Improvement in Management of Oral Medications	54.0%	51.6%	74.8%	76.0%
Improvement in Dyspnea	69.6%	64.1%	88.1%	87.5%
TNC Change in Self-Care	1.710	1.566	2.161	2.162
TNC Change in Mobility	0.607	0.555	0.769	0.767

---

[14] AT is defined as the median measure value for all HHAs in the state during the baseline period, and the BM is defined as the mean measure value for the best performing decile of all HHAs in the state during the baseline period. See 2015 Final Rule here.

HHVBP Performance Measure	Average AT		Average BM	
	HHVBP	Non-HHVBP	HHVBP	Non-HHVBP
How often the home health team gave care in a professional way	89.0%	88.8%	94.3%	94.0%
How well did the home health team communicate with patients	86.2%	85.7%	92.0%	92.3%
Did the home health team discuss medicines, pain, and home safety with patients	83.7%	83.8%	90.3%	91.6%
How do patients rate the overall care from the home health agency	84.7%	84.7%	93.0%	93.2%
Would patients recommend the home health agency to friends and family	80.1%	79.5%	90.5%	90.4%

For the OASIS-based measures of patient outcomes, differences between the two groups in the average ATs typically ranged between two and five percentage points, with higher thresholds for the HHVBP group. This included the three outcome improvement measures and the discharge to community measure. For example, the average AT for the measure of improvements in management of oral medications was 54.0 percent among HHAs in HHVBP states and 51.6 percent among those in non-model states. Differences in the average BMs were smaller, generally within one percentage point. For the two TNC measures, differences between the two groups in the average ATs ranged between 0.05 and 0.14 points, with higher thresholds for the HHVBP group. Average BMs are very close between HHVBP and Non-HHVBP group for them.

Average agency ATs and BMs among agencies in HHVBP and non-HHVBP states were virtually identical for the five previous performance years, since they used the same baseline year (2015) as performance year 2021.[15] These comparisons do not suggest systematic, large differences between the HHVBP and non-HHVBP groups in baseline performance levels when comparing HHA measure scores and TPS values.

---

[15] See Section C.3 in our Third Annual Report Technical Appendix here.

A.2 Variable and Impact Measure Definitions

Below, we describe how we specified and defined descriptive variables and impact measures that were used in this Annual Report.

A.2.1 Descriptive Variables

A.2.1.1 Beneficiary Characteristics

Total Number of Beneficiaries Receiving Home Health Care. Home health claims and OASIS episodes of care were used to identify and count the number of unique home health beneficiaries with at least one home health claim or OASIS episode of care in a specified time period.

Age. Age was calculated based on the floored (i.e., rounding down to nearest integer) year difference between patient birth date on the OASIS assessment and the OASIS assessment effective date; if the OASIS information was missing, then age was calculated based on the floored year difference between patient date of birth and the claims-based episode start date.

For home health utilization analyses for the Medicare FFS population, the variable AGE_AT_END_REF_YR from the MBSF Base segment data file was exclusively used.

Gender. Gender indicator was primarily derived from the OASIS assessment item M0069; if the OASIS information was missing, then gender was derived from the variable SEX_IDENT_CD in the MBSF data file.

For home health utilization analyses for the Medicare FFS population, the variable SEX_IDENT_CD in the MBSF was exclusively used.

Race/Ethnicity. Race indicators (White, Black, Hispanic, Other Race) came from OASIS assessment item M0140; American Indian or Alaska Native, Asian and Native Hawaiian or Pacific Islander are grouped into the "other" race category. The OASIS item allows for selection of more than one race; therefore, a patient could have multiple race flags indicated. If the OASIS information was missing, then RTI_RACE_CD from the MBSF Base segment data were used to calculate race indicators. We recoded race categories to mutually exclusive groups using the following rules:

- Hispanic (regardless of Black/White/Other Race)
- Black (as the only race indicated; will be Non-Hispanic)
- White (as the only race indicated; will be Non-Hispanic)
- Other (as the only race indicated; will be Non-Hispanic)
- Multiracial (combination of Black/White/Other Race; will be Non-Hispanic)

For home health utilization analyses for the entire Medicare FFS population, the race and ethnicity indicator was derived exclusively from RTI_RACE_CD from the MBSF Base segment data. We recoded race categories using the following rules:

- Hispanic (regardless of Black/White/Other Race)
- Black (as the only race indicated; will be Non-Hispanic)
- White (as the only race indicated; will be Non-Hispanic)
- Other (Unknown, Other Race, Asian/Pacific Islander, American Indian/Alaska Native; will be Non-Hispanic)

Dual Eligibility. For the month that a given claims-based episode starts or an OASIS-based episode of care ends, dual eligibility status indicators were evaluated in the MBSF. If the beneficiary was in the MBSF Base segment data and had a Dual Status code value in ('01','02','03','04','05','06','08'), then their dual eligibility flag was set to 1 for that episode. Otherwise, if they did not have enrollment data for that month in the MBSF or if the Dual Status code was not in ('01','02','03','04','05','06','08'), then their dual eligibility flag was set to 0. For home health utilization analyses, the dual eligibility flag (indicated by whether the beneficiary was ever dually eligible throughout the year) was aggregated to the FFS beneficiary-year level.

Medicaid Only (either Health Maintenance Organization [HMO] or FFS without dual eligibility). For OASIS episodes of care, beneficiaries were marked as Medicaid Only, if they were not dually eligible, as defined via MBSF, and OASIS item M0150 ('Current Payment Sources for Home Care') indicated either '3 – Medicaid (traditional FFS)' or '4 – Medicaid (HMO/managed care).'

Rural/Urban. County Core-Based Statistical Area (CBSA) codes from the Area Health Resource File (AHRF) data were used to identify rural counties (i.e., those that lacked a CBSA code) and urban counties (i.e., those with a CBSA code). Rural/urban indicators were then matched to beneficiaries' county information as derived from the ZIP code reported on the OASIS assessment form. If ZIP code was not available from the OASIS assessment, then the county where home health services were provided was derived based on a hierarchy of data sources: CBSA code reported on the home health claim, beneficiary ZIP code from OASIS assessment nearest to the home health claim start date, beneficiary address reported on the home health claim, and the beneficiary county provided at month-level in the MBSF Base segment. If beneficiary county of residence/treatment was not available in any of these data sources, then the ZIP code of the HHA providing care was used to derive county information.

Health Conditions. The following chronic health conditions were reported for home health beneficiaries on an annual basis: chronic kidney disease, congestive heart failure, diabetes, ulcers, Alzheimer's disease or related senile dementia, ischemic heart disease, and anemia. These indicators were pulled from the MBSF Chronic Conditions and Other Chronic Conditions segments. The condition flags were provided at both the middle and end of each year for each Medicare beneficiary; for this report, only end-of-year condition flags were used. The original chronic condition flags have four levels: 1) neither claim nor coverage criteria were met; 2) claim criteria met, coverage criteria not met; 3) claim criteria not met, coverage criteria met; 4) claims and coverage criteria met. Claims criteria are met when the beneficiary has a claim that includes a related diagnosis or procedure code during the given condition's reference period. Coverage criteria are met when the beneficiary is enrolled in full FFS (Medicare Parts A and B) for the entire condition reference period. Our analyses reduced these chronic condition flags to three levels: 1) Beneficiary has condition (claims criteria were met, regardless of coverage criteria); 2) Beneficiary does not have condition (claims criteria were not met); 3) Beneficiary does not have MBSF Chronic Condition data available for the year.

Reason for Medicare Entitlement. Original and current reasons for Medicare entitlement were determined using the entitlement reason variables from the MBSF Base segment, associated with a claims-based home health episode based on the year in which the episode began. Beneficiary Medicare entitlement was coded as disabled, ESRD, or both.

Percentage of Persons aged 25 years or older with less than a high school diploma 2011-2015. The percentage of each level of education at the county level was reported on the AHRF data (see Section

A.3.5). This value was calculated by dividing the number of individuals aged 25 years or older with less than a high school diploma by the standard education level denominator provided on the AHRF then multiplying by 100. This county-level metric was then matched to each home health episode based on the county in which care was provided (see Section A.5.4.1 for a detailed description in how county was determined).

COVID-19 Infection and Hospitalization. COVID-19 infection and hospitalization indicators at the episode level history were determined by the presence of U071 or B9729 diagnosis code in any (inpatient, outpatient, SNF, home health, hospice, part B carrier and DME) claims ending after 12/31/2019. If any claim contained the diagnosis code (U071 or B9729), the COVID flag for that beneficiary would be marked as "Yes" and dated with the earliest claim from date with U071 or B9729 diagnosis. Additionally, if any inpatient claim contained U071 or B9729, the COVID hospitalization flag for that beneficiary would be marked as "Yes" and dated with the earliest inpatient claim from date with U071 or B9729 diagnosis.

OASIS Clinical Factors

Inpatient discharge within 14 days. For OASIS-based episodes of care, inpatient discharge within 14 days prior to the SOC was derived from OASIS assessment item M1000. For claims-based episodes, each home health beneficiary's FFS status was determined using the MBSF monthly indicators for the 14 days prior to the start of the episode. Among those beneficiaries who are Parts A & B eligible, inpatient and SNF claims were scanned for those with a CLM_THRU_DT (i.e., discharge) occurring within the 14-day lookback period.

Risk for hospitalization. For OASIS-based episodes of care, three indicators for risk for hospitalization were derived from one of two OASIS assessment items, depending on assessment version. For assessments using the C version, item M1032 was used, and for assessments using the C1 and later versions, item M1033 was used. The response categories differed across the two OASIS versions. For C1 and later (M1033), responses of '01' were coded as having a history of falls, responses of '03' were coded as having multiple hospitalizations, and responses of '07' were coded as taking five or more medications. For (M1032), responses of '03' were coded as having a history of falls, responses of '02' were coded as having multiple hospitalizations, and responses of '04' were coded as taking five or more medications.

Requires urinary catheter. For OASIS-based episodes of care, indicators for urinary incontinence or catheter presence were populated only in instances in which the patient had been discharged from an inpatient community (via M1000) or received a diagnosis requiring medical or treatment regimen change (via M1016 for C1 assessments or M1017 if C2 assessments). Among those patients, the indicator was populated when item M1610 had a response of '02.'

Surgical wound. For OASIS-based episodes of care, an indicator variable indicating that the patient has a surgical wound was populated based on OASIS assessment item M1340 with a response of '01,' indicating that the patient has an observable surgical wound.

Oxygen Therapy. The need for oxygen therapy used to be derived from item M1410 when the response was '01'. However, starting OASIS version D, the question M1410 was longer collected in the assessment form. Thus, a replacement for the OASIS-based oxygen variable was created using a combination of: primary and secondary diagnoses for supplemental oxygen reported on home health, DME, outpatient,

physician-supplier, and inpatient claims, as well as OASIS Assessment items M1021 (primary diagnosis) and M1023 (secondary diagnoses). Specifically, the ICD9 code V462 and the ICD10 code Z9981 were used to identify oxygen use for home health, outpatient, physician-supplier, and inpatient claims, as well as OASIS question M1021 and M1023. DME claims would be flagged with oxygen use if Healthcare Common Procedure Coding System (HCPCS) contained any of E1390, E1391, E0424, E0439, E1405, E1406, E0431, E0434, E1392, E0433, K0738, E0441, E0442, E0443 or E0444. In addition, the claim through dates of DME, outpatient, physician-supplier, and inpatient claims have to fall between 30 days before home health episode start date and home health episode end date.

Home Care Diagnosis: Neoplasms. For OASIS-based episodes of care, presence of neoplasm diagnosis was identified from a series of OASIS assessment items. We derived ***neoplasm diagnosis*** from a series of OASIS assessment items: M1020 (primary diagnosis ICD codes), M1022 (other ICD diagnosis codes), and M1024 (payment ICD diagnosis codes). These ICD codes were then used to indicate the presence of a diagnosis of neoplasm according to CMS documentation on OASIS measures.[16]

Stages of Pressure Ulcer: For OASIS-based episodes of care, indicators showing different stages of pressure ulcer were obtained from two OASIS items as shown below (Exhibit A-30)

Exhibit A-30. Pressure Ulcers

OASIS Item	OASIS Question	Variables	OASIS Response
M1308 (version C1), M1311 (version C2) – Pressure Ulcers	Current Number of Unhealed Pressure Ulcers at Each Stage (or Unstageable)	Pressure Ulcer Stage 2	A
		Pressure Ulcer Stage 3	B
		Pressure Ulcer Stage 4	C
		Pressure Ulcer Not Stageable	D.1-D.3

Source: OASIS-C2 Guidance Manual

As noted in Section A.1.4.2, we adjusted for outcome-specific SOC indicators of patient status. More specifically, we included the indicator of a patient's status from the initial OASIS assessment corresponding to the OASIS outcome of interest being examined, as covariates in the respective D-in-D model. For example, for the Improvement in Dyspnea OASIS outcome measure, we adjusted for the patient responses captured by the OASIS assessment question at the SOC (Exhibit A-32). Exhibit A-31 and Exhibit A-32 describe the responses for the OASIS assessment questions corresponding to the two OASIS improvement measures. Similarly, Exhibit A-33 through Exhibit A-43 describe the responses for the OASIS assessment questions that comprise the two TNC measures. In addition to being a component of the TNC Change in Mobility measure, ambulation and locomotion responses obtained from OASIS assessment question M1860 (Exhibit A-36) were included in the core set of factors for covariate adjustment (Section A.1.4.2).

Source: OASIS-C2 Guidance Manual

---

[16] Hittle DF, Nuccio EJ. (2017) Home Health Agency Patient-Related Characteristics Reports: Technical Documentation of Measures - Revision 4.1. Prepared for: Department of Health and Human Services; Centers for Medicare & Medicaid Services. University of Colorado School of Medicine - Division of Health Care Policy and Research.

Exhibit A-31. Oral Medications

OASIS Item	OASIS Question	Variables	OASIS Response
M2020 – Oral Medications	Management of Oral Medications: Patient's current ability to prepare and take all oral medications reliably and safely, including administration of the correct dosage at the appropriate times/intervals. Excludes injectable and IV medications. (NOTE: This refers to ability, not compliance or willingness.)	Patient is able to take oral medications if prepared in advance/another person develops a drug diary	01
		Able to take medications at the correct time if given reminders by another person at the appropriate times	02
		Unable to take medication unless administered by another person	03

Source: OASIS-C2 Guidance Manual

Exhibit A-32. Dyspnea

OASIS Item	OASIS Question	Variables	OASIS Response
M1400 – Dyspnea	When is the patient dyspneic or noticeably short of breath?	Patient is short of breath only when walking more than 20 feet	01
		With moderate exertion	02
		With minimal exertion or at rest	03, 04

Source: OASIS-C2 Guidance Manual

TNC SOC Measures. The SOC values for the TNC measures are different from the other OASIS SOC values in that they are composites of multiple OASIS assessment items, the sum of responses ranging from 0 to 15 for the TNC mobility SOC measure and from 0 to 23 for the TNC self-care SOC measure, with larger values implying worse health conditions. In order to use these SOC values as covariates in the models for the respective TNC outcome measures, we grouped the composite (sum of responses) values into four categories each, ranging from a "most healthy" category to a "least healthy" category.

TNC mobility at the SOC is composed of three OASIS assessment items at the SOC: Toilet Transferring, Bed Transferring, and Ambulation. The category construction of this SOC measure as well as the description of the three components that make up this measure are shown below in Exhibit A-33 through Exhibit A-36.

Exhibit A-33. TNC Measure of Mobility at SOC

OASIS Item	OASIS Question	Category	Sum of OASIS Response
M1840 – Toilet Transferring, M1850 – Bed Transferring, M1860 – Ambulation/Locomotion	TNC Measure of Mobility at the SOC (sum of the three OASIS items)	Sum less than 4	0, 1, 2, 3
		Sum between 4 and 6, inclusive	4, 5, 6
		Sum between 7 and 9, inclusive	7, 8, 9

OASIS Item	OASIS Question	Category	Sum of OASIS Response
		Sum greater than or equal to 10	10, 11, 12, 13, 14, 15

Exhibit A-34. Toilet Transferring

OASIS Item	OASIS Question	Variables	OASIS Response
M1840 – Toilet Transferring	Current ability to get to and from the toilet or bedside commode safely and transfer on and off toilet/commode	Able to get to and from the toilet and transfer independently with or without a device	00
		When reminded, assisted, or supervised by another person, able to get to and from the toilet and transfer	01
		Unable to get to and from the toilet but is able to use a bedside commode (with or without assistance)	02
		Unable to get to and from the toilet or bedside commode but is able to use a bedpan/urinal independently	03
		Is totally dependent in toileting	04

Source: OASIS-C2 Guidance Manual

Exhibit A-35. Bed Transferring

OASIS Item	OASIS Question	Variables	OASIS Response
M1850 – Bed Transferring	Transferring: Current ability to move safely from bed to chair, or ability to turn and position self in bed if patient is bedfast	Able to independently transfer	00
		Able to transfer with minimal human assistance or with use of an assistive device	01
		Able to bear weight and pivot during the transfer but unable to transfer self	02
		Unable to transfer self and is unable to bear weight or pivot when transferred by another person	03
		Bedfast, unable to transfer but is able to turn and position self in bed	04
		Bedfast, unable to transfer and is unable to turn and position self	05

Source: OASIS-C2 Guidance Manual

Exhibit A-36. Ambulation/Locomotion

OASIS Item	OASIS Question	Variables	OASIS Response
M1860 – Ambulation/Locomotion	Current ability to walk safely, once in a standing position, or use a wheelchair, once in a seated position, on a variety of surfaces.	Able to independently walk on even and uneven surfaces and negotiate stairs with or without railings (specifically: needs no human assistance or assistive device)	00
		Able to independently walk with the use of a one-handed device	01
		Requires two handed device or human assistance	02
		Walks only with supervision or assistance from another at all times	03
		Chairfast to bedfast	04, 05, 06

Source: OASIS-C2 Guidance Manual

TNC self-care at the SOC is composed of six OASIS assessment items at the SOC: Grooming, Upper Body Dressing, Lower Body Dressing, Bathing, Toileting Hygiene, Feeding or Eating. The category construction of this SOC measure as well as the description of the six components that make up this measure are shown below in Exhibit A-37 through Exhibit A-43.

Exhibit A-37. TNC Measure of Self-Care at SOC

OASIS Item	OASIS Question	Category	Sum of OASIS Response
M1800 – Grooming, M1810 – Ability to Dress Upper Body, M1820 – Ability to Dress Lower Body, M1830 - Bathing, M1845 – Toileting Hygiene, M1870 – Feeding or Eating	TNC Measure of Self-Care at the SOC (sum of the six OASIS items)	Sum less than 8	0, 1, 2, 3, 4, 5, 6, 7
		Sum between 8 and 10, inclusive	8, 9, 10
		Sum between 11 and 15, inclusive	11, 12, 13, 14, 15
		Sum greater than or equal to 16	16, 17, 18, 19, 20, 21, 22, 23

Exhibit A-38. Grooming

OASIS Item	OASIS Question	Variables	OASIS Response
M1800 – Grooming	Current ability to tend safely to personal hygiene needs (specifically: washing face and hands, hair care, shaving or make up, teeth or denture care, or fingernail care)	Able to groom self unaided, with or without the use of assistive devices or adapted methods	00
		Grooming utensils must be placed within reach before able to complete grooming activities	01

OASIS Item	OASIS Question	Variables	OASIS Response
		Someone must assist the patient to groom self	02
		Patient depends entirely upon someone else for grooming needs	03

Source: OASIS-C2 Guidance Manual

Exhibit A-39. Ability to Dress Upper Body

OASIS Item	OASIS Question	Variables	OASIS Response
M1810 – Ability to Dress Upper Body	Current ability to dress upper body safely (with or without dressing aids) including undergarments, pullovers, front-opening shirts and blouses, managing zippers, buttons, and snaps	Able to get clothes out of closets and drawers, put them on and remove them from the upper body without assistance	00
		Able to dress upper body without assistance if clothing is laid out or handed to the patient	01
		Someone must help the patient put on upper body clothing	02
		Patient depends entirely upon another person to dress the upper body	03

Source: OASIS-C2 Guidance Manual

Exhibit A-40. Ability to Dress Lower Body

OASIS Item	OASIS Question	Variables	OASIS Response
M1820 – Ability to Dress Lower Body	Current ability to dress lower body safely (with or without dressing aids) including undergarments, slacks, socks or nylons, shoes	Able to obtain, put on, and remove clothing and shoes without assistance	00
		Able to dress lower body without assistance if clothing and shoes are laid out or handed to the patient	01
		Someone must help the patient put on undergarments, slacks, socks or nylons, and shoes	02
		Patient depends entirely upon another person to dress lower body	03

Source: OASIS-C2 Guidance Manual

Exhibit A-41. Bathing

OASIS Item	OASIS Question	Variables	OASIS Response
M1830 – Bathing	Bathing: Current ability to wash entire body safely. Excludes grooming (washing face, washing hands, and shampooing hair).	Able to bathe self in shower or tub independently, including getting in and out of tub/shower	00
		With the use of devices in shower/tub	01
		With intermittent assistance in shower/tub	02
		Participates with supervision in shower/tub	03
		Independent at sink, in chair, or on commode	04
		Participates with assist at sink, in chair, or commode	05
		Unable to participate; bathed totally by another	06

Source: OASIS-C2 Guidance Manual

Exhibit A-42. Toileting Hygiene

OASIS Item	OASIS Question	Variables	OASIS Response
M1845 – Toileting Hygiene	Toileting Hygiene: Current ability to maintain perineal hygiene safely, adjust clothes and/or incontinence pads before and after using the toilet, commode, bedpan, urinal. If managing ostomy, includes cleaning area around stoma, but not managing equipment	Able to manage toileting hygiene and clothing management without assistance	00
		Able to manage toileting hygiene and clothing management without assistance if supplies/implements are laid out for the patient	01
		Someone must help the patient to maintain toileting hygiene and/or adjust clothing	02
		Patient depends entirely upon another person to maintain toileting hygiene	03

Source: OASIS-C2 Guidance Manual

Exhibit A-43. Feeding or Eating

OASIS Item	OASIS Question	Variables	OASIS Response
M1870 – Feeding or Eating	Feeding or Eating: Current ability to feed self meals and snacks safely. Note: This refers only to the process of eating, chewing, and swallowing, not preparing the food to be eaten.	Able to independently feed self	00
		Able to feed self independently but requires: (a) meal set-up; OR (b) intermittent assistance or supervision from another person; OR (c) a liquid, pureed or ground meat diet	01
		Unable to feed self and must be assisted or supervised throughout the meal/snack	02
		Able to take in nutrients orally and receives supplemental nutrients through a nasogastric tube or gastrostomy	03
		Unable to take in nutrients orally and is fed nutrients through a nasogastric tube or gastrostomy	04
		Unable to takin in nutrients orally or by tube feeding	05

Source: OASIS-C2 Guidance Manual

A.2.1.2 Episode Characteristics

Episode Type. Home health claims-based episodes with outlier payment adjustments were identified using the variable claim value code = 17. Low Utilization Payment Adjustment (LUPA) payment adjustments were identified using the variable *CLM_HHA_LUPA_IND_CD*, and Partial Episode Payment (PEP) payment adjustments were identified using *PTNT_DSCHRG_STUS_CD = '06'.* Otherwise, all episodes without outlier, LUPA, or PEP adjustments were categorized as "Normal".

Episodes within a Sequence. Claims-based episode sequences were put together by combining episodes whose end date and start dates were within 60 days of one another; a gap of at least 60 days indicated the start of a new sequence. Three different categories of episodes were created depending on the order in which an episode appears relative to the larger sequence of episodes in which it occurs: first in a sequence, second in a sequence, and third or higher in a sequence. All episodes, regardless of episode type (i.e., normal, outlier, LUPA, PEP), were included. The logic we employed is in alignment with the methodology for determining home health stays for the two HHVBP claims-based measures.[25]

Visits in an Episode. Using the revenue center codes associated with each home health claim, visits per claims-based episode were counted for each type of home health service: physical therapy visit (revenue center code 042x), occupational therapy visit (revenue center code 043x), speech language pathology visit (revenue center code 044x), skilled nursing visit (revenue center code 055x), medical social services visit (revenue center code 056x), and home health aide visit (revenue center code 057x). These visits were then summed to calculate the total visits per claims-based episode.

Visits in an Episode by Type of Visit. Using the revenue center codes associated with each home health claim, visits per episode were counted for each type of home health service: physical therapy visit (revenue center code 042x), occupational therapy visit (revenue center code 043x), speech language

pathology visit (revenue center code 044x), skilled nursing visit (revenue center code 055x), medical social services visit (revenue center code 056x), and home health aide visit (revenue center 057x).

HCC indicators and HCC risk scores. To evaluate the risk level of beneficiaries at the start of each home health episode, we calculated episode-level HCCs and HCC risk scores by using Research Identifiable Files (RIFs) claims data and software (Version 21, published in 2014 and 2019) provided by CMS.[17] For this analysis, we focused on the first episode in the sequence only. Specifically, for each first home health episode in a sequence, we looked back 30 days to include all diagnosis codes from Part B carrier, inpatient, and outpatient claims. Only professional carrier claims were eligible to be included based on HCPCS codes provided by CMS.[18] We excluded any carrier claims for which line item Berenson-Eggers Type of Service (BETOS) code variable equals D1A, D1B, D1C, D1D, D1E, D1F, D1G (which is DME), or O1A (which is ambulance services). The intent of the algorithm was to exclude claims where the services do not require a licensed health care professional. In addition, we also excluded any outpatient claims that only included lab testing, based on revenue center files.

The model software created 87 HCCs and three HCC scores: new enrollees, institutional and community. Beneficiaries were assigned to one of the three HCC scores as follows:

- If a beneficiary was not fully enrolled in Medicare FFS for the past 12 months before the start of the home health episode, the new enrollee score was used.
- Otherwise, if at least one 90-day assessment exists in the Minimum Data Set (MDS) within the 365 days prior to the start of the home health episode, the institutional score was used.
- Otherwise, the community score was used.

For second or later home health episodes in the sequence, the HCC score from first home health episode was used.

The individual HCC indicators we used for analysis in the annual report include:

- HCC 21: Protein-Calorie Malnutrition.
- HCC 23: Other Significant Endocrine and Metabolic Disorders.
- HCC 52: Dementia without Complication.
- HCC 78: Parkinson's and Huntington's Diseases.
- HCC 79: Seizure Disorders and Convulsions.
- HCC 85: Congestive Heart Failure.
- HCC 96: Specified Heart Arrhythmias.
- HCC 106: Atherosclerosis of the Extremities with Ulceration or Gangrene.
- HCC 159: Pressure Ulcer of Skin with Partial Thickness Skin Loss.
- HCC 170: Hip Fracture/Dislocation.
- HCC 176: Complications of Specified Implanted Device or Graft.

For beneficiaries with ESRD status at the start of the home health episode, we calculated an ESRD HCC risk score based on the Version 21 ESRD model software published by CMS.[17]

---

[17] See CMS Risk Adjustment model software. Available here.
[18] See CMS Medicare Risk Adjustment Eligible Current Procedural Terminology (CPT)/HCPCS Codes. Available here.

Similarly, we also created individual HCC indicators for OASIS based episodes, using exactly the same model/crosswalk, but based on the ICD diagnosis code from question M1020/M1021 and M1022/M1023[19] on the start-of-care/resumption-of-care assessments.

Conditions at risk of limited functional improvement indicator: We marked an OASIS episode of care at risk of limited functional improvement if at least one of 20 OASIS-based HCCs associated with limited improvement (listed in Exhibit A-44 below) were present at the SOC (see paragraph above for information on OASIS-based HCCs). We calculated TNC change in self-care and TNC change in mobility measures (for HHVBP and non-HHVBP states combined) during the pooled baseline period (2013-2015), stratified by the 87 OASIS-based HCCs. We then grouped the TNC change measures into quartiles (highest to lowest functionality) and the HCCs conditions that were in the bottom quarter for both the measures were considered to be the ones that were not likely to improve (in terms of functional status). We also solicited input from an expert home health clinical care manager to validate the list of HCC conditions. The consultant validated the list and recommended the inclusion of a few additional conditions that are at risk of limited functional improvement, only some of which could be specifically identified in claims data (Parkinson's and Huntington's diseases). Exhibit A-44 lists the 20 HCCs that were included in the resulting list of at-risk HCCs along with their corresponding baseline TNC change in self-care and TNC change in mobility values.

Exhibit A-44. 20 HCCs Present at SOC and at Risk of Limited Improvement for TNC Self-Care and Mobility among All OASIS Episodes, 2013-2015

Baseline average TNC change scores, 2013 - 2015	Label	Self-Care	Mobility
HCC Condition			
Other HCCs	Other HCCs with baseline average TNC change scores greater than the lowest quarter in either Self-Care or Mobility	1.40	0.44
HCC78	Parkinson's and Huntington's Diseases	1.10	0.37
HCC173	Traumatic Amputations and Complications	1.05	0.33
HCC140	Unspecified Renal Failure	1.05	0.31
HCC161	Chronic Ulcer of Skin, Except Pressure	1.02	0.32
HCC100	Ischemic or Unspecified Stroke	0.99	0.32
HCC77	Multiple Sclerosis	0.99	0.33
HCC17	Diabetes with Acute Complications	0.99	0.31
HCC52	Dementia Without Complication	0.96	0.34
HCC57	Schizophrenia	0.94	0.31

---

[19] See OASIS Assessment Form D available here.

Baseline average TNC change scores, 2013 - 2015	Label	Self-Care	Mobility
HCC76	Muscular Dystrophy	0.94	0.32
HCC159	Pressure Ulcer of Skin with Partial Thickness Skin Loss	0.93	0.31
HCC8	Metastatic Cancer and Acute Leukemia	0.92	0.27
HCC158	Pressure Ulcer of Skin with Full Thickness Skin Loss	0.89	0.30
HCC51	Dementia With Complications	0.86	0.32
HCC74	Cerebral Palsy	0.78	0.28
HCC110	Cystic Fibrosis	0.75	0.22
HCC71	Paraplegia	0.70	0.25
HCC157	Pressure Ulcer of Skin with Necrosis Through to Muscle, Tendon, or Bone	0.64	0.22
HCC73	Amyotrophic Lateral Sclerosis and Other Motor Neuron Disease	0.52	0.17
HCC70	Quadriplegia	0.43	0.17

Count of HCCs Present at the SOC: This *variable* was calculated by taking the sum of OASIS-based HCC *indicators* the at the start of the OASIS episode (previously described *above in the HCC indicators paragraph*).

ESRD indicator: A home health episode level ESRD status was defined as either having an unfailed kidney transplant at the start of home health episode or having a dialysis claim during the 365 days before the home health episode begins. Dialysis claims were defined as facility type code equal to 7 and service classification type equal to 2 (i.e., first 2 digits of type of bill equals to 72). Acute kidney injury (AKI) dialysis claims were excluded if HCPCS code equals to G0491 or claim-related condition code equals to 84. Similar to HCC score and HCC indicators, ESRD status was defined for the first episode in the sequence, and the same value was used for second and later episodes in the sequence.

For home health utilization analyses for the Medicare FFS population, the variable ESRD_IND in the MBSF was exclusively used.

FFS 12 months before home health episode start: In a given month, a beneficiary was determined to be enrolled in "full" Medicare FFS if they were enrolled in both Parts A and Part B (including dually eligible beneficiaries with enrollment in both Medicare and Medicaid), and were concurrently not enrolled in an HMO. Based on this definition, monthly indicator variables were created to determine a beneficiary's full FFS enrollment status based on MBSF monthly enrollment indicators. Then a FFS 12 month indicator was created if a beneficiary was full FFS for all 12 months prior to the home health episode start (including the month of home health start date).

PDGM Case-Mix Group of an Episode. For home health services beginning on or after January 1, 2020, CMS implemented the PDGM[20], a revised case-mix adjustment methodology that categorized home health episodes into 432 case-mix groups for the purposes of adjusting payment. We applied this PDGM approach back to home health episodes started from January 1, 2013 to December 31, 2019. In particular, home health episodes are placed into different subgroups for each of the following broad categories:

- Admission source. Per CMS PDGM rule, each home health episode was classified into one of two admission source categories: "community" or "institutional", depending on what healthcare setting was utilized in the 14 days prior to home health. The PDGM defines acute stays as inpatient ACHs and post-acute stays as inpatient psychiatric facility (IPF) stays, SNF stays, inpatient rehabilitation facility (IRF) stays, or long-term care hospital (LTCH) stays. Any home health episodes with acute stays within 14-days prior to a home health admission was designated as institutional admissions (For example, if the home health episode started on 01/15/2019, the lookback period was 01/01/2019-01/15/2019.). A post-acute stay in the 14 days prior to a 1st home health episode in the sequence or later episodes in the sequence with equal ''admission date'' and ''from date'' (which means the patient had been discharged from home health) would also classified as an institutional admission. All other home health episodes was designated as community admissions. For episodes with institutional admissions, we also recorded the facility type, claim from date and patient discharge status (PTNT_DSCHRG_STUS_CD) of the most recent institutional. Thus, 2 sets of admission sources variables were created, a 2 categorical set and a 6 categorical set:
    - Admission source (2 categories): community or institutional.
    - Admission source (6 categories): community, ACH, IPF, SNF, IRF, or LTCH.
- Admission source (Arbor Research-defined) for frontloading analysis: For the purposes of frontloading analyses, "true" post-institutional episodes were determined based on two criteria: 1) The episode was designated as "institutional" based on PDGM rules above and 2) the institutional claim linked to the HH episode contained a discharge status code[21] of either "06" or "86" indicating the patient was discharged to home health following release from the institution. All episodes not meeting these criteria were designated as community referrals.
- Timing (2 categories): early or late. Timing (early or late) was determined based on if there is a gap of at least 60 days between the end of one home health episode and the start of the next. When there was a gap of at least 60 days, the subsequent home health episode would be classified as being the first episode of a new sequence (and therefore, would be labeled as early). Otherwise, late.
- Clinical grouping (12 subgroups): musculoskeletal rehabilitation; neuro/stroke rehabilitation; wounds; medication management, teaching, and assessment (MMTA) - surgical aftercare; MMTA - cardiac and circulatory; MMTA - endocrine; MMTA - gastrointestinal tract and genitourinary system; MMTA - infectious disease, neoplasms, and blood-forming diseases; MMTA - respiratory; MMTA- other; behavioral health; or complex nursing interventions. The clinical grouping (12 subgroups) of each episode was determined based on the patient's principal diagnosis on the home health claim. The reported principal diagnosis provides

---

[20] See 2019 Final Rule here.
[21] Patient discharge status code obtained from ResDAC Patient Discharge Status Code (FFS).

information to describe the primary reason for which patients are receiving home health services under the Medicare home health benefit.

- Functional impairment level (3 subgroups): low, medium, or high. The functional impairment level (3 subgroups) of each episode was determined based on the following OASIS items: M1800, M1810, M1820, M1830, M1840, M1850, M1860 and M1033.
- Comorbidity adjustment (3 subgroups): none, low, or high based on secondary diagnoses. The comorbidity adjustment category (3 subgroups) of each episode was determined based on the presence of secondary diagnoses on the home health claim.

For each of the PDGM defined variables (except Arbor Research-defined admission source for frontloading analysis), we focused on the first episode in the sequence only and used the information from first home health episode for second and subsequent home health episodes in the sequence. More details about the complete PDGM rules can be found in the home health Final Rule.[20]

COVID-19 Indicators

COVID-19 risk-adjustment indicator. We used the earliest claim from date (of any claim type) for a Medicare FFS home health beneficiary with a COVID-19 diagnosis (ICD-10 B97.29 or U07.1) on or after January 1, 2020, which falls between 90 days prior to the home health episode start date and up to 30 days after the home health episode end date. New COVID-19 diagnoses are categorized into five, 30-day periods around home health episodes ending during the calendar month in 2020 and 2021. The categories are: (1) 61-90 days before the home health episode start date; (2) 31-60 days before the home health episode start date; (3) 1-30 days before the home health episode start date; (4) during home health episode; (5) 1-30 days following the home health episode end date.

Regional rates of COVID-19 hospitalizations. Includes any inpatient claim for a Medicare FFS beneficiary with a COVID-19 diagnosis (ICD-10 B97.29 or U07.1) that occurs during the calendar month in 2020 and 2021. The denominator includes all Medicare FFS beneficiaries enrolled in full FFS or Part A only, that are alive during the calendar month. Each beneficiary is assigned to the county of their home residence as reported in the MBSF. COVID-19 county level rates were calculated monthly by dividing the total number of inpatient stays with a COVID-19 diagnosis by the total number of FFS beneficiaries multiplied by 10,000. Monthly COVID-19 county level rates were then linked to home health episodes based on the month of the home health episode end date and the county of home health beneficiary address.

Regional rates of COVID-19 obtained from USAfacts.org Monthly, county-level COVID-19 incidence rates per 100,000 population, derived from publicly available cumulative daily cases counts aggregated directly from state and local health departments. Cumulative cases at the end of a given month were subtracted from cumulative cases on the last day of the previous month to determine case counts for that month. Monthly case counts were divided by publicly available county-level population counts, and case rates were multiplied by 100,000. For additional detail on aggregation of daily case counts, see methodology from USAFacts.[22] For the purposes of model covariate adjustment, year-specific regional rates were first linked with home health episodes and then categorized into three groups: rates less than 25th percentile, 25th to less than 75th percentile and greater than or equal to 75th percentiles.

---

[22] USAFacts available here.

HCC indicators and HCC risk scores for all FFS beneficiaries. To evaluate the risk level of all FFS beneficiaries, we calculated annual HCCs and HCC risk scores for all beneficiaries in the MBSFs for the calendar years (CYs) 2012 through 2021. We calculated these scores using the same methods we used to calculate home health episode-level scores, as described above in section A.2.1.2.

A.2.1.3   HHA Characteristics

Total Number of HHAs. Home health claims and OASIS episodes of care were used to generate a list of all unique HHAs with at least one home health claim or OASIS episode of care in a specified time period.

Ownership. Using publicly available CMS Provider of Services (POS) data, HHAs were categorized as for-profit, non-profit, or government-owned, conditional on control type. From the provider data, control type is recoded as "non-profit" (control type codes 1,2,3), "for-profit" (control type code 4), and "government-owned" (control type codes 5,6,7).

Setting: Hospital-Based vs. Freestanding. Using publicly available CMS POS data, HHAs were categorized as freestanding or hospital-based conditional on facility type. From the provider data, facility type is recoded as "freestanding" (facility type codes 1,2,3,7) or "hospital-based" (facility type codes 4,5,6).

HHA Age. HHA age was calculated for each episode based on the floored (i.e., rounding down to nearest integer) year difference between HHA original participation date and the episode start date (for claims-based episodes) or end date (for OASIS-based episodes). Categorical variables were also created for HHA age at 0~3 years, 4~10 years, and more than 10 years.

Chain Membership. HHA chain membership was determined for each individual year from 2013-2021 using two sources: Provider Enrollment, Chain, and Ownership System (PECOS) and HHA Cost Report data. Using Cost Report data, chain affiliation was determined using the information reported on Line 29 of Worksheet S-2 for a given FY. Extraction of PECOS chain affiliation data are described in Section A.3.8 below. PECOS-based chain affiliation data were assessed for any year in which the HHA was enrolled in Medicare (via the PECOS enrollment parent table) at the end of the CY. If the HHA met this condition and was also under ownership of a chain at the end of the CY, then the HHA was considered to be affiliated with a chain for that year. If the HHA was enrolled in Medicare at the end of the CY and was not under ownership of a chain at the end of the CY, then the HHA was not considered to be affiliated with a chain for that year. If the HHA did not have PECOS enrollment data covering the end of the CY, then chain affiliation based on PECOS data was considered missing.

Using the processed Cost Reports and PECOS, an agency was assigned chain membership if either data source indicated chain membership for the given year. If both sources indicated that the agency was not a chain, or if one source indicated not a chain and the other was missing, then the agency was assigned a non-chain status. If both sources were missing, then the prior year and following year were checked, and if the agency had the same status before and after, that status was assigned (e.g., if an HHA is chain in 2013, missing in 2014, and chain in 2015, their 2014 status would be set to "chain").

For this report, we only updated an HHA's chain affiliation indicator for 2021 based on updated cost report and PECOS data, as of July 2022; therefore, the chain affiliation indicator for an HHA in each of the years from 2013 through 2019 has been held constant from the previous Annual Report. We made this decision in order to mitigate the impact of inaccurate changes to historic provider enrollment and

chain affiliation data that are introduced in sequential updates to the PECOS data, which we describe in further detail in Section A.3.8. For the year 2020, the chain affiliation indicator for most HHAs has been held constant from the previous Annual Report; however, we found a few instances of chain affiliation indicators for 2020 that were not properly updated in the previous Annual Report. These 2020 indicators were updated for this report.

Newly available chain name information enabled us to enhance the chain status determination for this report. We used manual web searches and SAS automation to standardize the reported chain name and therefore increase the accuracy of our chain status assignment. Using the clean, standardized chain names, we added "Undetermined" to our chain status assignments of "Yes", "No" or "Missing". Agencies were classified as "Undetermined" if their chain names were linked to only a single agency in any given year (e.g., a potential "false positive" chain) or if a self-reported chain-affiliated agencies did not have a chain name.

HHA Size. HHA size was determined at an annual level by counting the number of OASIS episodes of care that end within a given year. Agencies were then further grouped into mutually exclusive categories based on the number of episodes they provided:

- 1-59 episodes
- 60-249 episodes
- 250-499 episodes
- 500-999 episodes
- 1000+ episodes

Profitability. Profitability measures the Medicare profit margin for agencies. The measure was defined as the difference between total Medicare payments for prospective payment system episodes and the total costs of Medicare services, including drugs and DME, divided by total Medicare payments for prospective payment system episodes, (payments – costs)/payments. Medicare payments and costs were taken from Medicare HHA and Hospital Cost Reports for freestanding and hospital-based agencies, respectively. Because cost reports may contain missing or extreme values, CMS, the Medicare Payment Advisory Commission (MedPAC), and others commonly trim the population of home health cost reports for statistical analysis. Leveraging both longitudinal and cross-sectional information from the cost reports, we utilized a trimming methodology previously employed by CMS to account for extreme values identify inconsistencies between cost reporting periods as well as missing, aberrant, and implausible cost report values.[23] Given differences in cost structure and cost reporting between HHAs in freestanding and hospital settings, we restricted the trimmed sample used for our analysis to freestanding HHAs, which represent the vast majority of HHAs in HHVBP states. To control for extreme values within our trimmed sample, we categorized freestanding home health agencies based on their reported profit margins and use the median, rather than the mean, as a measure of central tendency.

---

[23] Abt Associates. (2013) Analyses in Support of Rebasing & Updating Medicare Home Health Payment Rates; Prepared for the Centers for Medicare and Medicaid Services. Available here.

A.2.2 Claims-Based Impact Measures

This section presents how the claims-based measures were created. Of note, the bottom row of each table notes the data source(s) used to create the impact measure. Each of the impact measures, episode-level numerator and denominator indicators were merged with other variables to create the analytic file (Sections A.5.2 and A.5.4) that was used to conduct the analyses and produce the results presented in the report.

Exhibit A-45. Average Number of HH Days of Care per FFS Beneficiary

Measure Concept	Definition
Measure Category	Quality
Measure Description	Number of claims-based HH days of care in a given year per FFS beneficiary alive at the beginning of the year.
Measure Numerator	Total number of days of HH care from claims-based HH episodes starting in the year.
Numerator Details	Numerator includes days calculated from claim start and end dates from all claims-based HH episodes of all types (LUPAs, outliers, PEPs, etc.) irrespective of whether they are first, second, or higher in the sequence, starting in a given year.
Measure Denominator	Total number of Medicare-eligible FFS beneficiaries alive at the beginning of the given year.
Denominator Details	Total number of Medicare-eligible FFS beneficiaries alive at the beginning of the year (e.g., if a beneficiary is no longer FFS next month, they are still included) is obtained.
Data Sources	MBSF, HHA Claims

Exhibit A-46. Percent of FFS Beneficiaries with at Least One HH Episode

Measure Concept	Definition
Measure Category	Quality
Measure Description	Percent of Medicare-eligible FFS beneficiaries with at least one claims-based HH episode in a given year indicating the beneficiary used HH services.
Measure Numerator	Claims-based HH episodes starting in the year.
Numerator Details	Total number of Medicare-eligible FFS beneficiaries with at least one claims-based HH episode starting in a given year.
Measure Denominator	Total number of Medicare-eligible FFS beneficiaries alive at the beginning of the given year.
Denominator Details	Total number of Medicare-eligible FFS beneficiaries alive at the beginning of the year (e.g., if a beneficiary is no longer FFS next month, they are still included).
Data Sources	MBSF, HHA Claims

Exhibit A-47. Average Medicare Spending per Day during and following FFS Home Health Episodes of Care

Measure Concept	Definition
Measure Category	Spending
Measure Description	Pre-PDGM: Average Medicare Part A and Part B payments (or "Expenditure Components" listed below) per day during and up to 37 days following HH episodes of care. This measure includes payments that occur between the start of the HH episode (SOC) and a 37-day look-out period following the last HH visit (end of care [EOC]) or until the start of the next HH episode that begins on or before the 37th day or until

Measure Concept	Definition
	death, or loss of FFS Part A eligibility; whichever comes earlier. The length of the look-out period (37-day) is composed of 7 days post last HH visit and additional 30 days thereafter or until the start of the next HH episode that begins on or before the 37th day or until death or loss of FFS Part A eligibility; whichever comes earlier.
	Post-PDGM:
	Average Medicare Part A and Part B payments (or "Expenditure Components" listed below) per day during and up to 30 days following HH episodes of care. This measure includes payments that occur between the start of the HH episode (SOC) and the 59th day after the SOC, the start of the next HH episode, death, or loss of FFS Part A eligibility; whichever comes earlier.
Measure Numerator	Pre-PDGM:
	Total Medicare Part A and Part B payments (or "Expenditure Components" listed below) between the SOC and a 37-day look-out period following the last HH visit EOC or until the start of the next HH episode that begins on or before the 37th day or until death, or loss of FFS Part A eligibility; whichever comes earlier.
	Post-PDGM:
	Total Medicare Part A and Part B payments (or "Expenditure Components" listed below) between the SOC and the 59th day after the SOC, the start of the next HH episode, death, or loss of FFS Part A eligibility; whichever comes earlier.
Numerator Details	Pre-PDGM:
	Sum of Medicare payments on all Part A and Part B claims (or "Expenditure Components" listed below) with a claim start date (i.e., based on "CLM_FROM_DT") occurring between the SOC and a 37-day look-out period following the last HH visit (EOC) or until the start of the next HH episode that begins on or before the 37th day or until death or loss of FFS Part A eligibility; whichever comes earlier. Where applicable, the 37-day look-out period following the EOC is truncated to prevent possible double counting of payments for claims that occur during a subsequent HH episode beginning during this 37-day period.
	Post-PDGM:
	Sum of Medicare payments on all Part A and Part B claims (or "Expenditure Components" listed below) with a claim start date (i.e., based on "CLM_FROM_DT") occurring between the SOC and the 59th day after the SOC, the start of the next HH episode, death, or loss of FFS Part A eligibility; whichever comes earlier. Where applicable, the look-out period is truncated to prevent possible double counting of payments for claims that occur during a subsequent HH episode beginning during this period.
Measure Denominator	Pre-PDGM:
	Total number of eligible days accrued during and in periods of up to 37 days following the last HH visit date of all HH FFS episodes starting in a given calendar quarter.
	Post-PDGM:
	Total number of eligible days accrued during and in periods of up to 30 days following all HH FFS episodes starting in a given calendar quarter.
Denominator Details	Pre-PDGM:
	Denominator includes all days occurring between the SOC and a 37-day look-out period following the last HH visit (EOC) or until the start of the next HH episode that begins on or before the 37th day or until death, or loss of FFS Part A eligibility, for HH episodes of all types (LUPAs, outliers, PEPs, etc.) starting in a given calendar quarter, irrespective of whether they are first, second, or higher episodes in a sequence. HH episodes are excluded in the absence of a HH visit date. The maximum number of days that can be included in the denominator is 97 days for a

Measure Concept	Definition
	60-day episode of care (60 + 37 days), unless the last HH visit date occurs before the HH episode claim end date and/or a subsequent HH episode, death, or loss of FFS Part A eligibility occurs prior to the end of the 37-day look–out period. Post-PDGM: Denominator includes all days occurring between the SOC and the 59th day after the SOC, the start of the next HH episode, death, or loss of FFS Part A eligibility, for HH episodes of all types (LUPAs, outliers, PEPs, etc.) starting in a given calendar quarter, irrespective of whether they are first, second, or higher episodes in a sequence. HH episodes are excluded in the absence of a HH visit date. The maximum number of days that can be included in the denominator is 60 days for a 30-day episode of care (30 + 30 days), unless a subsequent HH episode, death, or loss of FFS Part A eligibility occurs prior to the end of the 30-day episode or 30-day look-out period.
Expenditure Components	Besides the total Medicare Part A and Part B spending measure, we repeated the same calculation for each individual expenditure component, including: Medicare Part B carrier and DME combined, HH, Hospice, Inpatient, Outpatient ED and Observation Stays, other Outpatient, Outpatient types combined, and SNF and obtained average Medicare spending per day during and following FFS home health episodes of care for each of the expenditure components.
Data Sources	Medicare Part B carrier, DME, HH, Hospice, Inpatient, Outpatient, and SNF claims.

This measure along with each of the components were individually capped at both the lower and upper ends to reduce the influence of extreme expenditure outliers. For each year, the measure was capped at the 99th percentile of the unweighted spending per-day measure (i.e., any values greater than 99th percentile were set to the 99th percentile value), and any negative payment values were set to zero dollars. The post-PDGM spending measure definition was applied retrospectively to 60-day HH episodes from 2013-19 (all Medicare payments between the SOC and the 89th day after the SOC, the start of the next HH episode, death, or loss of FFS Part A eligibility; whichever comes earlier) in order to draw accurate inferences about the impacts in 2020-2021, following the implementation of the PDGM.

Exhibit A-48. Average Medicare Spending per Day during FFS Home Health Episodes of Care

Measure Concept	Definition
Measure Category	Spending
Measure Description	Pre-PDGM: Average Medicare Part A and Part B payments (or "Expenditure Components" listed below) per day during HH episodes of care. This measure includes payments that occur between the SOC and a 7-day look-out period following the last HH visit (EOC) or until the start of the next HH episode that begins on or before the 7th day or until death or loss of FFS Part A eligibility; whichever comes earlier. Post-PDGM: Average Medicare Part A and Part B payments (or "Expenditure Components" listed below) per day during HH episodes of care. This measure includes payments that occur between the SOC and the 29th day after the SOC, the start of the next HH episode, death, or loss of FFS Part A eligibility; whichever comes earlier.
Measure Numerator	Pre-PDGM: Total Medicare Part A and Part B payments (or "Expenditure Components" listed below) between the SOC and a 7-day look-out period following the last HH visit (EOC) or until the start of the next HH episode that begins on or before the 7th day or until death or loss of FFS Part A eligibility; whichever comes earlier. Post-PDGM:

Measure Concept	Definition
	Total Medicare Part A and Part B payments (or "Expenditure Components" listed below) between the SOC and the 29th day after the SOC, the start of the next HH episode, death, or loss of FFS Part A eligibility; whichever comes earlier.
Numerator Details	Pre-PDGM: Sum of Medicare payments on all Part A and Part B claims (or "Expenditure Components" listed below) with a claim start date (i.e., based on "CLM_FROM_DT") occurring between the SOC and a 7-day look-out period following the last HH visit (EOC) or until the start of the next HH episode that begins on or before the 7th day or until death or loss of FFS Part A eligibility; whichever comes earlier. Where applicable, the 7-day look-out period following the EOC is truncated to prevent possible double counting of payments for claims that occur during a subsequent HH episode beginning during this 7-day period. Post-PDGM: Sum of Medicare payments on all Part A and Part B claims (or "Expenditure Components" listed below) with a claim start date (i.e., based on "CLM_FROM_DT") occurring between the SOC and the 29th day after the SOC, the start of the next HH episode, death, or loss of FFS Part A eligibility; whichever comes earlier. Where applicable, the look-out period is truncated to prevent possible double counting of payments for claims that occur during a subsequent HH episode beginning during this period.
Measure Denominator	Total number of eligible days accrued from all HH FFS episodes starting in a given calendar quarter.
Denominator Details	Pre-PDGM: Denominator includes all days occurring between the SOC and a 7-day look-out period following the last HH visit (EOC) or until the start of the next HH episode that begins on or before the 7th day or until death, or loss of FFS Part A eligibility, for HH episodes of all types (LUPAs, outliers, PEPs, etc.) starting in a given calendar quarter, irrespective of whether they are first, second, or higher episodes in a sequence. HH episodes are excluded in the absence of a HH visit date. The maximum number of days that can be included in the denominator is 67 days for a 60-day episode of care (60 + 7 days), unless the last HH visit date occurs before the HH episode claim end date and/or a subsequent HH episode, death, or loss of FFS Part A eligibility occurs prior to the end of the 7-day look-out period. Post-PDGM: Denominator includes all days occurring between the SOC and the 29th day after the SOC, the start of the next HH episode, death, or loss of FFS Part A eligibility, for HH episodes of all types (LUPAs, outliers, PEPs, etc.) starting in a given calendar quarter, irrespective of whether they are first, second, or higher episodes in a sequence. HH episodes are excluded in the absence of a HH visit date. The maximum number of days that can be included in the denominator is 30 days for a 30-day episode of care, unless a subsequent HH episode, death, or loss of FFS Part A eligibility occurs prior to the end of the look-out period.
Expenditure Components	Besides the total Medicare Part A and Part B spending measure, we repeated the same calculation for each individual expenditure component, including: Medicare Part B carrier and DME combined, HH, Hospice, Inpatient, Outpatient ED and Observation Stays, other Outpatient, Outpatient types combined, and SNF and obtained average Medicare spending per day <u>during</u> FFS home health episodes of care for each of the expenditure components.
Data Sources	Medicare Part B carrier, DME, HH, Hospice, Inpatient, Outpatient, and SNF claims.

This measure along with each of the components were individually capped at both the lower and upper ends
to reduce the influence of extreme expenditure outliers. For each year, the measure was capped at the 99th

percentile of the unweighted spending per-day measure (i.e., any values greater than 99th percentile were set to the 99th percentile value), and any negative payment values were set to zero dollars. The post-PDGM spending measure definition is applied retrospectively to 60-day HH episodes from 2013-19 (all Medicare payments between the SOC and the 59th day after the SOC, the start of the next HH episode, death, or loss of FFS Part A eligibility; whichever comes earlier) in order to draw accurate inferences about the impacts following the implementation of the PDGM.

Exhibit A-49. Average Medicare Spending per Day following FFS Home Health Episodes of Care

Measure Concept	Definition
Measure Category	Spending
Measure Description	Pre-PDGM: Average Medicare Part A and Part B payments (or "Expenditure Components" listed below) per day that occur after the 7th day following the last HH visit (EOC) and over the subsequent 30 days or until the start of the next HH episode that begins on or before the 30th day or until death or loss of FFS Part A eligibility; whichever comes earlier. Post-PDGM: Average Medicare Part A and Part B payments (or "Expenditure Components" listed below) per day that occur after the 29th day following the SOC and over the subsequent 30 days or until the start of the next HH episode, death, or loss of FFS Part A eligibility; whichever comes earlier.
Measure Numerator	Pre-PDGM: Total Medicare Part A and Part B payments (or "Expenditure Components" listed below) within 30 days following the 7th day after the last HH visit (EOC) or until the start of the next HH episode that begins on or before the 30th day or until death or loss of FFS Part A eligibility; whichever comes earlier. Post-PDGM: Total Medicare Part A and Part B payments (or "Expenditure Components" listed below) within the 30 days following the 29th day after the SOC, or until the start of the next HH episode, death, or loss of FFS Part A eligibility; whichever comes earlier.
Numerator Details	Pre-PDGM: Sum of Medicare payments on all Part A and Part B claims (or "Expenditure Components" listed below) with a claim start date (i.e., based on "CLM_FROM_DT") occurring within 30 days following the 7th day after the last HH visit (EOC) or until the start of the next HH episode that begins on or before the 30th day or until death or loss of FFS Part A eligibility; whichever comes earlier. Where applicable, the 30-day downstream period is truncated to prevent possible double counting of payments for claims that occur during a subsequent HH episode beginning during this 30-day period. Post-PDGM: Sum of Medicare payments on all Part A and Part B claims (or "Expenditure Components" listed below) with a claim start date (i.e., based on "CLM_FROM_DT") occurring within the 30 days following the last 29th day of the HH episode after the SOC, or until the start of the next HH episode, that begins on or before the 30th day of the look-out period or until death, or loss of FFS Part A eligibility; whichever comes earlier. Where applicable, the 30-day downstream period is truncated to prevent possible double counting of payments for claims that occur during a subsequent HH episode beginning during this 30-day period.

Measure Concept	Definition
Measure Denominator	Pre-PDGM: Total number of eligible days accrued from periods of up to 30 days that occur after the 7th day following the last HH visit date of HH FFS episodes starting in a given calendar quarter. Post-PDGM: Total number of eligible days accrued from periods of up to 30 days that occur after the 29th day following the SOC of HH FFS episodes starting in a given calendar quarter.
Denominator Details	Pre-PDGM: Denominator includes all days accrued from periods following the 7th day after the last HH visit date, for HH episodes of all types (LUPAs, outliers, PEPs, etc.) starting in a given calendar quarter, irrespective of whether they are first, second, or higher episodes in a sequence. HH episodes are excluded if: 1. There are no HH visit dates reported. 2. A measurement time period is not available since the claim start date ("CLM_FROM_DT") on a subsequent HH episode, date of death, or loss of FFS Part A eligibility does not exceed the last HH visit date of the HH episode by more than 1 day. The maximum number of days that can be included in the denominator is 30 days, unless a subsequent HH episode, death, or loss of FFS Part A eligibility occurs prior to the end of the 30-day downstream period. Post-PDGM: Denominator includes all days accrued from periods following the 29th day after the SOC, regardless of type (LUPAs, outliers, PEPs, etc.), starting in a given calendar quarter, irrespective of whether they are first, second, or higher episodes in a sequence. HH episodes are excluded if: 1. There are no HH visit dates reported. 2. A measurement time period is not available since the claim start date ("CLM_FROM_DT") on a subsequent HH episode, date of death, or loss of FFS Part A eligibility does not exceed the 30th day of the HH episode by more than 1 day. The maximum number of days that can be included in the denominator is 30 days, unless a subsequent HH episode, death, or loss of FFS Part A eligibility occurs prior to the end of the 30-day downstream period.
Expenditure Components	Besides the total Medicare Part A and Part B spending measure, we repeated the same calculation for each individual expenditure component, including: Medicare Part B carrier and DME combined, Hospice, Inpatient, Outpatient ED and Observation Stays, other Outpatient, Outpatient types combined, and SNF and obtained average Medicare spending per day following FFS home health episodes of care for each of the expenditure components.
Data Sources	Medicare Part B carrier, DME, Hospice, Inpatient, Outpatient, and SNF claims.

This measure along with each of the components were individually capped at both the lower and upper ends to reduce the influence of extreme expenditure outliers. For each year, the measure was capped at the 99th percentile of the unweighted spending per-day measure (i.e., any value greater than 99th percentile were set to the 99th percentile value), and any negative payment values were set to zero dollars. The post-PDGM spending measure definition is applied retrospectively to 60-day HH episodes from 2013-19 (all Medicare payments that occur after the 59th day following the SOC and over the subsequent 30 days or until the start

of the next HH episode, death, or loss of FFS Part A eligibility; whichever comes earlier) in order to draw accurate inferences about the impacts following the implementation of the PDGM.

Exhibit A-50. Outpatient ED Use (No Hospitalization)/First FFS Home Health Episodes

This impact measure is similar to the HHVBP measure, "Emergency Department Use without Hospitalization". [24] However, unlike the HHVBP measure, it is not risk adjusted.

Measure Concept	Definition
Measure Category	Quality
Measure Description	Percentage of HH stays in which patients used the ED but were not admitted to the hospital during the 60 days following the start of the HH stay.
Measure Numerator	Number of HH stays for patients who have a Medicare claim for outpatient ED use and no claims for ACH in the 60 days following the start of the HH stay.
Numerator Details	The 60-day time window is calculated by adding 60 days to the "from" date in the first HH claim in the series of HH claims that comprise the HH stay. If the patient has at least one Medicare outpatient claim with any emergency room revenue center codes (0450-0459, 0981) during the 60-day window AND if the patient has no Medicare inpatient claims for admission to an acute care hospital (identified by the CMS Certification Number [CCN] on the inpatient claim ending in 0001-0879, 0800-0899, or 1300-1399) during the 60-day window, then the stay is included in the measure numerator.
Measure Denominator	Number of HH stays that begin during the 12-month observation period. A HH stay is a sequence of HH payment episodes separated from other HH payment episodes by at least 60 days.
Denominator Details	See below for exclusions about HH stay construction. 1. HH stays for patients who are not continuously enrolled in Medicare FFS for the 60 days following the start of the HH stay or until death. 2. HH stays that begin with a LUPA claim. 3. HH stays in which the patient receives service from multiple agencies during the first 60 days. 4. HH stays for patients who are not continuously enrolled in Medicare FFS for the 6 months prior to the HH stay.

---

[24] See CMS Specifications for Home Health Claims-Based Utilization Measures, "Emergency Department Use without Hospitalization."

Measure Concept	Definition
Condition Specific ED Use	The reason for ED admittance (primary diagnosis code in Medicare outpatient and inpatient claims) was studied over 2013-2021. ICD-9 codes were converted to ICD-10 codes using the CMS General Equivalence Mapping (GEM) tool, and then all years' ICD-10 codes were grouped according to Part C (Chapter-Specific Coding Guidelines) of the ICD-10-CM Official Guidelines for Coding and Reporting FY 2021. Within each year, these groups were ranked by the percentage of ED visits whose primary diagnosis code they represented. ED visits whose diagnoses were classified as Chapter 18 (symptoms, signs, and abnormal clinical and laboratory findings, not elsewhere classified), were further categorized, grouping primary diagnosis codes in these visits by their first three characters (i.e. R00-R99). With the denominator and numerator calculation remaining the same, 17 condition specific ED use measures were identified using all populated diagnosis codes in Medicare outpatient and inpatient claims: 1. Chapter 4 (Endocrine, nutritional and metabolic diseases) 2. Chapter 6 (Diseases of the nervous system) 3. Chapter 9 (Diseases of the circulatory system) 4. Chapter 10 (Diseases of the respiratory system) 5. Chapter 11 (Diseases of the digestive system) 6. Chapter 12 (Diseases of the skin and subcutaneous tissue) 7. Chapter 13 (Diseases of the musculoskeletal system and connective tissue) 8. Chapter 14 (Diseases of the genitourinary system) 9. Chapter 19 (Injury, poisoning and certain other consequences of external causes) 10. Chapter 18, R07 (Pain in throat and chest) 11. Chapter 18, R10 (Abdominal and pelvic pain) 12. Chapter 18, R55 (Syncope and collapse) 13. Chapter 18, R53 (Malaise and fatigue) 14. Chapter 18, R06 (Dyspnea) 15. Chapter 18, R41 (Cognitive functions and awareness) 16. Chapter 18, R11 (Nausea and vomiting) 17. All other Chapter 18 diagnoses All diagnosis codes with the exception of the above list were categorized as Other ED Use.
Data Sources	Claims Predicted Probability file

Exhibit A-51. Inpatient ED Use/First FFS Home Health Episodes

Measure Concept	Definition
Measure Category	Quality
Measure Description	Percentage of HH stays in which patients used the inpatient ED services during the 60 days following the start of the HH stay.
Measure Numerator	Number of HH stays for patients who have a Medicare claim for inpatient ED use in the 60 days following the start of the HH stay.

Measure Concept	Definition
Numerator Details	The 60-day time window is calculated by adding 60 days to the "from" date in the first HH claim in the series of HH claims that comprise the HH stay. If the patient has at least one Medicare inpatient claim with any emergency room revenue center codes (0450-0459, 0981) during the 60-day window, then the stay is included in the measure numerator.
Measure Denominator	Number of HH stays that begin during the 12-month observation period. A HH stay is a sequence of HH payment episodes separated from other HH payment episodes by at least 60 days.
Denominator Details	See below for exclusions about HH stay construction. 1. HH stays for patients who are not continuously enrolled in Medicare FFS for the 60 days following the start of the HH stay or until death. 2. HH stays that begin with a LUPA claim. 3. HH stays in which the patient receives service from multiple agencies during the first 60 days. 4. HH stays for patients who are not continuously enrolled in Medicare FFS for the 6 months prior to the HH stay.
Condition Specific ED Use	The reason for ED admittance (primary diagnosis code in Medicare outpatient and inpatient claims) was studied over 2013-2021. ICD-9 codes were converted to ICD-10 codes using the CMS GEM tool, and then all years' ICD-10 codes were grouped according to Part C (Chapter-Specific Coding Guidelines) of the ICD-10-CM Official Guidelines for Coding and Reporting FY 2021. Within each year, these groups were ranked by the percentage of ED visits whose primary diagnosis code they represented. ED visits whose diagnoses were classified as Chapter 18 (symptoms, signs, and abnormal clinical and laboratory findings, not elsewhere classified), were further categorized, grouping primary diagnosis codes in these visits by their first three characters (i.e. R00-R99). With the denominator and numerator calculation remaining the same, 17 condition specific ED use measures were identified using all populated diagnosis codes in Medicare outpatient and inpatient claims: 18. Chapter 4 (Endocrine, nutritional and metabolic diseases) 19. Chapter 6 (Diseases of the nervous system) 20. Chapter 9 (Diseases of the circulatory system) 21. Chapter 10 (Diseases of the respiratory system) 22. Chapter 11 (Diseases of the digestive system) 23. Chapter 12 (Diseases of the skin and subcutaneous tissue 24. Chapter 13 (Diseases of the musculoskeletal system and connective tissue) 25. Chapter 14 (Diseases of the genitourinary system) 26. Chapter 19 (Injury, poisoning and certain other consequences of external causes) 27. Chapter 18, R07 (Pain in throat and chest) 28. Chapter 18, R10 (Abdominal and pelvic pain) 29. Chapter 18, R55 (Syncope and collapse) 30. Chapter 18, R53 (Malaise and fatigue) 31. Chapter 18, R06 (Dyspnea) 32. Chapter 18, R41 (Cognitive functions and awareness) 33. Chapter 18, R11 (Nausea and vomiting) 34. All other Chapter 18 diagnoses

Measure Concept	Definition
	All diagnosis codes with the exception of the above list were categorized as Other ED Use.
Data Sources	MBSF, HHA Claims, Inpatient Claims. Enrollment status and beneficiary death date are obtained from MBSF.

Exhibit A-52. Outpatient and Inpatient ED Use/First FFS Home Health Episodes

Measure Concept	Definition
Measure Category	Quality
Measure Description	Percentage of HH stays in which patients used either the outpatient ED services or the inpatient ED services during the 60 days following the start of the HH stay.
Measure Numerator	Number of HH stays for patients who have a Medicare claim for either outpatient ED use or inpatient ED use in the 60 days following the start of the HH stay.
Numerator Details	The 60-day time window is calculated by adding 60 days to the "from" date in the first HH claim in the series of HH claims that comprise the HH stay. If the patient has at least one Medicare outpatient claim or inpatient claim with any emergency room revenue center codes (0450-0459, 0981) during the 60-day window, then the stay is included in the measure numerator.
Measure Denominator	Number of HH stays that begin during the 12-month observation period. A HH stay is a sequence of HH payment episodes separated from other HH payment episodes by at least 60 days.
Denominator Details	See below for exclusions about HH stay construction. 1. HH stays for patients who are not continuously enrolled in Medicare FFS for the 60 days following the start of the HH stay or until death. 2. HH stays that begin with a LUPA claim. 3. HH stays in which the patient receives service from multiple agencies during the first 60 days. 4. HH stays for patients who are not continuously enrolled in Medicare FFS for the 6 months prior to the HH stay.
Data Sources	MBSF, HHA Claims, Inpatient Claims, Outpatient claims. Enrollment status and beneficiary death date are obtained from MBSF.

Exhibit A-53. Outpatient ED and Observation Stay Use (No Hospitalization)/First FFS Home Health Episodes

Measure Concept	Definition
Measure Category	Quality
Measure Description	Percentage of HH stays in which patients used the ED or observation stays but were not admitted to the hospital during the 60 days following the start of the HH stay.
Measure Numerator	Number of HH stays for patients who have a Medicare claim for outpatient ED and observation stay use and no claims for ACH in the 60 days following the start of the HH stay.
Numerator Details	The 60-day time window is calculated by adding 60 days to the "from" date in the first HH claim in the series of HH claims that comprise the HH stay. If the patient has at least one Medicare outpatient claim with any emergency room revenue center codes (0450-0459, 0981), observation room revenue center codes (0760-0769), or observation HCPCS codes (99217-99220, 99224-99226, 99234-99236, G0378-G0379) during the 60-

Measure Concept	Definition
	day window AND if the patient has no Medicare inpatient claims for admission to an acute care hospital (identified by the CCN on the inpatient claim ending in 0001-0879, 0800-0899, or 1300-1399) during the 60-day window, then the stay is included in the measure numerator.
Measure Denominator	Number of HH stays that begin during the 12-month observation period. A HH stay is a sequence of HH payment episodes separated from other HH payment episodes by at least 60 days.
Denominator Details	See below for exclusions about HH stay construction. 1. HH stays for patients who are not continuously enrolled in Medicare FFS for the 60 days following the start of the HH stay or until death. 2. HH stays that begin with a LUPA claim. 3. HH stays in which the patient receives service from multiple agencies during the first 60 days. 4. HH stays for patients who are not continuously enrolled in Medicare FFS for the 6 months prior to the HH stay.
Data Sources	MBSF, HHA Claims, Inpatient Claims, Outpatient claims. Enrollment status and beneficiary death date are obtained from MBSF.

Exhibit A-54. Unplanned ACH/First FFS Home Health Episodes

This impact measure is similar to the HHVBP measure, "Acute Care Hospitalization". [25] However, unlike the HHVBP measure, it is not risk adjusted.

Measure Concept	Definition
Measure Category	Quality
Measure Description	Percentage of HH stays in which patients were admitted to an acute care hospital during the 60 days following the start of the HH stay.
Measure Numerator	Number of HH stays for patients who have a Medicare claim for an admission to an acute care hospital in the 60 days following the start of the HH stay. COVID ACH Number of HH stays for patients who have a Medicare claim for an admission to an acute care hospital with a COVID-19 diagnosis (primary or secondary ICD-10 B97.29 or U07.1) in the 60 days following the start of the HH stay.

---

[25] See CMS Specifications for Home Health Claims-Based Utilization Measures, "Acute Care Hospitalization."

Measure Concept	Definition
Numerator Details	The 60-day time window is calculated by adding 60 days to the "from" date in the first HH claim in the series of HH claims that comprise the HH stay. If the patient has at least one Medicare inpatient claim from short term or critical access hospitals (identified by the CCN on the inpatient claim ending in 0001-0879, 0800-0899, or 1300-1399) during the 60-day window, then the stay is included in the measure numerator. Note that planned hospitalizations are excluded from the numerator. COVID ACH The 60-day time window is calculated by adding 60 days to the "from" date in the first HH claim in the series of HH claims that comprise the HH stay. If the patient has at least one Medicare inpatient claim from short term or critical access hospitals (identified by the CCN on the inpatient claim ending in 0001-0879, 0800-0899, or 1300-1399) and a primary or secondary diagnosis with a COVID-19 diagnosis (ICD-10 B97.29 or U07.1) after 2019 during the 60-day window, then the stay is included in the measure numerator. Note that planned hospitalizations are excluded from the numerator.
Measure Denominator	Number of HH stays that begin during the 12-month observation period. An HH stay is a sequence of HH payment episodes separated from other HH payment episodes by at least 60 days. COVID ACH Denominator and the denominator details unchanged
Denominator Details	1. HH stays for patients who are not continuously enrolled in Medicare FFS for the 60 days following the start of the HH stay or until death. 2. HH stays that begin with a LUPA claim. 3. HH stays in which the patient receives service from multiple agencies during the first 60 days. 4. HH stays for patients who are not continuously enrolled in Medicare FFS for the 6 months prior to the HH stay.
Data Sources	Claims Predicted Probability file, Inpatient claims, HHA claims

Exhibit A-55. Unplanned ACH/All FFS Home Health Episodes

Measure Concept	Definition
Measure Category	Quality
Measure Description	Percentage of HH episodes with at least one unplanned admission to an acute care hospital within 60 days of the start of the episode or until the start of the next HH episode that begins on or before the 60th day.
Measure Numerator	Number of HH episodes with at least one unplanned admission to an acute care hospital within 60 days of the start of the episode or until the start of the next HH episode that begins on or before the 60th day. COVID ACH Number of HH episodes with at least one unplanned admission to an acute care hospital with a COVID-19 diagnosis (primary or secondary ICD-10 B97.29 or U07.1) within 60 days of the start of the episode or until the start of the next HH episode that begins on or before the 60th day.

Measure Concept	Definition
Numerator Details	▪ The 60-day time window is calculated by adding 59 days to the "from" date of the HH episode. If a subsequent HH episode starts on or before the 60th day, the time window is ended early on the day prior to the start of the next episode.
	▪ ACH occurs (and the HH episode is included in the numerator) if the patient has at least one Medicare inpatient claim from short-stay or critical access hospitals during the 60-day window.
	▪ Planned hospitalizations (defined by a list of Agency for Healthcare Research and Quality [AHRQ] Procedure and Condition CCS and additional ICD-9-CM procedure codes) are excluded from the measure numerator. The measure specifications, including the AHRQ codes, were pulled from the CMS Home Health Claims-Based Utilization Measures Specifications.[25]
	COVID ACH
	Same as above with the exception that COVID hospitalization occurs (and the HH episode is included in the numerator) if the patient has at least one Medicare inpatient claim from short-stay or critical access hospitals with a primary or secondary diagnosis with a COVID-19 diagnosis (ICD-10 B97.29 or U07.1) during the 60-day window.
Measure Denominator	Total number of eligible HH episodes starting in a given year.
Denominator Details	All HH episodes that start in the quarter are included with the following exclusions:
	▪ HH episodes for patients who are alive and are not continuously enrolled in FFS Medicare for the 60 days following the start of the HH episode.
	▪ HH episodes for patients who were not FFS eligible in the six months prior.
	▪ HH episodes that begin with a LUPA claim.
	▪ HH episodes in which the patient receives service from multiple agencies during the 60-day window (see "Transfer HHAs within 60 days" in Glossary [Section A.6]).
	COVID ACH
	Denominator and the denominator details unchanged
Data Sources	MBSF, HHA Claims, Inpatient Claims.
	Enrollment status and beneficiary death date are obtained from MBSF.

Exhibit A-56. Mortality Rate/All FFS Home Health Episodes

Measure Concept	Definition
Measure Category	Quality
Measure Description	Percentage of HH episodes in which the beneficiary died either 1) within 60 days of the start of the episode or 2) before the start of the next HH episode that begins on or before the 60th day, whichever comes first.
Measure Numerator	Number of HH episodes in which the beneficiary died within 60 days of the start of the episode or until the start of the next HH episode that begins on or before the 60th day.

Measure Concept	Definition
Numerator Details	▪ The 60-day time window is calculated by adding 59 days to the "from" date of the HH episode. If a subsequent HH episode starts on or before the 60th day, the lookout window is ended early on the day prior to the start of the next episode. The truncation of the lookout period, wherever applicable, is done to avoid double counting of the event. ▪ Death occurs (and the HH episode is included in the numerator) if the patient has a non-missing death date during the 60-day window.
Measure Denominator	Total number of eligible HH episodes starting in a given quarter.
Denominator Details	All HH episodes that start in the quarter are included with the following exclusions: ▪ HH episodes for patients who are alive and are not continuously enrolled in FFS Medicare for the 60 days following the start of the HH episode. ▪ HH episodes for patients whose non-missing death date is before the episode start date
Data Sources	MBSF (for enrollment status and beneficiary death date) and HHA Claims.

Exhibit A-57. SNF Use/All FFS HH Episodes

Measure Concept	Definition
Measure Category	Quality
Measure Description	Percentage of HH episodes with at least one admission to a SNF within 60 days of the start of the HH episode or until the start of the next HH episode that begins on or before the 60th day.
Measure Numerator	Number of HH episodes with at least one admission to a SNF within 60 days of the start of the HH episode or until the start of the next HH episode that begins on or before the 60th day.
Numerator Details	▪ The 60-day time window is calculated by adding 59 days to the "from" date of the HH episode. If a subsequent HH episode starts on or before the 60th day, the time window is ended early on the day prior to the start of the next episode. ▪ The SNF admission is counted if the patient has at least one SNF claim during the 60-day window. ▪ SNF admissions following planned ACH (defined by a list of AHRQ Procedure and Condition CCS and additional ICD-9-CM procedure codes) are excluded from the measure numerator under the following conditions: 1. The planned hospitalization starts within the HH episode 60-day window. 2. The planned hospitalization ends within the HH episode 60-day window. 3. The SNF stay starts within the HH episode 60-day window. 4. The SNF stay starts on or after the planned hospitalization end date.
Measure Denominator	Total number of eligible HH episodes starting in a given quarter.
Denominator Details	All HH episodes that start in the quarter are included with the following exclusions: ▪ HH episodes for patients who are alive and are not continuously enrolled in FFS Medicare for the 60 days following the start of the HH episode. ▪ HH episodes for patients who were not FFS eligible in the six months prior. HH episodes that begin with a LUPA claim. HH episodes in which

Measure Concept	Definition
	the patient receives service from multiple agencies during the 60-day window (see "Transfer HHAs within 60 days" in Glossary [[Section A.6]).
Data Sources	HHA Claims, SNF Claims, MBSF, Inpatient RIFs. Enrollment status is identified using the Medicare Enrollment Database.

Exhibit A-58. Home Health Episodes with an Initial COVID-19 Diagnosis (%)

Measure Concept	Definition
Measure Category	COVID-19
Measure Description	Percentage of HH episodes with an initial COVID-19 diagnosis during or within 30 days (before or after) of the episode.
Measure Numerator	Number of HH episodes with an initial COVID-19 diagnosis during or within 30 days (before or after) of the episode.
Numerator Details	We used the earliest claim from date (of any claim type) for a Medicare FFS home health beneficiary with a COVID-19 diagnosis (ICD-10 B97.29 or U07.1) after 2019, which occurs during HH episodes ending during the calendar month in 2020 OR up to 30 days before the HH episode start date without the presence of an earlier HH episode OR up to 30 days after the HH episode end date without the presence of a later HH episode. This includes only the initial COVID-19 diagnosis per home health Medicare FFS beneficiary.
Measure Denominator	Total number of HH episodes ending in a given month
Denominator Details	N/A
Data Sources	HHA, Inpatient, Outpatient, SNF, Hospice, Part B Carrier, and DME claims

Exhibit A-59. Unplanned ACH/All MA OASIS HH Episodes

Measure Concept	Definition
Measure Category	Quality
Measure Description	Percentage of MA HH episodes with at least one unplanned admission to an acute care hospital within 60 days of the start of the OASIS episode or until the start of the next OASIS-based HH episode that begins on or before the 60th day.
Measure Numerator	Using Shadow Claims: Number of OASIS-based HH episodes with at least one unplanned admission to an acute care hospital identified using shadow claims within 60 days of the start of the episode or until the start of the next OASIS-based HH episode that begins on or before the 60th day. Using MA Encounters: Number of OASIS-based HH episodes with at least one unplanned admission to an acute care hospital identified using MA inpatient encounters within 60 days of the start of the episode or until the start of the next OASIS-based HH episode that begins on or before the 60th day.
Numerator Details	▪ The 60-day time window is calculated by adding 59 days to the "from" date of the OASIS-based HH episode. If a subsequent OASIS-based HH episode starts on or before the 60th day, the time window is ended early on the day prior to the start of the next episode. ▪ Planned hospitalizations (defined by a list of AHRQ Procedure and Condition Clinical Classifications Software (CCS) and additional ICD-9-CM procedure codes) are excluded from the measure numerator. The measure specifications, including the

Evaluation of the HHVBP Model
Sixth Annual Report: Technical Appendices

Measure Concept	Definition

	AHRQ codes, were pulled from the CMS Home Health Claims-Based Utilization Measures Specifications.[25]
	
	Shadow Claims
	ACH occurs (and the HH episode is included in the numerator) if the patient has at least one Medicare inpatient *shadow claim* (main analysis) from short-stay or critical access hospitals during the 60-day window.
	    o MA shadow claims are identified from the Medicare Provider Analysis and Review (MedPAR) file using National Claims History (NCH) claim type codes: 62, 63, or 64
	
	MA Encounters
	ACH occurs (and the HH episode is included in the numerator) if the patient has at least one MA Inpatient Encounter (alternate analysis) from short-stay or critical access hospitals during the 60-day window.
	    o ACH status is determined using a crosswalk to link organizational NPI from inpatient encounters to CCN obtained from other FFS inpatient claims. A portion of the remaining inpatient encounters that could not be linked to a CCN were then classified as ACH based on National Plan and Provider Enumeration System (NPPES) taxonomies.
	    o MA inpatient encounter chart reviews were excluded from the measure numerator.

Measure Denominator	Total number of eligible OASIS-based HH episodes starting in a given year.
Denominator Details	OASIS HH episodes included in the denominator where MA enrollment was established at the beginning of the episode using monthly MBSF Medicare HMO indicators (HMO_IND_[two-digit month] = "1", "2", "A", "B", or "C") .
Data Sources	MBSF, OASIS, MedPAR, MA Inpatient Encounters, NPPES (encounters only)

MA: Medicare Advantage

Exhibit A-60. Unplanned ACH/All FFS OASIS HH Episodes

Measure Concept	Definition
Measure Category	Quality
Measure Description	Percentage of HH episodes with at least one unplanned admission to an acute care hospital within 60 days of the start of the OASIS episode or until the start of the next OASIS-based HH episode that begins on or before the 60th day.
Measure Numerator	Number of OASIS-based HH episodes with at least one unplanned admission to an acute care hospital using Medicare claims within 60 days of the start of the episode or until the start of the next OASIS-based HH episode that begins on or before the 60th day.
Numerator Details	▪ The 60-day time window is calculated by adding 59 days to the "from" date of the OASIS-based HH episode. If a

Measure Concept	Definition
	subsequent OASIS-based HH episode starts on or before the 60th day, the time window is ended early on the day prior to the start of the next episode.
	▪ ACH occurs (and the HH episode is included in the numerator) if the patient has at least one Medicare inpatient claim from short-stay or critical access hospitals during the 60-day window.
	▪ Planned hospitalizations (defined by a list of AHRQ Procedure and Condition CCS and additional ICD-9-CM procedure codes) are excluded from the measure numerator. The measure specifications, including the AHRQ codes, were pulled from the CMS Home Health Claims-Based Utilization Measures Specifications.
Measure Denominator	Total number of eligible OASIS-based HH episodes starting in a given year.
Denominator Details	OASIS episodes included in the denominator where Medicare FFS enrollment was established at the beginning of the episode using the monthly MBSF Medicare Entitlement/Buy-in and HMO indicators (MDCR_ENTLMT_BUYIN_IND_[two-digit month] = "3" or "C" and HMO_IND_[two-digit month] = "0" or "4").
Data Sources	MBSF, OASIS, Inpatient Claims. Enrollment status obtained from MBSF.

MA: Medicare Advantage

Exhibit A-61. Percent of MA or FFS Beneficiaries with at Least One OASIS HH Episode

Measure Concept	Definition
Measure Category	Quality
Measure Description	MA: Percent of Medicare-eligible MA beneficiaries with at least one OASIS-based HH episode in a given year indicating the beneficiary used HH services. FFS: Percent of Medicare-eligible FFS beneficiaries with at least one OASIS-based HH episode in a given year indicating the beneficiary used HH services.
Measure Numerator	OASIS-based HH episodes starting in the year.
Numerator Details	MA: Total number of Medicare-eligible MA beneficiaries with at least one OASIS-based HH episode starting in a given year. FFS: Total number of Medicare-eligible FFS beneficiaries with at least one OASIS-based HH episode starting in a given year.
Measure Denominator	MA: Total number of Medicare-eligible MA beneficiaries alive at the beginning of the given year. FFS: Total number of Medicare-eligible FFS beneficiaries alive at the beginning of the given year.
Denominator Details	MA: Total number of Medicare-eligible MA beneficiaries alive at the beginning of the given year (e.g., if a beneficiary is no longer MA next month, they are still included).

	FFS: Total number of Medicare-eligible FFS beneficiaries alive at the beginning of the year (e.g., if a beneficiary is no longer FFS next month, they are still included).
Data Sources	MBSF, OASIS. Enrollment status is obtained from MBSF.

MA: Medicare Advantage

A.2.3 OASIS-Based Outcome Impact Measures

This section presents information on the OASIS-based outcome impact measures analyzed in this report. Of note, the measure values were included as part of our Quality Improvement and Evaluation System (QIES) extract (see Section A.3.6.2); no additional measure calculations were necessary. The tables below summarize the measure definitions, as defined by CMS.[26]

Exhibit A-62. Discharged to Community

Measure Concept	Definition
Measure Category	OASIS Outcome
Measure Description	Percentage of HH episodes after which patients remained at home.
Measure Numerator	Number of HH episodes where the assessment completed at the discharge indicates the patient remained in the community after discharge.
Measure Denominator	Number of HH quality episodes ending with a discharge or transfer to inpatient facility during the reporting period, other than those covered by generic or measure-specific exclusions.
Measure-Specific Exclusions	HH quality episodes that end in patient death.

Source: CMS OASIS-C2 Home Health Outcome Measures

Exhibit A-63. TNC Change in Mobility

Measure Category	OASIS Composite Outcome
Data Source	OASIS M1840, M1850, M1860
Measure Description **	This measure captures the change in home health patients' mobility between SOC or resumption of care (ROC) and the EOC. It is a composite of three OASIS items related to mobility (i.e., toilet transferring M1840, bed transferring M1850, and ambulation/locomotion, M1860).
Measure Calculation	Firstly, the raw change for each applicable OASIS item at the episode level between SOC/ROC and EOC is computed. Secondly, the normalized change (value between -1 and 1) for each applicable OASIS item at the episode level is calculated by dividing the raw change by maximum possible change value for the respective OASIS item. Then the normalized change for all applicable OASIS items at the episode level are summed up. Sum Normalized Change in Mobility = M1840 Normalized Change + M1850 Normalized Change + M1860 Normalized Change. This ranges from -3 to 3. Sum Normalized Change in Mobility (calculated in previous step) for all eligible home health quality episodes are then aggregated at the agency level and divided by Agency total number of eligible home health quality episodes.

**Because the TNC Change in Mobility measure is a composite measure rather than simply an outcome measure, the terms "Numerator" and "Denominator" do not apply.*

---

[26] See CMS OASIS-C2 Home Health Outcome Measures.

Source: HHVBP Computing the HHVBP Composite Measures; HHVBP Technical Specification Resources for Composite Outcome Measures

Exhibit A-64. TNC Change in Self-Care

Measure Category	OASIS Composite Outcome
Data Source	OASIS M1800, M1810, M1820, M1830, M1845, M1870
Measure Description**	This measure captures the change in home health patients' self-care between SOC or ROC and the EOC. It is a composite of six OASIS items related to self-care (i.e.,M1800 grooming, M1810 upper body dressing, M1820 lower body dressing, M1830 bathing, M1845 toilet Hygiene, and M1870 eating).
Measure Calculation**	Firstly, the raw change for each applicable OASIS item at the episode level between SOC/ROC and EOC is computed. Secondly, the normalized change (value between -1 and 1) for each applicable OASIS item at the episode level is calculated by dividing the raw change by maximum possible change value for the respective OASIS item. Then the normalized change for all applicable OASIS items at the episode level are summed up. Sum Normalized Change in Self Care = M1800 Normalized Change + M1810 Normalized Change + M1820 Normalized Change + M1830 Normalized Change + M1845 Normalized Change + M1870 Normalized Change. This ranges from -6 to 6. Sum Normalized Change in Self-Care (calculated in previous step) for all eligible home health quality episodes are then aggregated at the agency level and divided by Agency total number of eligible home health quality episode.

**Because the TNC Change in Self-Care measure is a composite measure rather than simply an outcome measure, the terms "Numerator" and "Denominator" do not apply.

Source: HHVBP Computing the HHVBP Composite Measures; HHVBP Technical Specification Resources for Composite Outcome Measures

Exhibit A-65. Improvement in Dyspnea

Measure Concept	Definition
Measure Category	OASIS Outcome
Measure Description	Percentage of HH quality episodes during which the patient became less short of breath or dyspneic.
Measure Numerator	Number of HH quality episodes where the discharge assessment indicates less dyspnea at discharge than at SOC/ROC.
Measure Denominator	Number of HH quality episodes ending with a discharge during the reporting period, other than those covered by generic or measure-specific exclusions.
Measure-Specific Exclusions	HH quality episodes for which the patient, at SOC/ROC, was not short of breath at any time, or episodes that end with inpatient facility transfer or death.

Source: CMS OASIS-C2 Home Health Outcome Measures

Exhibit A-66. Improvement in Management of Oral Medications

Measure Concept	Definition
Measure Category	OASIS Outcome
Measure Description	Percentage of HH quality episodes during which the patient improved in ability to take their medicines correctly (by mouth).
Measure Numerator	Number of HH quality episodes where the value recorded on the discharge assessment indicates less impairment in taking oral medications correctly at discharge than at SOC/ROC.
Measure Denominator	Number of HH quality episodes ending with a discharge during the reporting period, other than those covered by generic or measure-specific exclusions.
Measure-Specific Exclusions	HH quality episodes for which the patient, at SOC/ROC, was able to take oral medications correctly without assistance or supervision, episodes that end with inpatient facility transfer or death, patient is nonresponsive, or patient has no oral medications prescribed.

Source: CMS OASIS-C2 Home Health Outcome Measures

A.2.4 HHCAHPS-Based Impact Measures

For the five HHVBP performance measures that address beneficiary experience, we used the publicly available, HHA-level HHCAHPS data for 2013-2021. To receive the annual Home Health Prospective Payment System payment update, HHAs that do not qualify for an exemption from participating in the HHCAHPS Survey must contract with an approved HHCAHPS Survey vendor, administer the survey on an ongoing (monthly) basis, and submit HHCAHPS Survey data to the HHCAHPS Data Center on a quarterly basis. Agencies are exempted if they serve 59 or fewer survey-eligible patients a year. Survey-eligible patients are those who are at least 18 years old and have their skilled care covered by Medicare or Medicaid.[27] Additionally, due to the COVID-19 PHE, CMS did not require HHAs to report HHCAHPS survey responses for 2019 Q4, 2020 Q1, or 2020 Q2 so that providers could instead allocate resources to patient care.[28]

The five measures—constructed from 19 HHCAHPS questions—are summarized below.[29]

1. **How often the home health team gave care in a professional way (Professional Care)** reflects "patients who reported that their home health team gave care in a professional way."[29] This composite measure is comprised of four HHCAHPS questions that address how frequently the HHA treated the patient gently, with courtesy and respect, how frequently the HHA seemed informed and up-to-date, and if the patient had any problems with the care received.

2. **How well did the home health team communicate with patients (Communication)** reflects "patients who reported that their home health team communicated well with them."[29] This composite measure is comprised of six HHCAHPS questions related to different aspects of communication, including how frequently the HHA explained things in an easy to understand manner, listened carefully, and kept the patient informed about when staff would arrive.

3. **Did the home health team discuss medicines, pain, and home safety with patients (Discussion of Care)** reflect "patients who reported that their home health team discussed medicines, pain, and home safety with them."[29] This composite measure is comprised of seven HHCAHPS questions related to these three areas of care (that is, medicines, pain, and home safety).

4. **How do patients rate the overall care from the home health agency (Overall Care)** is a global rating measure that reflects the percentage of respondents who gave a rating of 9 or 10 to the question, "Using any number from 0–10, where 0 is the worst home health care possible, and 10 is the best home health care possible, what number would you use to rate your care from this agency's home health providers?"[29]

5. **Would patients recommend the home health agency to friends and family (Likely to Recommend)** is a global rating measure that reflects the percentage of respondents who answered "Definitely Yes" to the question, "Would you recommend this agency to your family and friends if they needed home health care?"[29]

---

[27] Additional criteria are available here.
[28] Additional information on reporting requirements in 2020 available here.
[29] Additional information on measure construction available here.

A.2.5 Measures Related to Entry/Exit

These two measures are reported through Q3 of 2020 due to a lag in the reporting of POS data (see Section A.3.4 for details). This year, there were additional data delays to the iQIES system migration that occurred in Q4 2021.

Exhibit A-67. Entering Home Health Agencies, Percent

Measure Concept	Definition
Measure Category	HHA Entry and Exit
Measure Description	Percentage of open HHAs that are new in a given quarter.
Measure Numerator	Count of HHAs with an original Medicare participation date occurring in a given quarter.
Numerator Details	N/A
Measure Denominator	Total number of open HHAs of the given quarter.
Denominator Details	Excluding HHAs located in DC or any US territory.
Data Sources	POS

Exhibit A-68. Exiting Home Health Agencies, Percent

Measure Concept	Definition
Measure Category	HHA Entry and Exit
Measure Description	Percentage of open HHAs that close in a given quarter.
Measure Numerator	Count of HHAs with a Medicare termination date occurring in a given quarter.
Numerator Details	N/A
Measure Denominator	Total number of open HHAs of the given quarter.
Denominator Details	Excluding HHAs located in DC or any US territory.
Data Sources	POS

A.2.6 APMs

The APMs that were active anytime between 2013-2021 and for which data were available are the BPCI Initiative, CJR, OCM, and three ACO initiatives:

BPCI Initiative: Under this voluntary initiative, participating ACHs and PAC providers received bundled payments, as opposed to fragmented, individual service-based payments, for all services rendered during a defined episode of care. BPCI providers were offered incentives based on lowering expenditures and improving quality of care. Two of the four models (Model 2 and 3) for participation in this initiative included bundled payments for PAC, and episodes of care for specific clinical outcomes were grouped into "clinical episodes" for the purposes of evaluation.[30] The performance period for the original BPCI model ran from 2013 through Q3 of 2018. Beginning October 2018, a new iteration of this model, BPCI Advanced, went live and has been extended to run through December 2025. The BPCI Advanced model remains voluntary, and features a single retrospective bundled payment and 90-day Clinical Episode duration.

CJR Model: This model was designed to facilitate better quality and more efficient care for Medicare beneficiaries undergoing hip and knee replacements. The performance period for this model began in April 2016 and was initially scheduled to end in September 2021. However, the model has received an extension through December 2024. Initial participation was mandatory for all hospitals in 67 randomly selected MSAs for the first two years of the model. From CY 2018 onwards, all rural and lower-volume

---

[30] See BPCI general information page, available here.

hospitals as well as all other hospitals located in 33 of the 67 MSAs were permitted to participate on a voluntary basis. Most recently, model participation stands at approximately 324 hospitals in 34 MSAs. A CJR episode of care begins with admission to a participant hospital for a beneficiary discharged under Medicare Severity Diagnosis Related Group (MS-DRG) 469,470, 521, or 522 and ends 90 days post-discharge to account for the complete period of recovery. CJR total expenditures (Parts A and B) expenditures are evaluated for annual reconciliation compared to performance-adjusted target episode prices. Through this reconciliation, participating hospitals may be owed money from or owe money to CMS, depending on quality and spending compared to episode targets.[31]

OCM: The OCM was initiated by CMS in order to promote higher-quality, coordinated care to Medicare FFS beneficiaries undergoing chemotherapy at a lower cost. An episode of care begins with the initiation of chemotherapy, continues for six months and includes all Medicare Part A and B services as well as certain Part D services that FFS beneficiaries receive during that period. Participating oncology care providers receive monthly payments for each aligned beneficiary, as well as retrospective performance-based payments based on the quality of care provided and reduced spending relative to a target-price set by CMS. The OCM is a voluntary model that began in July 2016 and will continue through June 2022 nationally.[32]

ACOs: ACOs are multi-disciplinary provider groups (doctor's offices, hospitals, and other providers including home health agencies) who come together voluntarily to provide consistent, efficient, and cost-effective care. By providing a continuous, coordinated care. ACOs aim to avoid unnecessary duplication of services and to prevent medical errors.[33] Since the enactment of the Affordable Care Act, CMS has established a number of ACO-centered APMs. As of 2021, the number of ACOs participating in the Medicare Share Savings Program ACO initiative had decreased from prior years, with 483 organizations serving approximately 11.1 million FFS beneficiaries nationwide.[34] The CMS ACO initiatives for which we have data include:

- **MSSP** – For providers serving FFS beneficiaries. The SSP model facilitates coordinated care among providers and suppliers to promote higher quality and more efficient care. MSSP offers multiple options where participating providers may select the level of financial risk they are willing to incur.[35] MSSP is currently active.
- Two additional Center for Medicare & Medicaid Innovation (CMMI) models, **the Advanced Payment ACO Model** and the **ACO Investment Model**, were designed to shepherd ACO-based by current or newly established MSSP providers care into rural and/or underserved areas:
    - **Advanced Payment ACO Model** – Model incentivized rural and physician-based providers to join together voluntarily to provide Medicare FFS beneficiaries better-coordinated and higher-quality care. These newly-formed ACOs, which were commonly smaller and lacking necessary resources for MSSP participation, received both upfront and monthly payments to invest in patient care and infrastructure through the MSSP.[36] The Advanced Payment ACO Model is no longer active.

---

[31] See CJR information page, available here.
[32] See OCM information page, available here.
[33] See ACO information page, available here.
[34] See MSSP fast facts archive, available here.
[35] See MSSP information page, available here.
[36] See Advance Payment ACO Model general information page, available here.

- **ACO Investment Model** – Model tests the use of pre-paid shared savings to encourage previously- and newly-established MSSP ACOs to expand to rural and underserved areas.[37] The ACO Investment Model is no longer active.
- **Pioneer ACO Model** – Designed to transition health care organizations and providers already experienced in coordinating care for patients across care settings into ACO-based care more quickly. These experienced organizations were expected to take on a slightly higher level of financial risk than SSP ACOs and consequently stood to receive greater shared savings. The model was run similarly to, though separately from the SSP.[38] The Pioneer ACO Model is no longer active.
- **Next Generation ACO Model** – For ACOs experienced in managing care for populations of patients. In this model, participating ACOs assume greater financial risk than those participating in the SSP model, with the possibility for greater financial rewards. This model was designed to test the effect of strong financial incentives and increased resources for improved patient care and management, on improving patient outcomes and decreasing ACO expenditures.[39] The Next Generation ACO Model concluded in December 2021.

Exhibit A-69. Active Dates and Data Availability for APMs

APM	2013	2014	2015	2016	2017	2018	2019	2020	2021
BPCI-Models 2 & 3	✓	✓	✓	✓	✓	✓			
BPCI Advanced						✓	✓	✓	✓
CJR				✓	✓	✓	✓	✓	✓¥
OCM				✓	✓	✓		✓	✓¥
ACO Initiatives									
Pioneer ACO	✓	✓	✓	✓					
MSSP*	✓	✓	✓	✓	✓	✓	✓	✓	✓
Next Generation ACO				✓	✓	✓	✓	✓	✓

* Included the Advanced Payment ACO and ACO Investment Model (AIM) for respective active model years. ¥Model data available for partial year.

A.2.7 TPS

Guided by parameters established by CMS for CY 2016,[40] the TPS for CYs 2013-2017 were calculated as an aggregate performance metric based on 17 HHVBP measures, including: seven OASIS-based outcomes, three OASIS-based processes, two claims-based measures, and the five HHCAHPS measures.[41]

HHA measure rates were created as 12-month weighted averages, weighted by the episode counts, and rolled up from the agency-month to the agency-year level. An HHA's Performance Year measure rates

---

[37] See ACO Investment Model general information page, available here.
[38] See Pioneer ACO Model general information page, available here.
[39] See Next Generation ACO Model general information page, available here.
[40] See 2015 HHVBP Final Rule.
[41] Scores for the three new self-reported measures were not factored into our calculation of the TPS since these data are unavailable for non-HHVBP HHAs. Thus, the adjusted composite score for the 17 performance-based measures will be given full weight, as compared to the 90% weight that has been stipulated by CMS.

(ranging from 0-100 points) were compared to its baseline year measure rates, as well as state-level performance standards: the ATs and BMs. In the original HHVBP Model, the baseline year is defined as CY 2015. For our computation of the TPS for years prior to the implementation of HHVBP, we defined the baseline year as the year prior to the designated Performance Year (e.g., for our calculation of TPS values for CY 2014, we used CY 2013 as the baseline year). ATs and BMs for each measure were calculated based on the distribution of baseline year measure rates for all eligible participating HHAs within a given state (see below for eligibility criteria). For each eligible measure, HHAs received the higher of either an Achievement Score or an Improvement Score, between 0 and 10 points. Achievement/Improvement Scores were summed across all eligible measures to form an unadjusted performance measure score. For each HHA, this score was then weighted based on the number of eligible measures reported. Note that we excluded Medicaid-certified only HHAs from the ATs/BMs/TPS calculation.

HHA eligibility criteria for the calculation of the ATs and BMs are as follows:

- For OASIS and claims-based measures, an HHA must have at least 20 episodes of care in the baseline year.
  - If an HHA did not have 20 or more episodes of care for a particular measure, the reported measure rates were recoded as missing.
- For HHCAHPS-based measures, an HHA must have at least 40 completed patient surveys during the baseline year for the five measure rates.
  - If an HHA did not have 40 or more completed patient surveys, the five HHCAHPS measure rates were recoded as missing.
- An HHA must have non-missing data for at least five of 17 eligible measures.
  - An "eligible measure count" (0-17) was created to tally the number of non-missing measures for each HHA to determine their inclusion/exclusion from AT/BM calculations.

HHA eligibility criteria for the calculation of TPS are as follows:

- HHAs must have data from the full 12 months of baseline year.
  - HHAs were flagged based on their participation date, extracted from the POS file. HHAs with a participation year greater than or equal to the baseline year were excluded from the data set of eligible agencies.
- HHAs must be in operation as of the end of the performance year or as of the release of the latest available POS file.
  - HHAs were flagged based on their termination status, extracted from the POS file; HHAs that were flagged as terminated (termination year is the same as or before the performance year and non-missing as of the POS data extraction) were excluded from the data set of eligible agencies.
- HHAs must have at least five eligible measures for both the baseline year and the performance year.
  - For measure-level eligibility, see prior list above ("HHA eligibility criteria for calculations of AT/BMs").
- Of an HHA's eligible measures, at least five measures must be the same for both the baseline year and the performance year.

- HHAs that did not have at least five shared measures between the baseline and performance years were excluded from the data set of eligible agencies.

Similarly, guided by parameters established by CMS for CY 2018,[42] the 2018 TPS were calculated as an aggregate performance metric based on 16 HHVBP measures: seven OASIS-based outcome measures, two OASIS-based process measures (of note, the drug education measure was dropped for CY 2018 and all subsequent years), two claims-based measures, and the five HHCAHPS-based measures. The measure eligibility criteria, measure score calculation and HHA eligibility criteria remain the same as previous years.

Finally, guided by parameters established by CMS for CY 2019[43] and CY 2020[20], the 2019 and 2020 TPS were calculated as an aggregate performance metric based on 13 HHVBP measures: six OASIS-based outcome measures, two claims-based measures, and the five HHCAHPS-based measures. Of note, the Influenza immunization measure and Pneumococcal vaccine measure were dropped for CY 2019 and all subsequent years, and three OASIS-based outcome measures (Improvement in Bathing, Bed, and Ambulation) were replaced by two composite measures: TNC Change in Self-Care and TNC Change in Mobility. The measure eligibility criteria and HHA eligibility criteria remain the same as previous years. The maximum amount of improvement points was reduced from 10 points to 9 points for CY 2019 and subsequent performance years for all measures except for the two TNC measures, for which the maximum improvement points would be 13.5. In addition, for CY 2019 and subsequent years, the methodology for calculating the TPS by weighting the measure categories changed significantly such that the OASIS-based measure category and the claims-based measure category would each count for 35 percent, and the HHCAHPS measure category would count for 30 percent of the TPS that is based on performance of the Clinical Quality of Care, Care Coordination and Efficiency, and Person and Caregiver-Centered Experience measures. For CY 2021, we used the same methodology as CY 2020 but with one less measure, which is the Improvement in Pain measure. CY 2021 data for this measure is not available due to non-mandatory reporting, and the measure weight is redistributed proportionally to other eligible measures in the OASIS domain for CY 2021 TPS calculation.

Using the above methodology, we calculated the TPS for CYs 2013-2021. We then validated our TPS calculations in the HHVBP group against those calculated by the HHVBP Implementation Contractor and reported in the Final Annual TPS and Payment Adjustment Report (released November 2017), the Preview Annual TPS and Payment Adjustment Report (released August 2018), the Preview Annual TPS and Payment Adjustment Report (released August 2019), the Preliminary Annual TPS and Payment Adjustment Report (released October 2020) and the Preliminary Annual TPS and Payment Adjustment Report (released October 2021) for 2016 TPS, 2017 TPS, 2018 TPS, 2019 TPS, and 2020 TPS respectively. Compared to the HHVBP Implementation Contractor, we included 24 additional HHAs in the 2016 TPS calculation, 15 additional HHAs in the 2017 TPS calculation, 16 additional HHAs in the 2018 TPS calculation, 17 additional HHAs in the 2019 TPS calculation, and 17 additional HHAs in the 2019 TPS calculation. Our inclusion of additional HHAs that were eligible for a TPS were due to differences in timing of access to the underlying measure data. Among HHAs that were included in both our and the HHVBP Implementation Contractor's calculations, the TPS were very close (e.g., correlation coefficient between our TPS and the HHVBP Implementation Contractor's TPS was 0.999 for the first three years

---

[42] See 2017 Final Rule here.
[43] See 2018 Final Rule here.

(i.e., CYs 2016-2018), the correlation coefficient between our TPS and the HHVBP Implementation Contractor's TPS was 0.998 for CY 2019, and the correlation coefficient between our TPS and the HHVBP Implementation Contractor's TPS was 0.997 for CY 2020). Note that 2021 TPS was not calculated by the HHVBP Implementation Contractor and therefore, the validation process is not available for CY 2021.

A.2.8   Relative Change

The relative change provides context for interpreting model estimates and indicates the magnitude by which the impact measures have changed due to HHVBP in the post-implementation period relative to the baseline period values. We calculated the relative change by dividing the respective D-in-D estimate by its measure's corresponding baseline average value in HHVBP states and expressing it as a percentage. For example, the cumulative D-in-D estimate of 0.24 for ED Use (No Hospitalization)/First FFS HH Episodes reported in Exhibit 43 of the Annual Report was divided by its baseline average of 11.7 percent to yield a 2.1 percent increase (0.24/11.7=0.021).

As noted in Section A.1.4.2, for the spending measures, we estimated impacts for 2016 through 2019 from one regression model and impacts for 2020-2021 from a separate regression model using the alternative standardized approach. The baseline means were also calculated using two methods. For years 2016-2019, D-in-D yearly impact estimates corresponded to a baseline mean calculated using the pre-PDGM approach. On the other hand, for post-PDGM years 2020-2021, the yearly estimates corresponded to a baseline mean that incorporated the post-PDGM standardized approach.

Relative changes for 2016-2019 express the impact estimate as a percentage of the average spending per day calculated using the pre-PDGM method during the baseline period in HHVBP states. Estimates of the relative change for 2020 and 2021 represent the impact estimate as a percentage of the average spending per day calculated using the post-PDGM approach during the baseline period in HHVBP states. Estimates of the relative change for cumulative estimate represent the impact estimate as a percentage of the weighted average baseline (Refer to Section A.1.4.2 in the Technical Appendix to see how it is calculated) in HHVBP states. However, these three baseline averages are very close in magnitude and hence for easier understanding, in the Annual Report (Exhibit 55) we only show the baseline value corresponding to 2016-2019. Even though one pre-PDGM baseline average is shown, the yearly (2016-2021) and cumulative relative changes are calculated using three (2016-2019 pre-PDGM, 2020-2021 post-PDGM, weighted average of 2016-2021) corresponding underlying baseline averages. All three baseline averages and their corresponding relative changes are shown in Supplemental Table Exhibit B-56. To reiterate, the relative change column (last column) is the same in both the tables (Exhibit 55 in the Annual report and Exhibit B-56).

A.2.9   Annual Savings Calculations

We estimated the annual savings to the Medicare program by multiplying the yearly D-in-D estimate for the Medicare spending per day measures by the total number of eligible days in the HHVBP states for the respective year. Similarly, we obtained estimates of total savings since implementation of HHVBP by multiplying the cumulative D-in-D estimate for the Medicare spending per day measures (Exhibit 55) by the total number of eligible days during 2016-2021 in the HHVBP states (Exhibit B-51). To obtain estimates of average annual savings due to HHVBP, we then divided the calculated total savings estimate (obtained from the cumulative D-in-D estimate) by the number of years in the post-implementation period (in this case, six years).

To illustrate with an example, average daily Medicare spending during and following home health episodes among FFS beneficiaries declined by $2.63/day in HHVBP states, relative to non-HHVBP states for 2016-2021 (i.e., the cumulative D-in-D estimate reported in Exhibit 55 in the Annual Report).

- The number of eligible days in HHVBP states for 2016-2021 included in the calculation of this measure is 524,020,806 (357,115,126days for 2016-2019 + 166,905,680 for 2020-2021) (Exhibit B-51).
- We multiplied the D-in-D estimate (which corresponds to estimated savings per day) by the total number of days during the corresponding time period to estimate the reduction in total Medicare spending over the six-year period (2016-2021): $2.63 savings/day * 524,020,806 days = $1,378,174,719.78.
- We then divided this number by 6 to estimate the average annual savings during 2016-2021 among FFS beneficiaries receiving home health services: $1,378,174,719.783/6 = $229,695,786.63, or $230 million after rounding.

Average annual savings corresponding to Medicare component expenditure estimates are calculated exactly in the same way, by multiplying the respective cumulative D-in-D estimates of the measure components (Exhibit A-55) by the total number of eligible days during 2016-2021 in the HHVBP states and dividing the total savings by the number of post-implementation years.

A.2.10 Sensitivity Analyses

We conducted two sensitivity analyses on select claims-based measures to better understand the potential impacts of PDGM and COVID during 2020 and 2021.

Analysis 1: We performed a sensitivity analysis for two claims-based utilization measures to evaluate the impact of home health episode length change from 60 days to 30 days due to implementation of PDGM effect in January 2020. These measures include:

- Unplanned ACH/All FFS HH Episodes
- SNF Use/All FFS HH Episodes

Instead of truncating the measure lookout window at the day prior to the start of the next episode, we construct standardized 60-day lookout windows. Within each episode sequence, we add 59 days to the first episode start date. If the next episode in the sequence is entirely contained within the first episode's 60-day lookout window, the next episode is ignored. If the next episode in the sequence starts during the first episode's 60-day lookout window and ends outside of that window, we create another 60-day lookout window starting one day after the end of the first episode's lookout window. If the next episode in the sequence starts one or more days after the end of the first episode's 60-day lookout window, we create another 60-day lookout window starting on the next episode's start date.

We continue with this logic through all of the episodes in each sequence, for both the pre-PDGM period (2013-2019) and the post-PDGM period (2020-2021). In the scenario where the standardized 60-day window covers multiple episodes (11.6% among all the episodes), we take the covariate values from the earliest of episode ids that overlaps with the window. All the denominator exclusions remain the same as the main measures defined in Section A.2.2.

Analysis 2: For our second sensitivity analyses, we estimated the HHVBP impact in 2020 and 2021 for claims-based utilization and Medicare spending measures from a D-in-D model that did not adjust for

COVID indicators (other covariates remaining unchanged). Results indicate that the 2020 and 2021 impact estimates from this model (Exhibit B-45 for utilization measures and Exhibit B-59 for spending measures) were very similar to that obtained from our base model (Exhibit 43, Annual Report for utilization measures and Exhibit 55, Annual Report for spending measures) that adjusted for COVID indicators, which implied that COVID is not a large source of confounding, assuming that unobserved geographic variation due to COVID is similar to observed variation in the COVID indicators that we control for in the D-in-D models.

A.3 Data Sources

For this Annual Report, we accessed CMS administrative data from several sources, including the Chronic Conditions Data Warehouse (CCW) via the Virtual Research Data Center (VRDC), publicly available data sources, and other CMS HHVBP Contractors. We also received varying analytic levels of measure-specific OASIS data, extracted from CMS' iQIES. We used these data sources to create the analytic file necessary to conduct the analyses included in this Annual Report. Claims-based impact measures were calculated and analyzed using several data sources, including:

- Common Medicare Environment (CME) enrollment data
- HHA claims
- SNF claims
- Inpatient hospitalization claims
- Outpatient claims (e.g., Eds, renal dialysis facilities, outpatient rehabilitation facilities)
- Part B claims
- DME claims
- Hospice claims
- POS files
- AHRF

The data sources discussed below were combined to create impact measures and descriptive variables, inform and construct comparison groups, and contribute to the analytic file that was used to conduct the analyses and produce the results presented in the report. Below, we describe the process for obtaining data from these sources in more detail.

A.3.1 Home Health Agency Claims

Purpose. HHA claims defined the home health care episodes for the claims-based impact measures.

Data Acquisition. HHA claims data were pulled from the CCW's RIFs in July 2022, which included all final action claims with claim type code 10 and a service end date (claim "through" date) ranging from January 1999 through June 2022. Although the measurement period for this evaluation began in January 2013, prior years of HHA claims data were needed to establish accurate episode sequence information.

Data Processing. In order to establish the complete set of home health episodes of care, all final-action HHA claims that met the following conditions were included:

- Claim frequency code not equal to each of the following: missing; '0' (Non-payment/Zero Claim); or '2' (Request for Anticipated Payment)
- Included at least one covered visit
- Received a Medicare payment amount greater than $0

Furthermore, if a beneficiary had multiple claims with the same "Statement Covers From" date (i.e., "claim from" date), only the claim with the latest Fiscal Intermediary claim process date was included. In the event that multiple claims for the same beneficiary overlap in a statement period "from" and "through" dates, the "Statement Covers Through" date (i.e., "claim through" date) on the claim starting earlier was adjusted to be the date before the ensuing claim from date. These data steps ensure that a given beneficiary could not be attributed to multiple HHAs on a given day when calculating episode-based impact measures (discussed below).

Each of the resulting HHA claims were considered a final home health episode with episode start date corresponding to the "claim from" date, and episode end date corresponding to the "claim through" date. In concordance with the measure specifications for the two HHVBP claims-based measures,[25] sequence of episodes (or "home health stay") was defined as a series of consecutive home health episodes for a given beneficiary in which the maximum time between consecutive episodes, end date to start date, was 60 days or less. If the time between the prior episode end date and ensuing episode start was greater than 60 days, the ensuing episode start date began a separate home health stay.

An important by-product of HHA claims processing is a beneficiary finder file that includes a unique list of all beneficiaries with a claims-based home health episode ending on or after January 1, 2013, which includes the full measurement period associated with this report (2013-2021). For the remainder of this report, we refer to this data set as the "HH Beneficiary Finder File."

A.3.2 Master Beneficiary Summary File

Purpose. MBSF data were the source for determining: beneficiary eligibility in impact measures based on FFS or MA enrollment status, beneficiary demographics, and chronic condition status.

Data Acquisition. MBSF data, sourced from the Common Medicare Environment, were included in the CCW as annual snapshots that were divided into multiple segments: Base (Parts A/B/C/D), Chronic Conditions, Other Chronic or Potentially Disabling Conditions, Cost and Use, and National Death Index. For this Annual Report, we utilized the Base, Chronic Conditions, and Other Chronic Conditions segments.

The MBSF Base segment data provided monthly indicators of enrollment status, in addition to beneficiary demographic information (e.g., state and county of residence, date of birth, gender, race, etc.), for all Medicare enrollees. For this report, beneficiary year-level MBSF Base data were compiled from 2013 to 2021. For beneficiary gender, race, date of birth and date of death, only information from the most recent year of available MBSF for a given beneficiary was included in analyses.

As of the time of this report, the MBSF Chronic Conditions and Other Chronic or Potentially Disabling Conditions segments contained 67 beneficiary-year-level condition flags that were "developed from algorithms that search the CMS administrative claims data for specific diagnosis codes, MS-DRG codes, or procedure codes."[44] The condition flags were provided at both the middle and end of each year for each Medicare beneficiary; for this report, only end-of-year condition flags were used.

Data Processing. In a given month, a beneficiary was determined to be enrolled in "full" Medicare FFS if they were enrolled in both, Parts A and B (including dually eligible beneficiaries with enrollment in both Medicare and Medicaid) and were concurrently not enrolled in an HMO. Based on this definition, monthly indicator variables were created to determine a beneficiary's full FFS enrollment status, which was later used as one of the factors to determine eligibility in claims-based impact measure denominator populations (See Section A.2.2).

Alternatively, a beneficiary was determined to be enrolled in MA in a given month if the MBSF indicated beneficiary participation in a Medicare HMO during that month, i.e. in a given month MBSF monthly HMO indicator (HMO_IND_[2-digit month]) value was NOT equal to "0" (Not a member of an HMO) or

---

[44] See CCW Condition Categories.

"4" (FFS participant in case or disease management demonstration project). Based on this definition, monthly indicator variables were created to determine a beneficiary's MA enrollment status, which was later used as one of the factors to determine eligibility in impact measure denominator populations (See Section A.2.2).

End-of-year condition indicator variables from both Chronic Condition MBSF segments indicated whether the beneficiary met the CCW claims criteria and/or whether the beneficiary meets the coverage criteria (enrolled in Medicare Parts A and B for the entire specified period). From these indicator variables, we further derived condition flags that indicate whether a beneficiary met the claims criteria portion of the CCW condition algorithm, regardless of whether the beneficiary met the FFS coverage criteria (FFS coverage is separately accounted for in the MBSF Base segment).

The total number of Medicare-eligible FFS beneficiaries alive at the beginning of every quarter (e.g., if a beneficiary is no longer FFS next month, they are still included) was also calculated and then divided by 1000.

A.3.3 Non-Home Health Agency Claims

Purpose. We analyzed non-home health claims in order to create impact measures for spending and utilization of services outside of home health care. These claims were also used to determine a beneficiary's care setting immediately prior to a sequence of home health episodes. In this section, we discuss preliminary data processing to support impact measure calculation.

Data Acquisition. For this Annual Report, final action SNF (claim type codes 20 and 30), Inpatient (claim type code 60), and Outpatient (claim type code 40) claims were pulled from the CCW RIFs in July 2022, including claims with a claim through date from April 2010 through June 2022. Claims occurring in this date range potentially contributed to impact measure calculation and determining a home health beneficiary's prior care setting.

Additionally, all claims featuring a beneficiary in our home health Beneficiary Finder File were pulled in July 2022 from the CCW RIFs for Part B, DME, home health, Hospice, SNF, Inpatient, and Outpatient for claims with a claim through date from October 2011 through June 2022. This set of claims was used to calculate total Medicare expenditures and HCC risk scores for FFS home health beneficiaries.

Data Processing. For impact measure calculation, SNF stays were constructed based on SNF claims with an admission date starting on or after October 1, 2011; furthermore, this set of claims was subset to include only claims corresponding to beneficiaries in the HH Beneficiary Finder File (see Section A.3.1). SNFs submit monthly claims throughout a beneficiary's duration of stay, which spans from admission date to discharge date; therefore, a beneficiary's SNF stay was constructed by combining each of the individual SNF claims with the same associated admission date. The SNF stay start date corresponded to the first claim's "claim from" date, while the SNF stay end date corresponded to the last claim's "claim through" date. Medicare payment amounts for each claim within a given stay were summed up to a final stay-level payment amount.

Inpatient and outpatient claims were used to support impact measures related to unplanned ACH and ED use, spending and utilization of services. Inpatient claims were included for beneficiaries in the HH Beneficiary Finder File. Planned ACH inpatient claims were determined by scanning all diagnoses (ICD 9 or 10 codes) reported on the inpatient claim and cross-referenced the list of AHRQ CCS that defined

planned hospitalization, as was done in the measure developer's documentation for the two HHVBP claims-based measures.[25] Medical or Surgical type diagnosis and Major Diagnostic Categories (MDCs) were also included in inpatient claims. Medical or Surgical type of diagnosis were derived from MS-DRG[45]: a medical DRG is assigned when no significant procedure was performed, and surgical DRG is assigned when a significant procedure was performed. MDCs are formed by dividing all possible principal diagnoses (from MS-DRG) into 26 mutually exclusive diagnosis areas largely corresponding to a single organ system. Outpatient claims were included for beneficiaries in the HH Beneficiary Finder File. Outpatient claims with ED visits were identified by the presence of revenue center codes 0450-0459 or 0981. This approach is in alignment with the measure developer's documentation for the HHVBP claims-based ED use without hospitalization measure.[25] We also marked inpatient claims with ED visits using the same approach. In addition, we added flags for inpatient and outpatient claims with observation services for spending analysis, if the HCPCS code of the claim contains any of (99217, 99218, 99219, 99220, 99224, 99225, 99226, 99234, 99235, 99236, G0378 or G0379) or presence of revenue center codes 0760, 0761, 0762 or 0769.

In addition, the reason for ED admittance (primary diagnosis code in Medicare outpatient and inpatient claims) was studied over 2013-2021. ICD-9 codes were converted to ICD-10 codes using the CMS GEM tool, and then all years' ICD-10 codes were grouped according to Part C (Chapter-Specific Coding Guidelines) of the ICD-10-CM Official Guidelines for Coding and Reporting FY 2021. Within each year, these groups were ranked by the percentage of ED visits whose primary diagnosis code they represented. ED visits whose diagnoses were classified as Chapter 18 (symptoms, signs, and abnormal clinical and laboratory findings, not elsewhere classified), were further categorized, grouping primary diagnosis codes in these visits by their first three characters (i.e., R00-R99).[46] These calculations for ED visits were performed without ACH, and separately for ED visits that were followed by ACH.

Seventeen condition specific ED use indicators were identified using all populated diagnosis codes in Medicare outpatient and inpatient claims:

1. Chapter 4 (Endocrine, nutritional and metabolic diseases)
2. Chapter 6 (Diseases of the nervous system)
3. Chapter 9 (Diseases of the circulatory system)
4. Chapter 10 (Diseases of the respiratory system)
5. Chapter 11 (Diseases of the digestive system)
6. Chapter 12 (Diseases of the skin and subcutaneous tissue
7. Chapter 13 (Diseases of the musculoskeletal system and connective tissue)
8. Chapter 14 (Diseases of the genitourinary system)
9. Chapter 19 (Injury, poisoning and certain other consequences of external causes)
10. Chapter 18, R07 (Pain in throat and chest)
11. Chapter 18, R10 (Abdominal and pelvic pain)
12. Chapter 18, R55 (Syncope and collapse)
13. Chapter 18, R53 (Malaise and fatigue)
14. Chapter 18, R06 (Dyspnea)
15. Chapter 18, R41 (Cognitive functions and awareness)
16. Chapter 18, R11 (Nausea and vomiting)

---

[45] See MS-DRG Classifications and Software, available here.
[46] See ICD-10-CM Official Guidelines for Coding and Reporting FY 2021, available here.

17. All other Chapter 18 diagnoses

All diagnosis codes with the exception of the above list were categorized as Other ED Use.

For the purposes of total expenditure calculations, all claims for home health beneficiaries were pulled from Part B, DME, home health, Hospice, SNF, Inpatient, and Outpatient CCW RIFs. Claim payment amount was summed across all claims based on each home health episode (for full expenditure measure specifications, see Section A.2.2).

To support MA inpatient hospitalization analysis, MedPAR data was pulled from the CCW MedPAR library for 2013-2020. These records were subset to those with NCH Claim Type Code = 62 (MA Indirect Medical Education/Graduate Medical Education [IME/GME] claims), 63 (MA [no-pay] claims), or 64 (MA [paid as FFS] claim). Facility geographic data was merged to these records by CCN from the relevant years' POS files in the CCW PROVIDER library.

A.3.4 Provider Data

Purpose. We utilized publicly available data on HHAs to control for a variety of agency characteristics (i.e., ownership status, hospital-based vs. freestanding) in construction of comparison groups and D-in-D modeling.

Data Acquisition. Provider data was downloaded from the CMS "POS" site.

Data Processing. The final annual POS data sets from each year 2013-2021 were subset to HHAs based on provider category code "5". Control types provided in the POS data were re-coded into larger groups of "non-profit" (control type codes 1,2,3; church, private not-for-profit, and other, respectively), "for-profit" (control type code 4; private for-profit), and "government-owned" (control type codes 5,6,7; federal, state, and local, respectively). Additionally, facility type codes were re-coded into groups of "hospital-based" (facility type codes 4,5,6; rehabilitation facility, SNF, and hospital, respectively), and "freestanding" (facility type codes 1,2,3,7; visiting nurse association, combination government voluntary, official health agency, and other, respectively). For agencies that first show up in the POS data after their certification dates, we backfilled their characteristics for the years in between (including the year of certification). In 2021 Q4, QIES migrated to iQIES, impacting the HHA data in the 2021 POS data set. It appears that some HHAs that opened in the last quarter of 2021 were not included in the final 2021 POS data set. CMS was not able to provide an estimate for when this issue will be fixed.

A.3.5 County-Level AHRF Data

Purpose. Utilize county-level data from the AHRF to inform comparison group construction based on key county-level demographic information.

Data Acquisition. AHRF data are publicly available from the Health Resources and Services Administration data warehouse, from which we downloaded the 2020 county-level data set.

Data Processing. The 2021 AHRF was not finalized at time of reporting, so the 2020 county-level data set represented the most current data available. The following data elements from the AHRF data set were used in the analyses: indication of whether the county was in a rural or urban area (based on CBSA indicator), and the county level average education. The rural/urban variable was used to define rurality of a county, including beneficiaries receiving care in that county, across all analyses. The county level

average education was used to define the percentage of persons aged 25 years and older in a county with less than a high school diploma.

A.3.6 OASIS Data

A.3.6.1 Predicted Probabilities for the Risk Adjusted OASIS-Based Outcome Impact Measures

Purpose. We obtained predicted probabilities for the risk adjusted OASIS-based outcome impact measures to support OASIS-based outcomes impact measure calculation and analysis.

Data Acquisition. We received OASIS-based episode-level data (extracted from QIES, later renamed to iQIES starting 2020) for each of the HHVBP OASIS-based outcome impact measures, in which episodes of care were determined from a series of OASIS assessments and had an episode end date ranging from 2013 through 2021.

Data Processing. The data set contained episode-level measure-specific observed and predicted probability values for each of the HHVBP OASIS-based outcome impact measures, as well as a state and facility identifier (unique only within a given state) in which the episode of care occurred. The combination of state and facility identifier were used to look up the HHA's CCN using the CCW's HHA facility file.

A.3.6.2 QIES Roll-Up Measure Data for the OASIS-Based Outcome Measures

Purpose. We obtained roll-up measure data for OASIS-based outcome measures in order to calculate and analyze the TPS scores for all HHAs, regardless of participation in HHVBP.

Data Acquisition. We received HHA-month-level data sets that contain observed measure values and episode counts for each of the outcome measures, spanning 2013 through 2020, from iQIES. Starting 2020, we received this data from Abt.

Data Processing. Similar to the episode-level QIES data set described above, the data set also contained state and facility identifier (unique only within a given state) in which the episode of care occurred; the combination of state and facility identifier were used to look up the HHA's CCN using the CCW's HHA facility file.

A.3.6.3 Raw OASIS Assessment Data

Purpose. Raw item-level OASIS data for January 2010 to December 2021 were obtained to provide covariates for our analytic models and support our OASIS impact measure analyses.

Data Acquisition. Assessment data were extracted from the CCW Oracle database.

Data Processing. The assessments were subset to versions C, C1, C2, D, or D1. The most recent SOC/ROC assessments for each beneficiary were flagged based on M0100. Risk factor variables were calculated based on raw assessment data according to CMS documentation[47]. Response-level indicator variables were created for a subset of assessment items, including M0100, M1000, M1810, M1620, M1710, M1870, M2110, M1800, M1880, M1730, M1308, M1311, M2200, M1830, M1400, M1610, M1034,

---

[47] Hittle DF, Nuccio EJ. (2017) Home Health Agency Patient-Related Characteristics Reports: Technical Documentation of Measures - Revision 4.1. Prepared for: Department of Health and Human Services; Centers for Medicare & Medicaid Services. *University of Colorado School of Medicine - Division of Health Care Policy and Research*.

M1840, M1860, M2020, M1720, M1230, M1220, M1870, and M1910. Patient diagnostic information, from which chronic and acute conditions were derived, was pulled from items M1010, M1016, M1011, M1017, M1020, M1022, M1024, M1021, M1023, and M1025.

We noticed that the missing rate of bene_id in OASIS assessment data increased over time, especially after 2018. To resolve this issue and achieve a more consistent (i.e., lower) bene_id missing rate on claims, we supplemented our current matching approach by also using the Health Insurance Claim Number (HICN) from OASIS assessment data, and the HICN to bene_id crosswalk available in the CCW.[48] By incorporating the HICN and these improvements in linkage, the bene_id non-missing rates improved (especially for 2018-2019) and was more consistent over the years (i.e., 2013-2021).

A.3.7 HHCAHPS and Star Ratings Data

Purpose. We utilized HHCAHPS data to analyze the five patient experience impact measures.

Data Acquisition. We downloaded publicly available data from the Home Health Compare (HHC) website in Oct 2020 for CYs 2013-2019.[49] For CY 2020-2021 HHCAHPS data, we received the data directly from RTI.

Data Processing. The HHCAHPS data included a score value for each of the five HHCAHPS-based impact measures (see Section A.2.4), rounded to the nearest whole number, HHA's CCN, the number of completed surveys by respondents that received care from the given HHA, and the response rate. For this report, we used data from the January through December report from each year of our analyses, 2013-2020 (i.e., measurement period is the CY). We used the CMS Quality of Patient Care Star Ratings to assess disparities in utilization of lower quality HHAs. We downloaded publicly available data from data.cms.gov in June 2022 for CY 2015 – 2020. The data was then linked to beneficiary enrollment and home health utilization date based on the CCN of the HHA providing the service and the CY reflected in the respective measure data range (i.e., the period based on which the performance of the agency was assessed).

A.3.8 PECOS Data

Purpose. PECOS data were used to determine HHA chain information.

Data Acquisition. PECOS data were downloaded from the Integrated Data Repository (IDR) in multiple iterations corresponding to monthly updates of the PECOS enrollment and chain affiliation data.

Data Processing. In order to determine HHA chain affiliation at a given point in time, we extracted data from two views in the Medicare Virtual Data Mart: V2_MDCR_PRVDR_MDCR_ID (parent table for PECOS enrollment database) and V2_MDCR_PRVDR_CHAIN (provider chain affiliation history). All available data were extracted for providers that were identified as HHAs, based on the last four digits of CCN, by joining the two data views based on the tables' key identifier: PRVDR_ENRLMT_ID. The resulting data set provided a history of chain affiliation for each HHA represented in the PECOS database. This process was repeated in multiple iterations from July 2018 through July 2022, in order to account for monthly

---

[48] If a HICN could be mapped to a bene_id in the crosswalk, then the bene_id in the crosswalk was used to supplement the bene_id listed in the OASIS assessment. For patients who had multiple OASIS assessments but with incomplete bene_id information on all of the forms, we applied the bene_id to the entire group of the patient's assessments.

[49] These data are available here.

updates to the PECOS enrollment and chain affiliation data. Per CMS IDR Support, the PECOS data extracts they receive via the "Global Extract File" do not consistently and reliably preserve historical enrollment and chain affiliation data; therefore, we decided to combine monthly extracts and, for each HHA, choose the most recent extract in which the HHA was present. Further, as described in Section A.2.1.3, the most recent chain affiliation data extracted from PECOS would only contribute to the chain affiliation indicator for CY 2021 in this report, while pre-2021 chain affiliation data would be carried over from the previous Annual Report.

A.3.9   Cost Reports

Purpose. Public use HHA Cost Report files (CMS Form 1728-94 and Form 2552-10) for FYs 2012–2021 were used to obtain chain information.

Data Acquisition. Cost Report data sets for both freestanding and hospital-based HHAs are publicly available via CMS' Healthcare Cost Report Information System.[50]

Data Processing. For any provider number with more than one Cost Report record in a given year, the Cost Report representing the latest FY end date was maintained for analyses.

A.3.10   Master Data Demonstration (MDD)

Purpose. Identify Medicare FFS beneficiaries who were aligned with ACOs (i.e., MSSP ACO, the Next Generation ACO Model, and the Pioneer ACO Model) during their home health episode.

Data Acquisition. The MDD is available in the CMS VRDC as part of the CCW, in association with the CMS Master Data Management (MDM) system. The data were pulled from the MDD library using the extracts from multiple dates, depending on the specific ACO model.

Data Processing. For the MSSP, we obtained the finalized list of retrospectively aligned beneficiaries for 2013-2021 from the MDD_BENE_EXTRACT_LINKED_220606 extract. SSP ACO-aligned beneficiaries were identified by program_id = '08' and bene_ctgry_cd = 'F', which included beneficiaries aligned to the Advance Payment ACO and ACO Investment Model when those models were active.

For the Next Generation ACO, we obtained prospectively aligned beneficiaries for 2016-2021 from the first MDD_BENE_EXTRACT_LINKED extract released in March of the year following the year of interest. Next Generation ACO beneficiaries were identified by program_id = '21'.

For the Pioneer ACO, we obtained prospectively aligned beneficiaries for 2013-2016 from the first MDD_BENE_EXTRACT_LINKED extract released in March of the year following the year of interest. Pioneer ACO beneficiaries were identified by program_id = '07'. Beneficiary alignment effective and alignment end dates were used.

With these data, we defined a window of ACO participation. In combination with home health episode start and end dates, we created a flag for Medicare home health beneficiaries whose home health episode overlapped with participation in an ACO.

---

[50] These data are available here.

A.3.11 Data on CMMI Models

Purpose. Identify Medicare FFS beneficiaries who were aligned with the BPCI Model (specifically, Model 2 or Model 3), the BPCI Advanced Model, the CJR model or the OCM during their home health episode.

Data Acquisition. These files were provided directly by CMMI, covering Q3 2013 through Q3 2018 for BPCI, Q4 2018-Q4 2021 for BPCI Advanced, Q2 2016 through Q3 2021 for CJR and Q3 2016 through Q2 2021 for OCM. Partial 2021 data were obtained for the CJR model due to an attenuated performance year and for the OCM model due to a lag in data availability.

Data Processing. The data sets contained beneficiary-level information on APM clinical episode begin date and end dates. With these data, we defined a window of model participation. In combination with home health episode start and end dates, we created a flag for Medicare home health beneficiaries whose home health episode overlapped with participation in BPCI, BPCI Advanced, CJR, or OCM.

A.3.12 Data on RCD from CMMI

Purpose. Identify Medicare FFS beneficiaries who were aligned with the RCD.

Data Acquisition. This file was provided directly by CMMI, covering home health providers in Illinois (cycles 1-5), Ohio (cycles 1-4), Texas (cycles 1-4), Florida (cycles 1-3), and North Carolina (cycles 1-3).

Data Processing. The data set contained agency-level information on participation in the RCD cycles. Using cycle start and end dates and home health episode start dates, we created flags for Medicare home health beneficiaries whose home health episode began while their providing agency was either actively participating in an RCD cycle or had previously participated in an RCD cycle but was between cycles. The variables are:

- RCD Participant – Active: The home health agency was an active participant in an RCD cycle on the home health episode start date.
- RCD Participant – Inactive: The home health agency was an active participant in an RCD cycle prior to the home health episode start date but was in between RCD cycles on the home health episode start date.
- RCD Non-participant: The home health agency was not an active participant in any RCD cycle prior to or on the home health episode start date.

A.3.13 MA Data

Purpose. MA data was used to evaluate spillover effects of the HHVBP model on home health care recipients covered by a MA plan

Data Acquisition. MA episodes were designated by linking enrollment information from the MBSF to OASIS episodes in the UAF, based on MA enrollment status at the beginning of the HH episode. MA beneficiary characteristics also were taken from OASIS episode data.

MA inpatient hospitalization data was pulled in October 2022 from two different sources (1) data from CCW's inpatient base encounter files that included all inpatient stays with a service end date ranging from January 2015 through December 2020, and (2) data from shadow claims from CCW's MedPAR files, that included all MA inpatient claims (those with NCH_CLM_TYPE_CD = 62, 63, or 64) with a service end date ranging from January 2013 through December 2020. CY 2021 MedPAR data was not available.

Ultimately, the ACH measure for MA episodes included in Section 6 of the Annual Report was based on the inpatient shadow claims from MedPAR.

Data Processing. A beneficiary was determined to be enrolled in MA in a given month based on a value of the MBSF monthly HMO indicator (HMO_IND_[2-digit month]) NOT equal to "0" (Not a member of an HMO) or "4" (FFS participant in case or disease management demonstration project).

Planned inpatient hospitalizations (for both MA encounters and shadow claims) were identified the same way they were identified in FFS claims (described in section A.3.3).

Using MedPAR data, inpatient ACH records were identified the same way they were identified in FFS inpatient claims: a CCN ending in 0001-0879, 0800-0899, or 1300-1399. We also determined the county of the facility in each MedPAR record by merging POS geographic data by CCN and year.

CCN is not available in CCW's inpatient encounter data, so we used a different method to identify ACH encounters. We began by creating an NPI-CCN crosswalk using organizational NPIs and their corresponding CCNs in all inpatient FFS claim files from 2012-2021. We identified ACH claims based on CCN (as with MedPAR data, described above), then de-duplicated the crosswalk by NPI to create a crosswalk between organizational NPI and ACH indicator. In the rare occurrence when an NPI mapped to at least one ACH CCN as well as at least one non-ACH CCN, we counted that NPI as ACH (this most often occurred when the non-ACH CCN was a unit within an acute care hospital, i.e. the third CCN character was M, R, S, or T). Next, we subset ACH facilities in CCW's December 2021 NPPES file by including all records with a primary taxonomy in the following list:

- 282N00000X (General Acute Care Hospital)
- 282NC0060X (Critical Access Hospital)
- 282NR1301X (Rural Acute Care Hospital)
- 2865M2000X (Military General Acute Care Hospital)

NPIs for the ACH facilities in this subset were added to the list of ACH NPIs if they were not already identified as ACH using the FFS inpatient claims. We then used this list to identify ACH facilities in the IP encounter data by merging on the organizational NPI in the encounters.

To assess the validity of this method of ACH identification, we compared the MA inpatient encounter results to FFS ACH percentages. We subset all Final Action MA inpatient encounters from 2015-2020, identified ACH records using the above method, and de-duplicated by unique hospital stay (i.e. unique values of BENE_ID, CLM_FROM_DT, and CLM_THRU_DT). In cases where duplicates had different ACH values, we kept the record identified as ACH.

A.3.14 Primary Data Collection: Home Health Agency Survey

We conducted a survey of HHAs to examine key agency structural and operational characteristics and the impact of the HHVBP Model on agency operations in the original HHVBP states compared to agencies in the expansion HHVBP states.

A.3.14.1 Sample Design

The survey was designed comprising two samples: (i) agencies in the nine original HHVBP states and (ii) agencies in the other 41 states. Agencies were excluded from either sample if they had fewer than 20 episodes reported in claims in 2020. All original HHVBP agencies with 20 or more episodes in 2020 were

included in the initial sample. The comparison, non-HHVBP agency sample was drawn using information from Medicare claims, HHA Cost Reports (CMS-1728-94), and the POS file. The following characteristics were used to draw the sample of non-HHVBP HHAs:

(i) Ownership type: For-profit or other (non-profit or government-owned);
(ii) Chain affiliation: Affiliated or not affiliated;
(iii) Setting: Freestanding or hospital-based;
(iv) HHA size: <250 annual Medicare FFS episodes and 250+ annual Medicare FFS episodes

The universe of eligible agencies was distributed among cells based on the joint distributions of the agency characteristics above, separately for HHVBP and comparison agencies that were eligible for the survey. A sample of non-Model agencies was selected to mimic the distribution of HHVBP agencies across the cells defined by these characteristics. The final sample sizes were all 1,545 original HHVBP agencies and 3,249 agencies in non-HHVBP states.

A.3.14.2 Questionnaire Design

We designed the survey instrument, drawing on the 2018 HHA survey administered as part of this evaluation and augmenting to cover recent changes in the industry. The content of the HHA survey instrument for HHVBP agencies was also informed by findings from interviews with HHAs conducted in previous years of the evaluation. The specific set of questions emphasized impacts on agency operations and quality improvement activities, perceived effects of payment adjustments and emphasis on performance improvement, and challenges to operations. Additionally, based on the increasing CMS focus on promoting health equity, we included several questions that explored HHA awareness and understanding of the importance of meeting the cultural and language needs of the populations they serve.

Prior to finalizing the survey instrument and given that many of the questions were drawn from the 2018 survey, we conducted a limited survey pretest with four agency respondents. The purpose of the pre-test was to test the survey flow, whether questions were interpreted as intended and respondents were able to answer, wording was clear and terminology was used appropriately, and response categories were complete. Pre-test respondents completed the survey independently followed by a debriefing with a member of the survey team to assess needed changes. The final survey instrument incorporated feedback from the pre-test as well as feedback from CMS.

A.3.14.3 Fieldwork

The survey was fielded from April through September 2022, using a mixed mode approach of mail and web administration with telephone follow-up to non-responders. An option to complete the web version of the survey was offered through a link provided in the cover letter. Contact information for the HHAs, including agency name, address, and phone number, was obtained from the POS file. For agencies in the original HHVBP Model states, we also used the list of contact information for each HHA's Primary Point of Contact and Corporate Point of Contact developed by the HHVBP Technical Assistance contractor.

Of the 4,794 sampled HHAs, a small number of agencies (n = 43) that opted not to be contacted for research studies were excluded from the final sample,[51] translating to a total of 4,751 HHAs that were

---

[51] These agencies were excluded because they were listed on the vendor's "do not call" list.

invited to complete the survey. The final number of completed surveys was 1,148 (395 HHAs in HHVBP states and 753 HHAs in non-HHVBP states) for an overall response rate of 24.2 percent (24.6 percent for HHAs in HHVBP states, 24.0 percent for HHAs in non-HHVBP states). See Exhibit B-72 for additional detail on the response rates and characteristics of responding agencies in both samples. As indicated in Exhibit B-72, results from statistical tests indicated comparability between agency respondents across HHVBP and non-HHVBP states by key organizational attributes (i.e., ownership type, chain status, setting, and volumne of Medicare FFS episodes).

A.3.14.4 Analysis

The survey data analysis was based on simple univariate and bivariate analyses and descriptive statistics to summarize results by the HHAs located within or outside of HHVBP states. We used frequency counts and cross-tabulations to show distributions of HHAs' responses regarding performance improvement activities, factors motivating these efforts, perceptions of the TPS or scores on performance measures, and perspectives related to the diversity of home health patients. Comparisons were made between agencies in HHVBP and non-HHVBP states using statistical tests (i.e., Chi-square and t tests).

A.3.15 Primary Data Collection: Home Health Agency Interviews

To learn about the impact of the model on HHA operations, we conducted interviews with key informants at 38 agencies in the original HHVBP Model states and 37 agencies in comparison states (75 interviews total). Interviews took place between April and September of 2022. Below we describe our methods for selecting a purposive sample of agencies, data collection, and analysis. While these qualitative interview data are not representative of all intervention or comparison state HHAs, we selected a diverse sample along key dimensions to capture a range of issues and factors likely impacting the broader agency population. Our findings provide a real-world context for interpreting quantitative evaluation results.

A.3.15.1 HHA Interview Sample Allocation and Selection

Sample Allocation

We categorized agencies in both HHVBP and comparison states into one of six groups according to a combination of the following three key characteristics:

- Ownership: For-profit or non-profit[52]
- HHA Size: <450 annual Medicare FFS episodes and 450+ annual Medicare FFS episodes
- Chain status: Part of a HHA chain or not

Obtaining input from agencies with different characteristics helped to ensure that we captured a range of viewpoints. We then allocated a target number of interviews to each of the six groups (see further detail in Exhibit A-70 below). Knowing that some agencies would be unresponsive or decline to be interviewed, we initially identified three times the number of agencies we intended to interview. For both intervention and comparison groups, 120 HHAs were identified as potential interviewees, with a target of 37 – 40 interviews each. This target number enabled us to collect enough data to identify themes on a range of research topics. We set the target number of interviews per group based on the distribution of agencies in HHVBP states across those selected characteristics. The distribution of interviews conducted across states is described in Exhibit A-71.

---

[52] The non-profit category is comprised of non-profit and government-owned HHAs.

Evaluation of the HHVBP Model
Sixth Annual Report: Technical Appendices

Exhibit A-70. Number of HHAs Interviewed by Agency Characteristics

Group	Size	Profit status	Chain status	No. of Target interviews*	No. of HHAs interviewed	
					Original HHVBP	Comparison
1	Large	Non-profit	Chain affiliated	3	2	3
2	Large	For profit	Chain affiliated	8	6	8
3	Large	N/A	Not chain affiliated	9	10	8
4	Small	For profit	Chain affiliated	3	2	3
5	Small	Non-profit	N/A	4	6	4
6	Small	For profit	Not chain affiliated	13	12	11
Total				37 to 40	38	37

The same number of interviews were targeted for the original HHVBP and comparison states.

Exhibit A-71. Number of HHAs Interviewed by State

Original HHVBP states	No. of HHA Interviews	Comparison states	No. of HHA Interviews
Florida	20	Texas	8
Arizona	4	California	4
Iowa	3	Illinois	4
Massachusetts	3	Ohio	4
Nebraska	3	Indiana	3
Maryland	2	Pennsylvania	2
Tennessee	2	South Carolina	2
Washington	1	Virginia	2
		Alaska	1
		Michigan	1
		Missouri	1
		Montana	1
		New Mexico	1
		Oklahoma	1
		Utah	1
		West Virginia	1
Total	38	Total	37

Below we describe how we selected the comparison state agency and HHVBP state agency samples, followed by a description of the process for replacing HHAs when outreach was unsuccessful.

Comparison State HHA Selection Process

To select the sample of 120 comparison state HHAs, we identified agencies that did not receive our 2022 HHA survey (to reduce participant burden) and provided at least 20 home health episodes in 2020. We drew a simple random sample of the specified number of agencies, stratified by agency characteristic group as defined in Exhibit A-70. Within those 120 HHAs, we selected 40 HHAs for initial outreach to match the distribution across groups. We conducted the interviews with comparison state agencies first,

117

between April and June of 2022, selecting from agencies that were not also asked to complete the HHA survey which was fielded beginning in April 2022.

HHVBP State HHA Selection Process

We drew the sample of 120 original HHVBP state HHAs using the same approach as outlined above for the comparison state sample selection. However, because all HHVBP HHAs received our 2022 HHA survey, we could not exclude these agencies from the eligible pool. We began conducting interviews with HHVBP state HHAs in July 2022 in order to allow for some time to lapse between when agencies received the HHA survey and a request for an HHA interview. Of the 120 HHAs in the HHVBP state sample, 14 HHAs were deprioritized for outreach given our prior communications with those agencies.[53] Of the remaining HHAs in the sample, the target number was selected from each group outlined in Exhibit A-70. HHAs were selected to reflect the group targets and to ensure that at least one agency from each of the nine intervention states was included.

Replacing Nonresponsive or Unwilling HHAs

Agencies that declined to be interviewed or that did not respond after repeated outreach attempts were replaced with agencies that were as similar as possible in the three key characteristics described above as well as location. Whenever possible, HHAs were replaced with an HHA in the same group or a similar group (i.e., group with same size, profit, or chain status). When possible, the replacement also was located in the same state as the originally selected HHA. For large states with many HHAs in the sample (e.g., California and Texas), we chose the HHA in the state that was nearest in location to the original HHA. If there were no other HHAs in the same group and state as the HHA that was being replaced, we selected an HHA from the same group that was in the nearest state, preferably in the same census division or region. If after considering both group and location there were multiple possible HHAs in the sample to replace the original HHA, we selected the HHA with the nearest number of episodes.

A.3.15.2 HHA Outreach

We assigned an interview team to each HHA consisting of a lead interviewer and a note-taker, both of whom were trained on the discussion guide and outreach protocol. The lead interviewer contacted agencies via telephone and email to invite them to voluntarily participate in the interviews and explained the topics that would be covered during the interview.

Whenever possible, we attempted to identify the administrator or clinical leader that had been at the agency since 2016 or at least 2019 to ensure sufficient experience with implementing the HHVBP Model at that agency. In some instances, if that was not possible, we asked the individual to compare their experience at that agency with their previous agency or agencies since the introduction of the original HHVBP Model. While the titles of interviewees varied across agencies, we generally spoke with one or more of the following agency representatives: the administrator for the agency or multiple agencies within a chain (e.g., administrator, branch manager, regional director); the senior staff member responsible for clinical services; and/or the senior staff member responsible for quality improvement

---

[53] Exclusions based on prior communication include: HHA part of a large chain already interviewed at regional or corporate level as part of the comparison state interviews this year (10 HHAs); Outreach to HHA had been unsuccessful in more than one year of past HHA interviews (4 HHAs); HHA was interviewed in more than one prior year (3 HHAs); and HHA administrator had already been interviewed this year as a key stakeholder (1 HHA).

efforts. Interviews with agencies that were part of regional or national chains typically included multiple corporate staff in addition to a local administrator and lasted longer, often up to an hour.

A.3.15.3 Data Collection and Analysis

The qualitative research team developed semi-structured discussion guides for the pilot and comparison state interviews, which CMS reviewed before they were finalized. The team used the guides during interviews to discuss: (1) their approach to performance improvement and response to payer emphasis on performance measurement; (2) how key performance improvement activities have changed since 2016; and (3) the impact of HHVBP on agency operations. The guides also included introductory questions to learn about agency characteristics, such as ownership, chain status, and market, as well as the role of the interviewee(s) to provide context for the interviewee's feedback on the main topics. The guides for the pilot and comparison states covered the same topics and varied primarily in their framing of HHVBP as a potential motivator of performance improvement efforts.

We audio recorded the majority of interviews with permission of the interviewees, and research staff produced transcript-style notes for each interview in a note-taking template that mirrored the discussion guide. The template reinforced consistency in data collection across the HHAs and organized information under pre-defined headings to facilitate analysis.

The research team included interviewers who had been part of the HHVBP Model evaluation team since its inception and decades of experience as qualitative health researchers. This collective experience aided in our ability to ask essential probing questions during interviews and interpret the data within the long-term context of HHVBP implementation. Key research staff summarized agency-level findings at the top of each note taking template. The full team of interviewers and notetakers met once to debrief following completion of the comparison agency interviews, and again following the HHVBP agency interviews. Research staff then incorporated the agency summaries along with descriptive characteristics of each agency in an Excel database. The database included columns by key topic areas, and open-ended fields for additional relevant data and quotes. We designed the Excel workbook to include key information gleaned from the interviews, including:

- Characteristics of the HHAs (based on group status as shown in Exhibit A-70)
- Key performance and quality improvement activities
- Reported impact of HHVBP

Three senior researchers, after completing the data entries, reviewed the data, identified trends, and summarized findings according to key topic areas. This analysis formed the basis of the findings presented in the Annual Report. The team selected quotations to demonstrate common themes or interesting insights and reviewed them for quality and illustrative value.

A.4 Enhancements to Analytic Files

Since completing the analyses for the Fourth Annual Report, we made several changes that improved our linking technique between claims and OASIS assessments, especially for 2019. In this section we provide a brief summary of these changes and their effect on the Medicare spending results.

- ***Incorporating the HICN***. As part of our preparation for compiling current data for each annual report, we refreshed our analytic file. We used updated HH RIFs from the CCW (pulled in April 2021) that reflected longer runout for HH claims than the analytic file used in the Fourth Annual Report (especially for 2019, where all months now had over 12 months of runout), and then linked these claims to OASIS data via the "bene_id" variable. During this process, we noticed that the missing rate of bene_id in OASIS assessment data increased over time, especially after 2018. To resolve this issue and achieve a more consistent (i.e., lower) bene_id missing rate on claims, we supplemented our current matching approach by also using the HICN from OASIS assessment data, and the HICN to bene_id crosswalk available in the CCW.[54] By incorporating the HICN, the bene_id non-missing rates improved (especially for 2018-2019) and was more consistent over the years (i.e., 2013-2020).
- ***Using claims occurrence code instead of claims authorization code***. For final claims with a "from" date 1/1/2020 or later, the claim authorization code is no longer available on claim files. Thus, we could not link 2020 claims with OASIS assessments using the claim authorization code. Instead, as suggested in the Medicare claims manual,[55] we linked the date associated with the claim occurrence code "50" to the OASIS assessment completion date (OASIS item M0090).
- ***Tightening dates used in matching.*** Finally, instead of allowing for up to a 1-day difference in start dates between the HH claims and OASIS assessment, we now required the dates used for linking to match exactly between the two data sources.

Overall, these enhancements improved the linkage between HH claims and OASIS assessments by decreasing the missing rate for many of the OASIS-derived covariates used in our D-in-D models of the spending measures. In all, these changes increased our 2013-2019 sample size for the D-in-D models by approximately 2 percent, with the largest increase occurring for 2019. We continued to include all these enhancements in data processing and linkage techniques for 2021.

---

[54] If a HICN could be mapped to a bene_id in the crosswalk, then the bene_id in the crosswalk was used to supplement the bene_id listed in the OASIS assessment. For patients who had multiple OASIS assessments but with incomplete bene_id information on all of the forms, we applied the bene_id to the entire group of the patient's assessments.

[55] Medicare Claims Processing Manual Chapter 10 - Home Health Agency Billing Table of Contents (Rev. 10696, 03-31-21).

A.5 Analytic File Creation

Below, we first describe the methods that were employed for the different subtopics that are included in the main report, followed by a description of how we created a single Unified Analytic File (UAF) that was used to generate the results presented in this report. The unit of observation of the UAF was either a claims-based episode or an OASIS-based episode.

A.5.1 Analytical Methods for Subtopics

A.5.1.1 Case-Mix

Purpose: To determine if case-mix at the SOC among beneficiaries receiving home health care have changed over time between HHVBP states and non-HHVBP states.

Data Acquisition: The case-mix analyses used home health episode claims data, OASIS assessment data, the MBSF, and Part B carrier, inpatient and outpatient claims.

Data Processing: We included all HH episodes that occurred between 2013 and 2021, excluding DC and US territories. We defined five measures of case-mix: HCC score (first episode), home health utilization among all Medicare FFS beneficiaries at risk of limited functional improvement and those not at risk, for comparison, TNC measure of mobility at the SOC, TNC measure of self-care at the SOC, and count of HCC conditions present at SOC. We examined trends in the mean values of these measures between HHVBP states and non-HHVBP states in the baseline (2013-2015) and post-HHVBP period (2016-2021). We computed yearly and cumulative D-in-D estimates for each of the case-mix measures, adjusting for agency characteristics (setting, ownership, HHA age, HHA size, and chain status), rural status, education level, COVID hospitalization regional rate, COVID regional rate categories, interactions between the treatment indicator and each of the agency characteristics, rural indicator, and education indicator, state fixed effects and state-specific linear trends in the regression model (with the exception of the home health utilization among those at risk of limited functional improvement, where we did not add state-specific linear trends). Details on how these measures were constructed are given below.

HCC Score (First Episode)
One claims-based case-mix measure used in this analysis was the episode-level HCC risk scores, calculated for the first episode in the sequence or for the earliest episode during the previous year among sequences that began more than a year ago (previously described in Section A.2.1.2).

Home Health Utilization among all Medicare FFS Beneficiaries at Risk of Limited Functional Improvement
Another claims-based case-mix measure used in this analysis was an indicator of home health utilization among all Medicare FFS beneficiaries that are at risk of limited functional improvement. A beneficiary was considered to be at risk of limited functional improvement if they had at least one of 20 HCC conditions present during a given year (previously described in A.2.1.2; see Exhibit A-44 for the list of HCCs included).

TNC Measures of Mobility and Self-Care at the SOC
Two of the OASIS-based case-mix measures used in this analysis were the two composite measures of mobility and self-care at the SOC (previously described in Section A.2.1.1). The sum of SOC responses was treated as a continuous variable for this analysis with values ranging from 0 to 15 for mobility SOC measure and from 0 to 23 for self-care measure.

Count of HCCs Present at the SOC

Another OASIS-based case mix measure used in the analysis is the count of HCCs present at the SOC. The measure was calculated by taking the sum of OASIS-based HCCs at the start of the OASIS episode (previously described in Section A.2.1.2). This measure was treated as continuous measure and ranged from 0 to 8 HCCs per episode. Preliminary exploration showed that as the count of HCC conditions increased, the values of the two TNC change measures decreased in both the pooled baseline period and the pooled post-HHVBP period, which means less improvement in self-care and mobility for those with more HCC conditions at the SOC (see Exhibit A-72 below).

Exhibit A-72. Pooled Baseline and Post-HHVBP TNC Change in Self-Care and TNC Change in Mobility Measures by Count of HCC Conditions at the SOC

Number of HCC Conditions at the SOC	TNC Change in Self Care		TNC Change in Mobility	
	2013-2015	2016-2021	2013-2015	2016-2021
0	1.517	2.083	0.479	0.727
1	1.315	1.859	0.419	0.661
2	1.234	1.782	0.395	0.640
3	1.194	1.752	0.383	0.633
4	1.165	1.715	0.375	0.621
5	1.132	1.660	0.366	0.602
6 or more	1.088	1.583	0.349	0.575

A.5.1.2   HHA Operations: Frontloading

Purpose: To determine the frequency, timing, and discipline of home health visits within home health episodes in order to further examine Arbor Research-defined frontloading measures in the Medicare FFS population. Skilled nurse and therapist visit frontloading was evaluated as outcomes using our standard multivariable D-in-D model (see details below) to estimate the relative impact of the HHVBP Model on agency frontloading practices. The impact of frontloading on ACHs, ED visits, and SNF use was also examined using regression models. Subgroup analyses were conducted to further evaluate the effect of frontloading on adverse patient outcomes and the relationship between HHVBP and frontloading practices, stratified by the risk of limited functional improvement, dual eligibility status for Medicare and Medicaid, or the race/ethnicity of beneficiaries. A mediation analysis was conducted to examine frontloading as a potential driver of quality improvement in claims-based utilization measures under the HHVBP model.

Data Acquisition: Frontloading analyses were completed using home health visit claims data, home health episode claims data, the institutional claims, and HHA POS data.

Data Processing: Descriptive analyses included all first home health episodes that occurred between 2013 and 2021, excluding DC and US territories and used the home health visits SAF (see Section A.2.1.2 to determine average cumulative visits by a skilled nurse or by a therapist (occupational, physical, and speech therapists combined) for two time checkpoints: 7 and 14 days following the start of a home health episode. Home health first episodes were stratified by the Arbor Research-defined admissions

source (community vs. institutional, see Section A.2.1.2 above) and HHVBP status. Based on the average cumulative visit counts within the first 7 and 14 days of the HH episode, two binary indicator flags were created to signify episodes in which the number of SN visits or the number of therapy visits that occurred in the first week of home health care was greater than the number of visits in the second week for each respective type. Episodes with more than half of their cumulative 2-week visits occurring in the first week relative to the second week of care were flagged as "frontloaded." Once frontloading was determined in first-in-sequence episodes, a corresponding frontloading flag was assigned at the beneficiary-episode sequence-level; later-in-sequence episodes were determined to be frontloaded based on their first episode status.

Frontloading regression analyses were confined to post-institutional episodes only. Included episodes lasted at least two weeks and did not have a hospitalization in that two-week timeframe in order to ensure a "baseline" period of time in which frontloading could occur. We also excluded episodes not linked to an OASIS assessment and episodes with missing values for any model covariates. Predictive regression analyses were run to examine the association between the indicator that the first week proportion of SN or therapy visits was greater than the second week proportion (Arbor Research-defined frontloading) and clinical outcomes, including ACH (first and all episodes), ED use (first episodes only), and SNF use (all episodes). Frontloading D-in-D models contained all covariates included in our main D-in-D models (Exhibit A-3, Exhibit A-6) and also adjusted for the number of ED visits occurring within that two-week timeframe. We adjusted for the number ED visits during the first two weeks of home health care to control for potential confounding between ED use that may prohibit some home health visits and also indicate greater likelihood to use the ED after the initial two weeks of care. Statistically significant falsification results, indicating a lack of parallel trends, dictated the inclusion of state linear time trends in the model to reduce bias. Models were also adjusted for HCC score as another means to reflect patient case mix acuity.

A traditional mediation analysis was conducted for a pooled sample (not stratified by prior care setting) of claims-based episodes, applying frontloading baseline exclusions of episodes not at least two weeks long or where a hospitalization occurred within those first two weeks of home health care. This analysis is reported in Section 4.3.3 of this Sixth Annual Report. A D-in-D model was run for each of four claims-based utilization outcomes: Unplanned ACHs in *first* and in *all* FFS HH episodes, ED use (no hospitalization) in *first* FFS home health episodes, and SNF use in *all* FFS HH episodes. These models were adjusted for the core list of claims-based model covariates as well as ED visits in the first two weeks of home health care and HCC score. A second iteration of these models was run, including an additional adjustment for either Skilled Nurse or Therapy frontloading. The *direct effect* of HHVBP on these outcomes was defined as the cumulative D-in-D effect estimate for the HHVBP model, in models with the additional adjustment for frontloading. The *indirect or mediated* effect could be determined by subtracting that direct effect estimate from the D-in-D estimate from the model that was **not** adjusted for frontloading. This process is known as the "Difference Method" of mediation analysis,[56] often applied in epidemiologic and social sciences research.

For frontloading subgroup analyses, we divided post-institutional episodes into four sets of subgroups. The subgroups include (1) index discharges among FFS beneficiaries considered high risk of limited

---

[56] VanderWeele, Tyler J. "Mediation Analysis: A Practitioner's Guide." *Annual review of public health* vol. 37 (2016): 17-32.

functional improvement based on their HCCs versus all other index discharges (see Exhibit A-44 and related text in Section A.2.1.2 of this Technical Appendix for more details about identification of at-risk HCCs), (2) Dually Eligible versus Non-Dually Eligible, (3) Black non-Hispanic versus White non-Hispanic and (4) Hispanic versus White non-Hispanic. Stratified regression analyses of the impacts of frontloading on claims-based utilization outcomes and stratified D-in-D analyses of the HHVBP impact on episode-level frontloading were conducted for each of these four subcategories. We also used a D-in-D-in-D approach to evaluate differential impacts of the HHVBP model within each subgroup for post-institutional, first-in-sequence episodes (see Section A.5.1.7 for details regarding D-in-D-in-D model specification).

A.5.1.3   Entry and Exit of HHAs

Purpose: To calculate the rates of HHA openings and closures over time.

Data Acquisition: We used POS data (see Section A.3.4). Empirically, there was a data lag in certification and termination dates in CMS POS data beyond the lag for other data sources used in this report. The completion rate of CMS POS data is about 99 percent for participation dates and 93 percent for termination dates, with a one year lag in reporting. See Exhibit B-8 below for the quarterly counts of entering, exiting, and open HHAs in HHVBP and non-HHVBP states for 2013 Q1 through 2020 Q3.

In addition to the normal one year data lag in certification and termination dates described above, in 2021, Q4 QIES migrated to iQIES introducing an additional delay in POS data extracted after October 2021. To account for this delay, we did not use any POS data released after 2021 Q3 and therefore only show entry and exit results through 2020 Q3 for this Annual Report.

Data Processing: Entry of new HHAs was determined by the HHA certification date in CMS POS data. The HHA entry rate was calculated by dividing the number of HHAs with certification dates in a given quarter divided by the number of HHAs open at any point in a given quarter. Exit of existing HHAs was determined by the HHA termination date in CMS POS data. The HHA exit rate was calculated by dividing the number of HHAs with termination dates in a given quarter divided by the number of HHAs open at any point in a given quarter (see Section A.2.5 for measure definitions).

We also calculated periods of inactivity when an HHA is open according to the POS certification and termination date, but the HHA does not have any OASIS or claims-based home health episodes. We observed that these HHAs are often small, in the process of opening or closing, and tend to serve specialized groups of patients such as pediatric patients (who are excluded from OASIS assessments and may not have Medicare coverage). We excluded these inactive HHAs from most of our analyses based on OASIS or claims-based episodes, where HHA counts are determined using the presence of OASIS or claims-based home health episodes in a given year and where home health episodes are the basis of the HHVBP program quality measures. However, we *included* these inactive facilities in the denominator of the HHA entry and exit analyses, which uses CMS POS data to determine the number of open HHAs. Therefore, the HHA counts used in the entry and exit analyses may differ from other analyses that exclude agencies without OASIS or claims-based home health episodes in a given time period.

A.5.1.4   Low/High Performers and Social Risk Factors

Purpose: To examine the association between agency TPS and patient mix based on social risk factors.

Data Acquisition: Agency TPS calculated using QIES roll-up data, POS data, and HHCAHPS data.

Data Processing: We identified 7,552 agencies eligible for TPS based on performance year 2021 (HHVBP: 1,505; Non-HHVBP: 6,047). We then classified agencies into three groups (high, middle, and low performers) based on TPS quartiles by state. The top 25% of agencies was defined as the "higher TPS" cohort, the bottom 25% of agencies was defined as the "lower TPS" cohort, and the middle 50% of agencies was defined as the "middle TPS" cohort. The percentages were 24.9%, 24.8%, and 50.3% for each category, respectively. The distribution was similar in HHVBP and non-HHVBP states.

Below are the definitions used for comparing patient demographics and social risk factors among HHAs that are high/low performers:

- Age greater than 85: proportion of HHA episodes for patients age greater than 85 years
- Black: proportion of HHA episodes for Non-Hispanic Black patients
- Hispanic: proportion of HHA episodes for Hispanic patients
- Rural: proportion of HHA episodes for patients living in rural areas
- Dual Eligibility: proportion of HHA episodes for dually eligible beneficiaries
- Poverty: proportion of HHA episodes for patients living in "high poverty" areas (defined as >=20% poverty in their county of residence)

A.5.1.5   Home Health Utilization and Access to care

Purpose: To examine the extent to which there is geographic variation in FFS beneficiary utilization of home health care and access to home health care, and to investigate if HHVBP has affected beneficiary access to or utilization of home health care.

Data Acquisition: These analyses used the following data sources: MBSF and Medicare FFS claims data including home health and inpatient, AHRF, and USAfacts.org.

Data Processing: We carried out analyses at the beneficiary-year level and county-year level. Medicare beneficiaries with at least one month of FFS coverage in a given year were included in the analysis. Beneficiaries residing in US territories or Washington DC were excluded. Beneficiary-year level data were aggregated to the county-year level and merged on SSA state and SSA county codes with ARHF county-level data and county-level regional COVID indicator data to obtain county-level rural status and county-level COVID-19 rates and COVID-19 hospitalization rates. The county-level regional COVID indicator used for this analysis is described in Section A.2.1.2 with one difference. The variable was categorized into three groups (0-25th percentile, 35th-75th percentile, and 75th-100th percentile) based on the distribution of counties without ever linking to home health episodes. For these analyses, the population of interest is all Medicare FFS beneficiaries rather than home health beneficiaries.

Descriptive rates are shown at the beneficiary-year level. Modeling was performed at the county-year level weighting on the total number of FFS beneficiaries per county-year clustering standard errors on state and county. Since state level models (HHVBP states vs. their regional comparison groups) failed falsification tests, to be consistent between state and national findings, the D-in-D models at the national level were also adjusted for state-specific linear time trends (Refer to Section A.5.1.4 for more details)

A.5.1.6 Underserved populations

Purpose: To examine potential unintended consequences of HHVBP for more underserved populations. Specifically, we assess whether or not the HHVBP program has resulted in widened or reduced disparities in outcomes involving home health beneficiaries enrolled in Medicaid or living in rural areas.

Data Acquisition: Underserved population analyses used the same analytical files that were created for the standard D-in-D models for the main comparison group approach of the HHVBP evaluation.

Data Processing: Analyses were carried out at the home health episode level for both the Medicare FFS and OASIS populations with a focus on home health beneficiaries with socioeconomic and geographic characteristics that were associated with poorer outcomes prior to the implementation of HHVBP. Underserved populations were defined as (1) home health beneficiaries enrolled in Medicaid and (2) Hispanic ethnicity and Non-Hispanic Black, White, Other, and Multiracial home health beneficiaries. These subgroups were compared to non-Medicaid and Non-Hispanic White reference groups, respectively. Analyses restricted to the Medicare FFS population compared home health beneficiaries with dual eligibility in Medicaid and Medicare FFS to the rest of the Medicare FFS home health beneficiaries.

We examined potential disparities prior to the implementation of HHVBP (2013-2015) by Medicaid status and race/ethnicity using linear regression models with HHA clustered standard errors and covariate adjustments for beneficiary and agency characteristics (see Exhibit A-3) and clinical factors and reason for entitlement (Exhibit A-6) also used as covariates in the standard D-in-D models for the main comparison group approach. We additionally included adjustments for state Medicaid expansion, HCC score (for claims-based outcomes), measures of TNC mobility and self-care at the SOC, and TNC SOC variables interacted with an indicator for HHVBP intervention state (for OASIS outcomes; described in Section A.2.1.1).

We used an extension of the standard D-in-D model to examine the differential impact of HHVBP by HH beneficiary subgroup on a selective set of five measures. These included two FFS claims-based HHVBP utilization measures (Unplanned ACH/First FFS HH Episodes and Outpatient ED Use [No Hospitalization]/First FFS HH Episodes), and two OASIS-based improvement in functional status measures (TNC Change in Self-Care and TNC Change in Mobility). The difference-in-difference-in-differences (D-in-D-in-D) approach (as described below) tests for differences in subgroup D-in-Ds by including two- and three-way interactions for treatment, post-HHVBP, and subgroup while using the same covariate adjustments in the baseline models. These models included adjustments for APM and RCD alignment (Exhibit A-8) and COVID-19 (Exhibits A-4 and A-5) also used as covariates in the standard D-in-D models for the main comparison group approach. Additionally, Medicaid, Hispanic, and Non-Hispanic were interacted with post-institutional care and surgical wounds for a total of six interactions terms. Using the same model, we are able to simultaneously test for the effect of HHVBP within the individual subgroups.

We also tested the potential disparities of skilled nursing and therapy visit frontloading status for underserved population. We examined the baseline period (2013-2015) differences using linear regression model, and the difference of HHVBP effect between dual eligibility status and race/ethnicity subgroups with D-in-D-in-D model (See Section A.5.1.2 for details regarding refined study sample and model covariates).

A.5.1.7 Difference-in-Difference-in-Differences Model

The D-in-D model enables estimation of overall treatment effect of the HHVBP by comparing changes in observations in the HHVBP states to those in the non-HHVBP states. An extension of this model enables subgroup analyses to assess whether the effect of the HHVBP differs (is heterogeneous) among groups. A D-in-D analysis is fit within a subgroup, that is, the changes in impact measures observed over time within the subgroup in the HHVBP states is compared to corresponding changes in the same subgroup in the non-HHVBP states. Mathematically, we have

$$D\text{-in-}D_{SG} = [Y_{INT,POST,SG} - Y_{INT,PRE,SG}] - [Y_{COMP,POST,SG} - Y_{COMP,PRE,SG}].$$

Note that this expression is the same as the overall D-in-D model with the subscript "SG" indicating subgroup. A D-in-D model fit for the reference subgroup yields

$$D\text{-in-}D_{Ref} = [Y_{INT,POST,Ref} - Y_{INT,PRE,Ref}] - [Y_{COMP,POST,Ref} - Y_{COMP,PRE,Ref}],$$

with the subscript "Ref" indicating the reference subgroup.

The subgroup D-in-D model is then contrasted with the reference subgroup D-in-D:

$$D\text{-in-}D_{SG} - D\text{-in-}D_{Ref} = \{[Y_{INT,POST,SG} - Y_{INT,PRE,SG}] - [Y_{COMP,POST,SG} - Y_{COMP,PRE,SG}]\} - \{[Y_{INT,POST,Ref} - Y_{INT,PRE,Ref}] - [Y_{COMP,POST,Ref} - Y_{COMP,PRE,Ref}]\}.$$

This is the difference in two D-in-D estimates, the difference in difference in differences (D-in-D-in-D). It estimates the effect of the intervention on a subgroup of interest over and above the general effect of the intervention. Mathematically, it is represented by a three-way interaction between indicators of treatment, post-intervention, and subgroup membership. The associated D-in-D-in-D model also includes the two-way interactions among pairs of subgroup, intervention, and post-intervention indicators as well as the main effect of subgroup membership. Building on the D-in-D model presented earlier, the D-in-D-in-D model for this analysis is

$$Y_{i,p,t} = \alpha_0 + \alpha_1 Treat_i + \sum_{k=1}^{k=6} \beta_k I(t = t_k) + \lambda_0 I_d(p) + \sum_{k=1}^{k=6} \delta_k Treat_i * I(t = t_k) + \varphi_0 I_d(p) Treat_i$$

$$+ \sum_{k=1}^{k=6} \lambda_k I_d(p) * I(t = t_k) + \sum_{k=1}^{k=6} \varphi_k I_d(p) Treat_i * I(t = t_k) + \sum_{j=1}^{j=3} \rho_j I(q = j)$$

$$+ \sum_{s=3}^{s=50} \theta_s I(S = s) + \sum_{s=1}^{s=50} \gamma_s time * I(S = s) + \omega P_{Cov} + \epsilon_{i,p,t}.$$

Where k = 1 to 6 for years 2016-20201 Additionally:

- $Treat_i$: 1, 0 indicator (1= HHVBP states, 0= Non-HHVBP states)
- $I_d(p)$: 1, 0 indicator (= 1 if episode p belongs to the subgroup, 0 otherwise)
- $I(t = t_1)$: 1, 0 indicator (1 when year = 2016, 0 otherwise)
- $I(t = t_2)$: 1, 0 indicator (1 when year = 2017, 0 otherwise)
- $I(t = t_3)$: 1, 0 indicator (1 when year = 2018, 0 otherwise)
- $I(t = t_4)$: 1, 0 indicator (1 when year = 2019, 0 otherwise)
- $I(t = t_5)$: 1, 0 indicator (1 when year = 2020, 0 otherwise)
- $I(t = t_6)$: 1, 0 indicator (1 when year = 2021, 0 otherwise)

- α_0 is an intercept
- α_1 is the average difference between the HHVBP and comparison populations over the pre-implementation period
- β_k is the average change from pre- to post-implementation for the HHVBP population in a given year, where k = 1 for year 2016, k = 2 for year 2017, k = 3 for year 2018, k = 4 for year 2019, k = 5 for year 2020, and k = 6 for year 2021
- δ_k is the yearly D-in-D effect, for k = 1, 2, 3, 4, 5, 6; the difference in the change from pre-implementation to post-implementation for the HHVBP population relative to the comparison population (i.e., to estimate the treatment effect of HHVBP)
- λ_0 is the main effect of belonging in the subgroup, the average difference between belonging to the subgroup vs. not over the pre-implementation period
- λ_k is the average change from pre- to post-implementation in a given year for the subgroup population, where k = 1 for year 2016, k = 2 for year 2017, k = 3 for year 2018, k = 4 for year 2019, k = 5 for 2020, and k = 6 for 2021.
- φ_0 is the average difference between the subgroup in the HHVBP states and the subgroup in the comparison states during the pre-implementation period (i.e., the interaction effect of subgroup and HHVBP status).
- φ_k is the yearly D-in-D-in-D effect for years indexed by k; the D-in-D-in-D estimates from pre-implementation to post-implementation for the HHVBP population relative to the comparison population between belonging to a subgroup vs. not (i.e., the subgroup effect)
- ρ_j coefficients capture seasonal effects associated with the four quarters of the year, where j = 1, 2, 3 (one quarter omitted as reference)
- ω is a vector of coefficients associated with vector of covariates $\mathbf{P}_{Cov}$
- $I(S = s)$: 1, 0 indicator (1 when from state s, 0 otherwise); two states omitted as reference since "treat" is also included in the model
- θ_s coefficients are fixed effects for each state s
- $time$: linear term ranging from 2013-2021
- γ_s: coefficients associated with state-specific linear trends, time trends for each state interacted with fixed effects indicator for each state s
- $\epsilon_{i,p,t}$ episode-specific error term.

We evaluated the treatment effect of the HHVBP within a given subgroup, comparing the response in the subgroup in the treatment group to that of the same subgroup in comparison group using a D-in-D framework. We then tested the subgroup D-in-D estimates forming the D-in-D-in-D model. Illustrating with an example, with dually eligible patients being a subgroup we first calculate a D-in-D estimate of the measure for dually eligible patients and non-dually eligible patients respectively. Then we calculate the difference in the subgroup D-in-D estimates resulting in the D-in-D-in-D estimate.

As with the D-in-D model, we included three estimates (ρ_1, ρ_2, ρ_3) capturing quarterly effects. Again, each episode was given an equal weight except for the four average Medicare spending per day measures, which were appropriately weighted by the number of days included in the denominator (see Section A.2.2). In order to obtain the average annual (cumulative) impact estimate over the six HHVBP Model years (i.e., 2016-2021), we calculated a linear combination of the six year-specific impact

estimates with each year's impact weighted by the number of HHVBP episodes in that year, or in the case of the spending measures, weighted by the sum of denominator days in HHVBP states for the year.

Also consistent with the D-in-D model, standard errors were clustered at the agency-level. Similar to D-in-D model specification, in this model we stratified at the state level to account for greater homogeneity within states than across states.

Estimations for various effects appear in Exhibit A-73. Note that the effects in the "Reference Subgroup (Indicator = No)" section correspond to those presented for the simple D-in-D model in Exhibit A-10. The yearly D-in-D estimators are given by the coefficients δ_i, I = 1, 2, 3, 4, 5 and 6. The D-in-D-in-D coefficient, φ_k indicates whether the between-intervention group differences for each subgroup of interest, increased ($\varphi_k > 0, k = 1, 2, 3, 4, 5, 6$) or decreased ($\varphi_k < 0, k = 1, 2, 3, 4, 5, 6$) after implementation of HHVBP.

Exhibit A-73. D-in-D-in-D Estimators for Individual Post-Implementation Years

Subgroup	Intervention Group	Pre-Implementation	Post-Implementation	Pre-Post Difference
Yearly Estimators, i =1, 2, 3, 4, 5 and 6 for 2016, 2017, 2018, 2019, 2020, and 2021 respectively				
Reference Subgroup (Indicator = No)	HHVBP	$\alpha_0 + \alpha_1$	$\alpha_0 + \alpha_1 + \beta_i + \delta_i$	$\beta_i + \delta_i$
	Non HHVBP	α_0	$\alpha_0 + \beta_i$	β_i
	Between intervention groups within subgroup (D in-D estimate for this subgroup)	α_1	$\alpha_1 + \delta_i$	δ_i
Each Subgroup of Interest (Indicator = Yes)	HHVBP	$\alpha_0 + \alpha_1 + \lambda_0 + \varphi_0$	$\alpha_0 + \alpha_1 + \beta_i + \lambda_0 + \varphi_0 + \delta_i + \lambda_i + \varphi_i$	$\beta_i + \delta_i + \lambda_i + \varphi_i$
	Non HHVBP	$\alpha_0 + \lambda_0$	$\alpha_0 + \beta_i + \lambda_0 + \lambda_i$	$\beta_i + \lambda_i$
	Between intervention groups within subgroup (D in-D estimate for this subgroup)	$\alpha_1 + \varphi_0$	$\alpha_1 + \delta_i + \varphi_0 + \varphi_i$	$\delta_i + \varphi_i$
	Between subgroups (D-in-D-in-D)	φ_0	$\varphi_0 + \varphi_i$	φ_i

The subgroups that were analyzed are:
a) Medicaid versus non-Medicaid
b) Dually Eligible versus Non-Dually Eligible
c) Race was categorized into 5 groups: White, Black, Hispanic, Multiracial, and Other. Following the race/ethnicity definition explained in Section A.2.1, we analyzed each race group in respect to Non-Hispanic White.

As with the D-in-D model, we calculate the cumulative estimate as the weighted average of the
yearly estimates to ensure that the cumulative estimate is consistent with the yearly D-in-D
estimates. We calculated the weights for each of the measure domains as follows:

- For the claims-based utilization measures - the proportion of claims episodes in each year
- For OASIS-based outcome measures – the proportion of OASIS episodes in each year

A.5.1.8 Substitution among PAC Alternatives

Purpose: To examine changes in use of alternative forms of PAC following the HHVBP Model
implementation, which may be considered substitutes for home health care. The alternative forms of
PAC include SNFs, IRFs, LTCHs, and discharges to home with no PAC or only outpatient therapy service.

Data Acquisition: Substitution of care analyses used the following data sources: Medicare FFS inpatient
hospitalization, outpatient, HHA, and SNF claims, the MBSF, and the AHRF.

Data Processing: Analyses were carried out at the index discharge level. An analytic file was constructed
using inpatient claims for all Medicare FFS beneficiaries with a short-term acute hospital discharge
during 2013-2021. The analytic sample was restricted to beneficiaries based on the following criteria: (1)
enrollment in Medicare FFS Parts A and B during 12 consecutive months prior to the index discharge
date; (2) alive at discharge with continued enrollment in FFS Parts A and B for at least 14 days following
the index discharge date; (3) the DRG reported on the index discharge inpatient claim was among the
top 10 MDCs among beneficiaries who are discharged to the care of an HHA.

Next, we looked out 14 days from each index discharge date for Medicare FFS claims from HHAs,
institutional care (i.e., IRFs, SNFs, and LTCs) and hospital outpatient therapy care (i.e., physical therapy
[revenue center code 0420:0429], occupational therapy [revenue center code 0430:0439], or speech
language pathology [0440:0449]) provided to the same FFS beneficiary. PAC type for each index
discharge was then defined based on the earliest claim from date within 14 days of the discharge date.
Home health was additionally defined as the PAC type in the event that an earlier home health episode
for the same beneficiary overlapped the index discharge date with no other claims from alternate forms
of PAC found within 14 days of discharge.

The distribution of PAC types was then calculated separately for HHVBP states and non-HHVBP states
during the pre- (2013-2015), early post- (2016-2017), post-(2018-2019), and PDGM post-(2020-2021)
implementation periods. We used linear regression models with D-in-D to estimate the effect of HHVBP
on the selection of PAC type (each defined as a binary indicator) clustering for hospital provider and
adjusting for covariates that were not sufficiently balanced between groups during baseline (2013-2015)
including patient age, rural beneficiary residence, and ACO SSP and Pioneer APM indicators, poverty and
education indicators aggregated to the county level. We additionally adjusted for seasonality, county-
month-level inpatient COVID-19 rates, and three USA facts county-month COVID-19 case rate
categories.

We additionally used the D-in-D-in-D approach to examine the differential impact of HHVBP by two sets
of subgroups on the selection of PAC. The subgroups include (1) index discharges associated with ACOs
versus all other index discharges and (2) index discharges among FFS beneficiaries considered high risk
for limited functional improvement based on their HCCs versus all other index discharges (see Exhibit A-
44 and related text in Section A.2.1.2 of this Technical Appendix for more details about identification of

at-risk HCCs). These linear regression models used the same clustering for hospital provider and covariate adjustments as with our D-in-D approach. Because of evidence of non-parallel trends in the baseline for our main regression model when applied using a D-in-D-in-D, we further specified a fully interacted model for the at-risk HCCs versus other subgroups by interacting the binary subgroup indicator with all of the model covariate adjustments. This revised covariate approach produced baseline evidence consistent with the parallel trends assumption.

A.5.1.9   Changes in OASIS-Reported Functional Status

For our analyses that investigated changes in three OASIS-based functional performance outcomes, we focused on FFS home health users with a prior inpatient stay and falling into one of three "cohorts"—heart failure, pneumonia, or knee/hip replacement—defined by the primary diagnosis associated with the inpatient admission stay that preceded the home health episode. These diagnoses are highly prevalent in the Medicare population, involve beneficiary populations with diverse characteristics, and provide different scenarios through which to observe how case-mix factors could impact performance measures. In the period between 2013 and 2019, heart failure diagnosis was associated with 5.0 percent of all acute care discharges, pneumonia with 4.4 percent and knee/hip replacement with 6.2 percent.

For each of these three cohorts, we examined three OASIS-based functional performance measures: Improvement in Dyspnea, Improvement in Ambulation, and Improvement in Grooming. We conducted stepwise multivariate regression analysis to assess the time trends of improvement in these functional measures from the initial or SOC OASIS assessment to the discharge or EOC OASIS assessments, when 2018 to 2019 results were compared to 2014 to 2015 results. Our analysis accounted for beneficiary health upon their SOC with HHAs, length of care, and patterns of clinical care HHA delivered, including visit timing, intensity, and visit mix (i.e., visits by different types of providers).

A.5.1.10 MA

Purpose: To examine the "spillover" impact of the HHVBP model on the MA beneficiary population. We have seen that the HHVBP model has had an impact on key utilization measures, as well as an impact on overall functionality among the broader home health population (OASIS). We examine beneficiary characteristics and home health utilization among all MA beneficiaries, using OASIS episode data. Additionally, we utilize MedPAR and MA encounters to determine what effect, if any, the original HHVBP model has had on measures of unplanned ACH for the MA population.

Data Acquisition: MA analyses use the following data sources: OASIS episode data, MBSF, Medicare inpatient claims, MedPAR inpatient shadow claims, and MA inpatient encounters.

Data Processing: Unlike traditional Medicare, MA Organizations (MAOs) are responsible for providing benefits to enrollees in Medicare Part C. However, the MAOs are not required by CMS to follow Medicare claims processing procedures and methods of payment (e.g. capitated payments versus bundled services) to the providers may vary.[57] Consequently, MA encounter data for home health stays do not capture all services and do not correspond closely to 60-day periods (30 day periods starting in 2020), which is why we were unable to construct home health episodes from MA encounters in the same manner as FFS claims. Alternatively, we were able to obtain periods of home health care for MA

---

[57] Centers for Medicare & Medicaid Services. (2021) Chronic Conditions Warehouse Medicare Encounter Data File User Guide V-2.5. Available at: https://www2.ccwdata.org/web/guest/home/. Accessed 11/21/22.

beneficiaries by using OASIS and restricting the data to MA enrollees using monthly HMO indicators in the MBSF linked at the start of the OAISIS episode.

As a result, analyses were carried out at the OASIS episode level for measures of unplanned ACH. An analytic file was constructed using OASIS episodes starting in 2013-2020 for all home health beneficiaries enrolled in Medicare FFS (Parts A and B) or MA (Part C). This included linkage to inpatient data to construct the numerators for measures with 60-day look out periods from the start of the OASIS episodes as described earlier in Exhibit A-59. The file also included variables for patient and agency characteristics as well as OASIS SOC clinical indicators. We examined differences in the patient mix and agencies treating MA beneficiaries compared to FFS beneficiaries in both HHVBP and non-HHVBP states during the pre- (2013-2015) and post- (2016-2020) implementation periods.

Two methods were used to construct the ACH numerator for the MA home health beneficiaries: (1) The primary method included zero-dollar inpatient shadow claims corresponding to hospital admissions between 2013-2020 pulled from the MedPAR file and (2) the alternate method included inpatient encounters corresponding to hospital admissions between 2015-2020. For both methods OASIS episodes were excluded from Nov-Dec 2020 due to insufficient inpatient data needed for the 60-day look out period. For comparison purposes we also constructed the numerator for the Medicare FFS beneficiaries using inpatient claims corresponding to hospital admissions between 2013-2020. We then compared the trends in unadjusted unplanned ACH rates for the MA home health beneficiaries from 2013-2020 based on the inpatient shadow claims to the Medicare FFS home health beneficiary unadjusted unplanned ACH rates from 2013-2020 using inpatient FFS claims.

Measurement Differences due to Use of Truncated OASIS Episodes. As discussed above, while traditional Medicare claims are not available for MA beneficiaries, we were able to construct a measure of unplanned ACH use with (1) zero-dollar "shadow claims," for the numerator and (2) OASIS episodes as the denominator. This denominator is considerably different from our preferred measure definition for unplanned ACH, which uses traditional Medicare home health claims. Medicare claims-based home health episodes use a maximum of 60 days, but OASIS episodes have no maximum and often span a home health patient's entire duration of care.

To improve comparability, we restrict the OASIS episodes for our measure of unplanned ACH in MA to the first 60 days, truncating approximately one-quarter of OASIS episodes. This is important as short durations of home health care often end in a transfer to ACH. These short durations of care are included in our truncated OASIS episodes, while periods of care beyond the first 60 days that have relatively lower rates of unplanned ACH are excluded.

To examine the sensitivity of our results, in our MA analyses, to this methodological difference with other Medicare claims-based analyses, we used these methods with the traditional Medicare FFS data, confirming these methods result in higher rates of unplanned ACH (main report Exhibit 50) than our preferred specification (main report Exhibit 42). We also tested applying weights to untruncated OASIS episodes (extending beyond 60 days) reflecting the total untruncated duration of the OASIS episode. We found this mitigated much of the difference in measure levels across methods; however, because weighted analyses did not substantially affect the bottom line impact estimates from D-in-D analysis (main report Exhibit 51), we report the simpler unweighted results.

D-in-D analyses. For the main analysis, we used linear regression models with D-in-D to estimate the "spillover" effect of the HHVBP model on unplanned ACH (used as a binary indicator) based on shadow claims for the MA beneficiary population while clustering for agency and adjusting for patient and agencies characteristics, OASIS SOC clinical indicators, and state fixed effects. Similar regression models with D-in-D estimates were used to conduct sensitivity analyses to test the impact estimates in a few other ways: (1) We modeled unplanned ACH among the MA beneficiary population using inpatient encounters as an alternate approach, which was limited to only 2015 data for a baseline period; (2) We reaffirmed the impact of HHVBP in the Medicare FFS beneficiary population using the analogous measure of ACH constructed with inpatient FFS claims, in which the D-in-D model included an additional adjustment for state linear trends; (3) Since not all acute care hospitals submit shadow claims, we conducted a sensitivity analysis that excluded home health episodes from counties where more than 10 percent of all FFS claims were from hospitals that did not submit shadow claims and repeated the D-in-D models for the MA beneficiary population.

When determining the unplanned ACH rates using OASIS episodes as a denominator, the HHVBP model resulted in a 0.93 percentage point decrease for FFS beneficiaries in HHVBP states relative to non-HHVBP states, across all post-implementation years (see Exhibit A-49 in the Supplemental Tables and Results for D-in-D results). This has the same direction but greater magnitude than the 0.19 percentage point impact of HHVBP when using our preferred denominator approach with FFS claims data (Section 6.3). Noted above, this measure was constructed to create a reasonable comparison between the FFS population and the MA population.

Analyses were also carried out at the beneficiary level for measures of home heath utilization. We compared the trend in the percentage of MA beneficiaries with at least one OASIS episode from 2013-2021 to an analogous measure constructed for Medicare FFS beneficiaries.

A.5.2 Claims-Based Episodes

For observations that represent a claims-based home health episode, the data set provided claims-based episode information (e.g., episode type, therapy visits), HHA information, claims-based measures, MBSF-based beneficiary enrollment and chronic condition data, linked OASIS-based episode information (e.g., start date, end date, OASIS assessment ID), and OASIS assessment information (e.g., demographics, payment, inpatient diagnosis, timing). OASIS information was extracted from the overlapping OASIS-based episode with the earliest episode start date; the rationale behind this was that claims-based episodes were included in claims-based measure denominators based on episode start date, and our goal was to include OASIS information corresponding to the same measurement period.

A.5.3 OASIS-Based Episodes

For observations that represent an OASIS-based home health episode, the data set provided OASIS-based episode information (e.g., start date, end date, OASIS assessment ID), OASIS-based measures, OASIS assessment information (e.g., demographics, payment, inpatient diagnosis, timing), MBSF-based beneficiary enrollment and chronic condition data, linked claims-based episode information (e.g., episode type, therapy visits), and HHA information. Claim information was extracted from the overlapping claims-based episode with the latest episode start date; the rationale behind this was that OASIS-based episodes were included in OASIS-based measure denominators based on episode end date, and our goal was to include claims-based information corresponding to the same measurement period.

A.5.4 Construction of Unified File

The unification of the claims-based and OASIS-based home health episodes began with compiling the base data sources: claims-based episodes, OASIS-based episodes, and OASIS assessment-level data. For claims-based episodes, we maintained all episodes that began on or before 12/31/2021 and ended on or after 01/01/2013. For OASIS-based episodes of care, we maintained all episodes with an end date from 2013 through 2021, including those with end reason for assessment equal to "Death" although these episodes were excluded from the HHVBP OASIS outcome measures. We maintained all OASIS assessments that were pulled from the CCW Oracle database, which covers assessments effective from 2009 through 2021; this ensured that we had all available assessments that could potentially be linked to a claims- or OASIS-based episode during our measurement period. Among these assessment-level records, we kept only the variables of interest to analyses in the Annual Report (see Section A.2.1.1 for list of variables pulled from OASIS assessments). Note that for OASIS-based data, the CCW beneficiary identifier was not always populated, presumably for a variety of reasons related to the beneficiary matching process and the wider scope of insurance coverage among OASIS beneficiaries (e.g., Medicare FFS, MA, Medicare and Medicaid, Medicaid only). For these episodes/assessments, we were unable to link to the CCW-based Medicare claims and enrollment data.

After compiling the basic data sources, we further processed the OASIS-based episodes to ensure there were no overlaps between episodes for the same patient (occurs for approximately 0.1% of all OASIS-based episodes). First, we removed any OASIS-based episodes that began and ended within a longer OASIS-based episode for the same patient. For example, if a patient had an OASIS-based episode that began on 01/01/2013 and ended on 12/31/2014, and also a shorter episode beginning on 12/23/2013 and ending on 12/26/2013, then the shorter episode beginning on 12/23/2013 would be excluded from further analyses. Second, if multiple OASIS-based episodes for the same patient overlapped in time, but did not meet previously defined exclusion criteria, then we truncated the end of the preceding episode so that the episode ended one day prior to the ensuing episode start date. Although each of these overlapped OASIS-based episodes may be included in HHVBP measure calculation individually, their overlapping nature are problematic when trying to link the OASIS-based episodes of care to their constituent claims-based episodes.

Next, we merged the claims-based episodes and OASIS-based episodes described in the preceding paragraphs based on CCW beneficiary ID and whether the episodes overlap in time. As a result, there could be 0, 1, or multiple OASIS-based episodes that link to one claims-based episode; likewise, there could be 0, 1, or multiple claims-based episodes that link to one OASIS-based episode. In the case, for example, when an OASIS-based episode overlapped with multiple claims-based episodes, the OASIS-based episode would be represented by a record for each of the overlapping claims-based episodes. If, for example, an OASIS-based episode does not link to any claims-based episodes, that OASIS-based episode would be represented by only one observation. Repeated observations for a particular episode, claims-based or OASIS-based, was de-duplicated in a later step.

For the purposes of assigning OASIS assessment data to each resulting linked episode, the set of episodes were conceptually categorized as follows: 1) claims-based episodes that overlap with at least one OASIS-based episode for the same beneficiary and ending prior to 01/01/2015; 2) claims-based episodes that overlap with at least one OASIS-based episode for the same beneficiary and ending on or after 01/01/2015; 3) claims-based episodes that do not overlap with an OASIS-based episode for the

same beneficiary; 4) OASIS-based episodes that ended prior to 01/01/2015; and 5) OASIS-based episodes that ended on or after 01/01/2015. OASIS-based episodes were divided into groups based on episode end date due to an issue in the source assessment data, in which the assessment identifier for assessments effective prior to 2015 was not linkable to the assessment identifier provided in the QIES-based OASIS episode-level data. For these cases, there was a suitable alternative for linking the two sources (described below), although not as accurate as linking by the assessment identifier itself. For assessments effective on or after 2015, the assessment identifier was consistent with the assessment identifier provided in the OASIS episode-level data, which meant these assessments were directly linkable to their corresponding episodes.

For episodes belonging to categories 1 and 4, the associated OASIS-based episode was linked to start and end OASIS assessments by matching on the following data elements: QIES state identifier, QIES resident identifier (uniquely identifies a patient when combined with state identifier), assessment effective date corresponding to OASIS episode start and end dates, assessment reason, and QIES provider identifier. For episodes belonging to categories 2 and 5, the associated OASIS-based episode was linked to an OASIS assessment by matching directly on the assessment identifier for the assessments corresponding to the start and end of the OASIS-based episode. For episodes belonging to category 3, we used assessment data elements derived from the claim treatment authorization code[58] submitted with each home health claim to link to the OASIS assessment submitted at the beginning of the claims-based episode of care. For final claims with "from" date starting January 1, 2020, authorization code is no longer available on claim files. Thus, we could not link claim with OASIS assessments using claim authorization code anymore from 2020 . Instead, we utilized the date associated with claim occurrence code 50 for each claim and linked that to OASIS assessment completion date (OASIS item M0090), as suggested in Medicare Claims Processing Manual Chapter 10 – Home Health Agency Billing Table of Contents (Rev. 10696, 03-31-21). In addition, we did a minor change that we required the dates used for linking to match exactly between claim and OASIS (before, we allowed 1 day difference). Because this linked assessment does not always represent a SOC/ROC, the next step was to trace back to the most recent SOC/ROC assessment previously submitted for that beneficiary, if possible. The goal of getting the assessment associated with the SOC/ROC was desirable because these assessment types required completion of more assessment items, as opposed to re-certification assessments (for example) which required fewer items to be completed.

The next step was to ensure that each record in the UAF uniquely represented a home health episode, whether sourced from claims or OASIS. For claims-based episodes that linked to multiple OASIS-based episodes, we only maintained the claims-based episode record that linked to the earliest OASIS-based episode based on start date. For OASIS-based episodes that linked to multiple claims-based episodes, we only maintained the OASIS-based episode record that linked to the latest claims-based episode based on start date. Episodes that linked to zero or one episode were also maintained in the data set as one record per episode. Thus, the resulting file contained one record for each claims- and OASIS-based episode occurring during the measurement period, where the vast majority of episodes had been linked to OASIS data based on previously described logic. Each episode's data source (claims vs. OASIS) was distinguished by a source indicator variable. The CY and quarter to which an episode was assigned was

---

[58] For more information on treatment authorization code, see p. 54-55 of CMS Medicare Claims Processing Manual, Chapter 10. Available here.

based on the episode start date for claims-based episodes, while for OASIS-based episodes, it was based on episode end date.

For each episode in the data set, we determined both the county in which care was provided (i.e., county of beneficiary residence) and also the state in which the HHA operates. For OASIS-based episodes and claims-based episodes that could be linked to an OASIS assessment, the beneficiary county was derived from the ZIP code reported on the SOC OASIS assessment. If beneficiary ZIP code was invalid or not available from a linked OASIS assessment and the episode is claims-based, then we used the ZIP code provided on the home health claim. If the ZIP code was invalid or unavailable on the linked OASIS assessment and home health claim, then we used the HHA's ZIP code as provided on the POS data set. The resulting ZIP code was mapped to one or more counties using the US Department of Housing and Urban Development (HUD) ZIP-to-county crosswalk file. For cases where the ZIP code overlapped multiple counties, we selected the county that contained the largest proportion of the ZIP code population. For claims-based episodes that still did not have an associated county of beneficiary residence, we went through hierarchical logic spanning several data sources to determine the beneficiary residence at the time of the claims-based episode. This process is described in detail below in Section A.5.4.1. In order to determine the state in which an HHA operates, we used the first two digits of the HHA's CCN and referred to the current CMS CCN documentation.[59]

With the basic units of observation established, the rest of the UAF construction process involved adding data elements from various sources. The list below provides each of the data sources and a brief description of the associated data elements that were added to the UAF. For more detail on each of the data elements as they were incorporated in analyses, see Section A.3.

- Monthly Medicare FFS and dual eligibility indicators derived from the MBSF Base segment data; merged onto the UAF by beneficiary identifier and month
- Beneficiary enrollment and demographic data from the MBSF Base segment data; merged onto the UAF by beneficiary identifier and year
- Beneficiary chronic condition indicator variables derived from the MBSF Chronic Conditions segments data; merged onto the UAF by beneficiary identifier and year
- Various HHA-year level characteristics (e.g., chain affiliation, ownership type, count of episodes in year, etc.) sourced from POS data, PECOS and Cost Report data, and OASIS process measure data; merged onto the UAF by HHA CCN and year
- Home health claims-based data elements, either directly pulled from or derived from claim header and line item data; merged onto the UAF for only claims-based episodes using the CCW claim identifier
- OASIS-based episode-level outcome measure predicted probability and measure inclusion flags; merged onto the UAF for only OASIS-based episodes based on OASIS-based episode identifier
- Claims-based episode-level impact measure predicted probability and measure inclusion flags; merged onto the UAF for only claims-based episodes based on beneficiary identifier and episode start date
- OASIS process measure data received at the HHA-month level, but aggregated to the HHA-quarter level using an average weighted by episode count; merged onto the UAF based on HHA CCN and quarter

---

[59] See CMS Manual System Pub 100-07 State Operations Provider Certification - 2779A1. Available here.

- County-level AHRF variables; merged onto the UAF based on beneficiary county of residence. See preceding two paragraphs in this section for information regarding how beneficiary county of residence was determined, as well as Section A.5.4.1 below for details on how that information was supplemented.
- The total number of Medicare eligible FFS beneficiaries are merged onto the UAF based on quarter in which the episode occurs (as defined by end date for OASIS episodes of care and start date for claims-based episodes) and beneficiary county of residence. See preceding two paragraphs in this section for information regarding how beneficiary county of residence was determined, as well as Section A.5.4.1 below for details on how that information was supplemented.
- Prior care setting indicator variables based on the 30 days prior to each episode; merged onto the UAF by episode identifier for all claims-based episodes and for OASIS-based episodes in which the beneficiary was full FFS enrolled for the entire 30-day lookback period
- OASIS-assessment items used for risk factor calculations; merged onto the UAF based on the linked OASIS assessment identifier for both the assessment that starts an episode and the assessment that ends an episode

Finally, we excluded all records in which the patient was treated by an HHA that operates in one of the US territories or the District of Columbia (as determined by first two digits of CCN). The resulting UAF was used for all analysis reported in this report.

A.5.4.1 Identifying Beneficiary County of Residence

To supplement OASIS-based beneficiary ZIP code information used to determine county of residence, we constructed a process for identifying the county in which each home health claims-based episode occurred (i.e., beneficiary residence). The CBSA where services were provided is a claim line item, indicated by value code 61; in our analyses, this is considered the most reliable source of service location. However, in the case where the beneficiary lives in a rural area (outside of a CBSA), the line item only indicates the state of service; further, many CBSAs included multiple counties. To address these situations while still leveraging the accuracy of the CBSA for determining location of service, we followed a multi-step approach for determining the county in which services were provided during a home health episode:

1. Using the National Bureau of Economic Research's CBSA to Federal Information Processing Standards county crosswalk file, we mapped any valid CBSA code to one or more of its associated counties.
    a. If a non-rural CBSA mapped to one valid county, then the episode was associated with that county in analyses.
    b. If the line item indicated a rural area (i.e., no valid CBSA), or if the CBSA did not map to a single valid Federal Information Processing Standards county code, then we proceeded to the next step.
2. We next used patient ZIP code on the OASIS assessment nearest to the claims-based episode start date to determine the county where home health services were provided. We included any OASIS assessment within 90 days of the claims-based episode start date.
    a. For the selected OASIS assessment, we used the HUD ZIP to county crosswalk to map the county of service. For instances when the CBSA from Step 1 mapped to multiple counties,

we ensured that the county derived from the OASIS assessment ZIP code matched one of the counties within the CBSA.

b. For instances when the episode of care was provided in a rural area, we ensured that the county derived from the OASIS assessment ZIP code existed in the same state that was indicated by the claim line item value.

c. If there were no OASIS assessments for the beneficiary within 90 days of the claims-based episode start date, *or* the county derived from the OASIS ZIP code did not align with the CBSA or rural area's state, then we proceeded to the next step.

3. Next, we examined the monthly beneficiary county of residence data from the MBSF for the month in which the claims-based episode ended.

a. If the CBSA from Step 1 mapped to multiple counties, we maintained the county from the MBSF if it matched one of the counties within the CBSA.

b. If services were provided in a rural area, we maintained the county from the MBSF provided that the corresponding state matched the state of the rural area.

c. Otherwise, we proceeded to the next step.

4. We next examined the mailing address county associated with the home health claim. We applied the same logic as described in Step 3, but maintained the county from the claim (vs. MBSF).

5. Next, we examined the MBSF monthly beneficiary county of residence data, but expanded our search from Step 3 to include the 3 months preceding and following the month in which the home health episode ended. We applied the same logic as described in Step 3, giving higher priority to counties from months that were closer to and preceding the month in which the home health episode ended (e.g., 1 month before takes precedence over 2 months before, and also takes precedence over 1 month after). If none of the 6 months evaluated yielded a county that aligns with the CBSA or rural area, we proceeded to the next step.

6. Next, we examined the ZIP in which the HHA is located, sourced from the CCW's HHA facility files. Using the HUD ZIP code to county crosswalk file (as in Step 2), we mapped the associated county in which the HHA is located.

a. If the CBSA from Step 1 mapped to multiple counties, then we assigned the HHA's county to the episode only if it matched one of the counties within the CBSA.

b. If services were provided in a rural area, then we assigned the HHA's county to the episode only if the corresponding state matched the state of the rural area.

c. Otherwise, we proceeded to the final step to determine the county in which services were provided.

7. Finally, to account for any remaining episodes that had not yet been assigned a county through this multi-step process (<10% of total episodes), we repeated Steps 2 through Step 5, but *without* enforcing that the county align with the CBSA or rural area state found on the claim.

A.6 Glossary

Term	Definition
Claims-Based Episode of Care	Standard episode of HH care as defined by Medicare claims data. Each episode is 60 days or less and defined by CLM_FROM_DT and CLM_THRU_DT reported on the claim.
PEP	Claims-based episodes subject to a PEP are identified by patient discharge status code in the HH claims RIFs (PTNT_DSCHRG_STUS_CD) equal to 06.
LUPA	Claims-based episodes subject to a LUPA are identified by the LUPA indicator variable (CLM_HHA_LUPA_IND_CD) in the HH claims RIFs.
OASIS-Based Episode of Care	Standard episode of HH care as defined by OASIS assessments. Unlike claims-based episodes, OASIS episodes do not have time limits and can span years. Episode start is defined by the effective date of the SOC/ROC assessment that begins an episode. Episode end is defined by the effective date of the assessment indicating patient discharge, admission to inpatient facility, or death.
Outlier	Outlier payment adjustments are made for claims-based episodes representing a relatively high utilization of HH services. Episodes subject to an outlier payment are identified by the presence of a claim line value code (CLM_VAL_CD) equal to 17 in the HH claims RIFs.
MDC	MDCs, which are formed by dividing all possible principal diagnoses (from MS-DRG) into 26 mutually exclusive diagnosis areas largely corresponding to a single organ system.
Normal	A claims-based episode is considered normal if it did not receive a PEP, LUPA, or outlier payment adjustment.
FFS	A beneficiary is considered full FFS for a given month if they are enrolled in Medicare Parts A and B and are not receiving HMO coverage, based on MBSF monthly enrollment indicators.
Home Health Stay	A home health stay is a sequence of home health payment episodes separated from other home health payment episodes by at least 60 days. [25]
Encounter	MA plan paid claim record
Part C Diagnosis Groups	Chapter-specific coding guidelines used in Condition Specific ED Use measures. Chapter group definitions can be found in ICD-10-CM Official Guidelines for Coding and Reporting FY 2021, which can be downloaded from CDC website: https://www.cdc.gov/nchs/data/icd/10cmguidelines-FY2021.pdf
POS	Files can be downloaded from CMS website: https://www.cms.gov/Research-Statistics-Data-and-Systems/Downloadable-Public-Use-Files/Provider-of-Services/index
Predicted Probabilities	Episode-level values indicating the probability that the episode is included in the measure numerator, based on the measure-specific risk adjustment model.
Sequence of Episodes	Multiple claims-based episodes for the same beneficiary in which the subsequent episode starts within 60 days of the previous episode end date are considered to be part of the same episode sequence.
Sequence Start Date	Date on which the first episode in a sequence of claims-based episodes starts.
Sequence End Date	Date on which the last episode in a sequence of claims-based episodes ends.
Transfer HHAs within 60 days	If a beneficiary has multiple claims-based episodes for different HHAs in which one episode starts within 60 days of the previous episode, the first episode is flagged to indicate a transfer of HHAs within 60 days. These flagged episodes are excluded from the denominator of several measures in this report.
VRDC	CMS offers a secure way of accessing its program data through virtual access to the CMS VRDC. The CMS VRDC is a virtual research environment that provides timelier access to Medicare and Medicaid program data in a more efficient and cost effective manner. Researchers working in the CMS VRDC will have direct

Term	Definition
	access to approved data files and be able to conduct their analysis within the CMS secure environment.

Appendix B:
Supplemental Tables and Results

B.1 Characteristics of HHAs and Patients

Exhibit B-1. HHA Characteristics in 2013 – 2021, by HHVBP and Non-HHVBP States

	2013	2014	2015	2016	2017	2018	2019	2020	2021
Total number of HHAs									
HHVBP	2,413	2,301	2,192	2,119	2,035	1,983	1,941	1,908	1,952
Non-HHVBP	9,869	9,872	9,706	9,556	9,178	8,944	8,762	8,384	8,375
Received a TPS									
HHVBP				76.5%	79.4%	81.0%	78.8%	77.3%	
Non-HHVBP									
Ownership									
For-profit									
HHVBP	79.4%	79.0%	78.5%	78.2%	78.4%	79.2%	79.5%	79.6%	80.2%
Non-HHVBP	79.5%	79.9%	80.1%	80.6%	81.2%	82.0%	82.7%	82.9%	83.3%
Non-profit									
HHVBP	14.5%	14.5%	14.9%	15.3%	15.5%	15.4%	15.0%	15.2%	15.0%
Non-HHVBP	15.5%	15.3%	15.4%	15.3%	15.3%	14.6%	14.2%	14.1%	13.8%
Government-owned									
HHVBP	6.1%	6.5%	6.6%	6.5%	6.1%	5.4%	5.5%	5.2%	4.8%
Non-HHVBP	5.0%	4.8%	4.5%	4.2%	3.5%	3.4%	3.1%	3.0%	2.8%
Setting									
Hospital-based									
HHVBP	8.1%	8.4%	8.6%	8.2%	8.0%	7.8%	7.0%	7.0%	6.7%
Non-HHVBP	9.8%	9.2%	8.6%	8.1%	7.7%	7.3%	7.0%	6.8%	6.5%
Freestanding									
HHVBP	91.9%	91.6%	91.4%	91.8%	92.0%	92.2%	93.0%	93.0%	93.3%
Non-HHVBP	90.2%	90.8%	91.4%	91.9%	92.3%	92.7%	93.0%	93.2%	93.5%
Chain Affiliation									
Chain affiliated									
HHVBP	24.4%	25.9%	27.1%	28.2%	29.7%	31.0%	31.6%	32.1%	32.8%
Non-HHVBP	15.9%	16.0%	16.8%	17.6%	17.9%	19.2%	19.5%	20.2%	19.9%
No chain affiliation									
HHVBP	61.3%	61.6%	62.7%	62.4%	62.9%	64.3%	62.2%	62.4%	60.1%

	2013	2014	2015	2016	2017	2018	2019	2020	2021
Non-HHVBP	72.6%	72.8%	72.8%	73.0%	75.1%	76.6%	76.0%	75.9%	74.6%
Chain affiliation unknown									
HHVBP	2.6%	2.6%	2.6%	3.0%	2.9%	2.9%	4.4%	4.2%	5.6%
Non-HHVBP	2.6%	2.6%	2.6%	2.7%	2.8%	2.4%	2.7%	2.7%	4.5%
Chain affiliation missing									
HHVBP	11.7%	9.9%	7.5%	6.4%	4.5%	1.8%	1.8%	1.3%	1.5%
Non-HHVBP	8.9%	8.7%	7.8%	6.7%	4.2%	1.8%	1.9%	1.1%	1.0%
HHA Age									
HHA age < 4 years									
HHVBP	28.1%	20.8%	17.6%	15.7%	12.6%	10.5%	7.3%	7.3%	7.7%
Non-HHVBP	24.4%	20.0%	16.3%	13.3%	10.6%	9.3%	9.5%	10.9%	11.3%
HHA age 4-10 years									
HHVBP	32.4%	36.1%	35.9%	33.0%	32.1%	31.2%	31.3%	28.7%	22.5%
Non-HHVBP	33.0%	35.5%	36.6%	36.3%	35.1%	32.7%	29.8%	25.9%	21.5%
HHA age > 10 years									
HHVBP	39.6%	43.2%	46.5%	51.3%	55.3%	58.2%	61.4%	64.0%	69.8%
Non-HHVBP	42.6%	44.4%	47.2%	50.4%	54.3%	58.0%	60.7%	63.2%	67.2%
HHA Size									
1-59 OASIS Episodes									
HHVBP	19.5%	18.8%	19.6%	19.8%	20.7%	20.1%	20.2%	21.5%	21.4%
Non-HHVBP	25.9%	27.1%	27.0%	27.4%	26.5%	26.0%	27.1%	28.2%	27.9%
60-249 OASIS Episodes									
HHVBP	29.5%	28.8%	27.1%	26.7%	23.9%	23.2%	22.7%	22.7%	21.6%
Non-HHVBP	34.4%	33.8%	33.0%	31.3%	30.9%	30.2%	28.5%	28.7%	28,3%
250-499 OASIS Episodes									
HHVBP	18.4%	19.0%	17.4%	16.4%	16.2%	16.6%	16.4%	14.9%	15.0%
Non-HHVBP	16.5%	16.3%	16.1%	16.2%	15.6%	15.6%	15.6%	14.4%	14.1%
500-999 OASIS Episodes									
HHVBP	14.7%	15.1%	16.1%	15.2%	15.7%	14.7%	14.9%	15.9%	16.1%
Non-HHVBP	11.4%	10.9%	11.1%	11.5%	12.3%	12.6%	12.9%	12.9%	12.8%
≥1,000 OASIS Episodes									
HHVBP	17.9%	18.2%	19.8%	21.9%	23.6%	25.3%	25.8%	24.9%	26.0%
Non-HHVBP	11.8%	11.9%	12.7%	13.6%	14.7%	15.5%	15.9%	15.8%	16.9%

These numbers reflect all HHAs with at least one OASIS episode or Medicare claims episode in a given year, regardless if the HHA received a TPS in that year.

Exhibit B-2. OASIS Home Health Beneficiary Characteristics in 2013 – 2021, by HHVBP and Non-HHVBP States

	2013	2014	2015	2016	2017	2018	2019	2020	2021
Total number of home health patients with an OASIS episode									
HHVBP	994,211	995,267	1,018,413	1,037,761	1,051,413	1,066,965	1,040,739	1,015,668	1,090,708
Non-HHVBP	3,248,808	3,303,426	3,421,376	3,511,516	3,588,961	3,593,755	3,562,238	3,434,614	3,640,449
Total number of OASIS episodes									
HHVBP	1,494,074	1,492,326	1,526,371	1,566,447	1,605,150	1,674,257	1,699,559	1,600,533	1,685,319
Non-HHVBP	4,777,317	4,865,014	5,055,925	5,252,498	5,466,970	5,608,260	5,699,744	5,263,178	5,488,533
Average age (years)									
HHVBP	75.4	75.4	75.5	75.6	75.8	75.9	76.1	75.8	75.9
Non-HHVBP	74.5	74.3	74.4	74.5	74.6	74.8	74.9	74.7	74.7
Female									
HHVBP	61.7%	61.4%	61.1%	60.9%	60.6%	60.3%	60.2%	59.1%	59.4%
Non-HHVBP	61.9%	61.6%	61.3%	61.1%	60.8%	60.6%	60.4%	59.2%	59.4%
Rural									
HHVBP	4.2%	4.1%	4.1%	4.1%	4.1%	4.0%	4.0%	4.1%	4.0%
Non-HHVBP	7.3%	7.2%	7.1%	7.1%	7.0%	7.0%	6.9%	7.1%	7.0%
Persons aged ≥25 years with less than high-school (HS) diploma in the beneficiary's county									
HHVBP	12.5%	12.4%	12.2%	12.2%	12.1%	12.1%	12.1%	12.1%	12.1%
Non-HHVBP	13.7%	13.7%	13.6%	13.6%	13.5%	13.5%	13.5%	13.4%	13.4%
Race/Ethnicity									
Hispanic (regardless of race)									
HHVBP	9.9%	9.0%	7.8%	7.5%	7.0%	7.4%	7.2%	7.0%	7.2%
Non-HHVBP	7.2%	7.2%	7.1%	7.1%	7.1%	7.1%	7.1%	7.1%	7.1%
Black, non-Hispanic									
HHVBP	10.5%	10.6%	10.8%	11.1%	11.3%	11.3%	11.3%	11.7%	11.6%
Non-HHVBP	15.1%	15.0%	14.7%	14.5%	14.2%	14.2%	14.1%	14.1%	13.8%
White, non-Hispanic									
HHVBP	78.1%	78.9%	79.8%	79.7%	80.0%	79.5%	79.6%	79.6%	79.3%
Non-HHVBP	74.6%	74.7%	74.9%	75.1%	75.4%	75.2%	75.3%	75.4%	75.4%
Other, non-Hispanic									
HHVBP	1.3%	1.4%	1.5%	1.6%	1.6%	1.7%	1.7%	1.7%	1.8%
Non-HHVBP	2.9%	3.0%	3.0%	3.1%	3.2%	3.3%	3.4%	3.3%	3.5%
Multiracial, non-Hispanic									

	2013	2014	2015	2016	2017	2018	2019	2020	2021
HHVBP	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%
Non-HHVBP	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.1%	0.1%
Insurance									
% Dually eligible									
HHVBP	28.9%	27.6%	26.3%	25.5%	24.5%	23.7%	23.2%	22.8%	22.8%
Non-HHVBP	27.8%	27.4%	26.9%	26.5%	26.1%	25.7%	25.0%	25.1%	25.3%
% Medicaid only (either managed care or FFS without dual eligibility)									
HHVBP	3.7%	4.2%	4.4%	4.5%	4.3%	4.1%	4.0%	4.1%	3.9%
Non-HHVBP	5.5%	6.0%	6.3%	6.2%	6.1%	6.0%	5.9%	6.2%	6.2%
Change in % of home health beneficiaries from previous year									
HHVBP	N/A	0.1%	2.3%	1.9%	1.3%	1.5%	-2.5%	-2.4%	7.4%
Non-HHVBP	N/A	1.7%	3.6%	2.6%	2.2%	0.1%	-0.9%	-3.6%	6.0%

These numbers reflect all OASIS episodes in the CY, regardless if their HHA received a TPS that year.

Exhibit B-3. OASIS Clinical Factors in 2013 – 2021, by HHVBP and Non-HHVBP States

	2013	2014	2015	2016	20175	2018	2019	2020	2021
Total number of OASIS episodes									
HHVBP	1,494,074	1,492,326	1,526,371	1,566,447	1,605,150	1,674,257	1,699,559	1,600,533	1,685,319
Non-HHVBP	4,777,317	4,865,014	5,055,925	5,252,498	5,466,970	5,608,260	5,699,744	5,263,178	5,488,533
Discharged from inpatient facility in last 14 days									
HHVBP	67.1%	67.4%	68.8%	68.8%	69.4%	69.2%	68.8%	67.1%	65.9%
Non-HHVBP	71.5%	71.3%	71.5%	71.3%	71.5%	71.1%	71.0%	69.2%	68.2%
Neoplasm diagnosis									
HHVBP	8.0%	8.1%	8.2%	8.5%	8.6%	8.7%	9.0%	9.3%	8.9%
Non-HHVBP	8.7%	8.7%	8.6%	8.9%	8.9%	9.0%	9.2%	9.5%	9.2%
Requires urinary catheter									
HHVBP	4.3%	4.4%	4.4%	4.5%	4.6%	4.6%	4.6%	5.0%	4.9%
Non-HHVBP	4.6%	4.6%	4.6%	4.6%	4.7%	4.6%	4.6%	4.9%	5.0%
Surgical wound									
HHVBP	24.0%	24.4%	24.7%	25.4%	25.5%	25.5%	25.4%	25.5%	25.0%
Non-HHVBP	25.2%	25.9%	25.8%	26.3%	26.6%	26.7%	26.9%	26.8%	26.7%
Ambulation-Locomotion									
Able to independently walk and needs no human assistance or assistive device									
HHVBP	5.6%	4.5%	4.1%	3.2%	2.4%	2.1%	2.0%	1.9%	1.7%
Non-HHVBP	5.8%	5.0%	4.2%	3.3%	2.6%	2.1%	2.0%	1.7%	1.5%

	2013	2014	2015	2016	20175	2018	2019	2020	2021
Able to independently walk with the use of a one-handed device									
HHVBP	10.7%	9.0%	7.7%	5.8%	4.3%	3.6%	3.1%	2.6%	2.2%
Non-HHVBP	11.6%	10.1%	8.8%	7.0%	5.5%	4.6%	3.8%	2.9%	2.4%
Requires two handed device or human assistance									
HHVBP	35.9%	32.5%	28.7%	22.5%	17.7%	14.9%	13.0%	10.3%	8.9%
Non-HHVBP	35.2%	33.0%	30.3%	26.1%	22.4%	19.1%	16.7%	12.7%	11.0%
Walks only with supervision or assistance from another at all times									
HHVBP	37.0%	42.8%	47.9%	55.8%	61.9%	65.3%	67.6%	69.2%	70.7%
Non-HHVBP	35.8%	40.1%	44.6%	50.9%	56.3%	60.5%	63.7%	67.1%	69.1%
Chairfast to bedfast									
HHVBP	10.8%	11.2%	11.6%	12.6%	13.6%	14.0%	14.2%	16.0%	16.6%
Non-HHVBP	11.7%	11.9%	12.1%	12.7%	13.3%	13.7%	13.9%	15.6%	16.0%
Pressure Ulcer									
Pressure Ulcer Stage 2									
HHVBP	3.2%	3.2%	3.2%	3.0%	2.9%	3.0%	3.0%	3.3%	3.2%
Non-HHVBP	3.5%	3.4%	3.3%	3.2%	3.0%	3.1%	3.1%	3.4%	3.3%
Pressure Ulcer Stage 3									
HHVBP	0.9%	0.9%	0.9%	0.9%	0.8%	0.8%	0.8%	0.9%	0.9%
Non-HHVBP	1.0%	1.0%	1.0%	1.0%	0.9%	0.9%	0.9%	1.0%	1.1%
Pressure Ulcer Stage 4									
HHVBP	0.5%	0.5%	0.5%	0.5%	0.5%	0.5%	0.5%	0.5%	0.6%
Non-HHVBP	0.6%	0.6%	0.6%	0.6%	0.6%	0.6%	0.6%	0.6%	0.7%
Pressure Ulcer Not Stageable									
HHVBP	0.9%	0.9%	1.0%	1.0%	1.0%	1.0%	1.0%	1.1%	1.2%
Non-HHVBP	1.0%	1.0%	1.1%	1.1%	1.0%	1.1%	1.1%	1.3%	1.3%
Risk for Hospitalization*									
Multiple hospitalizations in past 6 months									
HHVBP	37.4%	38.4%	33.6%	32.0%	32.2%	32.3%	32.9%	36.5%	36.3%
Non-HHVBP	38.7%	38.9%	34.0%	32.2%	32.5%	32.5%	33.0%	35.8%	35.6%
History of falls									
HHVBP	31.6%	33.5%	33.4%	33.6%	34.7%	35.1%	35.9%	40.9%	42.3%
Non-HHVBP	30.8%	31.9%	31.6%	31.6%	32.3%	32.9%	33.5%	37.3%	38.6%
Currently taking 5 or more medications									
HHVBP	87.6%	87.8%	89.5%	91.1%	92.1%	92.3%	92.7%	94.2%	94.8%

	2013	2014	2015	2016	20175	2018	2019	2020	2021
Non-HHVBP	86.2%	86.6%	88.2%	90.0%	91.6%	92.0%	92.7%	94.0%	94.5%

These numbers reflect all OASIS episodes in the CY, regardless if their HHA received a TPS in 2021.

*Categories for this condition are not mutually exclusive.

Exhibit B-4. FFS Home Health Beneficiary Characteristics in 2013 – 2021, by HHVBP and Non-HHVBP States

	2013	2014	2015	2016	2017	2018	2019	2020	2021
Total number of beneficiaries with Medicare FFS home health claims									
HHVBP	850,868	834,565	840,408	833,486	820,040	821,059	805,113	738,571	751,099
Non-HHVBP	2,631,986	2,618,829	2,647,827	2,659,592	2,606,539	2,569,811	2,488,239	2,260,405	2,288,263
Total number of FFS episodes									
HHVBP	1,501,589	1,460,096	1,461,245	1,430,348	1,402,802	1,411,557	1,382,870	2,090,344	2,121,783
Non-HHVBP	5,173,186	5,113,875	5,130,487	5,080,946	4,916,118	4,816,522	4,612,707	6,987,737	7,064,967
Average age (years)									
HHVBP	76.8	77.0	77.2	77.3	77.5	77.6	77.8	77.7	78.0
Non-HHVBP	75.8	75.8	76.0	76.1	76.2	76.3	76.5	76.5	76.8
Female									
HHVBP	62.5%	62.0%	61.7%	61.4%	61.0%	60.6%	60.2%	59.3%	59.6%
Non-HHVBP	63.2%	62.7%	62.4%	62.1%	61.7%	61.3%	60.8%	59.7%	59.9%
Race/Ethnicity									
Hispanic (regardless of race)									
HHVBP	10.9%	9.6%	7.9%	6.8%	6.0%	6.0%	6.0%	5.8%	5.6%
Non-HHVBP	8.8%	8.5%	8.2%	7.9%	7.7%	7.5%	7.3%	7.2%	7.0%
Black, non-Hispanic									
HHVBP	10.1%	10.0%	10.2%	10.2%	10.2%	10.0%	9.7%	9.9%	9.2%
Non-HHVBP	17.1%	16.6%	15.8%	14.8%	14.1%	13.5%	13.0%	12.9%	11.6%
White, non-Hispanic									
HHVBP	77.7%	79.1%	80.5%	81.6%	82.3%	82.5%	82.8%	82.8%	83.5%
Non-HHVBP	71.0%	71.7%	72.7%	73.9%	74.6%	75.3%	75.8%	76.1%	77.2%
Other, non-Hispanic									
HHVBP	1.2%	1.2%	1.3%	1.3%	1.4%	1.4%	1.5%	1.4%	1.5%
Non-HHVBP	2.9%	3.0%	3.1%	3.2%	3.3%	3.5%	3.7%	3.7%	4.0%
Multiracial, non-Hispanic									
HHVBP	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%
Non-HHVBP	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%
Rural									
HHVBP	5.0%	4.9%	4.9%	5.0%	5.0%	4.8%	4.8%	5.2%	5.1%
Non-HHVBP	9.5%	9.4%	9.3%	9.3%	9.2%	9.1%	9.0%	9.5%	9.1%
Dually eligible									

	2013	2014	2015	2016	2017	2018	2019	2020	2021
HHVBP	32.0%	30.4%	28.4%	27.0%	25.8%	24.7%	24.0%	24.0%	23.0%
Non-HHVBP	35.1%	34.7%	33.7%	32.9%	32.7%	32.3%	31.5%	32.2%	31.5%
Persons aged >25 years with less than HS diploma in the beneficiary's county									
HHVBP	12.8%	12.6%	12.4%	12.3%	12.2%	12.2%	12.2%	12.2%	12.2%
Non-HHVBP	15.0%	14.9%	14.8%	14.7%	14.6%	14.5%	14.5%	14.7%	14.6%
Reason for Medicare Entitlement									
Original ESRD									
HHVBP	1.2%	1.2%	1.2%	1.2%	1.2%	1.2%	1.2%	1.3%	1.1%
Non-HHVBP	1.6%	1.6%	1.6%	1.6%	1.5%	1.6%	1.6%	1.7%	1.3%
Original Disabled									
HHVBP	25.4%	25.4%	25.2%	25.1%	24.8%	24.4%	23.9%	24.3%	23.2%
Non-HHVBP	28.7%	29.0%	28.7%	28.5%	28.1%	27.8%	27.2%	27.4%	26.0%
Current ESRD									
HHVBP	0.8%	0.8%	0.7%	0.5%	0.4%	0.4%	0.4%	0.4%	0.3%
Non-HHVBP	1.1%	1.1%	0.9%	0.6%	0.6%	0.6%	0.5%	0.6%	0.4%
Current Disabled									
HHVBP	12.4%	12.1%	11.6%	11.3%	10.8%	10.2%	9.7%	9.6%	8.6%
Non-HHVBP	14.6%	14.5%	14.1%	13.6%	13.1%	12.6%	11.9%	11.7%	10.5%
APMs									
BPCI2									
HHVBP	0.0%	0.3%	2.5%	3.9%	2.9%	1.9%	0.0%	N/A	N/A
Non-HHVBP	0.0%	0.5%	2.1%	3.0%	2.4%	1.8%	0.0%	N/A	N/A
BPCI3									
HHVBP	0.0%	0.1%	0.3%	0.5%	0.5%	0.3%	N/A	N/A	N/A
Non-HHVBP	0.0%	0.2%	0.3%	0.5%	0.4%	0.3%	N/A	N/A	N/A
BPCI Advanced*									
HHVBP	N/A	N/A	N/A	N/A	N/A	0.7%	3.4%	4.0%	3.6%
Non-HHVBP	N/A	N/A	N/A	N/A	N/A	0.7%	4.0%	3.5%	2.8%
ACO SSP									
HHVBP	13.0%	18.7%	23.1%	21.7%	27.9%	32.8%	32.9%	36.7%	35.4%
Non-HHVBP	9.3%	14.6%	20.2%	23.0%	26.4%	29.8%	31.5%	31.9%	31.5%
ACO Next Generation*									
HHVBP	N/A	N/A	N/A	3.3%	6.5%	8.9%	7.4%	4.6%	4.4%

	2013	2014	2015	2016	2017	2018	2019	2020	2021
Non-HHVBP	N/A	N/A	N/A	1.4%	3.6%	4.1%	3.5%	2.8%	2.8%
ACO Pioneer*									
HHVBP	4.1%	4.3%	5.1%	3.7%	N/A	N/A	N/A	N/A	N/A
Non-HHVBP	2.6%	1.7%	1.6%	0.5%	N/A	N/A	N/A	N/A	N/A
CJR*									
HHVBP	N/A	N/A	N/A	0.6%	1.0%	0.7%	0.9%	0.5%	0.2%
Non-HHVBP	N/A	N/A	N/A	0.8%	1.1%	0.8%	0.9%	0.4%	0.2%
OCM*									
HHVBP	N/A	N/A	N/A	1.3%	3.1%	3.1%	1.5%	0.9%	0.7%
Non-HHVBP	N/A	N/A	N/A	1.3%	3.0%	3.1%	1.5%	0.9%	0.6%
HCC score (1st episode)									
HHVBP	2.6	2.7	2.7	2.8	2.9	3.0	3.0	3.1	3.0
Non-HHVBP	2.6	2.6	2.6	2.7	2.8	2.9	3.0	3.0	2.9
Full FFS status for the past 12 months									
HHVBP	92.4%	92.4%	92.2%	92.1%	92.3%	92.3%	92.4%	93.0%	93.1%
Non-HHVBP	91.0%	90.6%	89.3%	89.4%	90.1%	89.8%	90.1%	90.6%	90.6%
ESRD Flag#									
HHVBP	2.8%	2.9%	3.0%	3.1%	3.2%	3.2%	3.3%	3.6%	3.1%
Non-HHVBP	3.6%	3.7%	3.7%	3.8%	3.8%	3.9%	4.0%	4.3%	3.7%
Oxygen									
HHVBP	14.6%	14.4%	14.5%	14.5%	14.2%	13.4%	12.9%	13.5%	14.1%
Non-HHVBP	16.6%	16.2%	16.2%	15.9%	15.6%	15.0%	14.5%	15.3%	16.0%
PDGM Home health admission source									
Acute Inpatient Hospital									
HHVBP	27.2%	27.9%	28.7%	29.3%	30.0%	29.5%	29.3%	28.9%	28.3%
Non-HHVBP	25.7%	26.1%	26.7%	27.2%	28.0%	27.8%	28.0%	27.1%	26.5%
IPF									
HHVBP	0.5%	0.5%	0.5%	0.5%	0.4%	0.4%	0.4%	0.4%	0.3%
Non-HHVBP	0.4%	0.4%	0.4%	0.4%	0.4%	0.3%	0.3%	0.3%	0.2%
IRF									
HHVBP	2.9%	3.0%	3.2%	3.3%	3.5%	3.7%	3.8%	4.1%	4.3%
Non-HHVBP	3.6%	3.8%	4.0%	4.1%	4.2%	4.4%	4.6%	5.1%	5.3%
LTCH									

	2013	2014	2015	2016	2017	2018	2019	2020	2021
HHVBP	0.4%	0.4%	0.4%	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%
Non-HHVBP	0.6%	0.7%	0.7%	0.6%	0.6%	0.5%	0.4%	0.4%	0.4%
Skilled Nursing Home									
HHVBP	17.1%	18.0%	19.0%	19.1%	19.1%	18.8%	18.6%	16.3%	16.1%
Non-HHVBP	14.5%	15.5%	16.3%	16.6%	16.8%	16.8%	16.6%	14.3%	13.8%
Community									
HHVBP	51.9%	50.2%	48.2%	47.6%	46.6%	47.3%	47.6%	50.0%	50.8%
Non-HHVBP	55.1%	53.5%	51.9%	51.1%	50.1%	50.2%	50.0%	52.8%	53.8%
Admission Source (Arbor defined)									
Institution									
HHVBP	23.1%	23.3%	23.8%	24.4%	25.9%	25.7%	25.7%	16.3%	14.8%
Non-HHVBP	21.1%	20.8%	21.1%	21.9%	23.3%	23.4%	23.8%	14.7%	13.3%
Community									
HHVBP	76.9%	76.7%	76.2%	75.6%	74.1%	74.3%	74.3%	83.7%	85.2%
Non-HHVBP	78.9%	79.2%	78.9%	78.1%	76.7%	76.6%	76.2%	85.3%	86.7%
PDGM defined clinical grouping									
Behavioral Health									
HHVBP	2.4%	2.5%	2.5%	2.3%	2.2%	2.3%	2.5%	2.9%	2.8%
Non-HHVBP	1.4%	1.6%	1.6%	1.6%	1.6%	1.5%	1.6%	1.8%	1.9%
Complex Nursing Interventions									
HHVBP	1.1%	1.2%	1.2%	1.2%	1.3%	1.3%	1.3%	2.1%	2.1%
Non-HHVBP	1.1%	1.2%	1.2%	1.2%	1.2%	1.2%	1.2%	1.9%	2.0%
MMTA Surgical Aftercare									
HHVBP	7.1%	7.3%	7.1%	6.3%	6.0%	5.9%	5.8%	4.9%	4.7%
Non-HHVBP	5.9%	6.1%	6.0%	5.2%	5.0%	4.8%	4.8%	4.2%	4.1%
MMTA Cardiac and Circulatory									
HHVBP	11.5%	11.7%	12.3%	12.4%	12.1%	12.4%	13.4%	14.6%	14.3%
Non-HHVBP	15.0%	15.9%	16.4%	16.3%	16.0%	16.0%	16.6%	17.7%	17.2%
MMTA Endocrine									
HHVBP	4.9%	5.2%	4.9%	4.3%	4.2%	3.9%	4.1%	5.1%	5.0%
Non-HHVBP	7.3%	7.7%	7.3%	6.3%	6.0%	5.7%	5.6%	6.8%	6.7%
MMTA Gastrointestinal tract/Genitourinary system									
HHVBP	3.0%	3.3%	3.6%	3.9%	4.1%	4.3%	4.6%	5.1%	5.1%

	2013	2014	2015	2016	2017	2018	2019	2020	2021
Non-HHVBP	2.9%	3.2%	3.4%	3.8%	4.0%	4.2%	4.5%	5.0%	5.0%
MMTA Infectious Disease									
HHVBP	2.1%	2.2%	2.3%	3.0%	3.3%	3.6%	4.1%	4.5%	4.4%
Non-HHVBP	2.3%	2.3%	2.5%	3.2%	3.4%	3.7%	4.1%	4.5%	4.5%
MMTA Other									
HHVBP	1.3%	1.3%	1.4%	1.6%	1.8%	1.9%	2.3%	3.2%	3.8%
Non-HHVBP	1.4%	1.4%	1.5%	1.7%	1.9%	2.0%	2.3%	3.0%	3.7%
MMTA Respiratory									
HHVBP	6.3%	6.3%	6.9%	7.0%	7.5%	7.4%	7.3%	7.9%	8.2%
Non-HHVBP	6.6%	6.7%	7.2%	7.3%	7.7%	7.7%	7.6%	8.4%	8.8%
MS Rehab									
HHVBP	11.5%	11.7%	13.0%	18.4%	19.4%	20.6%	21.9%	22.0%	22.8%
Non-HHVBP	9.8%	10.5%	12.2%	17.2%	18.6%	19.9%	21.4%	20.8%	21.6%
Neuro Rehab									
HHVBP	5.7%	6.1%	6.8%	8.4%	9.0%	9.4%	10.0%	11.6%	12.2%
Non-HHVBP	5.9%	6.4%	7.0%	8.2%	8.6%	8.8%	9.3%	10.7%	11.3%
Wounds									
HHVBP	2.6%	2.7%	4.2%	9.2%	10.0%	10.4%	10.9%	13.6%	13.6%
Non-HHVBP	2.4%	2.6%	3.7%	7.7%	8.7%	9.2%	9.6%	11.9%	12.0%
None									
HHVBP	40.6%	38.4%	33.8%	22.0%	19.1%	16.7%	11.7%	2.4%	0.9%
Non-HHVBP	38.1%	34.5%	30.1%	20.2%	17.4%	15.4%	11.4%	3.1%	1.3%
% Change in home health beneficiaries from previous year									
HHVBP	N/A	-1.9%	0.7%	-0.8%	-1.6%	0.1%	-1.9%	-8.3%	1.7%
Non-HHVBP	N/A	-0.5%	1.1%	0.4%	-2.0%	-1.4%	-3.2%	-9.2%	1.2%

*These numbers reflect the percentages of all Medicare FFS home health episodes in the CY, regardless if their HHA received a TPS that year. *Values listed as "N/A" reflect years where the APM is not active. #This is defined as either having an unfailed kidney transplant at the start of home health episode or having a dialysis claim during the 365 days before the home health episode begins.*

Exhibit B-5. FFS Episode Characteristics in 2013 – 2021, by Year, All HHVBP and Non-HHVBP States

	2013	2014	2015	2016	2017	2018	2019	2020	2021
Total number of FFS episodes									
HHVBP	1,501,589	1,460,096	1,461,245	1,430,348	1,402,802	1,411,557	1,382,870	2,090,344	2,121,783
Non-HHVBP	5,173,186	5,113,875	5,130,487	5,080,946	4,916,118	4,816,522	4,612,707	6,987,737	7,064,967
Episodes Type*									
Normal									
HHVBP	83.9%	84.5%	84.4%	83.9%	83.9%	84.2%	84.0%	84.4%	86.0%
Non-HHVBP	86.3%	86.9%	86.6%	86.0%	85.3%	85.5%	85.4%	86.3%	87.6%
LUPA									
HHVBP	9.2%	9.1%	9.1%	9.1%	8.9%	8.6%	8.7%	9.1%	8.6%
Non-HHVBP	8.8%	8.7%	8.7%	8.6%	8.6%	8.5%	8.5%	8.2%	7.7%
High cost outlier									
HHVBP	4.4%	3.9%	4.1%	4.5%	4.5%	4.5%	4.5%	5.7%	4.4%
Non-HHVBP	2.9%	2.5%	2.7%	3.3%	4.0%	3.9%	4.0%	4.9%	4.0%
PEP									
HHVBP	3.7%	3.6%	3.6%	3.7%	3.9%	3.9%	4.0%	1.4%	1.5%
Non-HHVBP	3.0%	2.8%	2.9%	3.0%	3.2%	3.1%	3.2%	1.2%	1.2%
Episodes within a Sequence									
1st in sequence									
HHVBP	59.3%	59.4%	58.9%	59.5%	59.8%	59.3%	59.3%	35.6%	34.3%
Non-HHVBP	48.6%	49.2%	49.9%	50.9%	52.0%	52.5%	53.1%	31.7%	30.6%
2nd in sequence									
HHVBP	15.3%	15.6%	15.7%	16.0%	16.4%	16.5%	16.3%	22.4%	22.3%
Non-HHVBP	15.0%	15.2%	15.4%	15.6%	16.0%	16.3%	16.2%	20.2%	19.9%
3rd+ in sequence									
HHVBP	25.5%	25.0%	25.3%	24.5%	23.8%	24.2%	24.4%	42.0%	43.4%
Non-HHVBP	36.3%	35.6%	34.7%	33.5%	32.0%	31.2%	30.6%	48.2%	49.5%
Average number of visits in an episode									
HHVBP	18.1	18.0	17.9	17.8	17.5	17.7	17.3	9.1	8.6
Non-HHVBP	16.4	16.3	16.2	16.3	16.3	16.4	16.2	8.5	8.1
Average # of Visits by Type									
Therapy (OT, PT, speech)									
HHVBP	7.5	7.7	7.9	8.1	8.4	8.6	8.6	4.2	4.3
Non-HHVBP	5.5	5.7	6.1	6.5	6.8	7.2	7.2	3.5	3.5

	2013	2014	2015	2016	2017	2018	2019	2020	2021
Skilled nurse									
HHVBP	8.8	8.6	8.4	8.1	7.9	7.8	7.6	4.3	3.9
Non-HHVBP	8.5	8.3	8.2	8.1	7.9	7.8	7.7	4.4	4.1
Home health aide									
HHVBP	1.7	1.6	1.5	1.3	1.2	1.1	1.0	0.4	0.4
Non-HHVBP	2.3	2.1	1.9	1.7	1.5	1.4	1.2	0.6	0.5
Medical social services									
HHVBP	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Non-HHVBP	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1

These numbers reflect all FFS home health episodes in the CY, regardless if their HHA received a TPS that year.

*PEP is not mutually exclusive with LUPA (Low-Utilization Payment Adjustment) and Outlier, so percentages may sum to > 100%. A PEP occurs when a beneficiary changes HHAs or is discharged and readmitted within a 60-day episode and results in an adjusted, partial payment to the HHA to reflect the time the beneficiary received care.

B.2 Annual Means for TPS, Spending Measures, and Quality Measures

Exhibit B-6. Unadjusted Annual Means (and Standard Errors[†]) for Impact Measures 2013 – 2021, by HHVBP and Non-HHVBP States

Measure	2013	2014	2015	2016	2017	2018	2019	2020	2021
TPS*									
HHVBP	30.9 (0.3561)	28.1 (0.3452)	30.9 (0.3621)	37.1 (0.4141)	42.6 (0.4102)	45.4 (0.4289)	38.9 (0.4151)	46.1 (0.4341)	46.8 (0.4441)
Non-HHVBP	30.4 (0.1762)	28.4 (0.1763)	30.6 (0.1834)	34.9 (0.1996)	40.0 (0.2007)	42.9 (0.2108)	36.6 (0.2048)	43.4 (0.2248)	44.2 (0.2325)
FFS Claims-Based Quality Measures									
Unplanned ACH/First FFS HH Episodes									
HHVBP	15.3% (0.0417)	15.6% (0.0427)	16.1% (0.0433)	16.3% (0.0439)	15.9% (0.0436)	15.6% (0.0434)	15.5% (0.0436)	14.1% (0.0445)	13.8% (0.0448)
Non-HHVBP	16.2% (0.0258)	16.2% (0.0258)	16.3% (0.0258)	16.5% (0.0257)	15.8% (0.0253)	15.6% (0.0254)	15.6% (0.0256)	14.0% (0.0261)	13.8% (0.0263)
Outpatient ED Use (no Hospitalization)/First FFS HH Episodes									
HHVBP	11.3% (0.0367)	11.7% (0.0378)	12.2% (0.0386)	12.6% (0.0395)	12.9% (0.0400)	12.9% (0.0400)	13.0% (0.0406)	11.0% (0.0400)	11.7% (0.0418)
Non-HHVBP	11.9% (0.0226)	12.4% (0.0230)	12.6% (0.0231)	12.7% (0.0231)	13.0% (0.0234)	12.9% (0.0234)	13.0% (0.0238)	11.1% (0.0236)	11.9% (0.0246)
ED Use followed by Inpatient Admission/First FFS HH Episodes									
HHVBP	13.8% (0.0399)	14.3% (0.0410)	14.5% (0.0414)	14.4% (0.0416)	14.8% (0.0423)	14.7% (0.0422)	14.6% (0.0425)	13.8% (0.0439)	13.6% (0.0442)
Non-HHVBP	14.2% (0.0243)	14.3% (0.0244)	14.2% (0.0242)	14.2% (0.0240)	14.3% (0.0242)	14.2% (0.0243)	14.2% (0.0246)	13.3% (0.0254)	13.2% (0.0257)
Total ED Use (Outpatient or Inpatient Claims)/First FFS HH Episodes									
HHVBP	25.8% (0.0506)	26.7% (0.0518)	27.4% (0.0524)	27.8% (0.0530)	28.3% (0.0537)	28.1% (0.0536)	28.2% (0.0541)	25.2% (0.0553)	25.7% (0.0564)
Non-HHVBP	27.2% (0.0310)	27.7% (0.0312)	27.9% (0.0311)	28.1% (0.0310)	28.3% (0.0312)	28.0% (0.0313)	28.1% (0.0317)	25.2% (0.0325)	25.8% (0.0331)
Outpatient ED Use and Observation Stay (no Hospitalization)/ First FFS HH Episode									
HHVBP	13.8% (0.0399)	14.1% (0.0407)	14.5% (0.0414)	15.1% (0.0424)	15.4% (0.0430)	15.4% (0.0430)	15.5% (0.0435)	13.4% (0.0434)	14.1% (0.0450)
Non-HHVBP	13.7% (0.0239)	14.1% (0.0243)	14.5% (0.0245)	14.8% (0.0245)	15.0% (0.0247)	15.0% (0.0249)	15.2% (0.0253)	13.3% (0.0254)	14.2% (0.0264)
Unplanned ACH/All FFS HH Episodes									
HHVBP	16.8% (0.0332)	17.2% (0.0339)	17.0% (0.0338)	16.8% (0.0340)	17.2% (0.0346)	16.9% (0.0343)	16.9% (0.0346)	11.2% (0.0237)	11.1% (0.0234)
Non-HHVBP	15.9% (0.0176)	15.9% (0.0177)	15.7% (0.0177)	15.6% (0.0177)	15.9% (0.0181)	15.8% (0.0183)	16.0% (0.0187)	10.3% (0.0126)	10.3% (0.0125)
SNF Use/All FFS HH Episodes									
HHVBP	4.7% (0.0189)	5.0% (0.0195)	5.0% (0.0196)	5.0% (0.0197)	5.1% (0.0201)	4.9% (0.0198)	4.9% (0.0199)	2.8% (0.0125)	3.1% (0.0130)
Non-HHVBP	3.9% (0.0093)	4.0% (0.0095)	4.1% (0.0097)	4.2% (0.0097)	4.2% (0.0100)	4.2% (0.0101)	4.2% (0.0103)	2.4% (0.0063)	2.7% (0.0066)

Measure	2013	2014	2015	2016	2017	2018	2019	2020	2021
FFS Claims-Based Spending Measures (Pre-PDGM approach)									
Average Medicare Spending per Day <u>during and following</u> FFS HH Episodes of Care									
HHVBP	$135.41 (0.1471)	$138.65 (0.1522)	$140.99 (0.1546)	$143.18 (0.1594)	$146.65 (0.1644)	$150.65 (0.1688)	$155.13 (0.1759)	$154.69 (0.1675)	$157.52 (0.1671)
Non-HHVBP	$128.79 (0.0816)	$131.80 (0.0834)	$134.25 (0.0844)	$137.36 (0.0867)	$141.84 (0.0904)	$146.56 (0.0939)	$152.59 (0.0995)	$154.96 (0.0945)	$159.33 (0.0955)
Average Medicare Spending per Day <u>during</u> FFS HH Episodes of Care									
HHVBP	$148.31 (0.1546)	$150.69 (0.1596)	$152.83 (0.1621)	$155.47 (0.1675)	$159.21 (0.1735)	$163.53 (0.1784)	$168.76 (0.1862)	$163.62 (0.1789)	$165.65 (0.1787)
Non-HHVBP	$132.49 (0.0832)	$135.31 (0.0850)	$138.26 (0.0861)	$142.17 (0.0889)	$147.43 (0.0931)	$152.99 (0.0970)	$159.90 (0.1030)	$159.83 (0.0988)	$163.75 (0.1000)
Average Medicare Spending per Day <u>following</u> FFS HH Episodes of Care									
HHVBP	$102.03 (0.2393)	$106.79 (0.2496)	$109.25 (0.2542)	$110.68 (0.2578)	$113.46 (0.2654)	$116.31 (0.2710)	$119.37 (0.2782)	$128.46 (0.3265)	$133.82 (0.3225)
Non-HHVBP	$113.66 (0.1569)	$117.45 (0.1610)	$118.51 (0.1612)	$119.47 (0.1607)	$122.06 (0.1650)	$124.34 (0.1690)	$128.38 (0.1754)	$136.88 (0.2042)	$142.58 (0.2021)
FFS Claims-Based Spending Measures (Post-PDGM approach)									
Average Medicare Spending per Day <u>during and following</u> FFS HH Episodes of Care									
HHVBP	$127.78 (0.1408)	$131.23 (0.1457)	$133.63 (0.1480)	$135.50 (0.1524)	$138.89 (0.1574)	$142.77 (0.1617)	$146.96 (0.1686)	$153.29 (0.1652)	$156.43 (0.1649)
Non-HHVBP	$124.94 (0.0790)	$127.97 (0.0808)	$130.19 (0.0817)	$132.89 (0.0838)	$136.98 (0.0873)	$141.43 (0.0908)	$147.09 (0.0962)	$154.40 (0.0936)	$159.00 (0.0945)
Average Medicare Spending per Day <u>during</u> FFS HH Episodes of Care									
HHVBP	$141.24 (0.1488)	$144.42 (0.1538)	$147.17 (0.1565)	$149.40 (0.1613)	$152.94 (0.1667)	$156.85 (0.1709)	$161.72 (0.1785)	$165.59 (0.1748)	$168.41 (0.1750)
Non-HHVBP	$132.82 (0.0821)	$135.89 (0.0839)	$138.69 (0.0850)	$142.06 (0.0874)	$146.78 (0.0911)	$151.77 (0.0948)	$158.24 (0.1005)	$162.97 (0.0972)	$167.56 (0.0986)
Average Medicare Spending per Day <u>following</u> FFS HH Episodes of Care									
HHVBP	$79.25 (0.2069)	$83.24 (0.2170)	$84.37 (0.2189)	$85.48 (0.2229)	$88.08 (0.2310)	$91.51 (0.2394)	$94.09 (0.2458)	$113.45 (0.3179)	$118.84 (0.3135)
Non-HHVBP	$87.21 (0.1348)	$90.27 (0.1383)	$90.66 (0.1378)	$91.75 (0.1384)	$93.98 (0.1426)	$96.70 (0.1473)	$100.23 (0.1531)	$120.62 (0.1996)	$126.34 (0.1969)
OASIS-Based Outcome Quality Measures									
Discharged to Community									
HHVBP	73.0% (0.0366)	72.8% (0.0367)	72.4% (0.0365)	72.9% (0.0358)	72.8% (0.0354)	73.2% (0.0345)	73.5% (0.0341)	73.2% (0.0353)	73.5% (0.0343)
Non-HHVBP	69.8% (0.0212)	70.1% (0.0209)	70.5% (0.0205)	71.0% (0.0200)	71.3% (0.0195)	71.8% (0.0192)	72.3% (0.0189)	72.4% (0.0197)	72.6% (0.0192)
TNC Change in Self-Care									
HHVBP	1.29 (0.0010)	1.37 (0.0011)	1.46 (0.0011)	1.65 (0.0011)	1.79 (0.0011)	1.88 (0.0011)	1.98 (0.0010)	2.10 (0.0011)	2.18 (0.0011)
Non-HHVBP	1.20 (0.0006)	1.27 (0.0006)	1.37 (0.0006)	1.52 (0.0006)	1.65 (0.0006)	1.75 (0.0006)	1.85 (0.0006)	2.00 (0.0006)	2.09 (0.0006)
TNC Change in Mobility									
HHVBP	0.39 (0.0004)	0.43 (0.0004)	0.48 (0.0004)	0.57 (0.0004)	0.64 (0.0004)	0.69 (0.0004)	0.72 (0.0004)	0.75 (0.0004)	0.78 (0.0004)

Measure	2013	2014	2015	2016	2017	2018	2019	2020	2021
Non-HHVBP	0.37 (0.0002)	0.40 (0.0002)	0.45 (0.0002)	0.52 (0.0002)	0.59 (0.0002)	0.63 (0.0002)	0.67 (0.0002)	0.71 (0.0003)	0.74 (0.0002)
Improvement in Dyspnea									
HHVBP	64.5% (0.0546)	65.2% (0.0541)	70.1% (0.0511)	74.9% (0.0464)	79.5% (0.0419)	81.9% (0.0383)	84.7% (0.0353)	85.1% (0.0356)	86.5% (0.0331)
Non-HHVBP	64.4% (0.0315)	65.1% (0.0309)	68.7% (0.0291)	72.2% (0.0270)	76.2% (0.0248)	79.0% (0.0228)	82.2% (0.0210)	83.4% (0.0209)	84.9% (0.0196)
Improvement in Management of Oral Medications									
HHVBP	48.8% (0.0569)	50.5% (0.0559)	55.0% (0.0538)	61.6% (0.0498)	67.5% (0.0460)	71.3% (0.0427)	76.5% (0.0394)	78.8% (0.0391)	81.0% (0.0364)
Non-HHVBP	51.6% (0.0323)	53.2% (0.0314)	56.5% (0.0300)	60.8% (0.0281)	65.3% (0.0260)	69.0% (0.0244)	74.7% (0.0224)	77.8% (0.0221)	80.1% (0.0206)
FFS Claims-Based Quality Measure									
Mortality Rate/All FFS Home Health Episodes									
HHVBP	3.4% (0.0150)	3.5% (0.0154)	3.5% (0.0155)	3.6% (0.0157)	3.7% (0.0161)	3.6% (0.0159)	3.6% (0.0160)	3.1% (0.0122)	3.0% (0.0119)
Non-HHVBP	3.2% (0.0080)	3.3% (0.0081)	3.3% (0.0080)	3.3% (0.0081)	3.3% (0.0083)	3.3% (0.0083)	3.3% (0.0085)	2.9% (0.0066)	2.8% (0.0063)
HHCAHPS-Based Patient Experience Measures									
How often the home health team gave care in a professional way (Professional Care)									
HHVBP	89.0% (0.1245)	88.7% (0.1412)	88.7% (0.1416)	88.5% (0.1298)	88.4% (0.1377)	88.4% (0.1383)	88.2% (0.1439)	88.2% (0.1611)	87.8% (0.1729)
Non-HHVBP	88.2% (0.0709)	88.2% (0.0702)	88.2% (0.0749)	88.0% (0.0763)	87.9% (0.0798)	88.0% (0.0755)	88.0% (0.0826)	88.2% (0.0886)	87.9% (0.0899)
How well did the home health team communicate with patients (Communication)									
HHVBP	86.2% (0.1467)	85.9% (0.1664)	85.7% (0.1583)	85.5% (0.1530)	85.5% (0.1541)	85.4% (0.1639)	85.3% (0.1721)	85.5% (0.1767)	84.9% (0.1889)
Non-HHVBP	85.4% (0.0761)	85.3% (0.0788)	85.2% (0.0832)	85.2% (0.0857)	85.1% (0.0876)	85.2% (0.0860)	85.2% (0.0894)	85.2% (0.0993)	85.1% (0.0988)
Did the home health team discuss medicines, pain, and home safety with patients (Discussion of Care)									
HHVBP	82.9% (0.1828)	82.8% (0.1835)	82.8% (0.1839)	82.3% (0.1902)	82.6% (0.1849)	82.2% (0.1998)	81.9% (0.2114)	80.8% (0.2186)	79.7% (0.2433)
Non-HHVBP	83.8% (0.0881)	83.9% (0.0875)	83.6% (0.0914)	83.6% (0.0932)	83.3% (0.0975)	83.4% (0.0965)	83.5% (0.0977)	82.5% (0.1131)	82.1% (0.1158)
How do patients rate the overall care from the home health agency (Overall Care)									
HHVBP	84.6% (0.1993)	84.3% (0.2245)	84.3% (0.2187)	84.3% (0.2086)	84.1% (0.2062)	84.3% (0.2014)	84.2% (0.2204)	84.4% (0.2320)	83.8% (0.2687)
Non-HHVBP	83.6% (0.1110)	83.7% (0.1127)	83.7% (0.1200)	83.7% (0.1215)	83.5% (0.1248)	83.4% (0.1246)	83.7% (0.1280)	83.9% (0.1412)	83.7% (0.1453)
Would patients recommend the home health agency to friends and family (Likely to Recommend)									
HHVBP	79.8% (0.2382)	79.8% (0.2735)	79.4% (0.2639)	79.2% (0.2578)	78.9% (0.2497)	78.8% (0.2687)	78.5% (0.2659)	78.1% (0.2931)	77.7% (0.3054)
Non-HHVBP	78.5% (0.1364)	78.5% (0.1378)	78.3% (0.1428)	78.1% (0.1427)	77.6% (0.1479)	77.4% (0.1483)	77.5% (0.1534)	77.8% (0.1692)	77.2% (0.1751)

*Original HHVBP Model measures indicated by italic text. *We calculated a TPS for each agency that was eligible to receive one, based on having at least five HHVBP measures with sufficient data and a Medicare participation date prior to the CY used as a baseline period for measuring improvement. | Standard Errors are reported in the same units as the corresponding measure means.*

B.3 Home Health Utilization Supporting Analyses

Exhibit B-7. Number of HHAs 2013 – 2021, by HHVBP State

State	2013	2014	2015	2016	2017	2018	2019	2020	2021
Arizona (AZ)	154	159	158	156	161	163	162	159	160
Florida (FL)	1,399	1,279	1,163	1,073	984	945	921	915	964
Iowa (IA)	168	164	162	162	159	156	146	139	134
Maryland (MD)	55	54	54	52	53	52	52	52	53
Massachusetts (MA)	174	187	204	229	238	236	230	222	217
Nebraska (NE)	78	76	76	76	76	75	74	69	68
North Carolina (NC)	177	177	174	172	171	169	167	166	167
Tennessee (TN)	146	143	138	137	131	127	125	124	124
Washington (WA)	62	62	63	62	62	60	64	62	65
All HHVBP States	2,413	2,301	2,192	2,119	2,035	1,983	1,941	1,908	1,952
All Non-HHVBP States	9,869	9,872	9,706	9,556	9,178	8,944	8,762	8,384	8,375

Reflects HHAs that have at least one home health episode in the year.

B.3.1 Entry/Exit Supporting Analyses

Exhibit B-8. Number of HHAs Opening and Terminating Quarterly in HHVBP and Non-HHVBP States, 2013 – 2021

Year	Quarter	Opening HHAs (n)		Terminating HHAs (n)		Open HHAs* (n)	
		HHVBP	Non-HHVBP	HHVBP	Non-HHVBP	HHVBP	Non-HHVBP
2013	Q1	37	141	23	55	2,452	10,015
	Q2	29	147	31	78	2,458	10,107
	Q3	24	111	63	66	2,451	10,140
	Q4	22	91	54	74	2,410	10,165
2014	Q1	22	71	56	81	2,378	10,162
	Q2	20	72	57	106	2,342	10,153
	Q3	24	70	41	108	2,309	10,117
	Q4	19	60	46	81	2,287	10,069
2015	Q1	28	51	27	69	2,269	10,039
	Q2	18	54	38	91	2,260	10,024
	Q3	28	69	24	78	2,250	10,002
	Q4	22	70	23	106	2,248	9,994
2016	Q1	39	52	31	93	2,264	9,940
	Q2	21	50	26	94	2,254	9,897
	Q3	17	82	27	173	2,245	9,885
	Q4	15	45	40	122	2,233	9,757
2017	Q1	6	37	21	119	2,199	9,672
	Q2	12	56	29	96	2,190	9,609
	Q3	7	48	30	105	2,168	9,561
	Q4	10	46	24	128	2,148	9,502
2018	Q1	10	62	22	93	2,134	9,436
	Q2	6	54	18	116	2,118	9,397

| Year | Quarter | Opening HHAs (n) | | Terminating HHAs (n) | | Open HHAs* (n) | |
		HHVBP	Non-HHVBP	HHVBP	Non-HHVBP	HHVBP	Non-HHVBP
	Q3	10	74	17	101	2,110	9,355
	Q4	9	65	21	86	2,102	9,319
2019	Q1	5	65	22	93	2,086	9,298
	Q2	10	69	17	128	2,074	9,274
	Q3	6	68	15	63	2,063	9,214
	Q4	8	108	12	102	2,056	9,259
2020	Q1	14	93	16	63	2,058	9,250
	Q2	9	78	4	37	2,051	9,265
	Q3	22	118	8	36	2,069	9,346
	Q4	N/A	N/A	N/A	N/A	N/A	N/A

Open HHAs are defined by the POS certification and termination dates and may include inactive HHAs that do not have HH episodes in a given quarter.

B.3.2   Utilization of Home Health by FFS Beneficiaries Supporting Analyses

Exhibit B-9. Unadjusted Annual Means (and Standard Errors) for Home Health Utilization Measures, 2013 – 2021

Measure	2013	2014	2015	2016	2017	2018	2019	2020	2021
% FFS Beneficiaries with at least one HH Episode									
HHVBP	9.9% (0.2)	9.7% (0.1)	9.7% (0.1)	9.5% (0.1)	9.3% (0.1)	9.2% (0.1)	9.1% (0.1)	8.5% (0.1)	8.9% (0.1)
Non-HHVBP	9.4% (0.1)	9.2% (0.05)	9.3% (0.05)	9.3% (0.05)	9.1% (0.05)	9.0% (0.05)	8.8% (0.05)	8.2% (0.04)	8.7% (0.05%)
Number of HH Days of Care per FFS Beneficiary									
HHVBP	7.6 (0.2)	7.4 (0.2)	7.4 (0.1)	7.1 (0.1)	6.9 (0.1)	6.9 (0.1)	6.8 (0.1)	6.3 (0.1)	6.6 (0.1)
Non-HHVBP	8.7 (0.1)	8.5 (0.1)	8.5 (0.1)	8.3 (0.1)	8.0 (0.1)	7.8 (0.1)	7.5 (0.1)	6.8 (0.1)	7.1 (0.1)

Exhibit B-10. Cumulative D-in-D Results at the State-Level, Home Health Utilization Measures

| Measure | Model Estimates | | | | Average in HHVBP States, Baseline (2013 – 2015) | % Relative Change |
	D-in-D	p-value	Lower 90% CI	Upper 90% CI		
Percent of FFS Beneficiaries with at least One HH Episode[a]						
Arizona	-0.03	0.91	-0.47	0.41	6.2%	-0.5%
Florida	0.42	0.53	-0.68	1.51	13.8%	3.0%
Iowa	0.18	0.36	-0.15	0.51	5.5%	3.3%
Maryland	0.15	0.64	-0.37	0.67	8.1%	1.9%
Massachusetts	-0.44	0.21	-1.02	0.14	12.0%	-3.7%
Nebraska	0.25	0.18	-0.06	0.55	5.9%	4.2%
North Carolina	-0.25	0.12	-0.53	0.02	8.4%	-3.0%
Tennessee	0.69	<0.001	0.38	1.00	9.4%	7.3%
Washington	-0.05	0.88	-0.55	0.46	5.6%	-0.9%
Number of HH Days of Care per FFS Beneficiary						
Arizona	0.06	0.88	-0.56	0.67	3.6	1.7%
Florida	0.23	0.83	-1.57	2.04	11.5	2.0%

| Measure | Model Estimates | | | | Average in HHVBP States, Baseline (2013 – 2015) | % Relative Change |
	D-in-D	p-value	Lower 90% CI	Upper 90% CI		
Iowa	0.53	0.01	0.22	0.85	3.2	16.6%
Maryland	0.22	0.36	-0.17	0.61	4.6	4.8%
Massachusetts	0.03	0.94	-0.73	0.80	8.7	0.3%
Nebraska	0.40	0.07	0.04	0.76	3.6	11.1%
North Carolina	-0.07	0.72	-0.40	0.26	5.6	-1.3%
Tennessee	1.54	<0.001	0.97	2.12	9.9	15.6%
Washington	0.45	0.17	-0.09	1.00	3.5	12.9%

aD-in-D and 90% CI values represent percentage point changes. |CI = Confidence Interval. | These models include state-specific linear time trends.

B.3.3   Case-mix of Home Health Beneficiaries Supporting Analyses

Exhibit B-11. Unadjusted Annual Means (and Standard Errors) for Health Status Measures at the SOC, non-HHVBP States, 2013 – 2021

Measure	2013	2014	2015	2016	2017	2018	2019	2020	2021
Home Health Utilization among all Medicare FFS Beneficiaries at Risk of Limited Functional Improvement a									
HHVBP	28.4% (0.0423)	28.3% (0.0422)	28.5% (0.0421)	28.6% (0.0426)	28.4% (0.0423)	28.5% (0.0426)	28.4% (0.0426)	27.8% (0.0442)	28.3% (0.0447)
Non-HHVBP	25.6% (0.0223)	25.7% (0.0224)	26.1% (0.0226)	26.5% (0.0229)	26.3% (0.0229)	26.2% (0.0229)	26.0% (0.0230)	25.5% (0.0241)	26.1% (0.0246)
Count of HCC Conditions Present at SOC									
HHVBP	1.6 (0.0010)	1.7 (0.0010)	1.7 (0.0010)	1.8 (0.0010)	1.9 (0.0010)	2.0 (0.0010)	2.0 (0.0010)	2.0 (0.0010)	1.9 (0.0010)
Non-HHVBP	1.7 (0.0005)	1.8 (0.0005)	1.8 (0.0005)	1.9 (0.0006)	2.0 (0.0006)	2.0 (0.0006)	2.1 (0.0006)	2.1 (0.0006)	2.0 (0.0006)
HCC Score at the SOC									
HHVBP	2.6 (0.0014)	2.7 (0.0015)	2.7 (0.0015)	2.8 (0.0016)	2.9 (0.0016)	3.0 (0.0016)	3.0 (0.0017)	3.1 (0.0014)	3.0 (0.0014)
Non-HHVBP	2.6 (0.0008)	2.6 (0.0008)	2.6 (0.0008)	2.7 (0.0008)	2.8 (0.0009)	2.9 (0.0009)	3.0 (0.0009)	3.0 (0.0008)	2.9 (0.0008)
TNC Mobility at the SOC									
HHVBP	4.7 (0.0022)	5.0 (0.0022)	5.2 (0.0021)	5.7 (0.0021)	6.1 (0.0020)	6.3 (0.0019)	6.4 (0.0018)	6.7 (0.0020)	6.8 (0.0019)
Non-HHVBP	4.8 (0.0013)	5.0 (0.0013)	5.2 (0.0012)	5.6 (0.0012)	5.9 (0.0011)	6.2 (0.0011)	6.3 (0.0010)	6.6 (0.0011)	6.7 (0.0011)
TNC Self-Care at the SOC									
HHVBP	9.3 (0.0037)	9.7 (0.0036)	10.1 (0.0035)	10.7 (0.0034)	11.2 (0.0032)	11.5 (0.0030)	11.6 (0.0030)	12.1 (0.0030)	12.3 (0.0029)
Non-HHVBP	9.3 (0.0021)	9.6 (0.0021)	9.9 (0.0020)	10.4 (0.0019)	10.9 (0.0018)	11.2 (0.0017)	11.3 (0.0016)	11.9 (0.0017)	12.1 (0.0016)

a Defined as the presence of at least one of 19 HCC conditions determined by diagnosis codes recorded at the SOC in OASIS data that are associated with lower average TNC Change in Mobility or Self-Care scores.

Exhibit B-12. Cumulative D-in-D Results at the State-Level, Case Mix of Home Health Patients

Measure	Model Estimates				Average in HHVBP States, Baseline (2013 – 2015)	% Relative Change
	D-in-D	p-value	Lower 90% CI	Upper 90% CI		
Count of HCC Conditions Present at SOC						
Arizona	-0.03	0.56	-0.10	0.05	1.6	-1.9%
Florida	0.05	0.09	0.001	0.09	1.5	3.3%
Iowa	-0.02	0.72	-0.12	0.07	1.8	-1.1%
Maryland	0.02	0.70	-0.06	0.10	1.8	1.1%
Massachusetts	0.02	0.72	-0.07	0.10	1.8	1.1%
Nebraska	0.04	0.57	-0.08	0.16	1.7	2.4%
North Carolina	0.02	0.58	-0.04	0.09	1.8	1.1%
Tennessee	0.03	0.50	-0.04	0.09	1.9	1.6%
Washington	-0.01	0.90	-0.13	0.11	1.8	-0.6%
HCC Score at the SOC						
Arizona	-0.14	0.07	-0.26	-0.01	2.9	-4.8%
Florida	-0.05	0.07	-0.09	0.00	2.6	-1.9%
Iowa	-0.20	<0.01	-0.30	-0.10	2.6	-7.7%
Maryland	0.07	0.17	-0.01	0.15	2.9	2.4%
Massachusetts	-0.06	0.13	-0.13	0.00	2.7	-2.2%
Nebraska	-0.03	0.68	-0.14	0.09	2.6	-1.2%
North Carolina	-0.01	0.73	-0.07	0.05	2.8	-0.4%
Tennessee	-0.15	<0.001	-0.22	-0.08	2.7	-5.6%
Washington	-0.02	0.79	-0.13	0.09	2.8	-0.7%
TNC Mobility at SOC						
Arizona	0.43	0.02	0.12	0.74	5.0	8.6%
Florida	-0.20	0.03	-0.35	-0.04	5.0	-4.0%
Iowa	0.24	0.34	-0.17	0.66	4.4	5.5%
Maryland	0.48	<0.01	0.19	0.78	5.1	9.4%
Massachusetts	0.12	0.67	-0.33	0.57	4.5	2.7%
Nebraska	-0.23	0.38	-0.65	0.20	4.5	-5.1%
North Carolina	0.25	0.12	-0.02	0.51	4.9	5.1%
Tennessee	-0.65	<0.001	-0.93	-0.36	5.7	-11.4%
Washington	-0.18	0.46	-0.58	0.22	5.4	-3.3%
TNC Self-Care at SOC						
Arizona	0.59	0.08	0.03	1.14	9.0	6.6%
Florida	-0.23	0.16	-0.50	0.04	9.9	-2.3%
Iowa	0.36	0.47	-0.46	1.17	8.3	4.3%
Maryland	0.73	0.02	0.20	1.25	10.0	7.3%
Massachusetts	-0.10	0.85	-0.94	0.74	9.0	-1.1%
Nebraska	-0.34	0.62	-1.45	0.77	8.4	-4.0%
North Carolina	0.33	0.26	-0.15	0.80	9.5	3.5%
Tennessee	-0.78	<0.01	-1.23	-0.33	10.9	-7.2%
Washington	-0.31	0.44	-0.98	0.35	9.9	-3.1%

CI = Confidence Interval. | These models include state-specific linear time trends.

[a] Defined as the presence of at least one of 19 HCC conditions determined by diagnosis codes recorded at the SOC in OASIS data that are associated with lower average TNC Change in Mobility or Self-Care scores.

B.3.4 Access to Home Health Care Supporting Analyses

Exhibit B-13. Percent Distribution of Episodes in Agencies, by Star Ratings in HHVBP vs. Non-HHVBP States, Pre- and Post- HHVBP

Star Rating	HHVBP States			Non-HHVBP States		
	2014-2015	2016-2017	2018-2019	2014-2015	2016-2017	2018-2019
All	100	100	100	100	100	100
Missing	1.9	1.6	0.7	1.4	1.6	1.4
1	0.0	0.1	0.2	0.0	0.1	0.2
1.5	0.4	0.5	0.9	0.7	1.2	1.7
2	2.3	2.2	2.4	4.4	4.9	4.4
2.5	9.2	7.4	6.2	11.4	11.2	12.2
3	21.0	13.7	15.4	23.6	21.1	19.9
3.5	27.8	26.1	22.8	28.9	26.6	23.3
4	23.3	23.8	24.0	19.3	17.9	17.7
4.5	11.0	18.4	18.5	8.2	11.5	13.6
5	3.1	6.1	8.9	1.9	4.0	5.5

B.3.5 Substitutes to Home Health Care Supporting Analyses

Exhibit B-14. Characteristics of Medicare FFS Beneficiary ACH Discharges among ACOs, Baseline and Post-HHVBP Performance Period

Characteristics of ACH Discharges	HHVBP States		Non-HHVBP States	
	Baseline (2013-2015)	Post-Period (2016-2021)	Baseline (2013-2015)	Post-Period (2016-2021)
Beneficiary Characteristics				
Age (years)				
0-64	14.9%	12.1%	16.1%	13.6%
65-84	61.2%	65.4%	60.4%	64.3%
85 and older	23.9%	22.5%	23.5%	22.1%
Female	56.6%	55.2%	56.7%	55.6%
Race/Ethnicity				
White, non-Hispanic	86.7%	86.4%	82.8%	85.0%
Black, non-Hispanic	9.0%	9.1%	11.2%	9.7%
Other, non-Hispanic	2.5%	3.0%	3.8%	3.7%
Hispanic, (regardless of race)	1.8%	1.5%	2.1%	1.5%
At-Risk HCCs	23.7%	23.4%	25.5%	24.6%
Characteristics of the precipitating hospital stay				
Discharged from short-term acute care hospital	98.3%	97.8%	97.7%	97.3%
Discharged from Critical Access Hospital	1.7%	2.2%	2.2%	2.5%
SNF Eligibility	70.0%	64.9%	71.1%	65.8%
Length of Inpatient Stay (days)	4.6	4.5	4.7	4.5
Rural Hospital Location	4.1%	5.5%	6.0%	7.9%
County-level characteristics				
County-Level Median Household Income 2011-2015, Average	$63,522	$61,648	$63,346	$61,530

Characteristics of ACH Discharges	HHVBP States		Non-HHVBP States	
	Baseline (2013-2015)	Post-Period (2016-2021)	Baseline (2013-2015)	Post-Period (2016-2021)
County-Level Percent of Persons 25+ Yrs w/<HS Diploma 2011-15, Average	11.1%	11.2%	12.3%	12.2%
County Level Percent of Persons in Deep Poverty 2013-17, Average	6.0%	6.1%	6.3%	6.4%
MDC group				
Nervous System	8.4%	8.5%	8.6%	8.5%
Respiratory System	15.4%	14.2%	15.0%	14.3%
Circulatory System	21.9%	23.1%	22.2%	23.1%
Digestive System	12.8%	11.6%	12.3%	11.2%
Hepatobiliary System and Pancreas	2.9%	2.9%	2.9%	2.8%
Musculoskeletal System and Connective Tissue	16.1%	16.3%	15.3%	15.5%
Skin, Subcutaneous Tissue and Breast	2.9%	2.5%	2.9%	2.5%
Endocrine, Nutritional and Metabolic System	3.8%	3.9%	4.0%	4.1%
Kidney And Urinary Tract	8.7%	8.3%	8.7%	8.4%
Infectious and Parasitic Diseases	7.0%	8.7%	8.1%	9.6%
PAC Selection among ACOs				
Home Health Care	25.0%	26.2%	23.4%	24.7%
Institutional Care	28.5%	25.4%	29.6%	26.2%
Self-Care	38.7%	40.3%	39.3%	40.9%
Hospital Outpatient Therapy	2.1%	2.4%	2.2%	2.4%
PAC Selection among non-ACOs				
Home Health Care	22.2%	22.7%	22.0%	22.2%
Institutional Care	29.5%	28.0%	29.7%	28.4%
Self-Care	39.7%	39.8%	40.0%	40.1%
Hospital Outpatient Therapy	2.2%	2.6%	2.4%	2.8%

Exhibit B-15. Characteristics of Medicare FFS Beneficiary ACH Discharges among HCCs with Highest Risk, Baseline, and Post-HHVBP Performance Period

Characteristics of ACH Discharges	HHVBP States		Non-HHVBP States	
	Baseline (2013-2015)	Post-Period (2016-2021)	Baseline (2013-2015)	Post-Period (2016-2021)
Beneficiary Characteristics				
Age (years)				
0-64	14.2%	13.8%	15.4%	15.4%
65-84	51.6%	54.8%	51.1%	54.3%
85 and older	34.2%	31.3%	33.5%	30.3%
Female	56.3%	54.3%	56.4%	54.4%
Race/Ethnicity				
White, non-Hispanic	81.7%	81.2%	80.5%	80.1%
Black, non-Hispanic	13.3%	13.1%	13.5%	13.0%
Other, non-Hispanic	2.6%	3.3%	3.7%	4.6%
Hispanic, (regardless of race)	2.5%	2.3%	2.3%	2.3%
Characteristics of the precipitating hospital stay				
Discharged from short-term acute care hospital	97.5%	97.8%	96.8%	97.1%
Discharged from Critical Access Hospital	2.5%	2.2%	3.2%	2.8%

Characteristics of ACH Discharges	HHVBP States		Non-HHVBP States	
	Baseline (2013-2015)	Post-Period (2016-2021)	Baseline (2013-2015)	Post-Period (2016-2021)
SNF Eligibility	79.3%	76.7%	80.2%	77.5%
Length of Inpatient Stay (days)	5.5	5.7	5.6	5.6
Rural Hospital Location	5.7%	5.6%	8.4%	8.4%
County-level characteristics				
County-Level Median Household Income 2011-2015, Average	$59,616	$60,108	$60,437	$60,987
County-Level Percent of Persons 25+ Yrs w/<HS Diploma 2011-15, Average	11.9%	11.7%	13.0%	13.0%
County Level Percent of Persons in Deep Poverty 2013-17, Average	6.5	6.4	6.7	6.6
MDC group				
Nervous System	17.8%	17.9%	17.5%	17.4%
Respiratory System	14.0%	12.9%	14.1%	12.8%
Circulatory System	14.5%	14.0%	14.2%	13.8%
Digestive System	9.7%	8.8%	9.5%	8.6%
Hepatobiliary System And Pancreas	2.0%	2.0%	2.0%	2.0%
Musculoskeletal System And Connective Tissue	9.8%	9.9%	9.5%	9.6%
Skin, Subcutaneous Tissue And Breast	4.0%	3.5%	4.0%	3.5%
Endocrine, Nutritional And Metabolic System	5.8%	6.4%	6.1%	6.7%
Kidney And Urinary Tract	12.2%	11.9%	11.7%	11.5%
Infectious and Parasitic Diseases	10.2%	12.7%	11.4%	14.1%
APM Flags*				
BPCI2	1.5%	2.3%	1.7%	2.2%
BPCI3	0.1%	0.3%	0.3%	0.3%
BPCI Advanced	0.0%	4.5%	0.0%	4.4%
ACO SSP	17.4%	28.8%	15.7%	28.3%
ACO Next Generation	0.0%	5.6%	0.0%	3.1%
ACO Pioneer	4.0%	0.5%	2.2%	0.1%
CJR	0.0%	0.3%	0.0%	0.3%
OCM	0.0%	2.6%	0.0%	2.6%
PAC Selection among At-Risk HCCs				
Home Health Care	22.4%	24.0%	21.3%	22.6%
Institutional Care	44.3%	41.7%	45.2%	42.6%
Self-Care	23.0%	23.1%	23.3%	23.8%
Hospital Outpatient Therapy	3.2%	3.3%	3.4%	3.5%
PAC Selection among all Other Index Discharges (not At-Risk HCCs)				
Home Health Care	23.0%	24.1%	22.6%	23.3%
Institutional Care	24.0%	21.7%	24.2%	22.2%
Self-Care	45.2%	46.0%	45.7%	46.4%
Hospital Outpatient Therapy	1.9%	2.2%	2.0%	2.3%

Not all APMs were active for all years of the baseline and intervention periods (see Exhibit A-69 for additional detail).

Exhibit B-16. Unadjusted Annual Means (and Standard Errors) for PAC for FFS Medicare Beneficiaries within 14 Days following Hospital Discharge, HHVBP States and Non-HHVBP States, 2013 – 2021

PAC Type	2013	2014	2015	2016	2017	2018	2019	2020	2021
Home Health Care									
HHVBP	22.9% (0.0315)	22.8% (0.0317)	22.9% (0.0313)	23.1% (0.0314)	23.2% (0.0312)	23.3% (0.0317)	23.3% (0.0320)	26.2% (0.0367)	26.2% (0.0383)
Non-HHVBP	22.2% (0.0170)	22.3% (0.0172)	22.3% (0.0170)	22.5% (0.0170)	22.6% (0.0170)	22.4% (0.0172)	22.3% (0.0175)	24.7% (0.0201)	24.9% (0.0211)
Institutional Care									
HHVBP	29.1% (0.0341)	29.5% (0.0344)	29.1% (0.0338)	28.4% (0.0336)	28.0% (0.0332)	27.7% (0.0335)	27.2% (0.0337)	24.7% (0.0360)	25.1% (0.0378)
Non-HHVBP	29.5% (0.0187)	29.9% (0.0190)	29.7% (0.0187)	29.0% (0.0185)	28.4% (0.0184)	28.3% (0.0186)	27.7% (0.0188)	25.6% (0.0203)	25.9% (0.0214)
Self-Care									
HHVBP	39.7% (0.0367)	39.4% (0.0369)	39.4% (0.0364)	39.7% (0.0364)	40.0% (0.0363)	40.1% (0.0367)	40.4% (0.0372)	40.0% (0.0409)	39.7% (0.0426)
Non-HHVBP	40.1% (0.0201)	39.7% (0.0203)	39.7% (0.0200)	40.0% (0.0200)	40.2% (0.0200)	40.5% (0.0203)	40.8% (0.0206)	40.6% (0.0229)	40.3% (0.0240)
Hospital Outpatient Therapy									
HHVBP	2.1% (0.0108)	2.2% (0.0110)	2.3% (0.0113)	2.5% (0.0116)	2.6% (0.0118)	2.6% (0.0120)	2.7% (0.0124)	2.2% (0.0123)	2.2% (0.0129)
Non-HHVBP	2.3% (0.0061)	2.3% (0.0062)	2.5% (0.0064)	2.6% (0.0065)	2.7% (0.0066)	2.8% (0.0068)	2.9% (0.0071)	2.4% (0.0071)	2.4% (0.0074)

Exhibit B-17. Unadjusted Annual Means (and Standard Errors) for PAC for FFS Medicare Beneficiaries Aligned with ACOs within 14 Days following Hospital Discharge, HHVBP States and Non-HHVBP States, 2013 – 2021

PAC Type	2013	2014	2015	2016	2017	2018	2019	2020	2021
Home Health Care									
HHVBP	24.8% (0.0769)	25.0% (0.0680)	25.2% (0.0602)	24.9% (0.0582)	25.3% (0.0537)	25.4% (0.0496)	25.0% (0.0505)	28.7% (0.0575)	28.2% (0.0604)
Non-HHVBP	23.1% (0.0478)	23.4% (0.0413)	23.5% (0.0355)	23.8% (0.0333)	24.3% (0.0310)	24.0% (0.0294)	23.7% (0.0291)	26.5% (0.0334)	26.6% (0.0352)
Institutional Care									
HHVBP	30.0% (0.0817)	28.6% (0.0709)	27.6% (0.0620)	26.7% (0.0595)	26.7% (0.0546)	26.3% (0.0502)	26.0% (0.0512)	22.9% (0.0534)	23.4% (0.0568)
Non-HHVBP	30.6% (0.0523)	29.8% (0.0446)	28.9% (0.0380)	28.0% (0.0351)	27.3% (0.0322)	27.0% (0.0305)	26.5% (0.0302)	24.0% (0.0323)	24.1% (0.0341)
Self-Care									
HHVBP	37.6% (0.0863)	38.7% (0.0764)	39.4% (0.0678)	40.2% (0.0660)	40.0% (0.0605)	40.2% (0.0559)	40.8% (0.0573)	40.3% (0.0624)	40.4% (0.0659)
Non-HHVBP	38.5% (0.0552)	39.2% (0.0476)	39.8% (0.0410)	40.2% (0.0384)	40.5% (0.0355)	40.9% (0.0338)	41.4% (0.0336)	41.2% (0.0372)	41.3% (0.0392)
Hospital Outpatient Therapy									

PAC Type	2013	2014	2015	2016	2017	2018	2019	2020	2021
HHVBP	2.0% (0.0250)	2.0% (0.0219)	2.2% (0.0204)	2.4% (0.0208)	2.5% (0.0192)	2.5% (0.0179)	2.5% (0.0183)	2.1% (0.0182)	2.1% (0.0192)
Non-HHVBP	2.2% (0.0166)	2.2% (0.0142)	2.3% (0.0126)	2.4% (0.0121)	2.5% (0.0112)	2.6% (0.0109)	2.7% (0.0111)	2.2% (0.0111)	2.1% (0.0115)

Exhibit B-18. Unadjusted Annual Means (and Standard Errors) for PAC for FFS Medicare Beneficiaries with HCCs at Risk of Limited Improvement During HH Care within 14 Days following Hospital Discharge, HHVBP States and Non-HHVBP States, 2013 – 2021

PAC Type	2013	2014	2015	2016	2017	2018	2019	2020	2021
Home Health Care									
HHVBP	22.5% (0.0619)	22.4% (0.0620)	22.4% (0.0611)	22.6% (0.0612)	22.8% (0.0609)	23.2% (0.0619)	23.3% (0.0628)	26.5% (0.0704)	26.9% (0.0739)
Non-HHVBP	21.2% (0.0328)	21.2% (0.0330)	21.3% (0.0328)	21.5% (0.0329)	21.7% (0.0328)	21.7% (0.0330)	21.8% (0.0335)	24.5% (0.0379)	25.1% (0.0403)
Institutional Care									
HHVBP	44.4% (0.0737)	44.4% (0.0738)	44.1% (0.0727)	43.6% (0.0726)	43.1% (0.0719)	42.6% (0.0726)	41.9% (0.0733)	39.2% (0.0779)	38.9% (0.0813)
Non-HHVBP	45.2% (0.0399)	45.4% (0.0402)	45.0% (0.0399	44.5% (0.0397)	43.9% (0.0395)	43.4% (0.0397)	42.5% (0.0402)	40.3% (0.0432)	39.8% (0.0454)
Self-Care									
HHVBP	23.0% (0.0625)	23.0% (0.0626)	23.0% (0.0616)	23.0% (0.0616)	23.3% (0.0614)	23.1% (0.0619)	23.3% (0.0628)	23.0% (0.0671)	23.0% (0.0701)
Non-HHVBP	23.4% (0.0340)	23.3% (0.0341)	23.3% (0.0339)	23.4% (0.0339)	23.6% (0.0338)	23.9% (0.0342)	24.2% (0.0348)	23.9% (0.0375)	23.8% (0.0395)
Hospital Outpatient Therapy									
HHVBP	3.1% (0.0258)	3.1% (0.0259)	3.2% (0.0259)	3.3% (0.0261)	3.3% (0.0260)	3.4% (0.0267)	3.5% (0.0274)	2.8% (0.0264)	3.0% (0.0286)
Non-HHVBP	3.4% (0.0145)	3.4% (0.0145)	3.4% (0.0146)	3.5% (0.0146)	3.6% (0.0148)	3.7% (0.0151)	3.9% (0.0157)	3.1% (0.0152)	3.2% (0.0165)

Exhibit B-19. Sensitivity Impact of HHVBP on Use of Alternative PAC Options with Expanded Covariate List

Measure	Model Estimates				Average in HHVBP States, Baseline (2013-2015)	% Relative Change
	D-in-D[a]	p-value	Lower 90% CI[a]	Upper 90% CI[a]		
Home Health Care						
2016	0.04	0.72	-0.14	0.22		0.2%
2017	0.03	0.81	-0.19	0.25		0.1%
2018	0.24	0.14	-0.03	0.50		1.0%
2019	0.28	0.11	<0.01	0.57	22.9%	1.2%
2020	0.71	<0.001	0.37	1.05		3.1%
2021	0.39	0.07	0.04	0.74		1.7%
Cumulative	0.26	0.07	0.03	0.49		1.1%
Institutional Care						

Measure	Model Estimates				Average in HHVBP States, Baseline (2013-2015)	% Relative Change
	D-in-D[a]	p-value	Lower 90% CI[a]	Upper 90% CI[a]		
2016	-0.30	<0.001	-0.44	-0.16	29.2%	-1.0%
2017	-0.21	0.05	-0.38	-0.03		-0.7%
2018	-0.25	0.05	-0.46	-0.04		-0.9%
2019	-0.24	0.08	-0.47	-0.01		-0.8%
2020	-0.57	<0.01	-0.86	-0.28		-2.0%
2021	-0.27	0.13	-0.57	0.02		-0.9%
Cumulative	-0.30	<0.01	-0.49	-0.11		-1.0%
Self-care						
2016	0.22	0.03	0.05	0.38	39.5%	0.6%
2017	0.21	0.09	0.01	0.41		0.5%
2018	0.03	0.84	-0.22	0.29		0.1%
2019	0.01	0.93	-0.25	0.28		0.03%
2020	-0.20	0.25	-0.49	0.09		-0.5%
2021	-0.15	0.43	-0.46	0.16		-0.4%
Cumulative	0.04	0.76	-0.17	0.25		0.1%
Hospital Outpatient Therapy						
2016	0.05	0.12	<0.001	0.10	2.2%	2.3%
2017	0.05	0.25	-0.02	0.11		2.3%
2018	0.07	0.10	<0.001	0.14		3.2%
2019	0.02	0.69	-0.06	0.09		0.9%
2020	0.10	0.02	0.03	0.17		4.5%
2021	0.13	<0.01	0.06	0.20		5.9%
Cumulative	0.06	0.04	0.01	0.12		2.7%

[a] *Values represent percentage point changes. | CI = Confidence Interval.*

Exhibit B-20. Cumulative D-in-D Results at the State-Level, Use of Alternative PAC Options

Measure	Model Estimates				Average in HHVBP States, Baseline (2013 – 2015)	% Relative Change
	D-in-D[a]	p-value	Lower 90% CI[a]	Upper 90% CI[a]		
Home Health Care						
Arizona	-1.17	0.03	-2.07	-0.28	15.3%	-7.6
Florida	1.00	<0.001	0.53	1.47	24.1%	4.1
Iowa	-1.88	<0.001	-2.59	-1.16	13.0%	-14.4
Maryland	2.32	<0.001	1.64	3.01	19.3%	12.0
Massachusetts	0.72	0.20	-0.21	1.65	25.9%	2.8
Nebraska	-0.11	0.81	-0.82	0.61	11.6%	-0.9
North Carolina	-0.96	0.03	-1.68	-0.25	20.2%	-4.8

Measure	Model Estimates				Average in HHVBP States, Baseline (2013 – 2015)	% Relative Change
	D-in-D[a]	p-value	Lower 90% CI[a]	Upper 90% CI[a]		
Tennessee	0.43	0.19	-0.10	0.96	18.8%	2.3
Washington	0.05	0.92	-0.76	0.86	13.2%	0.4
Institutional Care						
Arizona	1.39	<0.01	0.59	2.19	21.4%	6.5
Florida	-0.87	<0.01	-1.30	-0.43	25.6%	-3.4
Iowa	1.05	0.01	0.39	1.70	27.5%	3.8
Maryland	1.33	<0.01	0.62	2.03	24.3%	5.5
Massachusetts	-0.73	0.13	-1.54	0.07	30.7%	-2.4
Nebraska	-2.46	<0.001	-3.38	-1.54	31.2%	-7.9
North Carolina	0.21	0.58	-0.41	0.83	22.7%	0.9
Tennessee	-0.34	0.35	-0.95	0.26	25.1%	-1.4
Washington	-1.64	<0.001	-2.32	-0.96	23.5%	-7.0
Self-care						
Arizona	0.45	0.53	-0.71	1.61	51.3%	0.9
Florida	-0.15	0.61	-0.62	0.33	38.9%	-0.4
Iowa	1.11	0.04	0.20	2.01	46.0%	2.4
Maryland	-2.85	<0.001	-3.66	-2.03	43.3%	-6.6
Massachusetts	0.07	0.84	-0.53	0.67	34.8%	0.2
Nebraska	1.96	<0.001	1.25	2.67	45.6%	4.3
North Carolina	0.52	0.24	-0.21	1.25	46.1%	1.1
Tennessee	-0.07	0.88	-0.79	0.66	45.4%	-0.2
Washington	1.58	<0.01	0.69	2.47	52.1%	3.0
Hospital Outpatient Therapy						
Arizona	-0.11	0.38	-0.32	0.10	1.7%	-6.6
Florida	0.14	0.02	0.04	0.25	1.6%	8.7
Iowa	-0.03	0.88	-0.36	0.30	4.3%	-0.7
Maryland	-0.14	0.06	-0.26	-0.02	2.2%	-6.5
Massachusetts	-0.10	0.18	-0.22	0.02	1.7%	-5.9
Nebraska	0.47	0.05	0.07	0.87	3.8%	12.3
North Carolina	0.20	0.02	0.06	0.33	2.0%	10.0
Tennessee	0.07	0.54	-0.12	0.26	2.0%	3.5
Washington	-0.40	<0.001	-0.57	-0.23	2.0%	-19.6

[a] *Values represent percentage point changes. | CI = Confidence Interval.*

B.4 Home Health Agency Structure and Practices Supporting Analyses

Exhibit B-21. Unadjusted Annual Means (and Standard Errors*) for Frontloading Measures, HHVBP States and Non-HHVBP States, 2013 – 2021

Measure	2013	2014	2015	2016	2017	2018	2019	2020	2021
Frontloading Skilled Nurse Visits – Post-Institutional Episodes									
HHVBP	59.7% (0.1028)	58.7% (0.1039)	57.6% (0.1029)	56.7% (0.1032)	55.8% (0.1013)	54.8% (0.1017)	54.1% (0.1032)	53.2% (0.1059)	50.7% (0.1121)
Non-HHVBP	59.6% (0.0576)	58.9% (0.0584)	58.4% (0.0579)	57.5% (0.0575)	56.5% (0.0569)	55.3% (0.0574)	54.2% (0.0584)	53.7% (0.0607)	52.1% (0.0640)
Frontloading Therapist Visits – Post-Institutional Episodes									
HHVBP	30.5% (0.0965)	30.7% (0.0973)	30.8% (0.0961)	31.8% (0.0970)	32.6% (0.0956)	32.7% (0.0959)	33.1% (0.0974)	34.8% (0.1011)	34.0% (0.1062)
Non-HHVBP	27.7% (0.0526)	28.4% (0.0535)	28.9% (0.0532)	29.3% (0.0529)	30.0% (0.0526)	29.8% (0.0528)	30.3% (0.0539)	31.3% (0.0564)	30.3% (0.0589)

Trends displayed above represent a subset of claims-based episodes, only including post-institutional episodes which lasted at least 14 days without a hospitalization occurring during that time. *Standard Errors are reported in the same units as the corresponding measure means.

B.4.1 Supporting Analyses for Changes in OASIS-Reported Functional Status

Exhibit B-22. Improvement in Grooming Over Time among Beneficiaries with Pneumonia, Knee-hip Replacement, and Heart Failure

Panel 1 - Pneumonia: Grooming

HHVBP States
- Amount of change over time unexplained by control variables
- Total amount of change over time

M1: 7.7, M2: 7.5, M3: 7.1, Total: 8.7

Non-HHVBP States
- Amount of change over time unexplained by control variables
- Total amount of change over time

M1: 6.6, M2: 6.5, M3: 5.9, Total: 7.5

Panel 2 - Knee/Hip Replacement: Grooming

HHVBP States
M1: 0.3, M2: 0.3, M3: -0.1, Total: 1.3

Non-HHVBP States
M1: 1.0, M2: 1.0, M3: 0.5, Total: 1.7

Panel 3 - Heart Failure: Grooming

HHVBP States
M1: 7.6, M2: 7.5, M3: 6.8, Total: 9.7

Non-HHVBP States
M1: 7.6, M2: 7.5, M3: 6.8, Total: 9.4

Exhibit B-23. Regression Results for Improvement in Dyspnea Over Time among Beneficiaries with Pneumonia

	M0 Unadjusted Model	M1 (M0 + Initial OASIS + Length of care)	M2 (M1 + HCC)	M3 (M2 + Visit mix)
Change Over Time/Time Trends				
2014-2015	Reference	Reference	Reference	Reference
2016-2017	6.30*	5.68*	5.65*	5.20*
2018-2019	11.25*	9.45*	9.34*	8.52*
Intervention States				
Non-HHVBP States	Reference	Reference	Reference	Reference
HHVBP States	2.03*	1.49*	1.48*	1.21*
OASIS Documentation of Initial Functional Status				
Dyspnea 1: When walking 20+ feet	N/A	-29.42*	-30.67*	-31.43*
Dyspnea 2: When moderate exertion < 20 feet	N/A	-6.44*	-7.30*	-7.66*
Dyspnea 3: When minimum exertion	N/A	-0.31*	-0.12	-0.24
Dyspnea 4: At rest	N/A	Reference	Reference	Reference
Change Over Time in Intervention States				
2014-2015*HHVBP	Reference	Reference	Reference	Reference
2016-2017*HHVBP	0.26	0.20	0.31*	0.37*
2018-2019*HHVBP	0.99*	0.67*	0.66*	0.79*
Length of Care				
1-7 days	N/A	Reference	Reference	Reference
8-14 days	N/A	18.49*	17.69*	16.62*
15-21 days	N/A	27.07*	26.30*	24.29*
>21 days	N/A	27.00*	26.61*	24.83*
Clinical Complexity upon SOC				
HCC Scores 1st quartile	N/A	N/A	Reference	Reference
HCC Scores 2nd quartile	N/A	N/A	-4.23*	-4.22*
HCC Scores 3rd quartile	N/A	N/A	-6.99*	-6.92*
HCC Scores 4th quartile	N/A	N/A	-10.70*	-10.52*
Clinical Care Delivery				
Intensity of Care: Total N of visits	N/A	N/A	N/A	-0.13*
Timing of Care: % Visits first 7 Days	N/A	N/A	N/A	-0.02*
Care mix: % Therapy visits	N/A	N/A	N/A	0.11*
Model R^2	0.015	0.092	0.102	0.107
Model N		2,109,054		

$p < 0.05$. HCC= Hiearchical Condition Category; N/A= Not Applicable. |See Section 4 in the Main Report for definition of covariates in M1-M3.

Exhibit B-24. Regression Results for Improvement in Ambulation Over Time among Beneficiaries with Pneumonia

	M0 Unadjusted Model	M1 (M0 + Initial OASIS + Length of care)	M2 (M1+ HCC)	M3 (M2 + Visit mix)
Change Over Time/Time Trends				
2014-2015	Reference	Reference	Reference	Reference
2016-2017	6.38*	2.86*	2.80*	2.76*
2018-2019	12.45*	6.48*	6.37*	6.27*
Intervention States				
Non-HHVBP States	Reference	Reference	Reference	Reference
HHVBP States	3.13*	2.07*	2.10*	2.12*
OASIS Documentation of Initial Functional Status				
Ambulation 1 With use of one-handed device	N/A	-2.08*	-4.34*	-5.66
Ambulation 2 Requires use of two-handed device	N/A	2.56*	0.68	-0.26
Ambulation 3 Able to walk only with supervision or assistance	N/A	31.35*	29.76*	29.05*
Ambulation 4 Chairfast but able to wheel self independently	N/A	5.28*	4.48*	4.15*
Ambulation 5 Chairfast and unable to wheel self	N/A	8.03*	7.15*	6.96*
Ambulation 6 Bedfast	N/A	Reference	Reference	Reference
Change Over Time in Intervention States				
2014-2015*HHVBP	Reference	Reference	Reference	Reference
2016-2017*HHVBP	1.23*	0.91*	0.95*	0.96*
2018-2019*HHVBP	0.18	0.09	0.06*	0.08
Length of Care				
1-7 days	N/A	Reference	Reference	Reference
8-14 days	N/A	20.19*	19.65*	20.63*
15-21 days	N/A	25.95*	25.42*	27.18*
>21 days	N/A	26.09*	25.84*	29.71*
Clinical Complexity upon SOC				
HCC Scores 1st quartile	N/A	N/A	Reference	Reference
HCC Scores 2nd quartile	N/A	N/A	-3.53*	-3.40*
HCC Scores 3rd quartile	N/A	N/A	-4.95*	-4.80*
HCC Scores 4th quartile	N/A	N/A	-8.08*	-7.87*
Clinical Care Delivery				
Intensity of Care: Total n of visits	N/A	N/A	N/A	-0.16*
Timing of Care: % visits first 7 Days	N/A	N/A	N/A	0.02*
Care mix: % therapy visits	N/A	N/A	N/A	0.01*
Model R^2	0.016	0.124	0.129	0.130
Model N	2,228,355			

$p < 0.05$. HCC= Hiearchical Condition Category; N/A= Not Applicable. |See Section 4 in the Main Report for definition of covariates in M1-M3.

Exhibit B-25. Regression Results for Improvement in Grooming Over Time among Beneficiaries with Pneumonia

	M0 Unadjusted Model	M1 (M0 + Initial OASIS + Length of care)	M2 (M1+ HCC)	M3 (M2 + Visit mix)
Change Over Time/Time Trends				
2014-2015	Reference	Reference	Reference	Reference
2016-2017	2.71*	2.37*	2.33*	2.01*
2018-2019	7.50*	6.59*	6.49*	5.94*
Intervention States				
Non-HHVBP States	Reference	Reference	Reference	Reference
HHVBP States	2.64*	2.71*	2.73*	2.52*
OASIS Documentation of Initial Functional Status				
Grooming 1 Utensils must be placed within reach	N/A	6.12*	5.30*	4.80*
Grooming 2 Someone must assist	N/A	15.30*	14.77*	14.43*
Grooming 3 Entirely dependent	N/A	Reference	Reference	Reference
Change Over Time in Intervention States				
2014-2015*HHVBP	Reference	Reference	Reference	Reference
2016-2017*HHVBP	0.79*	0.67*	0.73*	0.77*
2018-2019*HHVBP	1.18*	1.07*	1.05*	1.17*
Length of Care				
1-7 days	N/A	Reference	Reference	Reference
8-14 days	N/A	21.01*	20.37*	21.27*
15-21 days	N/A	29.95*	29.30*	30.67*
>21 days	N/A	30.35*	29.98*	33.27*
Clinical Complexity upon SOC				
HCC Scores 1st quartile	N/A	N/A	Reference	Reference
HCC Scores 2nd quartile	N/A	N/A	-3.43*	-3.31*
HCC Scores 3rd quartile	N/A	N/A	-5.32*	-5.14*
HCC Scores 4th quartile	N/A	N/A	-8.59*	-8.24*
Clinical Care Delivery				
Intensity of Care: Total n of visits	N/A	N/A	N/A	-0.16*
Timing of Care: % visits first 7 Days	N/A	N/A	N/A	0.03*
Care mix: % therapy visits	N/A	N/A	N/A	0.08*
Model R^2	0.007	0.029	0.035	0.038
Model N	2,096,324			

*p < 0.05. HCC= Hiearchical Condition Category; N/A= Not Applicable. |See Section 4 in the Main Report for definition of covariates in M1-M3.

Exhibit B-26. Regression Results for Improvement in Dyspnea Over Time among Beneficiaries with Knee/Hip Replacement

	M0 Unadjusted Model	M1 (M0 + Initial OASIS + Length of care)	M2 (M1+ HCC)	M3 (M2 + Visit mix)
Change Over Time/Time Trends				
2014-2015	Reference	Reference	Reference	Reference
2016-2017	4.54*	4.14*	4.11*	3.77*
2018-2019	7.37*	6.42*	6.34*	5.70*
Intervention States				
Non-HHVBP States	Reference	Reference	Reference	Reference
HHVBP States	2.70*	2.92*	3.00*	2.99*
OASIS Documentation of Initial Functional Status				
Dyspnea 1 When walking 20+ feet	N/A	-9.03*	-10.07*	-10.38*
Dyspnea 2 When moderate exertion < 20 feet	N/A	-0.19*	-1.01*	-0.88*
Dyspnea 3 When minimum exertion	N/A	2.36*	1.83*	2.06*
Dyspnea 4 At rest	N/A	Reference	Reference	Reference
Change Over Time in Intervention States				
2014-2015*HHVBP	Reference	Reference	Reference	Reference
2016-2017*HHVBP	-0.46*	-0.64*	-0.72*	-0.70*
2018-2019*HHVBP	-1.85*	-2.13*	-2.08*	-2.06*
Length of Care				
1-7 days	N/A	Reference	Reference	Reference
8-14 days	N/A	5.29*	5.19*	6.27*
15-21 days	N/A	5.62*	5.62*	7.48*
>21 days	N/A	3.68*	4.04*	7.15*
Clinical Complexity upon SOC				
HCC Scores 1st quartile	N/A	N/A	Reference	Reference
HCC Scores 2nd quartile	N/A	N/A	-1.31*	-1.20*
HCC Scores 3rd quartile	N/A	N/A	-2.87*	-2.65*
HCC Scores 4th quartile	N/A	N/A	-5.45*	-5.02*
Clinical Care Delivery				
Intensity of Care: Total n of visits	N/A	N/A	N/A	-0.10*
Timing of Care: % visits first 7 Days	N/A	N/A	N/A	0.02*
Care mix: % therapy visits	N/A	N/A	N/A	0.10*
Model R^2	0.010	0.038	0.0433	0.0485
Model N	5,392,147			

$p < 0.05$. HCC= Hiearchical Condition Category; N/A= Not Applicable. |See Section 4 in the Main Report for definition of covariates in M1-M3.

Exhibit B-27. Regression Results for Improvement in Ambulation Over Time among Beneficiaries with Knee/Hip Replacement

	M0 Unadjusted Model	M1 (M0 + Initial OASIS + Length of care)	M2 (M1+ HCC)	M3 (M2 + Visit mix)
Change Over Time/Time Trends				
2014-2015	Reference	Reference	Reference	Reference
2016-2017	3.36*	0.71*	0.72*	0.58*
2018-2019	5.26*	1.03*	1.03*	0.81*
Intervention States				
Non-HHVBP States	Reference	Reference	Reference	Reference
HHVBP States	2.10*	1.49*	1.51*	1.48*
OASIS Documentation of Initial Functional Status				
Ambulation 1 With use of one-handed device	N/A	-50.14*	-51.04*	-51.12*
Ambulation 2 Requires use of two-handed device	N/A	-12.50*	-13.36*	-13.68*
Ambulation 3 Able to walk only with supervision or assistance	N/A	5.75*	4.98*	4.34*
Ambulation 4 Chairfast but able to wheel self independently	N/A	2.21*	1.98*	1.42*
Ambulation 5 Chairfast and unable to wheel self	N/A	4.96*	4.58*	3.88*
Ambulation 6 Bedfast	N/A	Reference	Reference	Reference
Change Over Time in Intervention States				
2014-2015*HHVBP	Reference	Reference	Reference	Reference
2016-2017*HHVBP	0.33*	-0.59*	-0.61*	-0.52*
2018-2019*HHVBP	-0.46*	-1.19*	-1.19*	-1.02*
Length of Care				
1-7 days	N/A	Reference	Reference	Reference
8-14 days	N/A	8.01*	7.99*	6.79*
15-21 days	N/A	10.25*	10.31*	8.72*
>21 days	N/A	11.15*	11.51*	9.34*
Clinical Complexity upon SOC				
HCC Scores 1st quartile	N/A	N/A	Reference	Reference
HCC Scores 2nd quartile	N/A	N/A	-1.07*	-1.04*
HCC Scores 3rd quartile	N/A	N/A	-2.16*	-2.08*
HCC Scores 4th quartile	N/A	N/A	-3.99*	-3.82*
Clinical Care Delivery				
Intensity of Care: Total n of visits	N/A	N/A	N/A	0.04*
Timing of Care: % visits first 7 Days	N/A	N/A	N/A	-0.03*
Care mix: % therapy visits	N/A	N/A	N/A	0.07*
Model R^2	0.009	0.138	0.141	0.144
Model N	8,860,396			

$p < 0.05$. HCC= Hiearchical Condition Category; N/A= Not Applicable. |See Section 4 in the Main Report for definition of covariates in M1-M3.

Exhibit B-28. Regression Results for Improvement in Grooming Over Time among Beneficiaries with Knee/Hip Replacement

	M0 Unadjusted Model	M1 (M0 + Initial OASIS + Length of care)	M2 (M1+ HCC)	M3 (M2 + Visit mix)
Change Over Time/Time Trends				
2014-2015	Reference	Reference	Reference	Reference
2016-2017	1.03*	0.66*	0.66*	0.34*
2018-2019	1.69*	1.03*	1.01*	0.47*
Intervention States				
Non-HHVBP States	Reference	Reference	Reference	Reference
HHVBP States	1.35*	1.38*	1.39*	1.37*
OASIS Documentation of Initial Functional Status				
Grooming 1 Utensils must be placed within reach	N/A	-4.93*	-5.20*	-5.63*
Grooming 2 Someone must assist	N/A	0.18*	0.02*	-0.14*
Grooming 3 Entirely dependent	N/A	Reference	Reference	Reference
Change Over Time in Intervention States				
2014-2015*HHVBP	Reference	Reference	Reference	Reference
2016-2017*HHVBP	-0.28*	-0.48*	-0.49*	-0.42*
2018-2019*HHVBP	-0.41*	-0.71*	-0.70*	-0.53*
Length of Care				
1-7 days	N/A	Reference	Reference	Reference
8-14 days	N/A	8.77*	8.75*	8.02*
15-21 days	N/A	10.32*	10.35*	9.56*
>21 days	N/A	10.02*	10.27*	9.35*
Clinical Complexity upon SOC				
HCC Scores 1st quartile	N/A	N/A	Reference	Reference
HCC Scores 2nd quartile	N/A	N/A	-0.79*	-0.73*
HCC Scores 3rd quartile	N/A	N/A	-1.44*	-1.28*
HCC Scores 4th quartile	N/A	N/A	-3.00*	-2.67*
Clinical Care Delivery				
Intensity of Care: Total n of visits	N/A	N/A	N/A	<0.00*
Timing of Care: % visits first 7 Days	N/A	N/A	N/A	-0.01*
Care mix: % therapy visits	N/A	N/A	N/A	<0.00*
Model R^2	0.001	0.018	0.020	0.010
Model N	8,101,133			

$p < 0.05$. HCC= Hierarchical Condition Category; N/A= Not Applicable. |See Section 4 in the Main Report for definition of covariates in M1-M3.

Exhibit B-29. Regression Results for Improvement in Dyspnea Over Time among Beneficiaries with Heart Failure

	M0 Unadjusted Model	M1 (M0 + Initial OASIS + Length of care)	M2 (M1+ HCC)	M3 (M2 + Visit mix)
Change Over Time/Time Trends				
2014-2015	Reference	Reference	Reference	Reference
2016-2017	6.50*	5.17*	5.12*	4.70*
2018-2019	12.54*	9.88*	9.82*	9.05*
Intervention States				
Non-HHVBP States	Reference	Reference	Reference	Reference
HHVBP States	1.27*	<0.00	<0.00	-0.28*
OASIS Documentation of Initial Functional Status				
Dyspnea 1 When walking 20+ feet	N/A	-36.66*	-37.63*	-37.87*
Dyspnea 2 When moderate exertion < 20 feet	N/A	-8.14*	-8.83*	-8.95*
Dyspnea 3 When minimum exertion	N/A	-0.28*	-0.69*	-0.74*
Dyspnea 4 At rest	N/A	Reference	Reference	Reference
Change Over Time in Intervention States				
2014-2015*HHVBP	Reference	Reference	Reference	Reference
2016-2017* HHVBP	2.61*	2.53*	2.56*	2.67*
2018-2019*HHVBP	2.15*	2.12*	2.06*	2.29*
Length of Care				
1-7 days	N/A	Reference	Reference	Reference
8-14 days	N/A	17.29*	16.96*	16.00*
15-21 days	N/A	28.94*	28.48*	26.93*
>21 days	N/A	31.15*	30.77*	26.96*
Clinical Complexity upon SOC				
HCC Scores 1st quartile	N/A	N/A	Reference	Reference
HCC Scores 2nd quartile	N/A	N/A	-2.82*	-2.84*
HCC Scores 3rd quartile	N/A	N/A	-5.04*	-5.07*
HCC Scores 4th quartile	N/A	N/A	-7.78*	-7.79*
Clinical Care Delivery				
Intensity of Care: Total n of visits	N/A	N/A	N/A	-0.16*
Timing of Care: % visits first 7 Days	N/A	N/A	N/A	-0.03*
Care mix: % therapy visits	N/A	N/A	N/A	0.09*
Model R^2	0.018	0.038	0.130	0.134
Model N	3,293,407			

$p < 0.05$. HCC= Hiearchical Condition Category; N/A= Not Applicable. |See Section 4 in the Main Report for definition of covariates in M1-M3.

Exhibit B-30. Regression Results for Improvement in Ambulation Over Time among Beneficiaries with Heart Failure

	M0 Unadjusted Model	M1 (M0 + Initial OASIS + Length of care)	M2 (M1+ HCC)	M3 (M2 + Visit mix)
Change Over Time/Time Trends				
2014-2015	Reference	Reference	Reference	Reference
2016-2017	8.73*	3.87*	3.80*	3.65*
2018-2019	15.08*	6.73*	6.66*	6.43*
Intervention States				
Non-HHVBP States	Reference	Reference	Reference	Reference
HHVBP States	3.27*	2.52*	2.51*	2.51*
OASIS Documentation of Initial Functional Status				
Ambulation 1 With use of one-handed device	N/A	-10.13*	-12.20*	-14.20*
Ambulation 2 Requires use of two-handed device	N/A	-7.37*	-9.17*	-10.46*
Ambulation 3 Able to walk only with supervision or assistance	N/A	27.52*	25.85*	24.91*
Ambulation 4 Chairfast but able to wheel self independently	N/A	1.96*	1.30*	0.72
Ambulation 5 Chairfast and unable to wheel self	N/A	12.69*	11.98*	11.80*
Ambulation 6 Bedfast	N/A	Reference	Reference	Reference
Change Over Time in Intervention States				
2014-2015*HHVBP	Reference	Reference	Reference	Reference
2016-2017* HHVBP	1.89*	0.78*	0.81*	0.87*
2018-2019*HHVBP	-0.06*	-0.44*	-0.48*	-0.35*
Length of Care				
1-7 days	N/A	Reference	Reference	Reference
8-14 days	N/A	17.95*	17.69*	17.68*
15-21 days	N/A	27.72*	27.35*	27.63*
>21 days	N/A	30.30*	29.99*	32.34*
Clinical Complexity upon SOC				
HCC Scores 1st quartile	N/A	N/A	Reference	Reference
HCC Scores 2nd quartile	N/A	N/A	-1.96*	-1.90*
HCC Scores 3rd quartile	N/A	N/A	-3.42*	-3.33*
HCC Scores 4th quartile	N/A	N/A	-6.63*	-6.47*
Clinical Care Delivery				
Intensity of Care: Total n of visits	N/A	N/A	N/A	-0.24*
Timing of Care: % visits first 7 Days	N/A	N/A	N/A	-0.020*
Care mix: % therapy visits	N/A	N/A	N/A	<0.00*
Model R^2	0.010	0.170	0.173	0.176
Model N	3,404,010			

*p < 0.05. HCC= Hiearchical Condition Category; N/A= Not Applicable. |See Section 4 in the Main Report for definition of covariates in M1-M3.

Exhibit B-31. Regression Results for Improvement in Grooming Over Time among Beneficiaries with Heart Failure

	M0 Unadjusted Model	M1 (M0 + Initial OASIS + Length of care)	M2 (M1+ HCC)	M3 (M2 + Visit mix)
Change Over Time/Time Trends				
2014-2015	Reference	Reference	Reference	Reference
2016-2017	4.87*	3.88*	3.80*	3.37*
2018-2019	9.43*	7.61*	7.52*	6.75*
Intervention States				
Non-HHVBP States	Reference	Reference	Reference	Reference
HHVBP States	3.19*	3.19*	3.17*	2.91*
OASIS Documentation of Initial Functional Status				
Grooming 1 Utensils must be placed within reach	N/A	-8.51*	-9.38*	-10.15*
Grooming 2 Someone must assist	N/A	5.02*	4.46*	3.99*
Grooming 3 Entirely dependent	N/A	Reference	Reference	Reference
Change Over Time in Intervention States				
2014-2015*HHVBP	Reference	Reference	Reference	Reference
2016-2017* HHVBP	0.85*	0.68*	0.71*	0.87*
2018-2019*HHVBP	0.22	-0.09	-0.12	0.17
Length of Care				
1-7 days	N/A	Reference	Reference	Reference
8-14 days	N/A	22.02*	21.71*	21.14*
15-21 days	N/A	34.58*	34.14*	33.41*
>21 days	N/A	37.40*	37.03*	38.26*
Clinical Complexity upon SOC				
HCC Scores 1st quartile	N/A	N/A	Reference	Reference
HCC Scores 2nd quartile	N/A	N/A	-1.67*	-1.65*
HCC Scores 3rd quartile	N/A	N/A	-3.64*	-3.60*
HCC Scores 4th quartile	N/A	N/A	-7.33*	-7.21*
Clinical Care Delivery				
Intensity of Care: Total n of visits	N/A	N/A	N/A	-0.27*
Timing of Care: % visits first 7 Days	N/A	N/A	N/A	-0.03*
Care mix: % therapy visits	N/A	N/A	N/A	0.08*
Model R^2	0.023	0.044	0.048	0.053
Model N	3,174,809			

$p < 0.05$. HCC= Hiearchical Condition Category; N/A= Not Applicable. | See Section 4 in the Main Report for definition of covariates in M1-M3.

Exhibit B-32. Regression Estimates for Selected Agency-level Outcomes Used for Calculating Adjusted Changes in Performance

Parameter	Unplanned Hospitalization	Outpatient ED Use	Overall Care	Improvement in Dyspnea	Improvement in Ambulation	Improvement in Bathing
Intercept	15.2*	12.3*	86.4*	51.7*	58.5*	62.6*
Average Number of Episodes (In Thousands)	0.1	0	-0.1*	0.8**	0.6	0.7*
Part of a Chain	0.5	1.0*	-0.5*	9.5*	6.0*	7.3*
HHVBP States	0.2	-1.3	-0.2*	7.1	4.7	5.2**
Regional Grouping						
Arizona	-0.5*	-1.2*	-5.5*	12.9*	3.4*	4.5**
Florida	Reference	Reference	Reference	Reference	Reference	Reference
Iowa	0.5*	2.0*	-2.3*	9.0*	0.2	-0.2
Maryland	1.0*	-0.5*	-2.0*	12.6*	3.2*	1.2
Massachusetts	1.0*	1.2*	-1.5*	8.4*	1.0*	-1.1
Nebraska	1.1*	0.9*	-0.7*	11.2*	3.0*	2.5
North Carolina	1.0*	0.8*	0.1*	9.9*	2.4*	0.5
Tennessee	0.4*	-0.4*	-1.8*	11.4*	3.6*	4.1**
Washington	-0.8*	3.3*	-3.8*	10.2*	-0.3	0.5
Time Period						
2014-2015	Reference	Reference	Reference	Reference	Reference	Reference
2016-2017	0.3**	0.3*	-0.1**	6.0*	7.7*	5.5*
2018-2019	-0.4*	0.4*	-0.3*	12.0*	12.5*	9.9*
Interaction Terms						
HHVBP x Chain	0	0.6	-0.3*	-4.5*	-5.0**	-5.7*
2016-2017 x Chain	-0.1	0.1	0.4**	4.5*	2.8*	4.0*
2018-2019 x Chain	-0.1	-0.1	1.1*	4.1*	3.7*	4.7*
HHVBP 2016-2017	-0.3**	0.2	0.2**	3.0*	2.2*	2.5*
HHVBP 2018-2019	-0.5**	0.4**	0.6*	3.0*	2.2**	2.6*
HHVBP x 2016-2017 x Chain	-0.1	-0.5*	0.2*	-3.9*	-2.3*	-2.5*
HHVBP x 2018-2019 x Chain	0.1	-0.4*	-0.4*	-4.4**	-2.3*	-2.7*

* p < 0.05; Standard errors clustered at the state level.
** p < 0.10; Standard errors clustered at the state level.

B.5 TPS Supporting Analyses

Exhibit B-33. Characteristics of HHAs by Eligibility for Calculating a TPS in 2021

HHA Characteristics	Agencies in HHVBP States			Agencies in Non-HHVBP States		
	Eligible for TPS		Total	Eligible for TPS		Total
	Yes	No		Yes	No	
Total number of HHAs	1,502	450	1,952	6,045	2,330	8,375
HHA Size: **Number of OASIS Episodes (%)**						
1-59	4.1%	86.3%	21.4%	5.7%	89.7%	27.9%
60-249	24.1%	12.2%	21.6%	35.2%	9.1%	28.3%
250-499	18.8%	0.7%	15.0%	18.8%	0.8%	14.1%
500-999	20.3%	0.5%	16.1%	17.4%	0.3%	12.8%
>1,000	32.8%	0.2%	26.0%	22.9%	0.1%	16.9%
Ownership (%)						
For-profit	77.2%	90.6%	80.1%	79.8%	92.9%	83.4%
Non-profit	17.7%	5.3%	15.0%	17.0%	5.3%	13.8%
Government-owned	5.1%	4.1%	4.8%	3.2%	1.8%	2.8%
Setting (%)						
Hospital-based	8.1%	1.7%	6.7%	8.4%	1.4%	6.5%
Freestanding	91.9%	98.3%	93.3%	91.6%	98.6%	93.5%
Chain affiliation (%)						
Chain=Yes	39.7%	7.1%	32.2%	25.2%	5.3%	19.7%
Chain=No	53.3%	78.4%	59.1%	68.8%	87.2%	73.9%
Chain=Missing/Unknown	6.9%	14.4%	8.7%	6.0%	7.6%	6.4%
HHA years in operation (%)						
<4 years	2.3%	27.1%	7.7%	5.7%	26.3%	11.3%
4-10 years	21.4%	26.6%	22.5%	19.6%	26.7%	21.5%
>10 years	76.4%	46.3%	69.8%	74.7%	47.0%	67.2%

Exhibit B-34. HHA Eligibility for Calculating a TPS in 2020

	Agencies in HHVBP States			Agencies in Non-HHVBP States		
	Eligible for TPS		Total	Eligible for TPS		Total
	Yes	No		Yes	No	
Total number of HHAs	1,491	417	1,908	5,947	2,437	8,384
% of HHAs	78.1%	21.9%	100.0%	70.9%	29.1%	100.0%
Number of OASIS episodes	1,587,215	13,298	1,600,513	5,174,800	88,306	5,263,106
% of OASIS episodes	99.2%	0.8%	100.0%	98.3%	1.7%	100.0%
Number of Medicare claims episodes	2,068,954	21,390	2,090,344	6,756,681	231,056	6,987,737
% of Medicare claims episodes	99.0%	1.0%	100.0%	96.7%	3.3%	100.0%

Exhibit B-35. Average Measure Scores among Agencies in 2016 – 2021, by HHVBP and Non-HHVBP States

HHVBP Performance Measure	2016	2017	2018	2019	2020	2021
ED Use (no Hospitalization)/First FFS HH Episodes						
HHVBP	2.3	2.2	2.2	2.0	3.9	3.2
Non-HHVBP	2.5	2.3	2.4	2.2	3.9	3.2
Unplanned ACH/First FFS HH Episodes						
HHVBP	2.2	2.7	2.9	3.0	4.2	4.5
Non-HHVBP	2.2	2.8	2.9	2.8	4.1	4.2
Discharged to Community						
HHVBP	2.9	2.8	3.1	3.3	3.2	3.4
Non-HHVBP	2.6	2.5	2.7	3.0	3.0	3.3
Improvement in Ambulation-Locomotion‡						
HHVBP	4.5	5.7	6.5	N/A	N/A	N/A
Non-HHVBP	3.9	5.0	5.9	N/A	N/A	N/A
Improvement in Bathing‡						
HHVBP	4.2	5.3	6.0	N/A	N/A	N/A
Non-HHVBP	3.6	4.4	5.1	N/A	N/A	N/A
Improvement in Bed Transferring‡						
HHVBP	4.5	6.5	7.5	N/A	N/A	N/A
Non-HHVBP	3.9	5.4	6.5	N/A	N/A	N/A
Improvement in Management of Oral Medications						
HHVBP	4.2	5.8	6.7	7.9	8.4	8.7
Non-HHVBP	3.6	4.9	5.9	7.1	7.5	7.8
Improvement in Dyspnea						
HHVBP	4.0	5.3	6.0	6.7	7.0	7.1
Non-HHVBP	3.6	4.6	5.3	6.1	6.2	6.4
Improvement in Pain Interfering with Activity						

HHVBP Performance Measure	2016	2017	2018	2019	2020	2021
HHVBP	4.2	5.2	5.7	6.4	6.5	N/A
Non-HHVBP	3.7	4.5	5.1	5.9	6.0	N/A
TNC Change in Self-Care						
HHVBP	N/A	N/A	N/A	7.5	9.9	10.8
Non-HHVBP	N/A	N/A	N/A	6.4	8.3	9.1
TNC Change in Mobility						
HHVBP	N/A	N/A	N/A	8.1	9.8	10.6
Non-HHVBP	N/A	N/A	N/A	6.9	8.1	8.9
Drug Education on Medications Provided to Patient/Caregiver during Episodes of Care[†]						
HHVBP	5.7	6.1	N/A	N/A	N/A	N/A
Non-HHVBP	5.2	5.7	N/A	N/A	N/A	N/A
Influenza Immunization Received for Current Flu Season[‡]						
HHVBP	4.6	4.8	5.0	N/A	N/A	N/A
Non-HHVBP	4.4	4.9	5.1	N/A	N/A	N/A
Pneumococcal Polysaccharide Vaccine Ever Received[‡]						
HHVBP	4.6	4.7	4.8	N/A	N/A	N/A
Non-HHVBP	4.6	4.9	5.1	N/A	N/A	N/A
How often the home health team gave care in a professional way						
HHVBP	2.5	2.5	2.7	2.5	2.5	2.2
Non-HHVBP	2.7	2.7	2.8	2.7	2.8	2.6
How well did the home health team communicate with patients						
HHVBP	2.8	2.8	3.0	2.8	2.9	2.6
Non-HHVBP	2.9	2.8	3.0	2.9	2.9	2.8
Did the home health team discuss medicines, pain, and home safety with patients						
HHVBP	2.6	2.8	2.8	2.6	1.9	1.7
Non-HHVBP	2.8	2.9	2.9	2.7	2.2	1.9
How do patients rate the overall care from the home health agency						
HHVBP	2.8	2.7	2.8	2.8	3.0	2.7
Non-HHVBP	2.9	2.8	2.8	2.8	3.0	3.0
Would patients recommend the home health agency to friends and family						
HHVBP	2.6	2.5	2.6	2.5	2.4	2.3
Non-HHVBP	2.7	2.6	2.6	2.5	2.6	2.4
TPS						
HHVBP	37.1	42.6	45.4	38.9	46.1	46.8
Non-HHVBP	34.9	40.0	42.9	36.6	43.4	44.2

[†]*This measure was dropped for performance year 2018 and all subsequent years of the HHVBP Model and dropped from the CMS Star Ratings in April 2019.* [‡] *These measures were dropped for performance year 2019 and all subsequent years of the HHVBP Model.*

Exhibit B-36. Average Agency TPS in HHVBP and Non-HHVBP States during the Baseline Period, 2013 – 2015

Exhibit B-37. Difference in Agency TPS between HHVBP States and their Regional Comparison Groups, 2016

*Graph shows 90% CIs. * p < 0.10, ** p < 0.05.*

Exhibit B-38. Difference in Agency TPS between HHVBP States and their Regional Comparison Groups, 2017

Graph shows 90% CIs. ** p < 0.05.

Exhibit B-39. Difference in Agency TPS between HHVBP States and their Regional Comparison Groups, 2018

Graph shows 90% CIs. ** p < 0.05.

Exhibit B-40. Difference in Agency TPS between HHVBP States and their Regional Comparison Groups, 2019

*Graph shows 90% CIs. ** p < 0.05.*

Exhibit B-41. Difference in Agency TPS between HHVBP States and their Regional Comparison Groups, 2020

*Graph shows 90% CIs. ** p < 0.05.*

B.6 Utilization of Services Supporting Analyses

Exhibit B-42. Unplanned ACHs among all FFS Home Health Episodes, Overall and COVID-Specific

Exhibit B-43. Impact of the HHVBP Model between early years (2016 – 2017) vs. later years of HHVBP (2018 – 2021) for Claims-Based Utilization Measures

Measure	D-in-D[a]	p-value	Lower 90% CI[a]	Upper 90% CI[a]
Unplanned ACH/First FFS HH Episodes	-0.10	0.12	-0.21	0.005
Outpatient ED Use (no Hospitalization)/First FFS HH Episodes	0.004	0.95	-0.10	0.10
ED Use followed by Inpatient Admission/First FFS HH Episodes	-0.15	0.03	-0.26	-0.04
Total ED Use (Outpatient or Inpatient Claims)/First FFS HH Episodes	-0.10	0.23	-0.24	0.04
Unplanned ACH/All FFS HH Episodes	-0.36	<0.001	-0.47	-0.25
SNF Use/All FFS HH Episodes	-0.30	<0.001	-0.35	-0.25

[a] *Values represent percentage point changes. |Original HHVBP Model measures indicated by italic text. | CI = Confidence Interval.*

Exhibit B-44. Results from Sensitivity Model Examining the Impact of Implementation of PDGM on the HHVBP Model, Claims-Based Utilization Measures

Measure	Model Estimates				Average in HHVBP States, Baseline (2013-2015)	% Relative Change
	D-in-D[a]	p-value	Lower 90% CI[a]	Upper 90% CI[a]		
Sensitivity Analyses Examining the Impact of Implementation Of PDGM						
Unplanned ACH/All FFS HH Episodes						
2016	-0.17	0.02	-0.28	-0.05		-1.0%
2017	-0.11	0.16	-0.24	0.02		-0.6%
2018	-0.22	0.01	-0.36	-0.08		-1.3%
2019	-0.29	<0.01	-0.44	-0.14	17.0%	-1.7%
2020	-0.33	<0.01	-0.50	-0.16		-1.9%
2021	-0.69	<0.001	-0.87	-0.51		-4.1%
Cumulative	-0.29	<0.001	-0.41	-0.17		-1.7%
SNF Use/All FFS HH Episodes						
2016	-0.20	<0.001	-0.25	-0.14		-4.1%
2017	-0.20	<0.001	-0.26	-0.14		-4.1%
2018	-0.27	<0.001	-0.34	-0.21		-5.5%
2019	-0.29	<0.001	-0.36	-0.22	4.9%	-5.9%
2020	-0.45	<0.001	-0.53	-0.37		-9.2%
2021	-0.55	<0.001	-0.63	-0.47		-11.2%
Cumulative	-0.32	<0.001	-0.37	-0.27		-6.5%

[a] *Values represent percentage point changes. CI = Confidence Interval. | For more details, refer to Section A.2.11 of Technical Appendix*

Exhibit B-45. Results from Sensitivity Model Not adjusted for COVID Covariates Showing Impact of the HHVBP Model on Claims-Based Utilization Measures

	Model Estimates				Average in HHVBP States, Baseline (2013-2015)	% Relative Change
	D-in-D[a]	p-value	Lower 90% CI[a]	Upper 90% CI[a]		
Unplanned ACH/First FFS HH Episodes						
2016	-0.23	<0.01	-0.36	-0.09		-1.5%
2017	-0.03	0.74	-0.17	0.12		-0.2%
2018	-0.13	0.15	-0.28	0.02		-0.8%
2019	-0.25	<0.01	-0.41	-0.10	15.7%	-1.6%
2020	-0.14	0.17	-0.32	0.03		-0.9%
2021	-0.51	<0.001	-0.70	-0.32		-3.2%
Cumulative	-0.21	<0.01	-0.33	-0.09		-1.3%
Outpatient ED Use (No Hospitalization)/First FFS HH Episodes						
2016	0.25	<0.001	0.14	0.37	11.7%	2.1%
2017	0.22	<0.01	0.10	0.35		1.9%

	Model Estimates				Average in HHVBP States, Baseline (2013-2015)	% Relative Change
	D-in-D[a]	p-value	Lower 90% CI[a]	Upper 90% CI[a]		
2018	0.37	<0.001	0.24	0.49		3.2%
2019	0.35	<0.001	0.21	0.49		3.0%
2020	0.21	0.02	0.06	0.36		1.8%
2021	-0.003	0.97	-0.16	0.16		-0.03%
Cumulative	0.24	<0.001	0.13	0.35		2.1%
ED Use Followed by Inpatient Admission/First FFS HH Episodes						
2016	-0.19	0.02	-0.32	-0.06		-1.3%
2017	-0.04	0.67	-0.17	0.10		-0.3%
2018	-0.11	0.24	-0.26	0.04		-0.8%
2019	-0.26	<0.01	-0.42	-0.11	14.2%	-1.8%
2020	-0.24	0.02	-0.41	-0.07		-1.7%
2021	-0.55	<0.001	-0.74	-0.36		-3.9%
Cumulative	-0.22	<0.01	-0.35	-0.10		-1.5%
Total ED Use (Outpatient or Inpatient Claims)/First FFS HH Episodes						
2016	0.03	0.77	-0.13	0.19		0.1%
2017	0.17	0.14	-0.02	0.35		0.6%
2018	0.25	0.03	0.06	0.44		0.9%
2019	0.12	0.32	-0.08	0.32	26.6%	0.5%
2020	-0.002	0.99	-0.22	0.22		-0.01%
2021	-0.56	<0.001	-0.78	-0.33		-2.1%
Cumulative	0.02	0.87	-0.14	0.17		0.1%
Unplanned ACH/All FFS HH Episodes						
2016	-0.16	0.02	-0.27	-0.04		-0.9%
2017	-0.10	0.21	-0.23	0.03		-0.6%
2018	-0.22	0.01	-0.35	-0.08		-1.3%
2019	-0.29	<0.01	-0.44	-0.14	17.0%	-1.7%
2020	-0.52	<0.001	-0.67	-0.36		-3.1%
2021	-0.84	<0.001	-1.01	-0.68		-4.9%
Cumulative	-0.40	<0.001	-0.52	-0.28		-2.4%
SNF Use/All FFS HH Episodes						
2016	-0.19	<0.001	-0.24	-0.14		-3.9%
2017	-0.20	<0.001	-0.26	-0.13		-4.1%
2018	-0.27	<0.001	-0.33	-0.20		-5.5%
2019	-0.29	<0.001	-0.36	-0.22	4.9%	-5.9%
2020	-0.61	<0.001	-0.69	-0.53		-12.4%
2021	-0.71	<0.001	-0.79	-0.64		-14.5%
Cumulative	-0.42	<0.001	-0.47	-0.36		-8.6%

[a] *Values represent percentage point changes. |Original HHVBP Model measures indicated by italic text. | CI = Confidence Interval.*

Exhibit B-46. Cumulative D-in-D Results at the State-Level, Utilization Measures

Measure	Model Estimates				Average in HHVBP States, Baseline (2013 – 2015)	% Relative Change
	D-in-D[a]	p-value	Lower 90% CI[a]	Upper 90% CI[a]		
Unplanned ACH/First FFS HH Episodes						
Arizona	-0.29	0.72	-1.61	1.03	15.8%	-1.8%
Florida	-0.53	0.098	-1.06	-0.003	14.0%	-3.8%
Iowa	-0.24	0.79	-1.73	1.25	17.3%	-1.4%
Maryland	0.64	0.23	-0.23	1.50	18.4%	3.5%
Massachusetts	-0.88	0.20	-2.01	0.25	16.9%	-5.2%
Nebraska	-0.90	0.37	-2.54	0.75	16.9%	-5.3%
North Carolina	0.56	0.29	-0.32	1.44	16.7%	3.4%
Tennessee	-1.16	0.07	-2.22	-0.10	17.5%	-6.6%
Washington	1.67	0.07	0.15	3.18	15.4%	10.9%
Outpatient ED Use (no Hospitalization)/First FFS HH Episodes						
Arizona	-1.04	0.19	-2.34	0.26	13.1%	-8.0%
Florida	0.71	0.01	0.24	1.17	9.9%	7.2%
Iowa	1.27	0.19	-0.33	2.86	14.0%	9.1%
Maryland	0.17	0.79	-0.89	1.22	12.0%	1.4%
Massachusetts	0.04	0.94	-0.96	1.05	12.5%	0.3%
Nebraska	1.33	0.14	-0.16	2.83	11.7%	11.4%
North Carolina	-0.48	0.34	-1.31	0.36	14.3%	-3.3%
Tennessee	-0.76	0.10	-1.53	0.01	13.0%	-5.8%
Washington	-1.09	0.31	-2.85	0.66	14.4%	-7.6%
ED Use followed by Inpatient Admission/First FFS HH Episodes						
Arizona	0.06	0.93	-1.16	1.28	14.2%	0.4%
Florida	-1.11	<0.001	-1.62	-0.60	13.2%	-8.4%
Iowa	-0.75	0.37	-2.12	0.63	12.1%	-6.2%
Maryland	0.32	0.50	-0.46	1.11	17.5%	1.8%
Massachusetts	-1.05	0.12	-2.16	0.06	15.5%	-6.8%
Nebraska	-0.64	0.55	-2.44	1.15	11.9%	-5.4%
North Carolina	0.74	0.14	-0.09	1.57	14.6%	5.1%
Tennessee	-0.60	0.33	-1.61	0.41	15.3%	-3.9%
Washington	1.44	0.12	-0.07	2.95	13.1%	11.0%
Total ED Use (Outpatient or Inpatient Claims)/First FFS HH Episodes						
Arizona	-1.17	0.27	-2.91	0.57	28.2%	-4.1%
Florida	-0.02	0.95	-0.69	0.64	23.3%	-0.1%
Iowa	0.79	0.50	-1.13	2.71	29.5%	2.7%
Maryland	0.70	0.40	-0.67	2.06	29.8%	2.3%
Massachusetts	-0.65	0.43	-2.00	0.70	28.4%	-2.3%
Nebraska	0.02	0.99	-2.34	2.38	26.3%	0.1%
North Carolina	0.16	0.82	-1.03	1.36	30.1%	0.5%
Tennessee	-1.53	0.04	-2.77	-0.30	29.4%	-5.2%
Washington	0.72	0.54	-1.20	2.63	29.2%	2.5%
Unplanned ACH/All FFS HH Episodes						
Arizona	-0.66	0.46	-2.12	0.80	16.9%	-3.9%

Measure	Model Estimates				Average in HHVBP States, Baseline (2013 – 2015)	% Relative Change
	D-in-D[a]	p-value	Lower 90% CI[a]	Upper 90% CI[a]		
Florida	-1.63	<0.001	-2.11	-1.16	15.6%	-10.4%
Iowa	-1.31	0.12	-2.71	0.09	18.3%	-7.2%
Maryland	0.59	0.37	-0.50	1.68	20.2%	2.9%
Massachusetts	-0.72	0.30	-1.86	0.42	19.1%	-3.8%
Nebraska	-1.24	0.24	-3.00	0.51	17.3%	-7.2%
North Carolina	0.64	0.21	-0.20	1.47	18.2%	3.5%
Tennessee	-1.43	0.01	-2.37	-0.49	17.2%	-8.3%
Washington	0.82	0.38	-0.71	2.36	16.0%	5.1%
SNF Use/All FFS HH Episodes						
Arizona	-0.44	0.36	-1.22	0.34	4.4%	-10.0%
Florida	-0.31	0.02	-0.53	-0.09	4.1%	-7.5%
Iowa	-1.88	<0.01	-2.81	-0.95	6.6%	-28.3%
Maryland	0.05	0.88	-0.49	0.58	6.0%	0.8%
Massachusetts	-0.49	0.24	-1.18	0.19	6.9%	-7.1%
Nebraska	-0.87	0.14	-1.84	0.11	6.7%	-12.9%
North Carolina	0.22	0.43	-0.23	0.67	4.6%	4.8%
Tennessee	-0.89	<0.01	-1.38	-0.41	5.0%	-17.9%
Washington	-0.15	0.80	-1.14	0.84	4.9%	-3.1%

[a]Values represent percentage point changes. | Original HHVBP Model measures indicated by italic text. | CI = Confidence Interval. | These models include state-specific linear time trends.

Exhibit B-47. Results from Common Causes of ED Visits Showing Impact of the HHVBP Model on ED Utilization Measures

Measure	Model Estimates				Average in HHVBP States, Baseline (2013 – 2015)	% Relative Change
	D-in-D[a]	p-value	Lower 90% CI[a]	Upper 90% CI[a]		
Inpatient ED Use/ First FFS Home Health Episodes						
Circulatory system	0.04	0.83	-0.30	0.38	23.7%	0.2%
Digestive system	0.18	0.13	-0.02	0.38	8.6%	2.1%
Endocrine, nutritional and metabolic system*	-0.15	0.39	-0.44	0.14	17.6%	-0.9%
Genitourinary system	-0.09	0.46	-0.29	0.11	9.8%	-0.9%
Injury, poisoning, and certain other consequences of external causes	-0.06	0.46	-0.19	0.07	6.9%	-0.9%
Musculoskeletal system and connective tissue*	0.20	0.09	0.01	0.39	8.6%	2.3%

Measure	Model Estimates				Average in HHVBP States, Baseline (2013 – 2015)	% Relative Change
	D-in-D[a]	p-value	Lower 90% CI[a]	Upper 90% CI[a]		
Nervous system	0.07	0.55	-0.12	0.25	8.4%	0.8%
Respiratory system	0.06	0.62	-0.14	0.26	9.3%	0.6%
Skin and subcutaneous tissue	-0.08	0.05	-0.16	-0.01	1.9%	-4.1%
Abdominal and Pelvic pain	-0.01	0.85	-0.12	0.10	3.2%	-0.3%
Cognitive functions and awareness	-0.02	0.71	-0.08	0.05	1.3%	-1.5%
Dyspnea	-0.02	0.78	-0.13	0.09	3.0%	-0.7%
Nausea and vomiting	0.02	0.72	-0.07	0.11	2.6%	0.8%
Syncope and collapse	0.05	0.07	0.004	0.09	0.9%	5.7%
Pain in throat and chest	-0.07	0.20	-0.16	0.02	2.9%	-2.4%
Other	-0.23	0.08	-0.45	-0.01	11.5%	-2.0%
Outpatient ED Use (No Hospitalization)/ First FFS Home Health Episodes						
Circulatory system*	0.47	0.10	-0.01	0.95	41.4%	1.1%
Digestive system	0.26	0.11	-0.01	0.53	14.6%	1.8%
Endocrine, nutritional and metabolic system*	0.24	0.38	-0.21	0.69	29.9%	0.8%
Genitourinary system	0.41	<0.01	0.20	0.62	14.1%	2.9%
Injury, poisoning, and certain other consequences of external causes	-0.05	0.70	-0.24	0.15	15.6%	-0.3%
Musculoskeletal system and connective tissue*	0.23	0.19	-0.06	0.52	18.2%	1.3%
Nervous system	-0.11	0.51	-0.37	0.16	15.9%	-0.7%
Respiratory system*	0.45	<0.001	0.23	0.67	12.8%	3.5%
Skin and subcutaneous tissue*	0.002	0.97	-0.08	0.08	3.1%	0.1%
Abdominal and Pelvic pain	-0.14	0.08	-0.27	-0.01	5.4%	-2.6%
Cognitive functions and awareness	-0.02	0.68	-0.09	0.05	1.8%	-1.1%
Dyspnea*	-0.12	0.08	-0.23	-0.01	4.0%	-3.0%
Nausea and vomiting	-0.14	0.05	-0.27	-0.02	4.4%	-3.2%
Syncope and collapse	0.0002	1.00	-0.06	0.06	2.0%	0.01%

Measure	Model Estimates				Average in HHVBP States, Baseline (2013 – 2015)	% Relative Change
	D-in-D[a]	p-value	Lower 90% CI[a]	Upper 90% CI[a]		
Pain in throat and chest	-0.10	0.15	-0.22	0.01	5.4%	-1.9%
Other	0.31	0.09	0.01	0.61	19.8%	1.6%

[a]Values represent percentage point changes. | *Conditions that failed falsification | CI = Confidence Interval.

Exhibit B-48. Unadjusted Yearly Means (and Standard Errors) of Unplanned ACHs among MA Beneficiaries in HHVBP and Non-HHVBP States, 2013-2020

	2013	2014	2015	2016	2017	2018	2019	2020
HHVBP	18.4% (0.0826)	19% (0.0793)	18.8% (0.0750)	18.2% (0.0707)	18.4% (0.0664)	18.3% (0.0621)	18.7% (0.0612)	17.4% (0.0581)
Non-HHVBP	18.3% (0.0387)	18.6% (0.0373)	18.3% (0.0351)	18% (0.0336)	18.3% (0.0318)	18.2% (0.0306)	18.7% (0.0301)	17.1% (0.0291)

Standard Errors are reported in the same units as the corresponding measure means.

Exhibit B-49. MA Sensitivity Analysis D-in-D Results

Measure	Model Estimates				Average in HHVBP States, Baseline (2013-2015)	% Relative Change
	D-in-D[a]	p-value	Lower 90% CI[a]	Upper 90% CI[a]		
Unplanned ACH among MA Beneficiaries Using Encounter Data						
2016	-0.65	<0.001	-0.90	-0.39	19.6%	-3.3%
2017	-0.63	<0.01	-1.00	-0.25		-3.2%
2018	-0.61	0.01	-1.00	-0.21		-3.1%
2019	-0.71	<0.01	-1.12	-0.29		-3.6%
2020	-0.33	0.25	-0.80	0.14		-1.7%
Cumulative	-0.59	<0.01	-0.92	-0.26		-3.0%
Unplanned ACH among FFS Beneficiaries (OASIS-based)*						
2016	-0.59	<0.001	-0.77	-0.41	20.8%	-2.8%
2017	-0.63	<0.001	-0.90	-0.36		-3.0%
2018	-0.88	<0.001	-1.23	-0.52		-4.2%
2019	-1.08	<0.001	-1.54	-0.63		-5.2%
2020	-1.05	<0.01	-1.58	-0.51		-5.0%
2021	-1.59	<0.001	-2.23	-0.95		-7.6%
Cumulative	-0.93	<0.001	-1.30	-0.56		-4.5%
Unplanned ACH among MA Beneficiaries Using Shadow Claims / 10% threshold sensitivity						
2016	-0.19	0.29	-0.49	0.10		-1.0%

Measure	Model Estimates				Average in HHVBP States, Baseline (2013-2015)	% Relative Change
	D-in-Dᵃ	p-value	Lower 90% CIᵃ	Upper 90% CIᵃ		
2017	-0.30	0.16	-0.66	0.05		-1.6%
2018	-0.25	0.25	-0.62	0.11		-1.3%
2019	-0.52	0.04	-0.94	-0.10	19.0%	-2.7%
2020	-0.18	0.54	-0.67	0.30		-0.9%
Cumulative	-0.30	0.14	-0.64	0.04		-1.6%

A state linear trend term was added to the model after a falsification test indicated a lack of parallel trends in the baseline period. ᵃ Values represent percentage point changes. | CI=Confidence Intervals.

B.7 Medicare Spending Supporting Analyses

Exhibit B-50. Average Number of Days in Baseline and Post-HHVBP Performance Periods for FFS-Claims Based Spending Measures, All HHVBP States and Non-HHVBP States

Measures (Pre-PDGM Approach)	HHVBP States		Non-HHVBP States		Change in Average Days	
	Baseline (2013-2015)	Intervention (2016-2019)	Baseline (2013-2015)	Intervention (2016-2019)	HHVBP States	Non-HHVBP States
Average Medicare Spending per Day during and following FFS HH Episodes of Care	64.9	65.2	64.6	65.0	0.3	0.4
Average Medicare Spending per Day during FFS HH Episodes of Care	46.0	46.2	49.0	48.5	0.2	-0.5
Average Medicare Spending per Day following FFS HH Episodes of Care	27.9	27.8	27.6	27.7	-0.1	0.1
Measures (Post-PDGM Approach)*	Baseline (2013-2015)	Post-PDGM Intervention (2020-2021)	Baseline (2013-2015)	Post-PDGM Intervention (2020-2021)	HHVBP States	Non-HHVBP States
Average Medicare Spending per Day during and following FFS HH Episodes of Care	75.7	40.2	72.8	39.0	-35.5	-33.8
Average Medicare Spending per Day during FFS HH Episodes of Care	58.1	29.6	58.3	29.6	-28.5	-28.7
Average Medicare Spending per Day following FFS HH Episodes of Care	27.9	27.7	27.9	27.7	-0.2	-0.2

*Average is based on capped expenditure measures. *For details, please refer A.1.4.2 of the Technical Appendix.*

Exhibit B-51. Total Number of Days in Baseline and Post-HHVBP Performance Periods for FFS-Claims Based Spending Measures, All HHVBP States and Non-HHVBP States

Measures (Pre-PDGM Approach)	HHVBP States		Non-HHVBP States		Change in Total Days	
	Baseline (2013-2015)	Intervention (2016-2019)	Baseline (2013-2015)	Intervention (2016-2019)	HHVBP States	Non-HHVBP States
Average Medicare Spending per Day during and following FFS HH Episodes of Care	274,799,923	357,115,126	928,214,126	1,199,552,681	82,315,203	271,338,555
Average Medicare Spending per Day during FFS HH Episodes of Care	194,924,885	253,109,617	704,232,470	895,411,658	58,184,732	191,179,188

Measures (Pre-PDGM Approach)	HHVBP States		Non-HHVBP States		Change in Total Days	
	Baseline (2013-2015)	Intervention (2016-2019)	Baseline (2013-2015)	Intervention (2016-2019)	HHVBP States	Non-HHVBP States
Average Medicare Spending per Day following FFS HH Episodes of Care	79,875,038	104,005,509	223,981,656	304,141,023	24,130,471	80,159,367
Measures (Post-PDGM Approach)*	**Baseline (2013-2015)**	**Post-PDGM Intervention (2020-2021)**	**Baseline (2013-2015)**	**Post-PDGM Intervention (2020-2021)**	**HHVBP States**	**Non-HHVBP States**
Average Medicare Spending per Day during and following FFS HH Episodes of Care	320,351,343	166,905,680	1,047,072,561	526,790,595	-153,445,663	-520,281,966
Average Medicare Spending per Day during FFS HH Episodes of Care	246,149,687	123,082,160	838,601,213	400,592,820	-123,067,527	-438,008,393
Average Medicare Spending per Day following FFS HH Episodes of Care	74,201,656	43,823,520	208,471,348	126,197,775	-30,378,136	-82,273,573

There are two different D-in-D regression models: one for pre-PDGM years and other for post-PDGM year. *For details, please refer A.1.4.2 of the Technical Appendix. | The number of days for each measure are derived from the corresponding D-in-D models.

Exhibit B-52. Impact of the HHVBP Model between early years (2016-2017) vs. later years of HHVBP (2018-2021) for Claims-Based Spending Measures

Measure	D-in-D	p-value	Lower 90% CI	Upper 90% CI
Average Medicare Spending per Day during and following FFS HH Episodes of Care	-$1.65	0.02	-$2.80	-$0.50
Average Medicare Spending per Day during FFS HH Episodes of Care	-$1.99	0.02	-$3.33	-$0.64
Average Medicare Spending per Day following FFS HH Episodes of Care	$0.20	0.81	-$1.12	$1.52

B.7.1 Spending Components

Exhibit B-53. Baseline and Performance Period Means for Medicare Spending Components Using Pre-PDGM Approach, All HHVBP States and Non-HHVBP States

Pre-PDGM Approach	HHVBP States				Non-HHVBP States				Change in Mean and Share of Spending			
	Baseline (2013-2015)		Intervention (2016-2019)		Baseline (2013-2015)		Intervention (2016-2019)		HHVBP States		Non-HHVBP States	
	Mean	Percent	Mean	Percent	Mean	Percent	Mean	Percent	Mean	Percentage Point	Mean	Percentage Point
Average Medicare Spending per Day during and following FFS Home Health Episodes of Care												
Total	$138.33	100.0%	$148.86	100.0%	$131.61	100.0%	$144.41	100.0%	$10.53	0.0	$12.80	0.0
Home health	$44.87	31.8%	$45.44	29.9%	$41.07	30.5%	$43.38	29.3%	$0.57	-1.9	$2.31	-1.2
Inpatient	$45.60	32.8%	$50.19	33.6%	$46.70	35.2%	$50.91	35.1%	$4.59	0.8	$4.21	-0.1
Outpatient institutional	$10.95	8.2%	$13.52	9.4%	$11.62	9.0%	$14.23	10.1%	$2.57	1.2	$2.61	1.1
ED and Observation Stays	$3.14	2.3%	$4.03	2.8%	$2.81	2.2%	$3.57	2.5%	$0.89	0.5	$0.76	0.3
Other	$7.72	5.9%	$9.37	6.6%	$8.73	6.9%	$10.55	7.6%	$1.65	0.7	$1.82	0.7
SNF	$11.36	8.1%	$11.69	7.7%	$9.93	7.4%	$10.84	7.4%	$0.33	-0.4	$0.91	0.0
Hospice	$2.81	2.0%	$3.45	2.3%	$2.19	1.6%	$2.86	1.9%	$0.64	0.3	$0.67	0.3
Part B non-institutional*	$23.32	17.1%	$25.08	17.1%	$21.20	16.2%	$22.99	16.1%	$1.76	0.0	$1.79	-0.1
Average Medicare Spending per Day during FFS Home Health Episodes of Care												
Total	$150.60	100.0%	$161.70	100.0%	$135.34	100.0%	$150.38	100.0%	$11.10	0.0	$15.04	0.0
Home health	$63.57	41.3%	$64.34	39.0%	$54.30	39.1%	$58.33	37.9%	$0.77	-2.3	$4.03	-1.2
Inpatient	$45.83	30.3%	$50.88	31.4%	$44.18	32.5%	$49.23	32.7%	$5.05	1.1	$5.05	0.2
Outpatient institutional	$11.23	7.8%	$13.98	8.9%	$11.79	8.9%	$14.56	9.9%	$2.75	1.1	$2.77	1.0
ED and Observation Stays	$3.43	2.3%	$4.44	2.8%	$2.98	2.2%	$3.85	2.6%	$1.01	0.5	$0.87	0.4
Other	$7.73	5.4%	$9.45	6.2%	$8.73	6.7%	$10.62	7.3%	$1.72	0.8	$1.89	0.6

| Pre-PDGM Approach | HHVBP States | | | | Non-HHVBP States | | | | Change in Mean and Share of Spending | | | |
| | Baseline (2013-2015) | | Intervention (2016-2019) | | Baseline (2013-2015) | | Intervention (2016-2019) | | HHVBP States | | Non-HHVBP States | |
	Mean	Percent	Mean	Percent	Mean	Percent	Mean	Percent	Mean	Percentage Point	Mean	Percentage Point
SNF	$5.64	3.7%	$6.10	3.7%	$4.43	3.2%	$5.15	3.4%	$0.46	0.0	$0.72	0.2
Hospice	$1.62	1.1%	$1.90	1.2%	$1.11	0.8%	$1.42	0.9%	$0.28	0.1	$0.31	0.1
Part B non-institutional*	$23.53	15.9%	$25.20	15.9%	$20.68	15.4%	$22.56	15.2%	$1.67	0.0	$1.88	-0.2
Average Medicare Spending per Day _following_ FFS Home Health Episodes of Care												
Total	$105.97	100.0%	$114.93	100.0%	$116.54	100.0%	$123.52	100.0%	$8.96	0.0	$6.98	0.0
Inpatient	$45.05	41.1%	$48.51	40.9%	$54.49	44.8%	$55.79	43.5%	$3.46	-0.2	$1.30	-1.3
Outpatient institutional	$10.15	9.7%	$12.29	10.8%	$11.09	9.4%	$13.24	10.7%	$2.14	1.1	$2.15	1.3
ED and Observation Stays	$2.51	2.4%	$3.16	2.7%	$2.35	2.0%	$2.90	2.3%	$0.65	0.3	$0.55	0.3
Other	$7.59	7.4%	$9.07	8.1%	$8.69	7.5%	$10.27	8.4%	$1.48	0.7	$1.58	0.9
SNF	$25.25	22.8%	$25.19	21.0%	$27.16	22.2%	$27.48	21.3%	-$0.06	-1.8	$0.32	-0.9
Hospice	$5.72	5.2%	$7.22	6.0%	$5.59	4.5%	$7.06	5.4%	$1.50	0.8	$1.47	0.9
Part B non-institutional*	$22.80	21.1%	$24.69	21.2%	$22.95	19.1%	$24.29	19.2%	$1.89	0.1	$1.34	0.1

*Includes Part B carrier and DME claims. By definition, there is no home health spending associated with average Medicare spending per day _following_ FFS home health episodes of care measure (see Exhibit A-49). Average is based on capped expenditure measures. Capping was done separately for total and for each component such that component means do not add up to the total mean. Percent column is based on uncapped expenditure measure values.

Exhibit B-54. Baseline and Performance Period Means for Medicare Spending Components Using Post-PDGM Approach, All HHVBP States and Non-HHVBP States

Post-PDGM Approach#	HHVBP States				Non-HHVBP States				Change in Mean and Share of Spending			
	Baseline (2013-2015)		2020-2021		Baseline (2013-2015)		2020-2021		HHVBP States		Non-HHVBP States	
	Mean	Percent	Mean	Percent	Mean	Percent	Mean	Percent	Mean	Percentage Point	Mean	Percentage Point
Average Medicare Spending per Day during and following FFS Home Health Episodes of Care												
Total	$130.85	100.0%	$154.88	100.0%	$127.69	100.0%	$156.73	100.0%	$24.03	0.0	$29.04	0.0
Home health	$38.44	28.9%	$44.18	27.7%	$36.38	27.9%	$46.22	28.5%	$5.74	-1.2	$9.84	0.6
Inpatient	$43.93	33.4%	$53.99	34.3%	$45.97	35.7%	$56.12	35.2%	$10.06	0.9	$10.15	-0.5
Outpatient institutional	$10.81	8.6%	$14.60	9.7%	$11.56	9.3%	$15.77	10.3%	$3.79	1.1	$4.21	1.0
ED and Observation Stays	$3.01	2.4%	$4.13	2.7%	$2.73	2.2%	$3.79	2.4%	$1.12	0.3	$1.06	0.2
Other	$7.71	6.2%	$10.37	7.0%	$8.75	7.1%	$11.89	7.9%	$2.66	0.8	$3.14	0.8
SNF	$12.15	9.1%	$11.21	7.1%	$11.13	8.6%	$11.08	6.9%	-$0.94	-2.0	-$0.05	-1.7
Hospice	$3.20	2.4%	$4.23	2.7%	$2.60	2.0%	$3.72	2.3%	$1.03	0.3	$1.12	0.3
Part B non-institutional*	$22.79	17.6%	$27.94	18.5%	$21.02	16.6%	$25.91	16.9%	$5.15	0.9	$4.89	0.3
Average Medicare Spending per Day during FFS Home Health Episodes of Care												
Total	$144.25	100.0%	$167.01	100.0%	$135.79	100.0%	$165.28	100.0%	$22.76	0.0	$29.49	0.0
Home health	$50.06	34.0%	$59.98	34.7%	$45.43	32.6%	$60.84	35.3%	$9.92	0.7	$15.41	2.7
Inpatient	$46.50	32.0%	$54.74	32.3%	$46.99	34.3%	$55.22	32.8%	$8.24	0.3	$8.23	-1.5
Outpatient institutional	$11.07	8.0%	$14.94	9.3%	$11.75	8.9%	$16.09	10.0%	$3.87	1.3	$4.34	1.1
ED and Observation Stays	$3.21	2.3%	$4.43	2.7%	$2.86	2.2%	$4.02	2.4%	$1.22	0.4	$1.16	0.2
Other	$7.78	5.7%	$10.42	6.6%	$8.81	6.7%	$11.99	7.5%	$2.64	0.9	$3.18	0.8
SNF	$10.98	7.5%	$7.93	4.6%	$9.50	6.9%	$7.48	4.4%	-$3.05	-2.9	-$2.02	-2.5

Post-PDGM Approach#	HHVBP States				Non-HHVBP States				Change in Mean and Share of Spending			
	Baseline (2013-2015)		2020-2021		Baseline (2013-2015)		2020-2021		HHVBP States		Non-HHVBP States	
	Mean	Percent	Mean	Percent	Mean	Percent	Mean	Percent	Mean	Percentage Point	Mean	Percentage Point
Hospice	$2.81	1.9%	$2.98	1.7%	$2.12	1.5%	$2.45	1.4%	$0.17	-0.2	$0.33	-0.1
Part B non-institutional*	$23.58	16.6%	$28.29	17.4%	$21.30	15.8%	$25.88	16.0%	$4.71	0.8	$4.58	0.2
Average Medicare Spending per Day _following_ FFS Home Health Episodes of Care												
Total	$82.25	100.0%	$116.22	100.0%	$89.38	100.0%	$123.55	100.0%	$33.97	0.0	$34.17	0.0
Inpatient	$35.00	40.9%	$51.15	42.6%	$41.09	43.8%	$57.86	44.9%	$16.15	1.7	$16.77	1.1
Outpatient institutional	$9.63	11.8%	$13.33	11.6%	$10.54	11.7%	$14.48	11.7%	$3.70	-0.2	$3.94	0.0
ED and Observation Stays	$2.35	2.8%	$3.28	2.8%	$2.20	2.4%	$3.05	2.4%	$0.93	0.0	$0.85	0.0
Other	$7.23	9.0%	$9.98	8.8%	$8.29	9.3%	$11.34	9.3%	$2.75	-0.2	$3.05	0.0
SNF	$15.99	18.5%	$20.30	16.8%	$17.64	18.6%	$22.27	17.2%	$4.31	-1.7	$4.63	-1.4
Hospice	$4.50	5.2%	$7.73	6.4%	$4.54	4.8%	$7.76	5.9%	$3.23	1.2	$3.22	1.1
Part B non-institutional*	$19.74	23.5%	$26.44	22.6%	$19.52	21.1%	$25.54	20.3%	$6.70	-0.9	$6.02	-0.8

*Includes Part B carrier and DME claims. By definition, there is no home health spending associated with average Medicare spending per day _following_ FFS home health episodes of care measure (see Exhibit A-49). Average is based on capped expenditure measures. Capping was done separately for total and for each component such that component means do not add up to the total mean. Percent column is based on uncapped expenditure measure values. #For details, please refer A.1.4.2 of the Technical Appendix.

Exhibit B-55. Cumulative D-in-D Results of the HHVBP Model on Medicare Spending Components

Medicare spending per day by type of service	Model Estimates				Average in HHVBP States, Weighted# Baseline (2013 – 2015)	% Relative Change
	D-in-D	p-value	Lower 90% CI	Upper 90% CI		
Average Medicare Spending per Day during and following FFS Home Health Episodes of Care						
Total	-$2.63	<0.01	-$4.03	-$1.23	$135.96	-1.9%
Home Health	-$0.54	0.09	-$1.07	-$0.02	$42.84	-1.3%
Inpatient	-$1.54	<0.01	-$2.46	-$0.62	$45.08	-3.4%
Outpatient Institutional	$0.03	0.82	-$0.20	$0.27	$10.91	0.3%
ED and Observation Stays	$0.19	<0.001	$0.10	$0.28	$3.10	6.1%
Other	-$0.17	0.15	-$0.36	$0.03	$7.72	-2.2%
SNF	-$0.45	0.02	-$0.75	-$0.14	$11.61	-3.9%
Hospice	<$0.01	0.96	-$0.12	$0.13	$2.93	0.0%
Part B non-institutional*	-$0.22	0.23	-$0.53	$0.09	$23.15	-1.0%
Average Medicare Spending per Day during FFS Home Health Episodes of Care						
Total	-$2.63	<0.01	-$4.22	-$1.04	$148.54	-1.8%
Home Health	-$0.19	0.69	-$0.96	$0.58	$59.18	-0.3%
Inpatient	-$1.97	<0.001	-$2.94	-$0.99	$46.05	-4.3%
Outpatient Institutional	$0.01	0.93	-$0.25	$0.28	$11.18	0.1%
ED and Observation Stays	$0.22	<0.001	$0.12	$0.32	$3.36	6.5%
Other	-$0.21	0.10	-$0.43	$0.00	$7.74	-2.7%
SNF	-$0.42	<0.01	-$0.67	-$0.18	$7.38	-5.7%
Hospice	$0.02	0.80	-$0.09	$0.12	$2.01	1.0%
Part B non-institutional*	-$0.23	0.25	-$0.57	$0.10	$23.55	-1.0%
Average Medicare Spending per Day following FFS Home Health Episodes of Care						
Total	-$0.25	0.82	-$2.05	$1.55	$98.99	-0.3%
Inpatient	$0.01	0.99	-$1.30	$1.31	$42.09	0.0%
Outpatient Institutional	$0.07	0.65	-$0.19	$0.33	$9.99	0.7%
ED and Observation Stays	$0.13	0.03	$0.03	$0.23	$2.46	5.3%
Other	-$0.06	0.63	-$0.28	$0.15	$7.48	-0.8%
SNF	-$0.19	0.67	-$0.94	$0.55	$22.52	-0.8%
Hospice	-$0.06	0.68	-$0.31	$0.19	$5.36	-1.1%
Part B non-institutional*	$0.02	0.91	-$0.32	$0.36	$21.90	0.1%

Includes Part B carrier and DME claims. By definition, there is no home health spending associated with average Medicare spending per day following FFS home health episodes of care measure (see Exhibit A-49). CI= Confidence Interval. | These models include state-specific linear time trends. | Average is based on capped expenditure measures. Capping was done separately for total and for each component such that the component means do not add up to the total mean. # Weighted Average Baseline Spending for HHVBP states during 2016-2021 is calculated by weighting the pre-PDGM baseline average and post-PDGM baseline average by the number of eligible home health days in HHVBP states in 2016-2019 and 2020-2021, respectively. For more details refer to Section A.1.4.2 and A.2.9.

Exhibit B-56. Impact of the HHVBP Model on Three Medicare Spending Measures and on Components for Average Medicare Spending per Day during and following FFS HH Episodes of Care

Measure	Model Estimates				Average in HHVBP States, Baseline (2013-2015) [#]	% Relative Change
	D-in-D	p-value	Lower 90% CI	Upper 90% CI		
Average Medicare Spending per Day during and following FFS HH Episodes of Care						
2016	-$1.12	<0.01	-$1.80	-$0.45	$138.33	-0.8%
2017	-$2.00	<0.01	-$3.06	-$0.95		-1.4%
2018	-$1.98	0.02	-$3.36	-$0.61		-1.4%
2019	-$2.68	0.01	-$4.39	-$0.97		-1.9%
2020	-$3.52	<0.01	-$5.57	-$1.47	$130.85	-2.7%
2021	-$4.82	<0.001	-$7.16	-$2.49		-3.7%
Cumulative	-$2.63	<0.01	-$4.03	-$1.23	$135.96	-1.9%
Average Medicare Spending per Day during FFS HH Episodes of Care						
2016	-$0.90	0.05	-$1.67	-$0.14	$150.60	-0.6%
2017	-$1.78	0.02	-$3.02	-$0.54		-1.2%
2018	-$1.80	0.07	-$3.46	-$0.15		-1.2%
2019	-$2.13	0.09	-$4.22	-$0.04		-1.4%
2020	-$4.27	<0.01	-$6.59	-$1.95	$144.25	-3.0%
2021	-$5.30	<0.001	-$7.90	-$2.70		-3.7%
Cumulative	-$2.63	<0.01	-$4.22	-$1.04	$148.54	-1.8%
Average Medicare Spending per Day following FFS HH Episodes of Care						
2016	-$0.41	0.56	-$1.56	$0.74	$105.97	-0.4%
2017	-$0.35	0.72	-$1.96	$1.26		-0.3%
2018	$0.74	0.54	-$1.25	$2.74		0.7%
2019	$0.19	0.90	-$2.26	$2.65		0.2%
2020	-$0.16	0.91	-$2.56	$2.23	$82.25	-0.2%
2021	-$1.70	0.32	-$4.54	$1.14		-2.1%
Cumulative	-$0.25	0.82	-$2.05	$1.55	$98.99	-0.3%
Components for Average Medicare Spending per Day during and following FFS HH Episodes of Care						
Home Health						
2016	$0.14	0.29	-$0.07	$0.35	$44.87	0.3%
2017	-$0.22	0.34	-$0.59	$0.16		-0.5%
2018	$0.07	0.81	-$0.44	$0.59		0.2%
2019	$0.07	0.87	-$0.59	$0.72		0.2%
2020	-$1.87	<0.001	-$2.67	-$1.07	$38.44	-4.9%
2021	-$1.74	<0.01	-$2.66	-$0.81		-4.5%
Cumulative	-$0.54	0.09	-$1.07	-$0.02	$42.84	-1.3%
Inpatient						
2016	-$0.82	<0.01	-$1.31	-$0.34	$45.60	-1.8%
2017	-$1.10	<0.01	-$1.80	-$0.40		-2.4%
2018	-$1.12	0.04	-$2.02	-$0.22		-2.5%
2019	-$1.80	<0.01	-$2.93	-$0.67		-3.9%
2020	-$1.56	0.05	-$2.90	-$0.23	$43.93	-3.6%
2021	-$3.02	<0.001	-$4.52	-$1.51		-6.9%

Measure	Model Estimates				Average in HHVBP States, Baseline (2013-2015) #	% Relative Change
	D-in-D	p-value	Lower 90% CI	Upper 90% CI		
Cumulative	-$1.54	<0.01	-$2.46	-$0.62	$45.08	-3.4%
Outpatient Institutional						
2016	$0.15	0.03	$0.04	$0.27	$10.95	1.4%
2017	$0.13	0.23	-$0.05	$0.31		1.2%
2018	$0.01	0.92	-$0.22	$0.25		0.1%
2019	-$0.07	0.69	-$0.35	$0.22		-0.6%
2020	<-$0.01	0.99	-$0.35	$0.35	$10.81	0.0%
2021	-$0.05	0.83	-$0.45	$0.35		-0.5%
Cumulative	$0.03	0.82	-$0.20	$0.27	$10.91	0.3%
Outpatient ED and Observation Stays						
2016	$0.13	<0.001	$0.08	$0.17	$3.14	4.1%
2017	$0.18	<0.001	$0.12	$0.25		5.7%
2018	$0.21	<0.001	$0.12	$0.30		6.7%
2019	$0.22	<0.001	$0.11	$0.33		7.0%
2020	$0.23	<0.01	$0.10	$0.36	$3.01	7.6%
2021	$0.16	0.07	$0.02	$0.31		5.3%
Cumulative	$0.19	<0.001	$0.10	$0.28	$3.10	6.1%
Other outpatient						
2016	$0.02	0.74	-$0.08	$0.12	$7.72	0.3%
2017	-$0.06	0.54	-$0.21	$0.09		-0.8%
2018	-$0.20	0.08	-$0.40	-$0.01		-2.6%
2019	-$0.31	0.03	-$0.54	-$0.08		-4.0%
2020	-$0.25	0.15	-$0.53	$0.03	$7.71	-3.2%
2021	-$0.23	0.24	-$0.56	$0.09		-3.0%
Cumulative	-$0.17	0.15	-$0.36	$0.03	$7.72	-2.2%
SNF						
2016	-$0.31	<0.01	-$0.46	-$0.15	$11.36	-2.7%
2017	-$0.48	<0.001	-$0.70	-$0.25		-4.2%
2018	-$0.53	<0.01	-$0.82	-$0.23		-4.7%
2019	-$0.64	<0.01	-$0.99	-$0.29		-5.6%
2020	-$0.39	0.16	-$0.85	$0.07	$12.15	-3.2%
2021	-$0.32	0.32	-$0.85	$0.21		-2.6%
Cumulative	-$0.45	0.02	-$0.75	-$0.14	$11.61	-3.9%
Hospice						
2016	-$0.01	0.82	-$0.07	$0.05	$2.81	-0.4%
2017	-$0.04	0.46	-$0.13	$0.05		-1.4%
2018	-$0.07	0.32	-$0.18	$0.05		-2.5%
2019	$0.06	0.47	-$0.08	$0.21		2.1%
2020	$0.09	0.45	-$0.10	$0.28	$3.20	2.8%
2021	<$0.01	0.98	-$0.22	$0.23		0.1%
Cumulative	<$0.01	0.96	-$0.12	$0.13	$2.93	0.1%
Part B non-institutional*						
2016	-$0.21	0.02	-$0.36	-$0.06		-0.9%

Measure	Model Estimates				Average in HHVBP States, Baseline (2013-2015) #	% Relative Change
	D-in-D	p-value	Lower 90% CI	Upper 90% CI		
2017	-$0.20	0.17	-$0.44	$0.04	$23.32	-0.9%
2018	-$0.23	0.21	-$0.54	$0.07		-1.0%
2019	-$0.25	0.27	-$0.62	$0.13		-1.1%
2020	-$0.21	0.43	-$0.65	$0.23	$22.79	-0.9%
2021	-$0.24	0.44	-$0.76	$0.27		-1.1%
Cumulative	-$0.22	0.23	-$0.53	$0.09	$23.15	-1.0%

Includes Part B carrier and DME claims. CI= Confidence Interval. | These models include state-specific linear time trends. | Average is based on capped expenditure measures. #Cumulative estimate corresponds to a weighted Average Baseline Spending for HHVBP states during 2016-2021 that is calculated by weighting the pre-PDGM baseline average and post-PDGM baseline average by the number of eligible home health days in HHVBP states in 2016-2019 and 2020-2021, respectively. Baseline average in HHVBP states for 2016-2019 corresponds to measures defined by pre-PDGM method and that for 2020-2021 corresponds to measures defined by post-PDGM method. For more details refer to Section A.1.4.2 and A.2.9.

Exhibit B-57. Cumulative D-in-D Results at the State-Level, Spending Measures

Measure	Model Estimates				Average in HHVBP States, Weighted Baseline* (2013 – 2015)	% Relative Change
	D-in-D	p-value	Lower 90% CI	Upper 90% CI		
Average Medicare Spending per Day during and following FFS HH Episodes of Care						
Arizona	-$5.90	0.09	-$11.61	-$0.19	$147.47	-4.0%
Florida	-$2.77	0.04	-$4.95	-$0.59	$131.05	-2.1%
Iowa	-$9.84	<0.01	-$16.09	-$3.59	$129.09	-7.6%
Maryland	$9.83	<0.01	$4.25	$15.41	$153.70	6.4%
Massachusetts	-$7.40	0.02	-$12.72	-$2.07	$168.48	-4.4%
Nebraska	-$11.09	0.03	-$19.29	-$2.89	$127.88	-8.7%
North Carolina	$0.90	0.66	-$2.52	$4.32	$133.41	0.7%
Tennessee	-$6.48	<0.01	-$9.88	-$3.09	$121.38	-5.3%
Washington	$1.43	0.72	-$5.10	$7.96	$137.76	1.0%
Average Medicare Spending per Day during FFS HH Episodes of Care						
Arizona	-$5.66	0.21	-$13.01	$1.70	$165.19	-3.4%
Florida	-$0.64	0.67	-$3.13	$1.84	$143.89	-0.4%
Iowa	-$13.99	<0.01	-$21.28	-$6.70	$145.28	-9.6%
Maryland	$6.81	0.09	$0.12	$13.51	$170.01	4.0%
Massachusetts	-$8.14	0.02	-$13.70	-$2.58	$187.93	-4.3%
Nebraska	-$11.72	0.01	-$19.61	-$3.83	$140.81	-8.3%
North Carolina	$2.05	0.41	-$2.08	$6.18	$147.42	1.4%
Tennessee	-$9.57	<0.001	-$13.83	-$5.31	$124.51	-7.7%
Washington	-$1.71	0.68	-$8.51	$5.08	$153.20	-1.1%
Average Medicare Spending per Day following FFS HH Episodes of Care						
Arizona	-$1.25	0.73	-$7.31	$4.81	$104.18	-1.2%
Florida	$1.38	0.52	-$2.15	$4.92	$93.19	1.5%
Iowa	-$4.19	0.36	-$11.75	$3.37	$88.55	-4.7%
Maryland	$12.63	<0.001	$7.22	$18.03	$108.07	11.7%

Measure	Model Estimates				Average in HHVBP States, Weighted Baseline* (2013 – 2015)	% Relative Change
	D-in-D	p-value	Lower 90% CI	Upper 90% CI		
Massachusetts	-$5.07	0.20	-$11.57	$1.42	$121.29	-4.2%
Nebraska	-$5.96	0.39	-$17.28	$5.36	$92.79	-6.4%
North Carolina	-$0.44	0.85	-$4.20	$3.32	$96.70	-0.5%
Tennessee	-$0.97	0.74	-$5.72	$3.77	$105.94	-0.9%
Washington	$3.34	0.53	-$5.47	$12.15	$96.57	3.5%

*CI= Confidence Interval. | These models include state-specific linear time trends. * Weighted Average Baseline Spending for HHVBP states during 2016-2021 is calculated by weighting the pre-PDGM baseline average and post-PDGM baseline average by the number of eligible home health days in HHVBP states in 2016-2019 and 2020-2021, respectively. For more details refer to Section A.1.4.2 and A.2.9.*

Exhibit B-58. Cumulative D-in-D Results of the HHVBP Model on Medicare Spending Components

Medicare spending per day by type of service	Model Estimates			
	D-in-D	p-value	Lower 90% CI	Upper 90% CI
Average Medicare Spending per Day <u>during and following</u> FFS Home Health Episodes of Care				
Total	-$2.63	<0.01	-$4.03	-$1.23
Inpatient				
Arizona	-$5.74	0.01	-$9.61	-$1.88
Florida	-$1.76	0.04	-$3.16	-$0.36
Iowa	-$5.68	0.08	-$11.01	-$0.36
Maryland	$8.40	<0.001	$4.43	$12.38
Massachusetts	-$5.31	0.01	-$8.85	-$1.78
Nebraska	-$6.34	0.05	-$11.64	-$1.05
North Carolina	$0.02	0.99	-$2.17	$2.22
Tennessee	-$2.49	0.06	-$4.63	-$0.34
Washington	$2.88	0.27	-$1.44	$7.20
SNF				
Arizona	$0.61	0.49	-$0.85	$2.08
Florida	-$0.22	0.42	-$0.68	$0.23
Iowa	-$4.07	<0.001	-$5.84	-$2.30
Maryland	$1.05	0.13	-$0.08	$2.18
Massachusetts	-$0.29	0.69	-$1.48	$0.90
Nebraska	-$1.64	0.20	-$3.73	$0.45
North Carolina	$0.39	0.37	-$0.33	$1.12
Tennessee	-$1.77	<0.001	-$2.54	-$1.00
Washington	-$1.14	0.42	-$3.49	$1.20
Home Health				
Arizona	-$1.77	0.13	-$3.69	$0.15
Florida	-$1.42	<0.01	-$2.29	-$0.55
Iowa	-$0.05	0.95	-$1.51	$1.40
Maryland	-$0.15	0.87	-$1.60	$1.31
Massachusetts	-$0.83	0.37	-$2.36	$0.69
Nebraska	-$0.75	0.52	-$2.70	$1.19

Medicare spending per day by type of service	Model Estimates			
	D-in-D	p-value	Lower 90% CI	Upper 90% CI
North Carolina	$0.62	0.34	-$0.45	$1.69
Tennessee	$0.13	0.85	-$1.04	$1.30
Washington	-$0.67	0.61	-$2.83	$1.50
Average Medicare Spending per Day during FFS Home Health Episodes of Care				
Total	-$2.63	<0.01	-$4.22	-$1.04
Inpatient				
Arizona	-$4.33	0.12	-$8.91	$0.25
Florida	-$1.78	0.04	-$3.22	-$0.34
Iowa	-$7.50	0.02	-$12.99	-$2.02
Maryland	$5.83	0.04	$1.13	$10.52
Massachusetts	-$6.20	<0.01	-$10.00	-$2.40
Nebraska	-$6.10	0.04	-$11.06	-$1.15
North Carolina	$1.08	0.49	-$1.50	$3.66
Tennessee	-$3.40	0.02	-$5.82	-$0.97
Washington	$2.71	0.35	-$2.04	$7.46
SNF				
Arizona	$0.59	0.42	-$0.61	$1.80
Florida	-$0.16	0.44	-$0.51	$0.18
Iowa	-$4.63	<0.001	-$6.42	-$2.84
Maryland	$1.15	0.04	$0.23	$2.07
Massachusetts	-$0.56	0.35	-$1.56	$0.43
Nebraska	-$1.81	0.14	-$3.84	$0.23
North Carolina	$0.32	0.43	-$0.35	$0.99
Tennessee	-$1.40	<0.001	-$2.01	-$0.80
Washington	-$1.80	0.11	-$3.64	$0.04
Home Health				
Arizona	-$2.86	0.09	-$5.66	-$0.06
Florida	$0.64	0.42	-$0.67	$1.96
Iowa	-$1.57	0.20	-$3.60	$0.46
Maryland	-$0.69	0.59	-$2.83	$1.44
Massachusetts	-$1.21	0.25	-$2.95	$0.53
Nebraska	-$1.35	0.41	-$4.03	$1.34
North Carolina	$0.97	0.26	-$0.45	$2.38
Tennessee	-$2.32	0.02	-$3.94	-$0.70
Washington	-$3.03	0.05	-$5.60	-$0.45

CI= Confidence Interval. | These models include state-specific linear time trends. | Average is based on capped expenditure measures. Capping was done separately for total and for each component such that the component means do not add up to the total mean.

Exhibit B-59. Results from Sensitivity Model Not adjusted for COVID Covariates Showing Impact of the HHVBP Model on Medicare Spending Measures

Measure	Model Estimates				Average in HHVBP States, Baseline (2013-2015)	% Relative Change*
	D-in-D	p-value	Lower 90% CI	Upper 90% CI		
Average Medicare Spending per Day <u>during and following</u> FFS HH Episodes of Care						
2016	-$1.12	<0.01	-$1.80	-$0.45		-0.8%
2017	-$2.00	<0.01	-$3.06	-$0.95		-1.4%
2018	-$1.98	0.02	-$3.36	-$0.60		-1.4%
2019	-$2.68	0.01	-$4.39	-$0.97	$138.33	-1.9%
2020	-$3.84	<0.01	-$5.86	-$1.83		-2.9%
2021	-$5.45	<0.001	-$7.77	-$3.13		-4.2%
Cumulative	-$2.78	<0.01	-$4.17	-$1.38		-2.0%
Average Medicare Spending per Day <u>during</u> FFS HH Episodes of Care						
2016	-$0.90	0.05	-$1.67	-$0.14		-0.6%
2017	-$1.78	0.02	-$3.02	-$0.54		-1.2%
2018	-$1.80	0.07	-$3.46	-$0.14		-1.2%
2019	-$2.13	0.09	-$4.23	-$0.04	$150.60	-1.4%
2020	-$4.35	<0.01	-$6.65	-$2.06		-3.0%
2021	-$5.72	<0.001	-$8.31	-$3.13		-4.0%
Cumulative	-$2.71	<0.01	-$4.30	-$1.12		-1.8%
Average Medicare Spending per Day <u>following</u> FFS HH Episodes of Care						
2016	-$0.41	0.56	-$1.56	$0.74		-0.4%
2017	-$0.35	0.72	-$1.96	$1.26		-0.3%
2018	$0.74	0.54	-$1.25	$2.74		0.7%
2019	$0.19	0.90	-$2.27	$2.65	$105.97	0.2%
2020	-$1.27	0.39	-$3.68	$1.14		-1.5%
2021	-$2.83	0.10	-$5.67	$0.02		-3.4%
Cumulative	-$0.58	0.60	-$2.38	$1.22		-0.6%

*CI= Confidence Interval.| These models include state-specific linear time trends. | Average is based on capped expenditure measures. *Relative changes for 2016 – 2019 express the impact estimate as a percentage of the average spending per day during the baseline period in HHVBP states as reported in the table. Estimates of the relative change for 2020-2021 and the cumulative 2016-2021 period incorporate the post-PDGM approach to measuring average spending per day and were calculated using a slightly different average baseline value. For more details, please refer to Section A.1.4.2 and A.2.9 of the Technical Appendix.*

B.8 Quality Measures Supporting Analyses

The below numbers reflect all OASIS home health episodes in the CY that were eligible for the specific OASIS outcome measure (regardless if their HHA received a TPS in 2019).

Exhibit B-60. "SOC" Values for Improvement in Management of Oral Medications in 2013 – 2021, HHVBP States and Non-HHVBP States

	2013	2014	2015	2016	2017	2018	2019	2020	2021
Sample Size									
HHVBP	771,673	800,332	852,267	953,693	1,035,285	1,119,804	1,156,907	1,088,794	1,155,420
Non-HHVBP	2,384,040	2,513,735	2,732,557	3,017,873	3,351,785	3,604,427	3,755,140	3,527,585	3,722,783
Patient is able to take oral medications if prepared in advance/another person develops a drug diary									
HHVBP	41.7%	39.6%	37.0%	31.6%	24.3%	18.8%	14.9%	12.2%	10.9%
Non-HHVBP	41.6%	39.8%	37.4%	33.8%	28.5%	23.4%	18.1%	13.8%	12.3%
Able to take medications at the correct time if given reminders by another person at the appropriate times									
HHVBP	20.3%	20.2%	19.5%	18.3%	16.6%	14.5%	12.7%	11.4%	10.0%
Non-HHVBP	22.0%	21.9%	21.5%	20.7%	19.5%	18.0%	16.1%	14.2%	12.8%
Unable to take medication unless administered by another person									
HHVBP	38.0%	40.3%	43.5%	50.1%	59.2%	66.6%	72.5%	76.4%	79.1%
Non-HHVBP	36.4%	38.3%	41.1%	45.5%	52.0%	58.6%	65.8%	72.0%	74.8%

Exhibit B-61. "SOC" Values for Improvement in Dyspnea in 2013 – 2021, HHVBP States and Non-HHVBP States

	2013	2014	2015	2016	2017	2018	2019	2020	2021
Sample Size									
HHVBP	766,654	775,275	799,997	869,254	926,175	1,009,849	1,039,456	996,610	1,054,926
Non-HHVBP	2,308,749	2,381,188	2,528,054	2,741,478	2,939,642	3,178,584	3,319,853	3,158,075	3,332,657
Patient is short of breath only when walking more than 20 feet									
HHVBP	38.4%	37.7%	37.6%	35.8%	33.1%	30.3%	29.1%	27.2%	27.1%
Non-HHVBP	37.1%	36.8%	36.6%	35.3%	33.5%	31.5%	30.2%	28.0%	27.7%
With moderate exertion									
HHVBP	43.4%	43.9%	43.5%	43.5%	45.3%	47.0%	46.8%	46.3%	46.3%
Non-HHVBP	42.9%	43.1%	42.8%	43.1%	44.5%	46.0%	45.9%	45.7%	45.4%
With minimal exertion or at rest									
HHVBP	18.2%	18.4%	18.9%	20.7%	21.7%	22.7%	24.1%	26.5%	26.7%
Non-HHVBP	20.0%	20.0%	20.6%	21.6%	22.0%	22.5%	23.9%	26.2%	26.9%

Exhibit B-62. "SOC" Values for TNC Change in Self-Care in 2013 – 2021, HHVBP States and Non-HHVBP States

	2013	2014	2015	2016	2017	2018	2019	2020	2021
Sample Size									
HHVBP	1,492,981	1,491,025	1,523,400	1,564,636	1,603,777	1,673,461	1,695,434	1,584,273	1,669,037
Non-HHVBP	4,772,073	4,860,254	5,048,055	5,238,999	5,446,512	5,605,275	5,686,297	5,206,201	5,437,051
Average SOC values									
HHVBP	9.3	9.7	10.1	10.7	11.2	11.5	11.6	12.1	12.3
Non-HHVBP	9.3	9.6	9.9	10.4	10.9	11.2	11.3	11.9	12.1

Exhibit B-63. "SOC" Values for TNC Change in Mobility in 2013 – 2021, HHVBP States and Non-HHVBP States

	2013	2014	2015	2016	2017	2018	2019	2020	2021
Sample Size									
HHVBP	1,492,981	1,491,025	1,523,400	1,564,636	1,603,777	1,673,461	1,695,434	1,584,273	1,669,037
Non-HHVBP	4,772,073	4,860,254	5,048,055	5,238,999	5,446,512	5,605,275	5,686,297	5,206,201	5,437,051
Average SOC values									
HHVBP	4.7	5.0	5.2	5.7	6.1	6.3	6.4	6.7	6.8
Non-HHVBP	4.8	5.0	5.2	5.6	5.9	6.2	6.3	6.6	6.7

Exhibit B-64. Impact of the HHVBP Model between early years (2016 – 2017) vs. later years of HHVBP (2018 – 2021) for OASIS-Based Measures and Mortality Rate among FFS Beneficiaries

Measure	D-in-D[a]	p-value	Lower 90% CI[a]	Upper 90% CI[a]
Discharged to Community	0.88	0.01	0.35	1.41
TNC Change in Self-Care	0.02	0.29	-0.01	0.05
TNC Change in Mobility	0.005	0.46	-0.006	0.02
Improvement in Dyspnea	-1.65	0.03	-2.93	-0.38
Improvement in Management of Oral Medications	-0.31	0.74	-1.86	1.23
Mortality Rate/All FFS Home Health Episodes	-0.06	0.01	-0.10	-0.02

[a] *Values represent percentage point changes with the exception of the TNC measures. | Original HHVBP Model measures indicated by italic text. | CI= Confidence Interval. | These models (with the exception of Mortality rate measure) include state-specific linear time trends (See Section A.1.5 for more details).*

Exhibit B-65. Cumulative D-in-D Results at the State-Level, OASIS Outcome Quality Measures

Measure	Model Estimates				Average in HHVBP States, Baseline (2013 – 2015)	% Relative Change
	D-in-D[a]	p-value	Lower 90% CI[a]	Upper 90% CI[a]		
Discharged to Community						
Arizona	-0.28	0.80	-2.10	1.54	76.3%	-0.4%
Florida	1.40	0.05	0.22	2.58	75.2%	1.9%
Iowa	-0.43	0.76	-2.71	1.86	67.4%	-0.6%
Maryland	1.06	0.38	-0.93	3.06	74.5%	1.4%
Massachusetts	1.55	0.25	-0.68	3.79	68.8%	2.3%
Nebraska	1.86	0.20	-0.55	4.26	73.1%	2.5%
North Carolina	-0.17	0.84	-1.55	1.21	73.5%	-0.23
Tennessee	-3.05	<0.01	-4.83	-1.27	65.9%	-4.6%
Washington	-3.53	0.02	-5.92	-1.14	75.3%	-4.7%
TNC Change in Self-Care						
Arizona	0.15	0.01	0.05	0.25	1.24	12.1%
Florida	-0.01	0.89	-0.06	0.05	1.45	-0.7%
Iowa	-0.04	0.64	-0.19	0.10	1.29	-3.1%
Maryland	0.15	0.03	0.04	0.26	1.45	10.3%
Massachusetts	-0.06	0.37	-0.16	0.05	1.36	-4.4%
Nebraska	0.01	0.85	-0.09	0.11	1.17	0.9%
North Carolina	0.004	0.93	-0.08	0.09	1.27	0.3%
Tennessee	-0.01	0.77	-0.09	0.06	1.44	-0.7%
Washington	0.07	0.32	-0.05	0.20	1.11	6.3%
TNC Change in Mobility						
Arizona	0.06	<0.01	0.03	0.09	0.40	15.0%
Florida	-0.02	0.10	-0.04	-0.0003	0.45	-4.4%
Iowa	-0.0004	0.99	-0.04	0.04	0.42	-0.1%
Maryland	0.08	<0.001	0.04	0.12	0.46	17.4%
Massachusetts	-0.02	0.49	-0.06	0.02	0.43	-4.7%
Nebraska	-0.01	0.56	-0.05	0.02	0.38	-2.6%
North Carolina	0.01	0.47	-0.02	0.04	0.41	2.4%
Tennessee	-0.01	0.46	-0.04	0.02	0.48	-2.1%
Washington	0.01	0.63	-0.03	0.05	0.37	2.7%
Improvement in Dyspnea						
Arizona	3.39	0.20	-0.98	7.77	68.7%	4.9%
Florida	-6.31	<0.001	-9.40	-3.21	64.0%	-9.9%
Iowa	-3.35	0.47	-11.01	4.32	69.1%	-4.8%
Maryland	2.91	0.28	-1.51	7.34	75.6%	3.8%
Massachusetts	0.74	0.77	-3.33	4.81	69.4%	1.1%
Nebraska	-2.74	0.37	-7.79	2.32	67.4%	-4.1%
North Carolina	-1.79	0.42	-5.48	1.90	68.7%	-2.6%
Tennessee	1.84	0.44	-2.05	5.73	66.5%	2.8%
Washington	0.68	0.82	-4.23	5.59	65.1%	1.0%
Improvement Management of Oral Medications						
Arizona	11.74	<0.001	6.50	16.98	50.2%	23.4%
Florida	1.03	0.59	-2.15	4.20	46.9%	2.2%

Measure	Model Estimates				Average in HHVBP States, Baseline (2013 – 2015)	% Relative Change
	D-in-D[a]	p-value	Lower 90% CI[a]	Upper 90% CI[a]		
Iowa	-1.49	0.67	-7.20	4.21	62.3%	-2.4%
Maryland	5.17	0.16	-0.95	11.29	59.0%	8.8%
Massachusetts	-4.38	0.11	-8.91	0.16	61.4%	-7.1%
Nebraska	-1.77	0.74	-10.44	6.90	51.3%	-3.5%
North Carolina	1.84	0.55	-3.25	6.94	49.0%	3.8%
Tennessee	2.03	0.47	-2.59	6.64	54.2%	3.7%
Washington	6.26	0.11	-0.21	12.73	42.9%	14.6%

[a] Values represent percentage point changes. | Original HHVBP Model measures indicated by italic text. | CI = Confidence Interval. | These models include state-specific linear time trends.

Exhibit B-66. Baseline and Post-HHVBP Performance Period Means for Patient Mortality among FFS Beneficiaries, All HHVBP States and Non-HHVBP States

Measure	HHVBP States		Non-HHVBP States		Change in Mean	
	Baseline (2013-2015)	Post-HHVBP (2016-2021)	Baseline (2013-2015)	Post-HHVBP (2016-2021)	HHVBP States	Non-HHVBP States
Mortality Rate/All FFS Home Health Episodes, Unadjusted	3.5%	3.4%	3.3%	3.1%	-0.1%	-0.2%
Mortality Rate/All FFS Home Health Episodes, Risk-Adjusted	3.9%	3.1%	3.6%	3.0%	-0.8%	-0.6%

Exhibit B-67. Trends in Unadjusted Mortality Rate among Medicare FFS HH Beneficiaries by HHVBP and Non-HHVBP States, 2013 – 2021

Exhibit B-68. Trends in Risk-Adjusted Mortality Rate among Medicare FFS HH Beneficiaries by HHVBP and Non-HHVBP States, 2013 – 2021

Exhibit B-69. Cumulative D-in-D Results at the State-Level, 60 Day Mortality

Measure	Model Estimates				Average in HHVBP States, Baseline (2013 – 2015)	% Relative Change
	D-in-D[a]	p-value	Lower 90% CI	Upper 90% CI		
60 Day Mortality/All FFS Episodes						
Arizona	-1.26	<0.001	-1.86	-0.66	4.4%	-28.7%
Florida	-0.04	0.70	-0.19	0.12	2.9%	-1.4%
Iowa	-0.16	0.73	-0.95	0.62	4.4%	-3.7%
Maryland	0.07	0.77	-0.33	0.47	4.3%	1.6%
Massachusetts	0.15	0.64	-0.37	0.67	3.2%	4.6%
Nebraska	-0.08	0.89	-1.09	0.92	4.2%	-1.9%
North Carolina	-0.29	0.16	-0.64	0.05	4.0%	-7.2%
Tennessee	-0.09	0.69	-0.45	0.27	3.7%	-2.5%
Washington	0.83	0.10	0.002	1.66	4.9%	16.9%

[a] *Values represent percentage point changes. | CI = Confidence Interval.*

B.9 Patient Experience with Care Supporting Analyses

Exhibit B-70. Impact of the HHVBP Model between early years (2016 – 2017) vs. later years of HHVBP (2018 – 2021) for HHCAHPS-Based Patient Experience Measures

Measure	D-in-D[a]	p-value	Lower 90% CI[a]	Upper 90% CI[a]
How often the home health team gave care in a professional way (Professional Care)	-0.34	<0.01	-0.55	-0.14
How well did the home health team communicate with patients (Communication)	-0.26	0.07	-0.49	-0.03
Did the home health team discuss medicines, pain, and home safety with patients (Discussion of Care)	-0.52	<0.01	-0.80	-0.25
How do patients rate the overall care from the home health agency (Overall Care)	-0.10	0.62	-0.41	0.22
Would patients recommend the home health agency to friends and family (Likely to Recommend)	-0.34	0.14	-0.72	0.04

[a] *Values represent percentage point changes. | Original HHVBP Model measures indicated by italic text. | CI= Confidence Interval.*

Exhibit B-71. Cumulative D-in-D Results at the State-Level, HHCAHPS-Based Patient Experience Measures

Measure	Model Estimates				Average in HHVBP States, Baseline (2013 – 2015)	% Relative Change
	D-in-D[a]	p-value	Lower 90% CI[a]	Upper 90% CI[a]		
How often the home health team gave care in a professional way (Professional Care)						
Arizona	-0.06	0.89	-0.76	0.65	86.6%	-0.1%
Florida	-0.44	0.03	-0.77	-0.12	88.1%	-0.5%
Iowa	-0.11	0.75	-0.69	0.47	87.7%	-0.1%
Maryland	-0.41	0.32	-1.10	0.28	88.3%	-0.5%
Massachusetts	-1.07	0.02	-1.83	-0.32	88.3%	-1.2%
Nebraska	-0.16	0.71	-0.86	0.54	87.9%	-0.2%
North Carolina	0.53	<0.01	0.20	0.87	89.8%	0.6%
Tennessee	0.64	0.01	0.22	1.06	90.1%	0.7%
Washington	0.41	0.27	-0.21	1.03	86.7%	0.5%
How well did the home health team communicate with patients (Communication)						
Arizona	0.21	0.68	-0.64	1.07	83.9%	0.3%
Florida	-0.47	0.04	-0.85	-0.10	85.1%	-0.6%
Iowa	-0.44	0.25	-1.06	0.19	86.1%	-0.5%
Maryland	-0.15	0.76	-0.95	0.64	85.7%	-0.2%
Massachusetts	-0.79	0.10	-1.57	-0.01	85.7%	-0.9%
Nebraska	-0.38	0.48	-1.27	0.50	86.1%	-0.4%
North Carolina	0.34	0.20	-0.10	0.78	87.5%	0.4%
Tennessee	0.66	0.02	0.21	1.11	87.9%	0.8%
Washington	-0.12	0.79	-0.81	0.58	83.9%	-0.1%
Did the home health team discuss medicines, pain, and home safety with patients (Discussion of Care)						
Arizona	-0.02	0.97	-0.98	0.93	79.8%	-0.03%
Florida	-0.87	<0.01	-1.31	-0.43	81.7%	-1.1%
Iowa	0.07	0.88	-0.70	0.83	85.5%	0.1%
Maryland	0.27	0.64	-0.68	1.23	82.5%	0.3%
Massachusetts	-1.14	0.03	-1.99	-0.29	84.2%	-1.4%

Measure	Model Estimates				Average in HHVBP States, Baseline (2013 − 2015)	% Relative Change
	D-in-D[a]	p-value	Lower 90% CI[a]	Upper 90% CI[a]		
Nebraska	0.54	0.38	-0.47	1.54	83.4%	0.6%
North Carolina	0.42	0.20	-0.12	0.97	84.7%	0.5%
Tennessee	0.84	<0.01	0.31	1.37	84.4%	1.0%
Washington	0.03	0.97	-1.17	1.23	80.5%	0.04%
How do patients rate the overall care from the home health agency (Overall Care)						
Arizona	0.47	0.54	-0.80	1.73	80.5%	0.6%
Florida	-0.12	0.70	-0.61	0.38	83.6%	-0.1%
Iowa	-0.37	0.52	-1.30	0.56	84.1%	-0.4%
Maryland	-0.53	0.31	-1.41	0.34	83.7%	-0.6%
Massachusetts	-1.15	0.13	-2.39	0.09	84.8%	-1.4%
Nebraska	0.26	0.75	-1.06	1.57	83.6%	0.3%
North Carolina	0.76	0.04	0.14	1.39	86.1%	0.9%
Tennessee	0.82	0.04	0.17	1.47	86.4%	0.9%
Washington	1.02	0.15	-0.14	2.17	80.6%	1.3%
Would patients recommend the home health agency to friends and family (Likely to Recommend)						
Arizona	0.23	0.80	-1.29	1.75	75.2%	0.3%
Florida	-0.26	0.48	-0.86	0.35	78.5%	-0.3%
Iowa	0.33	0.60	-0.70	1.36	78.9%	0.4%
Maryland	-0.13	0.87	-1.37	1.11	78.4%	-0.2%
Massachusetts	-1.42	0.08	-2.76	-0.08	82.1%	-1.7%
Nebraska	0.02	0.98	-1.48	1.53	79.0%	0.03%
North Carolina	0.81	0.07	0.06	1.55	81.8%	1.0%
Tennessee	1.26	0.01	0.45	2.08	82.9%	1.5%
Washington	0.43	0.56	-0.78	1.64	77.1%	0.6%

[a] *Values represent percentage point changes. Original HHVBP Model measures indicated by italic text. | CI = Confidence Interval.*

B.10 Agency Operational Changes Supporting Analyses

Exhibit B-72. HHA Survey Sample Sizes, Distribution, and Response Rates, by Agencies in Original HHVBP and Non-HHVBP States

Characteristic	Agencies in Original HHVBP States			Agencies in Non-HHVBP States		
	No. of Respondents	Percent of Respondents	Response Rate	No. of Respondents	Percent of Respondents	Response Rate
Ownership						
For-profit	274	69.4%	21.9%	502	66.7%	20.7%
Other*	121	30.6%	33.8%	251	33.3%	35.5%
Chain status						
Not affiliated	306	77.5%	27.0%	590	78.4%	26.5%
Affiliated	89	22.5%	18.7%	163	21.7%	18.1%
Setting						
Freestanding	342	86.6%	23.2%	657	87.3%	22.8%
Hospital-based	53	13.4%	40.2%	96	12.8%	38.1%
No. FFS Episodes						
Count of annual episodes < 250	106	26.8%	22.1%	211	28.0%	22.7%
Count of annual episodes >= 250	289	73.2%	25.6%	542	72.0%	24.6%
Total	395	100%	24.6%	753	100%	24.0%

Other includes Non-profit or government owned. | There were no statistically significant differences in survey response rates or by key organizational characteristics across HHAs in HHVBP and non-HHVBP states.

Exhibit B-73. Characteristics of Home Health Patients Served by Survey Respondents, by Agencies in Original HHVBP and Non-HHVBP States

Patient Characteristics	All	Original HHVBP States	Non-HHVBP States
	Proportion within Patient Population		
Admission sources			
Hospital (inpatient or ED)	46.4%	45.6%	46.9%
PAC setting	22.7%	23.0%	22.5%
Direct from the community/Independent or assisted living	31.4%	32.2%	31.0%
Care goals			
To maintain their current condition or to prevent/slow further deterioration	38.3%	37.9%	38.6%
To improve their condition	62.1%	62.6%	61.9%
Payment source			
Medicare FFS	53.3%	51.3%	54.4%
Medicaid only	10.7%	13.0%*	9.5%
Veterans Administration	6.7%	7.3%*	6.4%
Commercial non-MA	10.1%	10.4%*	9.9%
MA	23.1%	22.1%	22.6%
Self-pay	1.9%	2.8%*	1.4%

Results statistically different between HHVBP and non-HHVBP states at p < 0.05 (shown in HHVBP column only). Analytic sample restricted to agencies with sum of items within question set between 95% and 105%. Due to rounding, percentage within a question set may not sum to exactly 100%.

Exhibit B-74. Perceived Importance of Quality Improvement Strategies, by Agencies in Original HHVBP and Non-HHVBP States

	Original HHVBP States	Non-HHVBP States
	Percent of agencies rating item as "very important"	
Importance in driving agency's quality improvement activities		
Quality of Patient Care Star Ratings in HHC	76.7%	74.7%
HHCAHPS Patient Survey Star	74.6%	71.3%
Quality Assessment and Performance Improvement (QAPI) requirements in conditions of participation (CoPs)	72.8%	71.5%
Payer or health plan requirements	48.5%	48.3%
Health system or corporate initiatives	38.0%	38.2%
HHVBP Model	59.2%	54.6%
Participation in ACOs or managed care contracts	30.7%	30.8%
Importance of various approaches in improving performance		
For FFS claims-based measures		
Use of patient care processes/protocols for post-ED/inpatient discharge follow-up	58.6%	57.5%
Staff training on patient care processes/protocols for post-ED/inpatient discharge follow-up	60.2%	60.4%
Use of risk stratification to identify patients at high risk of ED use or re-hospitalization	62.4%	63.8%
Shifting or adding visits earlier in an episode to increase post-discharge follow-up ('frontloading')	57.3%	58.8%
Patient education about when to use the ED	73.8%	72.3%
Patient education about self-management of specific conditions or improving health behaviors	76.1%	75.0%
Changes to how interdisciplinary team works together in coordinating care	63.2%	67.2%
Tailoring of clinical strategies to patients with certain conditions or characteristics	64.5%	62.7%
For OASIS-based measures		
Staff training to better understand the OASIS assessment process	82.8%	80.8%
Changes in types of staff conducting patient assessments (for example, PT to conduct assessment of ambulation)	47.5%	47.5%
Ensuring same staff conducts patient assessment at both SOC and discharge	46.0%	49.9%
Initiating SOC assessment more promptly	67.1%	70.2%
Changes to discharge procedures	38.4%	39.8%
Increased review of completed OASIS assessments by clinical staff	70.5%	67.7%
Use of software to improve OASIS accuracy, e.g., data prompts or data validation for assessments	66.2%	62.6%
Contracting with third-party for OASIS assessment review and/or coding	39.4%	34.7%
Focusing staff resources or training on care of patients for whom showing improvement is more likely	42.9%	46.0%
For HHCAHPS-based measures		

	Original HHVBP States	Non-HHVBP States
	Percent of agencies rating item as "very important"	
Enhanced staff training on communication with patients about medications, including review of medications, when to take medications, and potential side effects	80.3%	81.1%
Enhanced staff training on communication with patients about other issues, for example, care and services to be provided, how to listen carefully, how to explain things clearly	73.0%	72.3%
Enhanced staff training on interaction with patients, for example, treating patients gently, with courtesy and respect, and providing up-to-date information on available treatments	73.1%	72.9%
Staff training on how to discuss HHCAHPS with patients	58.4%	59.8%
Agency outreach to patients to discuss their satisfaction with care	61.6%	63.0%

There were no statistically significant differences between the percentage of agencies in HHVBP and non-HHVBP states reporting a particular approach as "very important."

B.11 Health Equity Supporting Analyses

Exhibit B-75. Characteristics of OASIS Episodes by Medicaid and HHVBP Status, 2013 – 2021

	Baseline (2013-2015)		Post Period (2016-2021)	
	Medicaid	**Non-Medicaid**	**Medicaid**	**Non-Medicaid**
OASIS Episodes (N)				
HHVBP	1,428,599	3,080,096	2,737,660	7,068,110
Non-HHVBP	4,890,626	9,794,588	10,380,363	22,304,293
Average Age (Years)				
HHVBP	68.1	78.9	68.1	78.8
Non-HHVBP	67.0	78.1	67.3	78.2
Female				
HHVBP	65.5%	59.5%	64.4%	58.4%
Non-HHVBP	65.7%	59.5%	64.1%	58.5%
Race/Ethnicity (Mutually Exclusive)				
Hispanic				
HHVBP	22.3%	2.7%	17.1%	3.4%
Non-HHVBP	14.4%	3.6%	13.8%	4.0%
Black Non-Hispanic				
HHVBP	18.4%	7.0%	20.0%	8.0%
Non-HHVBP	25.5%	9.6%	24.3%	9.4%
White Non-Hispanic				
HHVBP	56.7%	89.2%	59.7%	87.3%
Non-HHVBP	54.3%	84.9%	55.9%	84.4%
Non-Hispanic Other Race				
HHVBP	2.4%	0.9%	3.0%	1.2%
Non-HHVBP	5.5%	1.7%	5.8%	2.1%
Non-Hispanic Multiracial				
HHVBP	0.2%	0.1%	0.2%	0.1%
Non-HHVBP	0.2%	0.2%	0.2%	0.1%
ESRD Flag				
HHVBP	5.2%	2.4%	6.9%	2.7%
Non-HHVBP	6.9%	2.9%	7.6%	3.1%
Discharge from Inpatient Facility within 14 Days				
HHVBP	61.6%	70.7%	66.5%	68.9%
Non-HHVBP	67.1%	73.6%	67.0%	72.0%
Rural				
HHVBP	5.2%	3.7%	5.1%	3.6%
Non-HHVBP	8.1%	6.8%	7.7%	6.7%
HHA Ownership				
For-Profit				
HHVBP	68.3%	62.9%	67.6%	66.3%
Non-HHVBP	61.8%	55.1%	63.4%	59.9%

	Baseline (2013-2015)		Post Period (2016-2021)	
	Medicaid	**Non-Medicaid**	**Medicaid**	**Non-Medicaid**
Non-Profit				
HHVBP	28.0%	33.4%	29.5%	31.0%
Non-HHVBP	35.1%	42.3%	34.3%	38.3%
Government-Owned				
HHVBP	3.7%	3.6%	2.9%	2.7%
Non-HHVBP	3.1%	2.6%	2.3%	1.8%
HHA Chain Affiliation				
Chain-Affiliated				
HHVBP	38.3%	51.0%	44.1%	53.5%
Non-HHVBP	30.4%	38.6%	34.3%	42.8%
No Chain Affiliation				
HHVBP	49.8%	40.4%	46.1%	36.7%
Non-HHVBP	59.6%	50.0%	56.7%	47.2%
Chain Affiliation Unknown/Missing				
HHVBP	11.8	8.6	9.8	9.8
Non-HHVBP	9.9	11.3	9.0	10.0
HHA Age				
<4 years				
HHVBP	9.0%	4.8%	2.5%	1.9%
Non-HHVBP	6.7%	3.8%	3.7%	2.3%
4-10 years				
HHVBP	26.9%	21.1%	18.1%	15.3%
Non-HHVBP	20.3%	16.2%	15.6%	11.4%
>10 years				
HHVBP	64.2%	74.1%	79.4%	82.8%
Non-HHVBP	73.1%	80.1%	80.7%	86.3%
HHA Size				
1-59 OASIS Episodes				
HHVBP	1.3%	0.4%	1.1%	0.3%
Non-HHVBP	2.2%	0.9%	1.8%	0.6%
60-249 OASIS Episodes				
HHVBP	10.0%	4.1%	6.9%	2.8%
Non-HHVBP	13.0%	7.2%	10.0%	5.0%
250-499 OASIS Episodes				
HHVBP	13.4%	8.3%	9.1%	6.1%
Non-HHVBP	13.6%	10.4%	10.8%	7.8%
500-999 OASIS Episodes				
HHVBP	17.0%	16.1%	13.0%	13.2%
Non-HHVBP	15.2%	15.6%	14.1%	14.1%
1000+ OASIS Episodes				

	Baseline (2013-2015)		Post Period (2016-2021)	
	Medicaid	Non-Medicaid	Medicaid	Non-Medicaid
HHVBP	58.3%	71.0%	69.9%	77.6%
Non-HHVBP	56.0%	65.9%	63.2%	72.4%

Exhibit B-76. Characteristics of OASIS Home Health Episodes by Race/Ethnicity and HHVBP Status, 2013 – 2021

	Baseline (2013-2015)					Post Period (2016-2021)				
	Hispanic	Non-Hispanic				Hispanic	Non-Hispanic			
		Black	Other	Multi-	White		Black	Other	Multi-	White
FFS Episodes (N)										
HHVBP	402,680	478,997	61,966	6,540	3,558,504	708,175	1,116,227	163,373	12,080	7,805,579
Non-HHVBP	1,056,282	2,192,957	433,218	26,282	10,976,479	2,320,057	4,620,912	1,070,666	55,144	24,616,013
Average Age (Years)										
HHVBP	73.0	69.2	73.2	72.5	76.6	74.2	70.3	74.1	72.0	76.8
Non-HHVBP	70.9	68.6	75.5	71.2	75.9	71.4	69.4	75.8	71.0	76.0
Female										
HHVBP	62.3%	62.8%	60.4%	62.7%	61.1%	61.9%	61.9%	59.1%	61.7%	59.6%
Non-HHVBP	59.8%	63.5%	59.9%	61.8%	61.4%	58.6%	62.6%	58.7%	60.7%	60.0%
Medicaid Eligible										
HHVBP	79.3%	54.9%	55.0%	39.6%	22.8%	66.2%	49.1%	50.2%	39.5%	20.9%
Non-HHVBP	66.8%	56.9%	61.8%	43.0%	24.2%	61.6%	54.6%	56.6%	42.5%	23.6%
ESRD Flag										
HHVBP	3.7%	11.6%	7.4%	5.3%	2.1%	6.6%	13.1%	8.3%	6.1%	2.3%
Non-HHVBP	10.8%	10.4%	6.8%	5.3%	2.4%	12.2%	12.0%	7.4%	5.6%	2.5%
Discharge from Inpatient Facility within 14 Days										
HHVBP	39.4%	72.2%	72.1%	71.1%	70.3%	55.9%	72.1%	70.5%	69.5%	68.7%
Non-HHVBP	65.5%	66.2%	63.9%	69.9%	73.4%	66.9%	68.3%	64.6%	69.9%	71.4%
Rural										
HHVBP	0.2%	4.0%	1.8%	3.9%	4.7%	0.4%	3.9%	1.6%	3.9%	4.5%
Non-HHVBP	2.1%	5.0%	2.9%	8.3%	8.3%	2.0%	5.1%	2.5%	7.5%	8.1%
HHA Ownership:										
For-Profit										
HHVBP	86.5%	64.8%	58.8%	59.3%	62.2%	82.3%	68.3%	60.8%	59.7%	65.1%

	Baseline (2013-2015)					Post Period (2016-2021)				
	Hispanic	Non-Hispanic				Hispanic	Non-Hispanic			
		Black	Other	Multi-	White		Black	Other	Multi-	White
Non-HHVBP	69.7%	65.7%	65.7%	56.3%	54.1%	70.2%	67.0%	67.8%	51.8%	58.8%
Non-Profit										
HHVBP	12.3%	31.1%	37.0%	36.5%	33.9%	16.8%	28.8%	35.7%	37.1%	32.0%
Non-HHVBP	28.5%	31.9%	32.6%	40.8%	42.9%	28.1%	31.0%	31.0%	45.9%	39.2%
Government-Owned										
HHVBP	1.2%	4.1%	4.3%	4.2%	3.9%	0.9%	3.0%	3.5%	3.3%	2.9%
Non-HHVBP	1.7%	2.4%	1.7%	2.9%	3.0%	1.7%	1.9%	1.3%	2.3%	2.0%
HHA Chain Affiliation:										
Chain-Affiliated										
HHVBP	15.1%	50.7%	42.8%	44.4%	50.2%	30.4%	53.4%	44.8%	45.5%	52.5%
Non-HHVBP	19.3%	33.4%	24.0%	32.4%	38.5%	24.2%	40.3%	27.3%	32.9%	42.2%
No Chain Affiliation										
HHVBP	67.0%	39.1%	47.6%	45.6%	41.2%	63.1%	36.6%	43.8%	44.0%	37.4%
Non-HHVBP	73.9%	55.9%	69.1%	56.7%	50.1%	68.9%	50.3%	66.1%	55.5%	47.7%
Chain Affiliation Unknown/Missing										
HHVBP	17.8%	10.2%	9.6%	10.0%	8.6%	6.5%	9.9%	11.3%	10.5%	10.1%
Non-HHVBP	6.8%	10.7%	6.2%	10.8%	11.4%	6.8%	9.5%	6.1%	11.6%	10.1%
HHA Age										
<4 years										
HHVBP	19.4%	5.3%	7.3%	7.6%	4.7%	3.9%	1.7%	3.0%	2.8%	1.9%
Non-HHVBP	8.2%	6.4%	11.3%	6.1%	3.8%	4.0%	2.1%	5.7%	3.1%	2.6%
4-10 years										
HHVBP	50.2%	18.3%	18.0%	19.4%	20.5%	32.0%	12.3%	15.5%	15.2%	15.2%
Non-HHVBP	29.4%	22.2%	25.3%	18.7%	15.2%	19.9%	14.5%	23.2%	13.0%	11.3%
>10 years										

	Baseline (2013-2015)					Post Period (2016-2021)				
	Hispanic	Non-Hispanic				Hispanic	Non-Hispanic			
		Black	Other	Multi-	White		Black	Other	Multi-	White
HHVBP	30.4%	76.4%	74.8%	73.0%	74.8%	64.0%	86.0%	81.5%	82.0%	82.9%
Non-HHVBP	62.4%	71.4%	63.4%	75.3%	81.1%	76.1%	83.3%	71.0%	84.0%	86.1%
HHA Size										
1-59 OASIS Episodes										
HHVBP	2.5%	0.8%	1.1%	0.9%	0.5%	2.1%	0.6%	0.8%	0.7%	0.4%
Non-HHVBP	2.4%	3.2%	2.0%	2.4%	0.8%	1.9%	2.2%	1.8%	1.8%	0.6%
60-249 OASIS Episodes										
HHVBP	21.5%	5.5%	6.1%	6.7%	4.3%	13.8%	3.3%	4.1%	4.8%	3.1%
Non-HHVBP	18.3%	13.8%	15.4%	13.5%	7.1%	13.3%	8.8%	11.8%	9.2%	5.4%
250-499 OASIS Episodes										
HHVBP	26.9%	8.9%	7.4%	8.4%	8.2%	15.1%	6.2%	7.3%	7.5%	6.3%
Non-HHVBP	17.9%	11.3%	16.8%	12.5%	10.6%	13.3%	8.1%	13.8%	10.4%	8.2%
500-999 OASIS Episodes										
HHVBP	19.2%	15.8%	16.8%	16.5%	16.2%	13.3%	12.1%	12.5%	12.1%	13.3%
Non-HHVBP	15.1%	12.6%	14.7%	15.6%	16.2%	14.1%	11.6%	14.2%	13.8%	14.6%
1000+ OASIS Episodes										
HHVBP	29.8%	69.0%	68.6%	67.5%	70.9%	55.6%	77.8%	75.4%	74.9%	76.9%
Non-HHVBP	46.3%	59.0%	51.1%	56.0%	65.4%	57.3%	69.2%	58.3%	64.8%	71.2%

Exhibit B-77. Differences in TNC Measures by Other Versus White Non-Hispanic Race, 2013-2015

Measure	Subgroup Comparison	Difference Estimate	P-value
Unplanned ACH/First FFS HH Episodes** [a]	Other vs. White Non-Hispanic	-0.66	<0.001
ED Use (No Hospitalization)/First FFS HH Episodes** [a]	Other vs. White Non-Hispanic	-2.90	<0.001
TNC Change in Self-Care*	Other vs. White Non-Hispanic	-0.01	0.20
TNC Change in Mobility*	Other vs. White Non-Hispanic	0.01	<0.01

* Results obtained from linear regression with state fixed effects | ** Results obtained from linear regression with state fixed effects and HCC risk score | [a] Difference estimates represent percentage point changes

Exhibit B-78. Differential Impact of HHVBP Based on Other Versus White Non-Hispanic Race, 2013-2021

| Measure	Other Non-Hispanic		White Non-Hispanic		Other - White Non-Hispanic	
	D-in-D	P-value	D-in-D	P-value	D-in-D-in-D	P-value
Unplanned ACH/First FFS HH Episodes** [a]	-0.58	0.10	-0.41	0.03	-0.17	0.57
ED Use (No Hospitalization)/First FFS HH Episodes** [a]	0.09	0.80	0.26	0.14	-0.17	0.57
TNC Change in Self-Care	0.07	<0.01	0.05	0.02	0.03	0.09
TNC Change in Mobility	0.03	<0.01	0.02	0.02	0.01	0.08

** Results obtained from linear regression with state fixed effects and HCC risk score | [a] Difference estimates represent percentage point changes

Exhibit B-79. Adjusted Odds of using Lower Quality HHAs (as measured by ACH rates) Varied among Racial/Ethnic Minority Beneficiaries relative to White Beneficiaries, but Overall moved in a more Unfavorable Direction in the post-HHVBP Era

	Model 1: Adjusted for individual and county characteristics only*				Model 2: Adjusted for Model 1 characteristics + county-level use of higher quality HHAs**			
	Non-HHVBP State		HHVBP State		Non- HHVBP State		HHVBP State	
	Pre-HHVBP (2014-15)	Post-HHVBP (2018-19)	Pre-HHVBP (2014-15)	Post-HHVBP (2018-19)	Pre-HHVBP (2014-15)	Post-HHVBP (2018-19)	Pre-HHVBP (2014-15)	Post-HHVBP (2018-19)
White	Reference	Reference	Reference	Reference	Reference	Reference	Reference	Reference
American Indian/Alaska Native (AIAN)	0.87	1.07	1.96	1.34	1.00	1.11	1.44	1.20
Asian American/ Pacific Islander (AAPI)	0.75	0.86	0.99^	1.13	0.97	1.06	0.99	1.04
Black	0.85	1.04	1.19	1.32	0.91	1.00^	1.05	1.12
Hispanic	0.83	0.94	0.50	0.90	1.05	1.07	0.91	0.96

ACH: Unplanned ACH. *Variables controlled for in Model 1: age, sex, dual eligibility status, rurality, HCC score, the Health and Human Services (HHS) region *from which a non-HHVBP or HHVBP state was drawn, the CDC Social Vulnerability Index, and the Racial Dissimilarity Index. **Variables controlled for in Model 2: all Model 1 control variables + whether higher quality HHAs deliver episodes in areas with lower quality HHAs. ^ Value is not statistically significant at p<0.05 (the absence of this symbol indicates that the value is statistically significant).*

Exhibit B-80. Adjusted Odds Ratios of using Lower Quality HHAs (as measured by ACH Rates) among Racial/Ethnic Minority Beneficiaries, Relative to White beneficiaries, by Race/Ethnicity

ACH: Unplanned ACH. ^ Value is not statistically significant at p<0.05 (the absence of this symbol indicates that the value is statistically significant).

Exhibit B-81. Adjusted Odds of using Lower Quality HHAs (as measured by ED rates) were lower among Racial/Ethnic Minority Beneficiaries relative to White beneficiaries; Differences in Lower Quality HHA use among Black and Hispanic Beneficiaries may be Influenced by the Presence of Higher Quality HHAs

|	Model 1: Adjusted for individual and county characteristics only*				Model 2: Adjusted for Model 1 characteristics + county-level use of higher quality HHAs **			
	Non-HHVBP State		HHVBP State		Non- HHVBP State		HHVBP State	
	Pre-HHVBP (2014-15)	Post-HHVBP (2018-19)	Pre-HHVBP (2014-15)	Post-HHVBP (2018-19)	Pre-HHVBP (2014-15)	Post-HHVBP (2018-19)	Pre-HHVBP (2014-15)	Post-HHVBP (2018-19)
White	Reference	Reference	Reference	Reference	Reference	Reference	Reference	Reference

	Model 1: Adjusted for individual and county characteristics only*				Model 2: Adjusted for Model 1 characteristics + county-level use of higher quality HHAs **			
	Non-HHVBP State		HHVBP State		Non- HHVBP State		HHVBP State	
	Pre-HHVBP (2014-15)	Post-HHVBP (2018-19)	Pre-HHVBP (2014-15)	Post-HHVBP (2018-19)	Pre-HHVBP (2014-15)	Post-HHVBP (2018-19)	Pre-HHVBP (2014-15)	Post-HHVBP (2018-19)
American Indian/Alaska Native (AI/AN)	0.95	1.01^	0.63	1.05	0.97	0.91	0.97	0.92
Asian American/ Pacific Islander (AAPI)	0.47	0.62	0.60	0.67	0.72	0.83	0.86	0.89
Black	0.98	1.01	1.01^	1.23	1.33	1.23	1.08	1.35
Hispanic	0.74	0.99	0.60	0.82	1.17	1.15	0.71	0.95

ED rate: Outpatient ED Use with no Hospitalization. *Variables controlled for in Model 1: age, sex, dual eligibility status, rurality, HCC score, the Health and Human Services (HHS) region from which a non-HHVBP or HHVBP state was drawn, the CDC Social Vulnerability Index, and the Racial Dissimilarity Index. **Variables controlled for in Model 2: all Model 1 control variables + whether higher quality HHAs deliver episodes in areas with lower quality HHAs. ^ Value is not statistically significant at p<0.05 (the absence of this symbol indicates that the value is statistically significant).

Exhibit B-82. Adjusted Odds Ratios of using Lower Quality HHAs (as measured by ED Rates) among Racial/Ethnic Minority Beneficiaries, Relative to White Beneficiaries, by Race/Ethnicity

ED rate: Outpatient ED Use with no Hospitalization. ^ Value is not statistically significant at p<0.05 (the absence of this symbol indicates that the value is statistically significant).

Exhibit B-83. Adjusted Odds of using Lower Quality HHAs (as measured by HHCAHPS-based Overall Care ratings) were Higher among Racial/Ethnic Minority Beneficiaries relative to White Beneficiaries; Despite some evidence of a Positive HHVBP impact, Effects Decreased after Accounting for Presence of Higher Quality HHAs

	Model 1: Adjusted for individual and county characteristics only*				Model 2: Adjusted for Model 1 characteristics + county-level use of higher quality HHAs **			
	Non-HHVBP State		HHVBP State		Non- HHVBP State		HHVBP State	
	Pre-HHVBP (2014-15)	Post-HHVBP (2018-19)	Pre-HHVBP (2014-15)	Post-HHVBP (2018-19)	Pre-HHVBP (2014-15)	Post-HHVBP (2018-19)	Pre-HHVBP (2014-15)	Post-HHVBP (2018-19)
American Indian/Alaska Native (AI/AN)	1.14	1.33	1.47	1.55	1.25	1.25	1.58	1.44
White	Reference	Reference	Reference	Reference	Reference	Reference	Reference	Reference
Asian American/ Pacific Islander (AAPI)	2.47	2.18	1.23	1.17	1.62	1.53	1.12	1.13
Black	1.54	1.54	1.40	1.38	1.37	1.30	1.27	1.34
Hispanic	1.46	1.66	0.71	0.96	1.33	1.42	0.85	1.00^

*Variables controlled for in Model 1: age, sex, dual eligibility status, rurality, HCC score, the Health and Human Services (HHS) region from which a non-HHVBP or HHVBP state was drawn, the CDC Social Vulnerability Index, and the Racial Dissimilarity Index. **Variables controlled for in Model 2: all Model 1 control variables + whether higher quality HHAs deliver episodes in areas with lower quality HHAs. ^ Value is not statistically significant at p<0.05 (the absence of this symbol indicates that the value is statistically significant).*

Exhibit B-84. Adjusted Odds Ratios of using Lower Quality HHAs (as measured by HHCAHPS-based Overall Care Rating) among Racial/Ethnic Minority Beneficiaries, relative to White Beneficiaries, by Race/Ethnicity

^ *Value is not statistically significant at p<0.05 (the absence of this symbol indicates that the value is statistically significant).*

Exhibit B-85. Adjusted Odds of using Lower Quality HHAs (as measured by CMS' Quality of Patient Care Star Ratings) were Higher among Racial/Ethnic Minority Beneficiaries relative to White Beneficiaries; Despite some Movement in a Favorable Direction in HHVBP States over time, Changes were not enough to Reverse Racial Differences

	Model 1: Adjusted for individual and county characteristics only*				Model 2: Adjusted for Model 1 characteristics + county-level use of higher quality HHAs **			
	Non-HHVBP State		HHVBP State		Non- HHVBP State		HHVBP State	
	Pre-HHVBP (2014-15)	Post-HHVBP (2018-19)	Pre-HHVBP (2014-15)	Post-HHVBP (2018-19)	Pre-HHVBP (2014-15)	Post-HHVBP (2018-19)	Pre-HHVBP (2014-15)	Post-HHVBP (2018-19)
White	Reference	Reference	Reference	Reference	Reference	Reference	Reference	Reference
American Indian/Alaska Native (AI/AN)	1.04	1.46	1.47	1.36	1.00^	1.22	1.22	1.15
Asian American/ Pacific Islander (AAPI)	1.09	1.39	1.13	1.17	1.03	1.24	1.06	1.16
Black	1.23	1.26	1.28	1.09	1.26	1.27	1.15	1.13
Hispanic	1.72	1.92	1.02	1.62	1.26	1.28	1.03	1.18

*Variables controlled for in Model 1: age, sex, dual eligibility status, rurality, HCC score, the Health and Human Services (HHS) region from which a non-HHVBP or HHVBP state was drawn, the CDC Social Vulnerability Index, and the Racial Dissimilarity Index. **Variables controlled for in Model 2: all Model 1 control variables + whether higher quality HHAs deliver episodes in areas with lower quality HHAs. ^ Value is not statistically significant at p<0.05 (the absence of this symbol indicates that the value is statistically significant).*

The following four Exhibits show county-level changes (pre-/post-HHVBP) in the relative use of lower quality-HHAs among racial/ethnic minority groups compared to White beneficiaries in those counties where the minority population is sufficiently sized to support robust calculations. These maps provide a more granular illustration of how, in any given state, the extent of inequities varies widely and differs by race/ethnicity.

In the Exhibit below, within the states of Washington and Arizona (both HHVBP states) and Oklahoma, there were counties in which American Indian/Alaska Native (AI/AN) beneficiaries experienced persistently worse or worsening equity levels, as well as counties where they experienced persistently better or improving equity levels, in lower quality HHA use. One HHVBP state (North Carolina) exhibited county-level changes that were all in a favorable and improving direction for AI/AN beneficiaries. But in all other states – Alaska, California, New Mexico, Michigan, and Texas (none of which were-HHVBP states) – AI/AN beneficiaries experienced only worsening or unchanging/'neutral' (neither worse nor better than White beneficiaries) levels of inequity over time.

Exhibit B-86. Changes in County-level Rates of Lower Quality HHA use among American Indian/Alaska Native (AI/AN) Compared to White Beneficiaries from the pre-HHVBP (2014-15) to post-HHVBP (2018-19) Eras Varied by Geography

In the Exhibit below, for the majority of states with measurable county data, of which about one-third were HHVBP states, there were counties in which Asian American/Pacific Islander (AAPI) beneficiaries experienced persistently worse or worsening equity levels, as well as counties where they experienced persistently better or improving equity levels, in lower quality HHA use. There were states where county-level changes were all in a favorable or improving direction for AAPI beneficiaries (e.g., Arizona, Iowa, Michigan, Missouri, North Carolina, Oregon, Pennsylvania, Utah – of which one-third (Arizona, Iowa, North Carolina) were HHVBP states). But there were also states where changes were all in a worsening direction or were unchanging/'neutral' (neither worse nor better than White beneficiaries) over time for AAPI relative to White beneficiaries (e.g., Indiana, Kansas, Minnesota, Nevada, Oklahoma – none of which were HHVBP states).

Exhibit B-87. Changes in County-level Rates of Lower Quality HHA use among Asian American/Pacific Islander (AAPI) Compared to White Beneficiaries from the pre-HHVBP (2014-15) to post-HHVBP (2018-19) Eras Varied by Geography

In the Exhibit below, for the majority of states with measurable data, there were counties in which Black beneficiaries experienced persistently worse or worsening equity levels, as well as counties where they experienced persistently better or improving equity levels, in lower quality HHA use. There were a few states where county-level changes were all in a favorable or improving direction for Black beneficiaries, but also a few states where changes were all in a worsening direction or were unchanging/'neutral' (neither worse nor better than White beneficiaries) over time for Black relative to White beneficiaries.

Exhibit B-88. Changes in County-level Rates of Lower Quality HHA use among Black Compared to White Beneficiaries from the pre-HHVBP (2014-15) to post-HHVBP (2018-19) Eras Varied by Geography

In the Exhibit below, for the majority of states with measurable county data, there were counties in which Hispanic beneficiaries experienced persistently worse or worsening equity levels, as well as counties where they experienced persistently better or improving equity levels, in lower quality HHA use. There were a states where county-level changes were all in a favorable or improving direction for Hispanic beneficiaries (e.g., Alabama, Arkansas, Iowa, Idaho, Kansas, Maryland, Missouri, Mississippi – with Iowa and Maryland being HHVBP states), but also states where changes were all in a worsening direction or were unchanging/'neutral' (neither worse nor better than White beneficiaries) over time for Hispanic relative to White beneficiaries (e.g., Minnesota, New Hampshire, Tennessee, Wyoming – with Tennessee being an HHVBP state).

Exhibit B-89. Changes in County-level Rates of Lower Quality HHA use among Hispanic Compared to White Beneficiaries from the pre-HHVBP (2014-15) to post-HHVBP (2018-19) Eras Varied by Geography

Exhibit B-90. Medicaid Share Over Time by HHVBP Status – Agencies

	HHVBP			Non-HHVBP		
	2014-2015	2016-2017	2018-2019	2014-2015	2016-2017	2018-2019
Count (# Agencies)	2,123	1,925	1,797	8,667	8,291	7,781
Medicaid Share						
Mean	4.4%	4.9%	5.1%	4.9%	4.9%	4.8%

	HHVBP			Non-HHVBP		
	2014-2015	2016-2017	2018-2019	2014-2015	2016-2017	2018-2019
Median	0.1%	0.2%	0.2%	1.2%	0.8%	0.5%
Percent High (≥ 10%)	12.1%	14.0%	14.5%	15.0%	14.6%	14.1%
Count High	257	269	261	1,300	1,214	1,093
Percent Zero (0%)	46.1%	43.7%	42.7%	35.3%	38.5%	41.1%
Count Zero	978	841	768	3,061	3,191	3,196

High Medicaid share agencies defined as those with 10% or more Medicaid patients in each year-pair.

Exhibit B-91. Medicaid Share Over Time by HHVBP Status – Episodes

	HHVBP			Non-HHVBP		
	2014-2015	2016-2017	2018-2019	2014-2015	2016-2017	2018-2019
Number of Episodes	1,320,591	1,383,028	1,464,562	4,225,112	4,591,243	4,863,003
Episodes Associated with High Medicaid Share Agencies						
Percent	10.9%	11.6%	10.0%	21.0%	21.0%	19.0%
Count	144,506	159,704	146,739	886,421	963,700	923,483
Episodes Associated with No Medicaid Share Agencies						
Percent	27.1%	25.4%	25.2%	11.4%	12.7%	13.9%
Count	357,170	350,940	369,342	481,703	584,005	677,001

High Medicaid share agencies defined as those with 10% or more Medicaid patients in each year-pair.

Exhibit B-92. Medicaid Share Over Time by HHVBP State – Agencies

	HHVBP		
	2014-2015	2016-2017	2018-2019
Arizona			
Count (# Agencies)	143	142	149
High Medicaid Share	31 (21.7%)	29 (20.4%)	34 (22.8%)
No Medicaid Share	62 (43.4%)	63 (44.4%)	64 (43.0%)
Florida			
Count (# Agencies)	1,158	964	857
High Medicaid Share	35 (3.0%)	27 (2.8%)	30 (3.5%)
No Medicaid Share	834 (72.0%)	697 (72.3%)	605 (70.6%)
Iowa			
Count (# Agencies)	153	147	138
High Medicaid Share	42 (27.5%)	42 (28.6%)	34 (24.6%)
No Medicaid Share	8 (5.2%)	6 (4.1%)	12 (8.7%)
Maryland			
Count (# Agencies)	52	52	51
High Medicaid Share	3 (5.8%)	5 (9.6%)	6 (11.8%)

	HHVBP		
	2014-2015	2016-2017	2018-2019
No Medicaid Share	9 (17.3%)	10 (19.2%)	10 (19.6%)
Massachusetts			
Count (# Agencies)	176	190	184
High Medicaid Share	90 (51.1%)	112 (59.0%)	100 (54.4%)
No Medicaid Share	10 (5.7%)	16 (8.4%)	26 (14.1%)
Nebraska			
Count (# Agencies)	69	69	66
High Medicaid Share	8 (11.6%)	5 (7.3%)	8 (12.1%)
No Medicaid Share	7 (10.1%)	6 (8.7%)	11 (16.7%)
North Carolina			
Count (# Agencies)	173	171	169
High Medicaid Share	19 (11.0%)	22 (12.9%)	26 (15.4%)
No Medicaid Share	2 (1.2%)	3 (1.8%)	6 (3.6%)
Tennessee			
Count (# Agencies)	137	129	121
High Medicaid Share	20 (14.6%)	17 (13.2%)	16 (13.2%)
No Medicaid Share	39 (28.5%)	34 (26.4%)	25 (20.7%)
Washington			
Count (# Agencies)	62	61	62
High Medicaid Share	9 (14.5%)	10 (16.4%)	7 (11.3%)
No Medicaid Share	7 (11.3%)	6 (9.8%)	9 (14.5%)

High Medicaid share agencies defined as those with 10% or more Medicaid patients in each year-pair.

Exhibit B-93. Agency Performance Over Time on Selected Measures by HHVBP Status and Medicaid Share

	HHVBP						Non-HHVBP					
	High Medicaid Share			No Medicaid Share			High Medicaid Share			No Medicaid Share		
	2014-2015	2016-2017	2018-2019	2014-2015	2016-2017	2018-2019	2014-2015	2016-2017	2018-2019	2014-2015	2016-2017	2018-2019
Average Percent with Improvement in Dyspnea												
Average % with improvement	60.8	65.8	69.6	60.0	71.3	78.3	60.1	65.8	70.8	55.4	62.4	69.6
HHAs reporting metric (N)	257	268	261	978	840	767	1,299	1,214	1,089	3,061	3,191	3,192
Average Percent with Improvement in Ambulation												
Average % with improvement	56.8	64.0	68.8	66.4	74.0	78.9	57.4	64.8	70.0	59.2	67.4	72.1
HHAs reporting metric (N)	257	269	261	978	840	767	1,300	1,214	1,090	3,061	3,191	3,192
Average Percent with Unplanned ACH												
Average % with ACH	16.1	14.1	14.3	14.6	15.4	14.6	15.8	15.5	14.6	14.2	14.8	14.3

	HHVBP						Non-HHVBP					
	High Medicaid Share			No Medicaid Share			High Medicaid Share			No Medicaid Share		
	2014-2015	2016-2017	2018-2019	2014-2015	2016-2017	2018-2019	2014-2015	2016-2017	2018-2019	2014-2015	2016-2017	2018-2019
HHAs reporting metric (N)	246	259	252	962	831	764	1,265	1,174	1,038	3,057	3,175	3,176
Average Percent with Outpatient ED Use with no Hospitalization												
Average % with outpatient ED use	12.0	12.3	11.9	9.9	10.6	11.4	12.9	13.4	13.2	11.8	11.9	12.0
HHAs reporting metric (N)	246	259	252	962	831	764	1,265	1,174	1,038	3,057	3,175	3,176
Agencies with 4- or 5- Quality of Patient Care Star Rating												
Total HHAs (%)	9.8	11.8	13.2	35.6	43.5	45.8	12.3	14.1	16.7	22.1	23.4	22.8
HHAs reporting metric (N)	204	238	227	812	768	706	1,110	1,023	883	2,686	2,917	2,896
Average HHCAHPS-based Overall Care Rating												
Average Rating (%)	82.4	82.5	81.8	82.5	82.4	84.2	80.9	81.3	82.4	81.1	81.2	83.2
HHAs reporting metric (N)	185	216	223	625	630	630	964	942	862	1,930	2,179	2,269

High Medicaid share agencies defined as those with 10% or more Medicaid patients in each year-pair.

Exhibit B-94. Share of Agencies with High and No Medicaid Share Over Time by Agency Characteristics and HHVBP Status

	HHVBP						Non-HHVBP					
	High Medicaid Share			No Medicaid Share			High Medicaid Share			No Medicaid Share		
	2014-2015	2016-2017	2018-2019	2014-2015	2016-2017	2018-2019	2014-2015	2016-2017	2018-2019	2014-2015	2016-2017	2018-2019
All	12.1%	14.0%	14.5%	46.1%	43.7%	42.7%	15.0%	14.6%	14.0%	35.3%	38.5%	41.1%
Size (# Episodes)												
<250	15.4%	19.9%	21.4%	55.6%	52.1%	51.2%	14.9%	14.0%	13.7%	48.6%	52.8%	57.5%
250-500	9.5%	9.8%	12.5%	51.7%	51.6%	49.5%	12.3%	13.1%	11.8%	22.9%	29.7%	34.2%
>500	9.1%	9.0%	8.4%	28.5%	29.8%	30.9%	17.4%	17.2%	16.1%	8.2%	11.8%	13.9%
Ownership												
For-Profit	11.2%	12.8%	13.3%	55.0%	52.0%	51.1%	12.3%	11.9%	11.7%	42.2%	45.2%	48.0%
Not-For-Profit	14.2%	15.6%	17.2%	18.2%	18.8%	15.1%	22.5%	24.9%	23.1%	11.7%	12.7%	11.3%
Gov't-Owned	18.3%	23.8%	24.5%	6.3%	6.4%	6.9%	31.7%	26.1%	27.4%	8.3%	12.0%	17.4%
Affiliation												
Hospital-Based	14.2%	12.8%	12.1%	7.4%	8.5%	7.9%	19.2%	21.9%	22.3%	9.1%	7.1%	9.8%
Independent	11.9%	14.1%	14.7%	49.9%	46.9%	45.7%	14.5%	14.0%	13.3%	38.2%	41.5%	43.8%
Chain Status												
Chain	7.4%	7.2%	6.8%	31.1%	32.3%	34.4%	13.2%	13.2%	12.0%	15.8%	18.8%	19.7%
Not Chain	14.0%	17.1%	18.5%	52.0%	48.8%	47.0%	15.4%	15.0%	14.6%	39.8%	43.2%	46.9%

High Medicaid share agencies defined as those with 10% or more Medicaid patients in each year-pair.

Exhibit B-95. Count of Agencies Over Time in Each Agency Characteristic and HHVBP Status-Defined Group

	HHVBP			Non-HHVBP		
	2014-2015	2016-2017	2018-2019	2014-2015	2016-2017	2018-2019
Count (# Agencies)	2,123	1,924	1,797	8,667	8,291	7,777
Size (# Episodes)						
<250	996	856	744	5,299	4,783	4,243
250-500	443	347	329	1,434	1,420	1,312
>500	684	721	724	1,934	2,088	2,222
Ownership						
For-Profit	1,656	1,490	1,404	6,770	6,586	6,260
Not-For-Profit	325	308	291	1,465	1,372	1,236
Gov't-Owned	142	126	102	432	333	281
Affiliation						
Hospital-Based	190	164	140	855	722	623
Independent	1,933	1,760	1,657	7,812	7,569	7,154
Chain Status						
Chain	607	601	607	1,616	1,605	1,677
Not Chain	1,516	1,323	1,190	7,051	6,686	6,100

B.12 Sample Size Tables

The exhibits in this section provide the sample size for their corresponding table in the report. For example, Exhibit 14n corresponds to Exhibit 14 in the Sixth Annual Report.

Exhibit 14n. Sample Size for Cumulative D-in-D Results for Home Health Utilization among FFS Beneficiaries

Measure	HHVBP	Non-HHVBP
Percent of FFS Beneficiaries with at Least One HH Episode	4,914	23,304
Number of HH Days of Care per FFS Beneficiary	4,914	23,304

These numbers represent the number of county-years. | Sample size reflects episodes from 2013-2021 with non-missing data.

Exhibit 16n. Sample Size for Cumulative D-in-D Results for Case-Mix of Home Health Patients

Measure	HHVBP	Non-HHVBP
HCC Score at the SOC	14,181,779	48,669,569
TNC Mobility at the SOC	14,293,619	47,277,777
TNC Self Care at the SOC	14,293,619	47,277,777
Count of HCC Conditions Present at SOC	14,340,533	47,459,629

Sample size reflects episodes from 2013 –2021 with non-missing data.

Exhibit 22n. Sample Size for Cumulative D-in-D Results for PAC FFS Medicare Beneficiaries

Measure	HHVBP	Non-HHVBP
Home Health Care	15,242,893	50,029,466
SNF	15,242,893	50,029,466
IRF	15,242,893	50,029,466
Self-Care	15,242,893	50,029,466
Hospital Outpatient Therapy	15,242,893	50,029,466

Sample size reflects hospital discharges from 2013 –2021 with non-missing data.

Exhibit 29n. Sample Size for Cumulative D-in-D Results for Frontloading Analyses

Measure	HHVBP	Non-HHVBP
Frontloading Skilled Nursing Visits – Post-Institutional Episodes	1,989,988	6,205,663
Frontloading Therapy Visits – Post-Institutional	1,989,988	6,205,663

Counts displayed above represent a subset of first-in-sequence, claims-based episodes, only including post-institutional episodes which lasted at least 14 days without a hospitalization occurring during that time.

Exhibit 30n. Sample Size for Cumulative D-in-D Results for Frontloading Mediation Analyses

Measure	HHVBP	Non-HHVBP
Unplanned ACH/First FFS HH Episodes	5,304,745	15,383,889
Outpatient ED Use (no Hospitalization)/First FFS HH Episodes	5,304,745	15,383,889
Unplanned ACH/All FFS HH Episodes	10,160,767	33,789,036
SNF Use/All FFS HH Episodes	10,160,767	33,789,036

Original HHVBP Model measures indicated by italic text. Counts displayed above represent a subset of claims-based episodes, which lasted at least 14 days without a hospitalization occurring during that time.

Exhibit 43n. Sample Size for Cumulative D-in-D Results for FFS Claims-Based Utilization Measures

FFS Claims-Based Health Care Utilization Measures	HHVBP	Non-HHVBP
Unplanned ACH/First FFS HH Episodes	6,031,222	17,328,641
Outpatient ED Use (no Hospitalization)/First FFS HH Episodes	6,031,222	17,328,641
ED Use followed by Inpatient Admission/First FFS HH Episodes	6,073,916	17,455,040
Total ED Use (Outpatient or Inpatient Claims)/First FFS HH Episodes	6,073,916	17,455,040
Unplanned ACH/All FFS HH Episodes	11,822,589	39,711,632
SNF Use/All FFS HH Episodes	11,822,589	39,711,632

Original HHVBP Model measures indicated by italic text. | Sample size reflects episodes from 2013 –2021 with non-missing data.

Exhibit 51n. Sample Size for Cumulative D-in-D Results for MA Shadow Claims Analysis

MA Shadow Claims-Based Utilization Measure	HHVBP	Non-HHVBP
Unplanned ACH/MA Shadow Claims	2,517,246	10,721,183

Sample size reflects episodes from 2013 –2020 with non-missing data.

Exhibit 55n. Sample Size for Cumulative D-in-D Results for FFS Claims-Based Spending Measures

FFS Claims-Based Spending Measures	HHVBP	Non-HHVBP
Average Medicare Spending per Day <u>during and following</u> FFS HH Episodes of Care	23,581,077	79,159,212
Average Medicare Spending per Day <u>during</u> FFS HH Episodes of Care	23,581,077	79,159,212
Average Medicare Spending per Day <u>following</u> FFS HH Episodes of Care	14,309,539	41,266,978

Sample size reflects episodes with non-missing data based on the pre-PDGM (2013-2019) and post-PDGM (2013-2021) approaches.

Exhibit 61n. Sample Size for Cumulative D-in-D Results for OASIS Outcome and Mortality Measures

OASIS-Based Outcome Impact Measures	HHVBP	Non-HHVBP
Discharged to Community	14,058,957	46,501,280
TNC Change in Self-Care	10,475,039	33,946,406
TNC Change in Mobility	10,475,039	33,946,406
Improvement in Dyspnea	8,238,520	25,888,923
Improvement in Management of Oral Medications	8,934,444	28,610,459
60 Day Mortality/All FFS Episodes	13,547,016	45,133,048

Original HHVBP Model measures indicated by italic text. | Sample size reflects episodes from 2013 –2021 with non-missing data.

Exhibit 66n. Sample Size for Cumulative D-in-D Results for HHCAHPS-Based Impact Measures

HHCAHPS-Based Patient Experience Impact Measures	HHVBP	Non-HHVBP
All 5 HHCAHPS-Based Patient Experience Impact Measures	13,686	56,119

Original HHVBP Model measures indicated by italic text. | Sample size reflects episodes from 2013 –2021 with non-missing data.